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1 Summary  
Pseudomonas aeruginosa is a multi-drug resistant opportunistic human pathogen that 
produces virulence factors. Among those, the blue phenazine compound pyocyanin plays 
a crucial role in lung infection by P. aeruginosa. As pyocyanin induces the formation of 
reactive oxygen species, the bacterium must have developed some intracellular protec-
tion machinery against this compound. In previous studies, the proteins PA0803, PA1353 
and PA4641 were identified as pyocyanin resistance proteins. These proteins bind pyo-
cyanin and shield it inside the bacterial cell. They belong to the family of βαβββ-module 
containing proteins which are generally involved in detoxification of small toxic mole-
cules.  
In this study, 22 βαβββ-module proteins were identified in P. aeruginosa and classified 
according to highly conserved residues in their binding pockets. A selection of these pro-
teins was characterized by X-ray crystallography, biochemical, biophysical and microbio-
logical methods. 
Furthermore, the crystal structures of three proteins of unknown function PA0880, 
PA1672 and PA4518 were determined. PA0880 is a protein probably involved in itaco-
nate metabolism. However, the functions of PA0880, PA1672 and PA4518 remain elu-
sive. 
Four of the 22 βαβββ-module proteins, namely PA0803, PA1353 and PA4641 as well as 
PA3127, use two aromatic amino acids to bind small aromatic compounds via π-stacking 
interactions. Interestingly, PA3127 differs from the other three proteins as it contains an 
additional N-acetyltransferase domain. The crystal structure of PA3127 was determined 
during this study, and the protein was found to be a tetramer in small angle X-ray scat-
tering measurements. The PA3127 tetramer binds bleomycin, a glycopeptide antibiotic 
produced by Streptomyces spp., and acetyl-CoA with affinities of 413 ± 4 nM and 523 ± 
33 nM, respectively. In spot plate assays, PA3127 confers bleomycin resistance to E. coli, 
most probably by transforming bleomycin into acetyl-bleomycin and rendering it inac-
tive. Bleomycin resistance is even increased in the presence of PA3128, encoded in an 
operon together with PA3127. Hence, PA3127-PA3128 is a genomic bleomycin resis-
tance operon in P. aeruginosa.     
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2 Introduction 
Bacteria and humans have evolved together ever since. Hence, bacterial weapons and 
human immune system have been undergoing continuous adaptions due to evolutionary 
pressure. In order to circumvent the human immune defense, pathogenic bacterial spe-
cies possess virulence factors, multi-drug efflux pumps and other detoxifying enzymes. 
These factors and proteins are especially successful in immunocompromised humans. 
Further problems in eradicating pathogenic bacteria are caused by emerging antibiotic 
resistances and the reduced amount of new antibiotics released by pharma industries. In 
developed countries, nosocomial infections cause severe infections and even death. One 
of the pathogens involved in these infections is Pseudomonas aeruginosa. 
 
2.1 The Opportunistic Human Pathogen Pseudomonas aeruginosa 
The rod-shaped gram-negative bacterium P. aeruginosa (Figure 1A) colonizes various ha-
bitats such as water, soil and other natural as well as artificial environments. P. aerugino-
sa is able to survive under aerobic as well as anaerobic conditions and is therefore very 
versatile.  
 
 
Figure 1: The opportunistic human pathogen P. aeruginosa. A: Colorized electron micrograph image of 
rod-shaped P. aeruginosa. B: Hyperwrinkled single colony of P. aeruginosa. Colonies are usually 
smooth and constrained, but under the absence of the respiratory pigment pyocyanin they extend to 
this hyperwrinkled state and form prominent spokes (Recinos et al., 2012).  
 
P. aeruginosa is an opportunistic pathogen in plants and mammals, including humans. It 
can cause severe infections of the respiratory tract, wounds, burns, blood and the urina-
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ry tract. Various studies have shown that these infections can have a huge impact on the 
infected host, leading to severe tissue damage and even to death (Nixon et al., 2001; 
Lyczak et al., 2002; Hauser et al., 2011). In humans, immunocompromised patients are 
highly susceptible to P. aeruginosa infections. These infections occur either in individuals 
who have been treated with immunosuppressive drugs after an organ transplant or in 
chemotherapy, or in patients who are suffering from immune deficiencies such as AIDS. 
In cystic fibrosis patients, P. aeruginosa is able to establish chronic lung infections. In-
deed, P. aeruginosa is the primary cause of death in cystic fibrosis-affected humans 
(Emerson et al., 2002) and responsible for about 10% of the nosocomial infections 
worldwide. Hence, it is crucial to understand the physiology of this pathogen and the 
way of how it infects the host and establishes and maintains an infection.  
The infections caused by P. aeruginosa are especially hard to eradicate. First, the oppor-
tunistic pathogen employs unspecific virulence factors that are used against a variety of 
different hosts. Upon infection of the host, the bacteria secrete virulence factors, such as 
exotoxin A, proteases or secondary metabolites. P. aeruginosa also possesses a variety 
of multi-drug efflux pumps that act in concert with antibiotic resistance proteins such as 
β-lactamases. Second, the growth of P. aeruginosa switches from a planktonic state to a 
biofilm-forming phenotype. In the biofilm, the bacteria are encapsulated in a dense ma-
trix of extracellular polysaccharides, DNA and proteins. This matrix, together with a bac-
terial cell wall of low permeability, protects the bacteria from antibiotic treatment. 
Third, the bacteria synchronize their behavior and conceal from the immune system until 
they reach a certain cell density threshold. At that threshold, they simultaneously re-
lease virulence factors such as the nitrogen-containing aromatic compound pyocyanin. 
Pyocyanin is one of the major virulence factors of P. aeruginosa, also providing the cha-
racteristic blue-greenish color to the bacterium. When the virulence factors are released, 
P. aeruginosa raid the host immune defense to establish the infection.  
For these reasons, the bacteria are a severe threat to human health. Continuous re-
search in the field is needed to investigate the mechanism underlying infection and proli-
feration in the host and in order to develop suitable treatment for P. aeruginosa infec-
tions. For instance, the systems that synchronize bacterial behavior and production of vi-
rulence factors are under intensive investigation. These systems are termed the quorum 
sensing (QS) systems.   
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2.2 Synchronization of Bacterial Behavior by Quorum Sensing 
A quorum sensing (QS) system is a regulatory network that is used to synchronize the 
behavior of a bacterial population by controlling the transcription of genes under QS 
control. The use of QS systems facilitates infection because the bacteria tightly suppress 
the production of virulence factors and hide from the host immune system. Only at a 
certain cell density threshold, they are able to switch on virulence factor production and 
flood the host with their virulence factors. This overcomes the host immune defense and 
often establishes a chronic infection. The most famous QS phenomenon has been obser-
ved in Vibrio fisheri. These bacteria accumulate in certain organs of sepia, where they 
live as symbionts and produce their bioluminescence after reaching a certain cell density 
threshold (Engebrecht et al., 1983). Later, QS systems have been discovered in various 
bacteria, for example in the complex Myxococcus xanthus (Kuspa et al., 1986) or in the 
opportunistic pathogen P. aeruginosa (Winson et al., 1995). 
Bacteria that use QS may have one ore multiple QS systems that are either arranged on 
the same or on multiple hierarchical levels. In the latter case, the QS systems are inter-
connected and their interplay is complex as they tightly regulate each other. Interesting-
ly, P. aeruginosa possesses a QS network consisting of four QS systems with complex in-
terconnections. 
 
2.2.1 Current Understanding of Quorum Sensing in P. aeruginosa 
The QS network of P. aeruginosa (Figure 2) is organized as a multi-layered hierarchy of at 
least four interconnected signaling systems that probably not only respond to cell densi-
ty, but also to environmental stress signals (Papaioannou et al., 2013; Lee & Zhang, 
2014). The four QS systems provide the bacterium with flexibility to adapt to different 
requirements and to fine-tune its pathogenicity by regulating the production of various 
virulence factors. The four QS systems in P. aeruginosa are the las-, rhl-, pseudomonas 
quinolone signal (pqs-) and integrated quorum sensing signal (iqs-) system. Each of the 
four P. aeruginosa QS systems las, rhl, pqs and iqs requires its corresponding autoindu-
cer molecule N-(3-oxododecanyl)-homoserine lactone (3OC12-HSL), N-(butyryl)-homose-
rine lactone (C4-HSL), 2-heptyl-3-hydroxy-4-quinolone, called Pseudomonas Quinolone 
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Signal (PQS), and 2-(2-hydroxyphenyl)-thiazole-4-carbaldehyde, called Integrated Quo-
rum Sensing Signal (IQS), respectively. 
 
 
Figure 2: Simplified scheme of the four QS systems of P. aeruginosa. The main genes and proteins 
involved in the QS systems and their interconnections are presented (color code: las: cyan/teal; rhl: 
green; pqs: red/pink; iqs: violet). All QS systems have further connections to other enzymes or tran-
scriptional regulators that are not depicted here. Skulls indicate the production of virulence factors 
such as pyocyanin. Pyocyanin (blue hexagon) and the pyocyanin-producing enzymes are under the 
control of the rhl, pqs and iqs systems. Pyocyanin itself then controls the PYO Stimulon, including the 
transcriptional regulator SoxR and the SoxR regulon. However, the exact mechanism of this regulation 
is not understood yet. Figure adapted from Papaioannou et al., 2013; Lee & Zhang, 2014. 
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One example for a virulence factor that is regulated by P. aeruginosa QS systems is the 
blue phenazine compound pyocyanin. Pyocyanin production is mainly controlled by the 
pqs system, but also by the iqs system which probably regulates pyocyanin production 
through the downstream pqs and rhl QS systems. However, it is not yet clear how IQS 
modulates PQS and C4HSL production (Lee et al., 2013).  
Interestingly, the phenazine pyocyanin is not only a virulence factor, but is a signaling 
molecule on its own. In fact, it is able to elicit a specific gene response and is therefore a 
terminal signaling factor in QS (Dietrich et al., 2006). The genes activated by pyocyanin 
are called the PYO Stimulon. The PYO Stimulon consists of 51 genes, including the trans-
cription factor SoxR and its regulon. 22 of these genes are upregulated, while 29 genes 
are downregulated in the presence of pyocyanin. Among the upregulated genes, eight 
genes encode putative efflux pumps and two encode transcriptional regulators (Dietrich 
et al., 2006). Hence, exposure of P. aeruginosa to pyocyanin subjects dramatic effects to 
the gene expression profile of the bacterium, activating or deactivating several hierarchi-
cal levels of genes.  
 
2.3 Phenazines  
2.3.1 Phenazines and Phenazine Biosynthesis Operons in P. aeruginosa 
Phenazines are small aromatic nitrogen-containing compounds. Due to their conjugated 
electron systems, they appear in different colors to the human eye. There are more than 
160 naturally occurring phenazines known (Dictionary of Natural Products, Taylor & 
Francis Group, dnp.chemnetbase.com). Even though a huge variety of phenazine com-
pounds is found in nature, all phenazines most probably derive from two core phenazine 
compounds, namely phenazine-1-carboxylic acid (PCA) and phenazine-1,6-dicarboxylic 
acid (PDC) (Figure 3). PCA is the precursor for asymmetric phenazines while PDC is the 
precursor for symmetrically modified phenazines. Phenazines are produced by a variety 
of bacterial species, but mainly by Pseudomonas and Streptomyces. Pseudomonas pro-
duces rather simple phenazines, while Streptomyces produce more complex and heavily 
modified phenazine compounds. 
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Figure 3: Naturally occurring phenazines and their origin organisms. All phenazine derivatives are pro-
bably derived from PCA and PDC which are depicted in blue. Pyocyanin (PYO) is the most abundant 
phenazine in P. aeruginosa.  
 
In general, phenazine-producing organisms employ the proteins PhzBDEFG, encoded in 
the genes phzBDEFG, in order to produce the core phenazines PCA and PDC (Figure 4). P. 
aeruginosa produces at least four phenazines: PCA, pyocyanin, 1-hydroxy-phenazine and 
phenazine-1-carboxamide. However, the most abundant phenazine in P. aeruginosa is 
pyocyanin which acts as a virulence factor, signaling molecule and electron shuttle. 
 
 
Figure 4: Phenazine biosynthesis gene clusters of P. aeruginosa PAO1. The core genes phzBDEFG are 
conserved in all phenazine producers. Colors indicate probable functions of the proteins (purple: core 
phenazine biosynthesis; green: phenazine-modifying enzymes; blue: resistance; red: regulation; 
orange: export proteins). Notably, P. aeruginosa possesses two phenazine biosynthesis (phz) operons 
which differ in architecture, expression profiles and regulation (Recinos et al., 2012). 
 
2   Introduction – βαβββ-Module Resistance Proteins   
 
9 
Two features of phenazine biosynthesis in P. aeruginosa have to be especially highligh-
ted. On the one hand, P. aeruginosa possesses genes encoding transcriptional regulators 
such as QscR or multi-drug efflux pumps such as MexGHI-OpmD in the vicinity of its 
phenazine biosynthesis (phz) operon. On the other hand, P. aeruginosa possesses two 
phz operons. These two operons differ in architecture as well as in expression profiles 
and regulation (Recinos et al., 2012). The presence of two operons is a unique feature of 
P. aeruginosa, and makes the physiology of the bacterium more complex and more 
difficult to study.  
 
2.3.2  Core Phenazine Biosynthesis 
The discovery of the phz operons in P. aureofaciens 30-84 (Pierson & Thomashow, 1992; 
Pierson et al., 1995) was the first step towards detailed investigation of the phenazine 
biosynthesis enzymes and their mechanisms of action. Since then, most of the bio-
synthetic steps have been discovered and investigated and phenazine biosynthesis has 
been extensively studied and reviewed (Mavrodi et al., 2006; Mentel et al., 2009; 
Mavrodi et al., 2010; Blankenfeldt & Parsons, 2014).  
The phenazine biosynthetic pathway in P. aeruginosa (Figure 5) starts from chorismate 
which is converted to 2-amino-2-desoxyisochorismic acid (ADIC) by the ADIC synthase 
PhzE. The second step is catalyzed by the α/β hydrolyase PhzD and produces trans-2,3-
dihydro-3-hydroxyanthranilic acid (DHHA) (Parsons et al., 2003). DHHA is converted to 
highly reactive 6-amino-5-oxocyclohex-2-ene-1-carboxylic acid (AOCHC) by the enzyme 
PhzF (Blankenfeldt et al., 2004; Parsons et al., 2004b). In order to prevent AOCHC from 
intoxicating the bacterial cell, the enzyme PhzB assists and accelerates the condensation 
of two AOCHC molecules (Ahuja et al., 2008). The product of the PhzB-catalyzed reaction 
is hexa-hydrophenazine-1,6-dicarboxylic acid (HHPDC). HHPDC can undergo isomeriza-
tion or decarboxylation to tetra-hydrophenazine-1,6-carboxylic acid (THPCA). The final 
step is catalyzed by the flavin-mononucleotide (FMN)-dependent PhzG (Parsons et al., 
2004a). PhzG is able to produce either dihydroxy-PCA (DHPCA) or dihydroxy-PDC 
(DHPDC) depending on the number of oxidation steps it conducts on its substrate. 
DHPCA and DHPDC in turn undergo spontaneous oxidation to form PCA and PDC, the 
final products, and at the same time the precursors of all phenazine derivatives.  
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Figure 5: Current understanding of core phenazine biosynthesis. Abstracted or shifted protons are 
shown in pink, uncatalyzed steps are shown with grey arrows. The key products of this pathway are 
depicted in teal. Figure adapted from Blankenfeldt & Parsons, 2014. 
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2.3.3 Derivatization of PCA to Pyocyanin in P. aeruginosa 
A unique feature of P. aeruginosa is the presence of two phenazine biosynthesis gene 
clusters. They are different in architecture (Figure 4) and it has been demonstrated that 
they are differently regulated (Recinos et al., 2012). Removal of the phz2 operon from 
the P. aeruginosa genome results in a more dramatic effect on the colony morphology of 
the bacterium than the removal of the phz1 operon. This might be due to the presence 
of the phzM and phzS genes in the vicinity of the phz2 operon. These genes encode the 
S-adenosyl-methionine (SAM)-dependent methyltransferase PhzM and the flavin-depen-
dent hydroxylase PhzS. Both enzymes are essential for the conversion of PCA to pyocya-
nin by P. aeruginosa (Figure 6). 
 
 
Figure 6: Pyocyanin production in P. aeruginosa. Both enzymes PhzM and PhzS probably form a qua-
ternary PhzM2PhzS2 complex (indicated by the dashed ellipse). PhzM catalyzes the reaction of PCA to 
5-Me-PCA, an unstable and highly reactive intermediate. This intermediate is directly transferred to 
PhzS. PhzS then catalyzes the reaction of 5-Me-PCA to pyocyanin.  
 
2.3.4 Pyocyanin – Properties, Functions and Toxic Effects 
The color of the most abundant phenazine in P. aeruginosa, pyocyanin (5-Methylphena-
zin-1-one), ranges from pink at acidic pH, to green at a pH of 5 and blue at basic pH. Pyo-
cyanin (Figure 7) can even be colorless in its reduced form. The compound imparts the 
specific blue-greenish color to the bacterium in stationary growth phase or in biofilms. 
This blue-greenish color is also visible in the sputum of individuals affected by a P. aeru-
ginosa lung infection, where it is found in up to 100 µM concentration (Wilson et al., 
1988; O’Malley et al., 2004). In addition to performing multiple tasks in P. aeruginosa, 
pyocyanin is a virulence factor and plays a crucial role during host infection. Pyocyanin 
promotes virulence by interfering with several cellular functions in host cells including 
electron transport, cellular respiration, energy metabolism, gene expression, and innate 
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immune mechanisms (Rada & Leto, 2013). For instance, pyocyanin was demonstrated to 
play a crucial role in lung pathogenesis (Caldwell et al., 2009), but  P. aeruginosa mutants 
lacking pyocyanin were attenuated in both acute and chronic lung infection models in 
mice (Lau et al., 2004). 
 
 
Figure 7: Redox-activity and electron shuttle properties of pyocanin from P. aeruginosa PAO1. PYO 
reacts with NAD(P)H to yield PYOH2. PYOH2 reduces O2 to O2
-
 or reacts with PYO to form two PYOH
•
 
radicals. PYOH
•
 reduces O2 to O2
-
 . Figure adapted from Reszka et al., 2004. 
 
The basis for the multifaceted role of pyocyanin is the compound’s fundamental ability 
to alter redox homeostasis, increase oxidative stress and induce apoptosis (Jacob et al., 
2011). It appears that pyocyanin is able to directly generate reactive oxygen species 
(ROS) without assistance of the mitochondrial respiratory chain (O’Malley et al., 2004; 
Reszka et al., 2004). Pyocyanin reacts with reducing agents such as NAD(P)H to yield 
hydrophenazine (PYOH2). Then PYOH2 primarily reduces O2 to H2O2, but may also react 
with a second pyocyanin molecule to form two radicals (PYOH•), which can reduce O2 to 
O2
-• (Reszka et al., 2004). Additionally, pyocyanin seems to accept one electron from glu-
tathione (GSH), thus using the cell’s own antioxidant defense to cause oxidative stress 
(O’Malley et al., 2004). Hence, pyocyanin can adapt different oxidation states and pos-
sesses zwitterionic properties. As a zwitterion, pyocyanin might be able to easily pene-
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trate the cellular membrane and enter a host cell. Inside the host cell, the oxidative ef-
fect of pyocyanin increases the innate immune response, for instance by upregulation of 
interleukin-8 expression (Denning et al., 1998b; Look et al., 2005). In neutrophils, ROS 
generation by pyocyanin and decrease in cyclic adenosine monophosphate (cAMP) con-
centration induce apoptosis and kill these cells (Usher et al., 2002). Furthermore, pyo-
cyanin is able to alter calcium signaling. Since Ca2+ is involved in regulation of ion trans-
port, mucus secretion and ciliary beat, disruption of Ca2+ homeostasis might be an addi-
tional explanation for the importance of pyocyanin in lung pathogenesis caused by P. ae-
ruginosa (Denning et al., 1998a). Interestingly, pyocyanin is important for chronic lung 
infection in mice and long-term administration of pyocyanin alone is able to induce a 
cystic fibrosis-like lung phenotype (Caldwell et al., 2009; Hao et al., 2012). Taken toge-
ther, pyocyanin alters several cellular functions and promotes virulence of P. aeruginosa 
in a broad range of target organisms, but especially in immunocompromised humans. 
The abilities of P. aeruginosa to interfere with redox homeostasis and signaling, gene re-
gulation and energy metabolism of respiratory epithelial cells have recently been re-
viewed in detail (Rada & Leto, 2013).  
In P. aeruginosa, pyocyanin acts as a mobile electron carrier and helps P. aeruginosa to 
survive under oxygen-poor conditions by accepting and transporting electrons produced 
in respiration away from the bacterium to acceptors in remote places (Rada & Leto, 
2013). First evidence was found when P. aeruginosa mutants lacking pyocyanin formed 
large wrinkled colonies compared to the wild type’s smooth and small colonies (Dietrich 
et al., 2008). This demonstrates the function of pyocyanin as a respiratory pigment and 
confirms its ability to modulate the structural organization of cellular communities. 
Later, the pyocyanin electrocline was discovered, a redox-potential gradient that can 
reach up to 400 µm beyond the biofilm surface (Koley et al., 2011). This electrocline is 
formed under electron-acceptor limiting conditions, and is also observable in planktonic 
growth state as a color gradient form oxidized blue pyocyanin to reduced colorless pyo-
cyanin (Rada & Leto, 2013). The phenazine-facilitated electron transfer was shown to 
promote anaerobic survival of P. aeruginosa (Wang et al., 2010). Interestingly, growth 
conditions favoring the formation of the electrocline correlate to an increase in soluble 
iron (Koley et al., 2011). In fact, pyocyanin is able to increase the bioavailability of ferric 
(hydr)oxides (Wang & Newman, 2008). 
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In contrast to its negative impact on host cell metabolism, gene regulation and redox ho-
meostasis, pyocyanin does interfere in a beneficial way with P. aeruginosa cells, promo-
ting survival of the bacterium. Most notably, the compound is able to regulate the gene 
expression profile of P. aeruginosa, since pyocyanin is a signaling molecule in QS and re-
gulates the PYO Stimulon (Section 2.2.1), including eight transmembrane efflux pumps 
and the transcriptional regulator SoxR. 
 
2.4 Phenazine Resistance 
Phenazines and especially pyocyanin are reversibly redox-active metabolites able to ge-
nerate reactive oxygen species. Hence, they act as virulence factors and are toxic to any 
living organism. For this reason, phenazine-producing bacteria must have developed re-
sistance mechanisms against their self-produced phenazines. These defense responses 
or resistance mechanisms can be of rather general type, or they can be pyocyanin-speci-
fic resistance factors. Recent findings indicate that P. aeruginosa possesses general as 
well as specific defense mechanisms against pyocyanin and pyocyanin’s action.  
 
2.4.1 General Mechanisms of Phenazine Resistance in P. aeruginosa 
Little is known about the defense response or resistance mechanisms to pyocyanin of P. 
aeruginosa itself. However, it is known that the bacterium is insensitive to the toxic 
effects of pyocyanin and that pyocyanin does not affect the growth rate of the bacte-
rium (Baron & Rowe, 1981). In contrast, the growth rate of E. coli is dramatically reduced 
upon pyocyanin exposure (Hassett et al., 1992). This effect is potentially caused by a 
more efficient uptake of exogenous pyocyanin by E. coli, and an increased formation 
rate of pyocyanin radicals and ROS in E. coli. In contrast, P. aeruginosa forms markedly 
less radicals when exposed to pyocyanin (Hassett et al., 1992). Interestingly, NAD(P)H is 
capable to reduce pyocyanin in a non-enzymatic reaction. P. aeruginosa maintains a 
four-fold lower NAD(P)H-level than E. coli, and it is tempting to speculate that this ex-
plains the decreased level of pyocyanin oxidation in this bacterium. In fact, upon addi-
tion of P. aeruginosa cell extracts, the velocity of the non-enzymatic reduction of pyo-
cyanin by NAD(P)H is reduced by two-fold. The reason for this remains elusive. In con-
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trast, E. coli cell extract accelerates the reaction due to the presence of a NAD(P)H oxido-
reductase (Hassett et al., 1992). Under low-phosphate conditions, pyocyanin production 
levels are elevated, and P. aeruginosa produces high levels of multiple catalases (Hassan 
& Fridovich, 1980; Hassett et al., 1992). A two-fold increase in catalase activity is also ob-
served upon exposure to exogenous pyocyanin, while the absence of pyocyanin in a pyo-
cyanin-deficient P. aeruginosa mutant is associated with 30% less catalase activity than 
in the wild type pathogen (Hassett et al., 1992).  
Additionally, P. aeruginosa produces two metal-dependent superoxide dismutases 
(SOD), an Fe(II)- and a Mn(II)-SOD, to detoxify ROS. The activity of both SODs and the ca-
talases is increased 5-fold under low phosphate conditions (Hassett et al., 1992). SOD ac-
tivity in P. aeruginosa is also increased upon exposure to pyocyanin (Hassett et al., 
1992). Later, the expression of catalase- and SOD-encoding genes was found to be under 
the control of QS (Hassett et al., 1999). In hindsight, the effect of pyocyanin on the 
expression profile of P. aeruginosa is not very surprising, as pyocyanin is a signaling mo-
lecule in QS (Dietrich et al., 2006) that regulates its own set of target genes, the PYO 
Stimulon. 
Taken together, the expression of catalases and SODs in P. aeruginosa is a rather a gene-
ral response to oxidative stress, as it occurs also upon exposure to other ROS-generating 
molecules (Hassett et al., 1992). Still, there is less intracellular pyocyanin-mediated 
redox cycling in P. aeruginosa than in E. coli. Furthermore, P. aeruginosa cell extracts 
probably contain soluble factors not present in E. coli which may contribute to its resis-
tance to pyocyanin-mediated oxidative stress and pyocyanin itself (Hassett et al., 1992). 
Hints to such factors are found in the phz operons of phenazine producers other than P. 
aeruginosa, for instance the non-pathogenic phenazine producer Pantoea agglomerans.   
 
2.4.2 Specific Phenazine Resistance in P. agglomerans 
In general, compound-specific resistance can occur in two different ways: either the 
toxic compound is destroyed by an enzyme, for instance as ampicillin is destroyed by β-
lactamase; or it is bound and shielded by a chaperone until it is secreted by export ma-
chinery. The former is not very likely in the case of phenazines, since the bacterium in-
vests energy to produce phenazines, and subsequent destruction of these would in turn 
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be a waste of energy. Hence, phenazine-producers might use a phenazine resistance 
protein which acts as a binding protein or chaperone towards phenazines. However, no 
evidence for such a chaperone-like protein can be found in the phz operons of P. aeru-
ginosa. 
Interestingly, such a phenazine resistance protein is found in the phz operon of the non-
pathogenic bacterium P. agglomerans (previously known as Enterobacter agglomerans 
or Erwinia herbicola). The P. agglomerans phz operon comprises 16 open reading frames 
(ORFs) (Figure 8A, Giddens et al., 2002). Among these genes, five encode the essential 
core phenazine biosynthesis enzymes PhzBDEFG, and nine additional genes encode the 
phenazine modifying enzymes EhpFGHIKLMNO which catalyze the modification of PCA 
to D-alanyl-griseoluteic acid (AGA, Figure 3), the phenazine derivative produced by P. 
agglomerans. Additionally, the phz operon of P. agglomerans includes two non-biosyn-
thetic genes (Figure 8A). The ehpJ gene was identified to encode an α-helical transmem-
brane protein that is potentially involved in AGA transport across the membrane of P. 
agglomerans. However, no fold or function could be assigned to the 16th gene of this 
operon. Notably, disruption of this gene by transposon insertion resulted in loss of AGA 
resistance in P. agglomerans (Giddens et al., 2002). In agreement with this result, the re-
moval of ehpR from P. agglomerans during the creation of a P. agglomerans ΔAGA yields 
a strain with similar sensitivity to AGA as E. coli (Giddens et al., 2002). On the basis of 
these observations, this 16th gene was termed ehpR (Erwinia herbicola phenazine resis-
tance protein). The potential phenazine resistance factor EhpR encoded by this gene was 
characterized in order to analyze the resistance mechanism mediated by EhpR on the 
molecular level. For this purpose, the crystal structure of this protein was determined in 
complex with griseoluteic acid (GA) (Figure 8B and C, Yu et al., 2011).  
The AGA resistance protein EhpR from P. agglomerans belongs to the βαβββ-module 
containing protein family or glyoxalase I/bleomycin resistance proteins. These proteins 
form obligate dimers and possess two ligand binding sites at the dimer interfaces. In 
fact, the GA binding site is located at the dimer interface (Figure 8C). EhpR is able to bind 
GA between two aromatic residues, Y43 and F109*, each belonging to one protein of the 
EhpR dimer. Binding of GA is mainly mediated through π-stacking interactions, but GA is 
also forming hydrogen bonds with R42 and W56. EhpR probably shields (A)GA from the 
intracellular space and prevents it from unraveling its toxic effects. EhpR does not alter 
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(A)GA chemically, but probably transports it to its export machinery EhpJ. The dissocia-
tion constant KD of GA and EhpR was determined as 244 ± 45 μM using microscale ther-
mophoresis (Yu et al., 2011). Even if this is a rather high KD, it confirms that EhpR acts as 
a molecular chaperone for (A)GA. The relatively low affinity of (A)GA to EhpR may be re-
quired for their molecular function and for the release of AGA to the extracellular space. 
 
 
Figure 8: The βαβββ-module protein EhpR confers resistance against self-produced phenazines to P. 
agglomerans. A: D-alanyl-griseoluteic acid biosynthesis operon of P. agglomerans. Core phenazine 
biosynthesis genes are shown in violet, phenazine-modifying enzymes in green, the probable trans-
porter in orange and the resistance gene ehpR in blue. B: EhpR in complex with griseoluteic acid (GA) 
at 1.0 Å resolution (Yu et al., 2011). The protein is a dimer with two GA binding sites at the dimer in-
terfaces. C: Phenazine binding site of EhpR with GA. GA is sandwiched between two aromatic residues 
Y43 and F109 via π-stacking interactions. R42 and W56 are engaged in hydrogen bonds with GA. 
 
Together, phenazine binding proteins like EhpR and efflux pumps like EhpJ might act in 
concert to protect the cell from the phenazines’ action and export them to extracellular 
space. The function of EhpR may be applicable to other aromatic or toxic compounds 
which could be shielded and cleared from the cell in this manner, especially in bacteria. 
Therefore it is interesting to examine the molecular architecture this protein and search 
the genome of P. aeruginosa for EhpR-like proteins. 
 
2.4.3 Evidence for Specific Pyocyanin Resistance in P. aeruginosa PAO1 
No evidence for an EhpR-like protein is found in the vicinity of the phz operons of P. ae-
ruginosa. Due to this fact, one may assume that either ehpR-like genes are not present in 
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P. aeruginosa, or they might be located elsewhere in the genome. For bacteria, the latter 
does not seem very obvious or convenient, since it is thought that proteins fulfilling a 
function together are encoded together in the same operon. Still, they might be located 
elsewhere, and regulated by QS systems or other transcriptional factors.  
 
 
Figure 9: Crystal structures of pyocyanin-binding βαβββ-module resistance proteins PA0803, PA1353 
and PA4641 from P. aeruginosa PAO1 (Yu, 2009; Kalawy-Fansa, 2010). The proteins form obligate di-
mers (monomers shown in yellow and teal). They harbor one pyocyanin binding site at each dimer in-
terface. In PA0803, Tyr122* would have to undergo a conformational change for the protein to bind 
pyocyanin between residues His49 and Tyr122*. In PA1353 and PA4641, pyocyanin (grey) is bound via 
π-stacking interactions between residues His53 and Tyr114* (Kalawy-Fansa, 2010). Crystals of PA4641 
soaked with 1 mM pyocyanin are pigmented by the compound (Kalawy-Fansa, 2010).   
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Notably, a BLAST search with the EhpR sequence identified a small protein encoded by 
the ORF PA0803 in P. aeruginosa PAO1. The sequence identity between these proteins is 
relatively low (14%), but PA0803 was predicted to have the same fold as EhpR. Indeed, 
this prediction was confirmed when its structure was determined (Figure 9, Yu, 2009). As 
soon as PA0803 was identified, a Dali search using the structure of PA0803 on the P. 
aeruginosa proteome identified PA1353 and second BLAST search with the PA1353 
sequence in turn identified PA4641. Again, both proteins share low sequence similarity 
with PA0803. In 2010, the crystal structures of PA1353 and PA4641 were both determi-
ned as apo forms and in complex with pyocyanin (Figure 9, Kalawy-Fansa, 2010). 
The three proteins PA0803, PA1353 and PA4641 from P. aeruginosa PAO1 share structu-
ral similarity with EhpR from P. agglomerans. The proteins form homodimers and pos-
sess two pyocyanin binding sites which are located at the dimer interfaces. In these cen-
ters, the proteins employ two aromatic residues, one residue from each protein chain of 
the homodimer, for pyocyanin binding which is accomplished by π-stacking interactions. 
PA0803 employs residues His49 and Tyr122* (* indicating a residue from the second pro-
tein of the dimer), while PA1353 and PA4641 use His53 and Tyr114* for pyocyanin bind-
ing. In isothermal titration calorimetry (ITC), pyocyanin binding constants have been de-
termined as 3.92 ± 0.22 µM for PA0803 (Yu, 2009), as 3.40 ± 0.25 μM for PA1353 and as 
0.64 ± 0.35 μM for PA4641 (Kalawy-Fansa, 2010). These findings suggest that P. aerugi-
nosa possesses pyocyanin resistance proteins similar to EhpR from P. agglomerans. 
 
2.5 βαβββ-Module Containing Resistance Proteins 
The GA resistance protein EhpR from P. agglomerans as well as the potential pyocyanin 
resistance proteins PA0803, PA1353 and PA4641 from P. aeruginosa PAO1 belong to the 
clan of glyoxalases (Pfam CL0104), also called vicinal oxygen chelate (VOC) superfamily 
(Armstrong, 2000) or βαβββ-module containing protein superfamily (Figure 10). This 
superfamily includes glyoxalase I, II, III, IV and V proteins as well as YecM proteins, CCpA-
N and 3-demethylubiquinone-9 3-methyltransferases. However, all of these proteins are 
α/β class proteins (Levitt & Chothia, 1976), very similar in three-dimensional architecture 
and are predominantly found in bacteria, but also in eukaryotes and archaea (Finn et al., 
2014). Members of the βαβββ-module containing protein family share low sequence 
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identity (usually <20%) but are very versatile regarding their function. The basic βαβββ-
module spans 50-60 amino acid residues. Each module is arranged in a sequential order 
of β1αβ2β3β4, but in a spatial order and a strand polarity of β1
+αβ4
+β3
-β2
+ (Bergdoll et al., 
1998). 
 
Figure 10: General architecture of glyoxalase I/bleomycin resistance proteins or βαβββ-module con-
taining proteins, using EhpR (Yu et al., 2011) as an example. On the left side, the βαβββ-module is de-
picted. Four of these modules are needed to form a fully functional protein. A functional protein is ei-
ther encoded as one protein composed of four modules, or as a protein with two modules that forms 
stable homodimers.  
 
A fully functional βαβββ-module protein is composed of four superimposable modules. 
These four modules can be either encoded in one protein chain or two modules can be 
in encoded in two protein chains each. Hence, βαβββ-module protein containing two 
modules are obligate dimers. However, dimerization of βαβββ-module containing pro-
teins can be achieved in two different ways (Bergdoll et al., 1998). The possible 
assemblies are illustrated in Figure 11 using 2,3-dihydroxy biphenyl 1,2-dioxygenase 
(DHBD) from Burkholderia xenovorans BL400 (PDB entry 1HAN, Han et al., 1995), human 
glyoxalase I (Glo1) (PDB entry 1FRO, (Cameron et al., 1997) and RHA04853 (PDB entry 
2R6U, Zhang et al., to be published). 
In all quaternary assemblies of βαβββ-module proteins, the β1 strands of each module 
are interacting to form an extended β-sheet structure (Bergdoll et al., 1998). In the first 
possible dimerization modus, two neighboring modules 1 and 2 can dimerize with other 
two modules 3 and 4 via back-to-back contacts. By doing so, the α-helices of modules 1 
and 3 and modules 2 and 4 are interacting with each other. Hence, spatial interaction of 
α-helices occurs between modules which are not neighboring in the protein sequence 
(Figure 11, DHBD monomer). 
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Figure 11: Different dimerization forms of βαβββ-module containing proteins, using DHBH (PDB entry 
1HAN), Glo1 (PDB entry 1FRO) and RHA04853 (PDB entry 2U6R) as examples. In this scheme, β-
strands are depicted as boxes and α-helices as circles. Connecting segments, shown as lines and 
arrows, may include additional secondary structure elements. Module numbering is from 1 to 4 in the 
protein chain, and for Glo1, letters A and B in superscript indicate the monomer. The active sites are 
marked by violet circles representing the divalent metal ions Fe(II) in DHBD and Zn(II) in Glo1. DHBD 
and RHA04853 dimerize via back-to-back contacts, while Glo1 dimerizes via edge-to-edge contacts. 
Figure adapted from Bergdoll et al., 1998. 
 
The second dimerization modus is via edge-to-edge contacts where the α-helices of 
modules 1A and 2A as well as 1B and 2B neighboring in sequence are interacting in space 
(Figure 11, Glo1). However, dimerization by back-to-back contacts is not only possible in 
βαβββ-module proteins with four modules per monomer (as DHBD), but also in proteins 
containing two modules per monomer. In this case, the α-helices 1A and 2B as well as 1B 
and 2A would interact with each other (Figure 11, RHA04853). Hence, α-helices of mo-
dules from different monomers are interacting. The βαβββ-module containing proteins 
vary in their tertiary and quaternary structure (Figure 12). 
Other than dimers, βαβββ-module containing proteins can adapt larger quaternary as-
semblies which can reach up to octameric complexes of homodimers as observed in 
DHBD (Han et al., 1995). Some βαβββ-module proteins harbor additional secondary 
structure elements or have been fused to additional domains due to gene editing. These 
modifications results in multi-domain proteins with altered functions. One example for 
such a βαβββ-module protein is the bleomycin-N-acetyltransferase (BAT) from Strepto-
myces verticillus (PDB entry 2ZW6, Oda et al., 2010). This protein combines its βαβββ-
module protein domain with an N-acetyltransferase domain, and detoxifies the complex 
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antibiotic bleomycin. Other βαβββ-module proteins harbor metal coordination sites in 
which divalent transition metal cations are chelated. These cations are essential for the 
catalytic mechanism, for instance Mn(II), Zn(II) or Fe(II). In DHBD, the active site contains 
an Fe(II) ion and in human Glo1 each active center coordinates a Zn(II) ion.  
 
 
Figure 12: Structural and functional diversity of βαβββ-module containing proteins from P. aerugino-
sa PAO1. FosA from P. aeruginosa harbors a catalytic Mn(II) and a K
+
 ion (violet) and detoxifies fosfo-
mycin. DHBD from B. xenovorans LB400 degrades polychlorinated biphenyls using a catalytic Fe(II) 
and forms an octamer of homodimers. PA1353 is a pyocyanin-binding protein from P. aeruginosa 
which involves two aromatic residues in pyocyanin binding via π-stacking interactions. BLMT from 
Streptomyces verticillus similarly acts as a chaperone for bleomycin. In contrast, BAT from S. verticil-
lus acetylates bleomycin under acetyl-CoA consumption, using its additional N-acetyltransferase do-
main. 
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Another example for a metal-binding βαβββ-module containing protein is FosA from P. 
aeruginosa, which coordinates a Mn(II) and a K+ ion to catalyze the addition of GSH to 
the broad spectrum antibiotic fosfomycin (Rife et al., 2002). In contrast, some βαβββ-
module proteins do not harbor metal cations or additional domains, but are involved in 
binding aromatic compounds, as previously mentioned. Examples for such proteins are 
PA1353 from P. aeruginosa, BLMT, a bleomycin chaperone-like protein from S. verticillus 
(PDB entry 1NIQ, to be published) or MRD, a protein from Streptomyces lavendulae in-
volved in mitomycin C binding (Martin et al., 2002). Taken together, βαβββ-module con-
taining proteins adopt a large variety of tertiary and quaternary assemblies which enable 
proteins of this folding family to execute various tasks and involve in a huge variety of 
cellular processes, for instance in detoxification, and are therefore important to investi-
gate. Possibly, P. aeruginosa possesses a variety of βαβββ-module containing proteins 
involved in diverse resistances that would be important to discover and characterize.  
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3 Research Objectives 
The opportunistic pathogen P. aeruginosa is the causative agent of acute and chronic in-
fections, especially in immunocompromised humans. The bacterium utilizes an arsenal 
of virulence factors as well as antibiotic resistance factors to facilitate survival and host 
infection. Most notably, it produces its own antibiotics, the phenazines. Among those, 
the blue phenazine pigment pyocyanin plays a crucial role in P. aeruginosa lung infec-
tions. Interestingly, pyocyanin assumes multiple physiological functions, for instance as a 
signaling molecule in QS, catalyst of redox reactions and regulator of biofilm morpholo-
gy. Since pyocyanin is also able to cause oxidative stress, P. aeruginosa has to shield it in-
tracellularly until it is secreted. Prior to this study, three pyocyanin-binding proteins 
PA0803, PA1353 and PA4641 from P. aeruginosa PAO1 were identified and characterized 
by X-ray crystallography (Yu, 2009; Kalawy-Fansa, 2010). Still, a crystal structure of 
PA0803 in complex with pyocyanin in 100% occupancy is missing and will be determined 
during this study. Furthermore, all three proteins will be tested for binding of aromatic 
compounds using ITC experiments. Their function as hypothetical pyocyanin resistance 
proteins will also be tested in vivo in E. coli and P. aeruginosa. 
The potential pyocyanin resistance proteins belong to the glyoxalase superfamily or the 
βαβββ-module containing resistance proteins. In this study, further βαβββ-module con-
taining resistance proteins encoded in the genome of P. aeruginosa will be identified and 
classified. A selection of these proteins will be investigated in order to reveal the resis-
tance mechanisms these proteins are involved in. Using X-ray crystallography, further 
proteins of this folding family will be structurally elucidated. Some of these proteins will 
be characterized with using bioinformatics tools as well as biophysical methods such as 
ITC and microbiological methods to confirm their function in vivo.  
This study will identify further βαβββ-module containing proteins in P. aeruginosa that 
potentially mediate resistance probably not only against pyocyanin, but against other 
antibiotic compounds. In the future, this approach will help to understand bacterial re-
sistance mechanisms and possibly lead to novel anti-infective strategies. 
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4 Principles of Protein X-ray Crystallography 
The foundations of X-ray crystallography were provided more than 100 years ago, when 
Max von Laue carried out the first X-ray diffraction experiment in 1912. In 1914, he was 
awarded the Nobel Prize in Physics for his discovery of the diffraction of X-rays by 
crystals. In 1958, the first crystal structure of a protein, sperm whale myoglobin, was de-
termined (Kendrew et al., 1958). Since then, protein X-ray crystallography and structural 
biology underwent and still undergo huge developments, pushed by the advance of 
computers and technical equipment. Furthermore, crystallography provides the founda-
tion of modern structural biology techniques and structure-based drug discovery. It can 
provide detailed molecular insight even into large biological assemblies.  
 
4.1 Crystallization of Proteins 
Unfortunately, the process of protein crystallization is empiric and non-deterministic, 
and it is only possible to increase the probability of a protein to crystallize, but it can ne-
ver be guaranteed that the process will actually yield protein crystals (Rupp, 2009). Prior 
to protein crystallization, construct design, cloning and test expressions are fundamental 
to most of the crystallographic projects. Depending on the protein, this task can be easy 
or rather challenging. Still it is necessary, since the protein sample has to meet high stan-
dards, for instance conformational homogeneity and high purity.  
Protein crystallization starts with a sufficient amount of protein solution of suitably high 
quality and concentration (usually in the mg/mL range). The protein sample is usually 
mixed in a 1:1 ratio with screening solution, containing a mixture of precipitants, buffers 
and salts. Then, the protein/precipitant mix is equilibrated against a reservoir of screen-
ing solution. The water vapor equilibrates from the protein/precipitant drop to the re-
servoir containing higher precipitant concentration. Thus, this technique is called the va-
por diffusion method. It is the most common method to set up protein crystallization 
trials (Figure 13A). In the vapor diffusion method, the equilibration process reduces the 
protein solubility in the hope that the protein separates from solution while self-assem-
bling into its crystalline form. The protein solution becomes supersaturated and metas-
table. Given that the condition is favorable, nucleation sites appear and crystals start to 
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grow. Crystal growth continues until the crystalline material is in equilibrium with the 
surrounding solution. At this point, the crystal has reached its final size. Nucleation and 
crystal growth are often described in crystallization diagrams (Figure 13B). 
 
 
Figure 13: Protein crystallization. A: Schematic views of common crystallization methods. The sitting 
drop vapor diffusion is commonly used for high-throughput crystal screening, while hanging drop set-
ups are used for manual optimization of crystallization experiments. B: Crystallographic phase dia-
gram. Usually, higher supersaturation is needed for homogenous nucleation, while low supersatura-
tion requires external crystallization seeds (for instance microcrystals). If the protein or precipitant 
concentration is too low, the protein will remain in solution, if it is too high, the protein will preci-
pitate. Figure adapted from Rupp, 2009. 
 
Fortunately, protein crystallization is an automatable process, and nowadays most crys-
tallization screens are set up using robots. The advantages of using robotics are the fast 
setup of multiple screening conditions at a time, usually in a 96-well plate, and the low 
amount of protein sample and crystallization solution consumed, in the order of 100 nL 
of protein solution per drop. The crystallization trials are inspected for crystal formation 
on a daily basis, often aided by an automated imaging system. Using such imaging sys-
tems helps to track and score the appearance of each crystallization drop.  
Once a crystallization hit has been identified in a crystallization trial, the crystals often 
have to be optimized in shape, size and ultimately in diffraction quality. In the optimiza-
tion plate, the original condition is varied in composition, regarding the pH of the buffer 
component or concentration of precipitants. In general, components can be added, their 
concentrations can be varied. Optimization plates can also be used for soaking experi-
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ments with ligand or heavy atom complexes. Once a protein crystal has been obtained, it 
is isolated using a nylon loop. After placing the crystal in a cryoprotecting solution, it is 
flash cooled in liquid nitrogen. Diffraction experiments are usually performed at cryoge-
nic temperatures. Unfortunately, cooling of protein crystals to these temperatures will 
lead to the formation of amorphous ice. This ice will in turn lower the diffraction. How-
ever, cryogenic temperatures mostly avoid the effects of radiation damage. Radiation 
damage is caused by radicals that are induced by high energy X-rays. As these radicals 
can migrate through the crystal, they cause radiation damage which reduces the diffrac-
tion quality of the crystals. Taken together, data collection at cryogenic temperatures 
often prolongues the lifetime of the crystal which in turn has to be protected with cryo-
genic agents. For instance, these agents can be glycerol or small polyethylene glycols 
(PEGs).  
 
4.2 Diffraction of X-rays 
In order to determine the structure of a protein on the molecular or atomic level, some 
intrinsic difficulties must first be considered. For instance, the chemical bonds lengths 
between two atoms are in the range of only a few angstroms Å. The smallest distance 
between two points in the sample of interest that is able to be distinguished determines 
the “resolution” of the crystal or protein structure. Among other parameters, the resolu-
tion depends on the wavelength of the utilized light. Hence, light of a wavelength of a 
few angstroms is needed to determine distances of a similar length. Thus, X-rays (λ = 0.1-
100 Å) are suitable for protein structure determination on the molecular level. Typically, 
an X-ray diffraction experiment on a protein crystal is done with X-rays of a wavelength 
of λ = 1.54 Å (Cu Kα radiation) at an X-ray home sources. Alternatively, synchrotron radia-
tion can be used for such experiments. However, X-rays are only weakly diffracted by or-
ganic materials. Only 5% of the X-ray beam are actually scattered by the electrons in 
matter, while 95% pass through the sample. Hence, it is necessary to raise the signal of 
the diffracted X-rays to a detectable level. For this purpose, sensitive detectors are nee-
ded to collect the diffraction data. Additionally, X-ray crystallography makes use of the 
physical principle of the positive interference of waves. The X-ray signal is amplified by 
the positive interference of waves scattered by many molecules of the same type 
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arranged in a regular array. In fact, protein crystals are such periodic arrays of large and 
flexible macromolecules, held together by weak intermolecular interactions (Rupp, 
2009). Hence, they are particularly suited to amplify the signal of diffracted X-rays which 
can then be detected.  
 
4.3 Bragg’s Law, Reciprocal Space and the Ewald Construction 
When X-rays hit a protein crystal, they are scattered by the electrons in the protein mo-
lecules. These protein molecules can be imagined to lie on crystallographic lattice planes 
in a protein crystal. The X-rays are then diffracted at these lattice planes (Figure 14).   
 
 
Figure 14: Graphical construction of Bragg's Law. The distance between two crystal planes is dhkl, and 
θ is the scattering angle. Hence, the total path difference between two scattered X-rays is equal to 
2dhkl sin θ (green). For maximum positive interference, 2dhkl sin θ has to be equal to a multiple n of 
the X-ray wavelength λ. 
 
The diffracted X-rays have the same wavelength as the incident beam, but they differ in 
path length. The interference between X-rays scattered on crystal planes is described the 
Bragg equation 
𝒏𝝀 =  𝟐𝒅𝒉𝒌𝒍 𝒔𝒊 𝒏𝜽       (1) 
where λ is the wavelength of the X-ray beam, dhkl is the interplanar distance and θ is the 
scattering angle. The total path difference between two X-ray waves is 2dhkl sin θ, and 
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this term has to be equal to a multiple n of the X-ray wavelength λ for maximum positive 
or constructive interference. 
When an X-ray beam hits a crystal lattice, some of the scattered waves will interfere con-
structively and add up to a detectable signal. Most of them, however, will interfere de-
structively and thus be cancelled out. For this reason, a distinct diffraction pattern can 
be detected (Figure 15).  
 
 
Figure 15: Diffraction of X-rays hitting a protein crystal. A: Only 5% of the incident beam is scattered 
and can be detected as a distinct diffraction pattern. The pattern is a Fourier transform (FT) of the 
electron envelope of the crystal content. After a FT of the pattern into the electron envelope, the 
structural model of the protein can be build. B: Diffraction pattern of a protein crystal. The a-axis of 
the crystal is aligned rotation axis (green arrow) of the crystal. Hence, in this orthogonal crystal, the c-
axis is aligned to the incident beam. In the diffraction pattern, the mirror symmetry m indicates a 2-
fold axis in the crystal system. The distances between the reflections are reciprocal to the unit cell 
axis parameters of the crystal. Figure adapted from Rupp, 2009. 
 
The diffraction pattern is made up of single spots that are called reflections. The pattern 
only contains information about the unit cell parameters and the space group. In con-
trast, the intensity of the measured reflections in the pattern contains information on 
the shape of the electron envelope of the protein. However, it is not possible to visualize 
the protein and its orientation and packing in the crystal without correct analysis and in-
terpretation of the unit cell parameters and space group. Since the relationship between 
the lattice plane distance dhkl and the spacing of the spots is reciprocal, the description 
of diffraction events and the following mathematical calculations can be simplified by 
defining the reciprocal space. The reciprocal space is the space that contains the possible 
spots of interference of the X-ray beam and the crystal lattice. Each direct crystal lattice 
(in real space) is associated with a reciprocal crystal lattice (in reciprocal space). Hence, 
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the latter can directly be constructed from the real space lattice. A simplified two-dimen-
sional construction of reciprocal space, presented in Figure 16, can also be interpreted as 
a projection of a three-dimensional lattice down the c-axis.   
 
 
Figure 16: Two-dimensional construction of reciprocal space. The direct lattice is represented in grey 
with blue lattice points. O is the origin of the direct lattice, the cell axis c is perpendicular to the a/b 
plane. A: The pink and violet lines each represent a set of direct lattice planes. The distance between 
two lattice planes of one lattice plane set is dhkl. B: In order to construct reciprocal space, normals to 
all direct lattice planes are constructed. Each normal terminates at a distance 1/dhkl from the origin. 
The end point of each normal is a reciprocal lattice point. The reciprocal lattice points constitute the 
reciprocal lattice. 
 
In real space, meaning in a direct crystal lattice, each lattice point can be indexed rela-
tive to a chosen origin O, either using direct Weiss indexing (uvw) or reciprocal Miller in-
dexing (hkl). In order to construct the reciprocal lattice, all possible direct lattice planes 
with Miller indices hkl are constructed. In Miller indexing, index h, k or l is defined as the 
number of how many times the a-, b- or c-axis of the unit cell is cut by a set of lattice 
planes, respectively. A set of lattice planes is defined as parallel, equidistant planes with 
Miller indices hkl. The index h, k or l is zero, if a set of lattice planes is parallel to the res-
pective unit cell axis a, b or c, respectively. After defining all possible lattice planes hkl, 
normals to these lattice planes are constructed. Each normal terminates at a point of 
distance 1/dhkl from the origin O where the interplanar distance vector dhkl is perpendi-
cular distance between two lattice planes of a given set of lattice planes hkl. Such a 
termination point represents a set of direct lattice planes and is defined as a reciprocal 
lattice point. The reciprocal lattice points are assigned the indices of the direct planes 
they represent. Together, the reciprocal lattice points constitute the reciprocal lattice. 
Having constructed the reciprocal space, it is easier to describe the geometric conditions 
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under which a diffraction event occurs. As described previously, diffraction can only 
occur if the Bragg equation nλ = 2dhkl sin θ is satisfied. The equation can be rewritten to 
?⃗? 𝒉𝒌𝒍
∗ = 𝟏 ?⃗? 𝒉𝒌𝒍⁄ =  𝟐𝒔𝒊𝒏𝜽/𝒏𝝀      (2)  
because the magnitude of each reciprocal lattice vector d*hkl, connecting the origin O 
with a reciprocal lattice point hkl, is reciprocal to the interplanar distance vector dhkl. 
The nth-order diffraction condition can be interpreted as diffraction originating from an 
n-times higher order set of lattice planes. Therefore, n can be eliminated from the equa-
tion (Rupp, 2009). For n = 1, the Bragg equation can be rewritten to  
?⃗? 𝒉𝒌𝒍
∗ = 𝟐𝒔𝒊𝒏𝜽 𝝀⁄         (3)  
This form of the Bragg equation can easily be visualized geometrically by the Ewald 
construction (simplified in Figure 17). 
 
 
Figure 17: The Ewald construction. The incident beam (grey) is passing through the crystal (green). 
The crystal’s reciprocal lattice is shown in black with blue lattice points. Around the crystal, the 
Ewald’s sphere is constructed with a radius r = 1/λ, passing through the origin O. If a reciprocal lattice 
point hkl (for instance 210) coincides with the Ewald’s sphere, the Bragg equation is satisfied and con-
structive interference is observed under the scattering angle 2θ. This means, that a reflection hkl can 
be observed on the detector, which represents the scattering from the set of direct crystal planes. 
       
In order to describe a condition under which diffraction occurs, a simplified two-dimen-
sional Ewald construction is used (Figure 17). First, the crystal is represented by its reci-
procal lattice. An origin O is chosen in the reciprocal lattice. The origin O is hit by the inci-
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dent beam. An Ewald’s circle (sphere in 3D) with the radius r = 1/λ, centered on the X-
ray beam, passes through the origin O. If a reciprocal lattice point coincides with the 
Ewald’s circle (sphere), for instance 210 or 310 in Figure 17, the condition of the Bragg 
equation is satisfied and constructive interference is observed under the scattering angle 
2θ. Hence, a reflection is detected for these reciprocal lattice points, each representing a 
set of direct lattice planes. The intensity of the observed reflection depends on the elec-
tron distribution on the respective set of lattice planes. 
The protein crystal is rotated during X-ray data collection. Hence, the Ewald’s sphere can 
potentially intersect with each reciprocal lattice point hkl with, thereby producing a re-
flection hkl on the detector. As the diffraction experiment proceeds, theoretically every 
possible reciprocal lattice point can produce a reflection on the X-ray detector. However, 
the maximum resolution of a crystal at a given wavelength λ is defined if the Bragg 
equation is rewritten to 
𝒅𝒎𝒊𝒏 =  𝒏𝝀/𝟐𝒔𝒊𝒏𝜽𝒎𝒂𝒙       (4)  
The maximum of diffraction angle θmax is 90°, hence the maximum of sin θ is 1. For n = 
1, the Bragg equation can be written as  
𝒅𝒎𝒊𝒏 = 𝝀 𝟐⁄         (5) 
This equation explains why X-rays (λ = 0.1 - 100 Å) are required to visualize the molecular 
detail of proteins (bond lengths are usually in the range of a few angstroms). The crys-
tal’s resolution, meaning the distance between two points in a crystal that can be distin-
guished, can alternatively be described as determined by the distance dhkl between two 
lattice planes belonging to the same set of lattice planes. This means, that the resolution 
for each reflection hkl is determined by the corresponding interplanar distance dhkl. The 
higher the reflection indices hkl, the smaller is the distance dhkl and thus, the finer is the 
structural detail that can be observed. 
 
4.4 The Crystallographic Phase Problem and Its Solution 
4.4.1 The Phase Problem 
Protein structure determination using crystallography relies on X-ray “light”. Light can be 
described as a wave, using the wave vector s0. Waves have a periodic character, and can 
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thus be described as complex numbers (Figure 18). This description helps to understand 
a central problem in protein crystallography, the crystallographic phase problem. If 
waves are described as complex numbers, they are defined by an amplitude |F| and a 
phase angle ϕ.  
 
 
Figure 18: X-ray waves in the complex number plane. A: In the complex number plane, an X-ray wave 
is described by the vector F. F is formed by a real part A and an imaginary component B. The length of 
F is given by the amplitude |F| and its direction is given by the phase angle ϕ. B: The interference of 
two X-ray waves described by vectors F1 and F2 results in a wave described by vector F3. 
 
In the complex number plane, an X-ray wave is described by the vector F with a length of 
|F| and a phase angle ϕ (Figure 18A). The vector F is the sum of the real part A and the 
imaginary component B (the latter multiplied with the imaginary number i). Using trigo-
nometry, the real part A of the vector F is equal to |F|cos ϕ and the imaginary compo-
nent B is equal to |F|sin ϕ. Hence, F can be written as   
?⃗? = |?⃗? | 𝐜𝐨𝐬𝝋 + |?⃗? |𝒊 𝐬𝐢𝐧𝝋       (6)  
Additionally, the complex number plane can be used to describe the interference of two 
X-ray waves (Figure 18B). The vectors F1 and F2 describing these two X-ray waves add up 
to a new vector F3. For instance, X-ray waves are scattered on different electrons of the 
same atom. The scattered waves have to be added up to define the entire scattering of 
the electron shell of this atom. This addition results in the atomic scattering factor fS 
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which is a result of the integration over the entire volume of the atom. Thus, the atomic 
scattering factor fS is defined by the function FS as 
𝑭𝑺 = 𝒇𝑺 = ∫ 𝝆(𝒓)𝒆
𝟐𝝅𝒊?⃗? ?⃗? 𝑽
?⃗? 
𝒅?⃗?        (7)  
when V is the volume of the atom, r is any given position in the atom, ρ(r) is the electron 
density, and S is the difference between the vectors s0 (describing incident X-ray wave) 
and s1 (describing the scattered X-ray wave). However, a protein consists of many atoms, 
and the unit cell of a protein crystal may be formed by more than one protein molecule. 
Thus, the waves scattered by all electrons in the molecule add up to  
?⃗? ?⃗? = ∑ 𝒇?⃗? ,𝒋𝒆
𝟐𝝅𝒊?⃗? ?⃗? 𝒋
𝒋         (8)  
for an entire unit cell, when j is the atoms contributing to the intensity of the scattered 
wave, fS,j is the scattering factor of an atom j, and 2πSrj is the relative phase each contri-
bution to the scattering factor, with rj as the position vectors of all atoms. This equation 
can be reformulated for reciprocal space using the reciprocal Miller indices hkl (as vector 
h) for substitution of the scattering vector S as well as fractional coordinates xyz (as vec-
tor x) for substitution of the position vector r. This substitution results in the structure 
factor Fh expressed as a function of the index vector h 
?⃗? ?⃗? = ∑ 𝒇?⃗? ,𝒋𝒆
𝟐𝝅𝒊?⃗? ?⃗? 𝒋
𝒋         (9)  
of a reflection h. In order to include the entire content of the unit cell, it is written as in-
tegration over the whole unit cell volume 
?⃗? ?⃗? = 𝑽∫ 𝝆(?⃗? )
𝟏
𝒙=𝟎
 𝒆𝟐𝝅𝒊?⃗?
 ?⃗? 𝒋𝒅?⃗?       (10) 
The structure factor Fh is a Fourier transform of the electron density ρ(x). If all structure 
factors Fh are Fourier-transformed together, this results in the electron density 
𝝆(?⃗? ) =
𝟏
𝑽
∑ ∑ ∑ ?⃗? ?⃗? 𝒆
−𝟐𝝅𝒊(𝒉𝒙+𝒌𝒚+𝒍𝒛)
𝒍𝒌𝒉      (11) 
However, as the X-ray wave, a structure factor Fh is a complex number. When X-ray 
waves hit a protein crystal, the intensities Ih of the X-ray waves are recorded on a detec-
tor as reflections hkl. The intensity Ih of each reflection hkl is equal to the square product 
of the respective structure factor Fh, meaning  
𝑰?⃗? = ?⃗?
 
?⃗? ?⃗?
 
?⃗? 
∗         (12) 
using a simplified description or, because Fhkl  is a complex number, 
𝑰?⃗? = |?⃗?
 
?⃗? |𝒆
𝒊𝒂𝒉𝒌𝒍|?⃗? 
?⃗? 
∗ |𝒆−𝒊𝜶𝒉𝒌𝒍      (13) 
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where |Fh| is the amplitude (the real part) and iαh is the phase (imaginary component) of 
the structure factor Fh. Complex conjugation of the vectors and subsequent multiplica-
tion eliminate the phase information from the intensity Ih. Thus, the Ih only contains in-
formation on the structure factor amplitude |Fh|. This crystallographic phase problem is 
also explained by the centrosymmetry of the diffraction pattern.  
 
4.4.2 Diffraction Data Quality 
The correct interpretation of the electron map is crucial to obtain a reasonable structural 
model. However, the quality of the collected X-ray diffraction data is a deciding factor in 
protein structure determination. For this purpose, data quality is already monitored 
during data collection using mathematical parameters and crystallographic R-factors. 
Among the mathematical parameters, the signal to noise ratio (I/σ(I)), the complete-
ness of the data (every unique reflection hkl has been collected) and the multiplicity or 
redundancy N (how often every unique reflection hkl has been recorded) are essential to 
define a resolution cutoff and assess the data quality. For instance, the R-factor  
𝑹 = ∑ ∑ |𝑰𝒉𝒌𝒍,𝒋 − 〈𝑰𝒉𝒌𝒍〉|𝒋𝒉𝒌𝒍 ∑ ∑ 𝑰𝒉𝒌𝒍,𝒋𝒋𝒉𝒌𝒍⁄     (14) 
is such a measure of data quality. However, the R-factor increases with increasing redun-
dancy. This increase is contradictory to the fact that higher redundancy should ensure 
more accurate data and therefore higher data quality, because every reflection is col-
lected several times. Thus, a redundancy-independent version of the R-factor called Rmeas 
can be calculated using 
𝑹𝒎𝒆𝒂𝒔 = ∑ √𝑵 𝑵 − 𝟏⁄𝒉𝒌𝒍 ∑ |𝑰𝒉𝒌𝒍,𝒋 − 〈𝑰𝒉𝒌𝒍〉|
𝑵
𝒋=𝟏 ∑ ∑ 𝑰𝒉𝒌𝒍,𝒋𝒋𝒉𝒌𝒍⁄   (15) 
where <Ihkl> is the average of symmetry-related observations of a unique reflection. Cal-
culation of Rmeas however, results in higher, but more realistic, numerical values than 
Rmerge (Diederichs & Karplus, 1997).  
In recent years, new R-factors have been developed. One of these R-factors is Rp.i.m.  
𝑹𝒑.𝒊.𝒎. = ∑ √𝟏 𝑵 − 𝟏⁄𝒉𝒌𝒍 ∑ |𝑰𝒉𝒌𝒍,𝒋 − 〈𝑰𝒉𝒌𝒍〉|
𝑵
𝒋=𝟏 ∑ ∑ 𝑰𝒉𝒌𝒍,𝒋𝒋𝒉𝒌𝒍⁄   (16) 
which is the precision-indicating merging R-factor of averaged intensities (Weiss, 2001).  
Rp.i.m. takes into account the improvement in precision from multiplicity and is a well-
established R-factor in modern crystallography. 
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4.4.3 Crystallographic Phasing Techniques  
The crystallographic phase problem, meaning the loss of phase information during data 
collection, has to be overcome to determine the molecular structure of a protein of inte-
rest. For this purpose, the phase information has to be acquired otherwise and fed into 
the electron density calculations. Three fundamental phasing techniques are known, 
namely experimental phasing using anomalous scatterers, molecular replacement and di-
rect phasing. While the latter is almost impossible to be used for proteins, the first two 
methods are frequently used in protein crystallography.  
 
4.4.3.1 Molecular Replacement 
Most of the protein structures determined are deposited in the Protein Data Bank (PDB, 
Berman et al., 2000), which has grown to more than 105 000 entries in early 2015. How-
ever, the number of distinct protein folds is not growing as fast. This is probably due to 
the fact that nature only has evolved a limited number of protein folds. The number of 
folds known to date varies between 1205 (SCOPe Database 2.04, July 2014) and 1375 
(CATH Database 4.0, March 2013), although these calculations do not include all entries 
in the PDB (Sillitoe et al., 2013; Fox et al., 2014). Hence, if the structure of a protein of in-
terest is to be determined, it is likely that a protein of similar fold has already been depo-
sited in the PDB. Proteins are usually classified as similar, if their structures have a root 
mean square deviation (r.m.s.d.) of less than 1.5 Å or if their sequences are more than 
30% identical. If a similar protein has been identified, it may serve as the search model in 
molecular replacement (MR). In the process of MR, the phases of the search model are 
borrowed to determine the phase of protein structure of interest. For this purpose, a 
calculated electron density is transformed into theoretical structure factors and intensi-
ties, which are then compared with the experimental data. However, the orientation of 
the protein molecule within the unit cell is unknown. For this reason, first a rotational 
search is performed. Then a translational search is used to define the exact position and 
orientation of the structure in the asymmetric unit. A correct MR solution is identified 
using mathematical parameters as the correlation coefficient, the R factor or the z-
score. Additionally, the MR solution can be validated by inspection of the crystal packing 
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and the electron density. Finally, the solution is subjected to the model building and re-
finement process. 
If MR using a single, unmodified MR search model is not successful, it is possible to 
optimize the MR process. The search model can be modified, for instance by side chain 
deletion, or multiple models can be generated. For this purpose, MR engines such as 
BALBES (Long et al., 2007) or MrBump (Keegan & Winn, 2008) have been developed re-
cently. These engines scan the sequence of interest against a PDB-derived database and 
derive appropriate search models for MR.  
    
4.4.3.2 Isomorphous Replacement and Anomalous Diffraction 
If no suitable MR model is available, the phase information for structure determination 
of the protein of interest has to be acquired otherwise. This can be accomplished by ex-
perimental phasing, which is dependent on heavy atoms introduced into the crystal. 
Experimental phasing can be achieved using either single or multiple isomorphous re-
placement (SIR or MIR). Both SIR and MIR are dependent on successful derivatization of 
a protein crystal with heavy atoms, which may be difficult. The more electrons the heavy 
atom possesses, the more suitable it is for SIR and MIR techniques. For instance, mer-
cury salts that modify cysteine residues are used for derivatization. Derivatization is not 
supposed to affect the crystal contacts or unit cell parameters, meaning that the native 
and derivative crystals are isomorphous, in order to successfully phase the structure 
later on. The molecular structure of the protein can then be determined by first subtrac-
ting the diffraction patterns of the native and the derivative crystal, and then calculating 
Patterson map from this difference. This approach will yield the position of the heavy 
atoms. When using SIR, one native and only one derivative crystal are needed, but the 
phase information will be ambiguous. When using MIR, more than one derivative crystal 
is needed in addition to the native crystal. In contrast to SIR, experimental phasing with 
MIR will lead to unambiguous phase information. However, SIR and MIR have largely 
been replaced by single and multiple anomalous diffraction (SAD and MAD) techniques 
in the last decades. Originally, SAD and MAD were invented out of necessity 
(Hendrickson, 1985). Today, SAD is particularly used on selenomethionine-derivatized 
crystals or for sulfur phasing using the protein’s intrinsic sulfur atoms. Nevertheless, 
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heavy atom derivatives are still used, and in some cases, an intrinsic catalytic ion, for in-
stance Fe(II) or Zn(II), can be used in these phasing techniques. SAD and MAD phasing 
take advantage of the centrosymmetry of the diffraction pattern. Friedel’s law 
𝑰𝒉𝒌𝒍 = ?⃗? 𝒉𝒌𝒍?⃗? 𝒉𝒌𝒍
∗ = ?⃗? −𝒉−𝒌−𝒍?⃗? −𝒉−𝒌−𝒍
∗ = 𝑰−𝒉−𝒌−𝒍   (17) 
states that a reflection hkl has the same intensity I as its centrosymmetrically related re-
flection -h-k-l, because hkl and -h-k-l are reflections of the same set of lattice planes. 
These symmetry-related reflections are called Friedel or Bijvoet pairs (Figure 19A). Frie-
del’s law only holds if the structure factors FS are real functions. In contrast, Friedel’s law 
is false if the diffraction data is collected at an X-ray absorption edge of an anomalous 
scatterer (Figure 19B). 
 
 
Figure 19: Friedel’s Law. A: Representation of a Friedel pair in the complex number plane. Two reflec-
tions hkl and -h-k-l (a Friedel pair) have the same intensity Ihkl if their structure factors are real 
functions. Friedel pairs are reflections originating from the same set of lattice planes, but from mir-
rored direction. B: An X-ray absorption scan (upper black curve) yields f′′ and can be used to derive f′. 
The negative peak of the f′ function coincides with the inflection point (blue circle) of the f′′ function. 
The largest anomalous differences can be obtained from data collected at the absorption peak 
wavelength. Figure B adapted from (Rupp, 2009) 
 
At X-ray absorption edges of anomalous scatterers, wavelength-dependent changes in 
the atomic scattering factor fS occur and can be described as  
𝒇(?⃗? ,𝝀) = 𝒇(?⃗? )
𝟎 + 𝒇′(𝝀) + 𝒊 · 𝒇′′(𝝀)      (18) 
where f′(λ) is the dispersive and f′′(λ) is the anomalous contribution to the structure factor. 
Both f′(λ) and f′′(λ) can be determined experimentally by an X-ray absorption scan, using 
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the tunable wavelength of a synchrotron source (Figure 19B). The phase shift Δϕ for f′(λ) 
(Δϕ = 90°) breaks down Friedel symmetry and enables the observation of anomalous 
differences in the dataset (Figure 20A-C).  
  
 
Figure 20: Friedel's law and its breakdown. FP/F-P is the contribution of the protein to the scattering, 
FA/F-A is the contribution of the anomalous scatterer and FPA/F-PA is the contribution of both. A: 
Friedel’s law is true if there are no anomalous scatterers. The structure factors FS are real functions 
and FPA is equal to F-PA. B: In the presence of an anomalous scatterer, changes in the atomic scatter-
ing factor fS occur and f′ and f′′ contribute to the scattering. Because f′′ contributes with Δϕ = 90°, 
anomalous differences can be observed in the data. C: When anomalous scattering occurs, FPA is not 
equal to F-PA anymore. D & E: Harker constructions yield two solutions for the phase (red arrows) and 
hence for the position of the anomalous scatterers. One of these solutions can be excludes after 
refinement because it will not lead to decreasing R-factors.    
 
For SAD phasing, it is crucial to obtain the maximal signal of the anomalous contribution 
f′′(λ). For this purpose, e. g. a dataset for selenium SAD should be collected at the peak 
wavelength, meaning at 0.9795 Å / 12.6578 keV for the selenium K-edge. For MAD 
phasing, after the peak dataset, the next dataset to be collected is the inflection data set 
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which maximizes the signal of f′(λ) (Figure 19B). Finally, a high energy remote dataset is 
collected, containing information on both f′(λ) and f′′(λ).  
The anomalous differences can be used to determine the positions of the anomalous 
scatterers in the unit cell. The most powerful tool to use is the Patterson function 
𝑷(?⃗? ) = 𝝆(?⃗? ) ∙ 𝝆(−?⃗? ) =
𝟏
𝑽
∑ ∑ ∑ |?⃗? 𝒉𝒌𝒍|
𝟐𝒆−𝟐𝝅𝒊(𝒉𝒙+𝒌𝒚+𝒍𝒛)𝒍𝒌𝒉   (19) 
This function can directly be calculated from the measured intensities, meaning that no 
prior phase information is needed. The Patterson function is centrosymmetric because it 
describes the autocorrelation of the electron density convoluted with its inverse. The 
function shows vectors between atoms in the unit cell. However, if there are N atoms in-
side the unit cell, there are N*(N-1) vectors between them. As only the positions of the 
heavy atoms should be considered in the Patterson map, the problem is simplified by 
calculating a difference Patterson map using 
∆𝑷(?⃗? ) =
𝟏
𝑽
∑ ∑ ∑ (|∆?⃗? 𝑷𝑨| − |∆?⃗? 𝑷|)
𝟐𝒆−𝟐𝝅𝒊(𝒉𝒙+𝒌𝒚+𝒍𝒛)𝒍𝒌𝒉   (20) 
with the intensities obtained from the native dataset, and subtracting them from the de-
rivative dataset. By doing so, only the anomalous scatterers are taken into account and 
there are only few peaks in the Patterson map. Using these peaks, the relative positions 
of the anomalous scatterers in the unit cell can be calculated. 
  
4.5 Model Building and Refinement  
Once the electron density has been obtained by experimental phasing or MR, it can be 
visualized by model building programs. These programs allow the interpretation of the 
electron density map. Thus, a structural model can be placed into the electron envelope. 
In this process, knowledge about proteins in general as well as about the protein of 
interest is applied to build the structural model. This knowledge includes the protein 
sequence, the geometry of single amino acids (e. g. proteins only consist of L-amino 
acids) as well as bonds between them (e. g. all peptide bonds are planar). The unique 
shape of the electron envelope may help to identify bulky amino acids like tryptophan or 
secondary structure elements, which underlie distinct geometry restraints. Similar to 
helices and β-sheet, loops adopt energetically favorable conformations, and the amino 
acids in the protein are usually present as their preferred rotamers. In recent years, the 
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initial rounds of manual model building are being replaced by automated model 
building, aided by computer programs. However, automated model building cannot 
completely replace manual model building done by a scientist. The reason for this is that 
such programs only work successfully under certain conditions, for instance a resolution 
of at least 2.7 Å or higher and good-quality initial phases.  
In the next step, computer-assisted refinement calculations optimize the geometry of 
the model, temperature factors and occupancies. For this purpose, a theoretically expec-
ted set of structure factors Fcalc is calculated from the model. Then, the structural model 
is refined against the experimentally observed structure factors Fobs. In the process, the 
structure factor amplitudes |Fcalc| and |Fobs| are constantly compared and their differen-
ces are minimized, guiding the structure towards a global minimum. Additionally, the re-
finement progress is monitored by the R-factor  
 𝑹 = ∑ ||?⃗? 𝒐𝒃𝒔| − 𝒌|?⃗? 𝒄𝒂𝒍𝒄||𝒉𝒌𝒍 ∑ |?⃗? 𝒐𝒃𝒔|𝒉𝒌𝒍⁄     (21) 
where k is a scaling factor. In order ensure correct structure optimization, 5% of the re-
flections are selected for the Rfree calculations (equation 21) and thus not included into R-
factor calculations. Only if both R-factor and Rfree decrease, the structure refinement is 
successful. In some cases, the refinement process is additionally facilitated by density 
modification or non-crystallographic symmetry (NCS). For instance, if there is more than 
one copy of a molecule in the asymmetric unit, the copies are related to each other 
using NCS operators. By defining an NCS mask around the molecule and using the NCS 
operator, the electron density can then be improved by NCS averaging.  
The structural model is optimized in alternating refinement and model building steps. In 
the next model building step, two types of electron density can be displayed. First, 
(2m|Fobs|-D|Fcalc|)eiαcalc density is displayed at 1σ. This density surrounds the whole struc-
tural model in areas where |Fobs| is equal to |Fcalc|. Second, positive (m|Fobs|-D|Fcalc|)eiαcalc 
electron density shows that additional features need to be added to the model, for 
instance side chains or ions, while negative (m|Fobs|-D|Fcalc|)eiαcalc density shows parts of 
the structure that are incorrectly modeled. Thus, these densities aid to build a correct 
structural model.  
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5 Materials and Methods 
5.1 Chemicals, Solutions and Materials 
5.1.1 Chemicals 
If not indicated differently, all chemicals were purchased in the highest purity available 
(p. a., pro analysis) from the companies AppliChem (Darmstadt, Germany), Fluka (Seelze, 
Germany), Merck (Darmstadt, Germany), Qiagen (Hilden, Germany), Roth (Karlsruhe, 
Germany) and Sigma-Aldrich (Deisenhofen, Germany). Bleomycin was acquired as Bleo-
medac® from medac GmbH (Wedel, Germany). 
 
5.1.2 Buffers, Media and Stock Solutions 
Buffers and stock solutions were prepared in ddH2O and filter sterilized. Media were au-
toclaved. Buffers used for protein preparation and ITC experiments were degased. Anti-
biotics were used at concentrations of 100 µg/mL ampicillin, 34 µg/mL chloramphenicol, 
12 µg/mL gentamicin and 20 µg/mL tetracycline. Stock solutions of hydrophobic ligands 
were prepared in 100% DMSO, stock solutions of hydrophilic ligands were prepared in 
H2O or 20 mM Tris/HCl pH 8, 150 mM sodium chloride. 
 
DNA Isolation  
Genomic DNA buffer 0.8 mL of 20% (w/v) sucrose, 50 mM Tris/HCl pH 8; 15 µL 
of 10 mg/mL lysozyme; 15 mg/mL proteinase K; 40 µL 10% 
(w/v) sodium dodecyl sulfate (SDS) 
Agarose Gel Electrophoresis  
50x TAE buffer 242 g Tris, 57.1 mL glacial acetic acid, 100 mL 0.5 M EDTA 
pH 8 in 1 L ddH2O 
1% agarose solution 1 g agarose in 100 mL of 1x TAE buffer 
DNA Standard 100 bp DNA Ladder Plus, Peqlab 
  1 kb DNA Ladder, New England Biolabs 
  Gene Ruler DNA Ladder Mix, Thermo Scientific 
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DNA sample buffer 40% glycerol, 0,25% bromophenol blue 
Media 
LB agar (pH 7,4)  10 g/L NaCl, 10 g/L bacto tryptone, 5 g/L yeast extract, 15 
g/L agar 
LB medium (pH 7,4)  10 g/L NaCl, 10 g/L bacto tryptone, 5 g/L yeast extract 
5x M9 salts 64 g/L Na2HPO4 x 7 H2O, 15 g/L KH2PO4, 5 g/L NH4Cl, 2.5 
g/L NaCl in 1 L ddH2O 
Glucose-salt stock 10 mL 20% (w/v) glucose, 2 mL 1 M MgSO4, 50 µL 1 M 
CaCl2 
M9-Agar  63,5 ml 2x agar (30 g/L), 25 mL 5x M9 salts, 34.5 mL 
ddH2O, 3 mL glucose-salt stock 
Purification 
Buffer A 300 mM NaCl, 50 mM Na2HPO4/NaH2PO4 pH 8 
Buffer B 500 mM imidazole in buffer A 
Dialysis buffer  150 mM NaCl, 20 mM Tris/HCl pH 8 
TEV cleavage buffer dialysis buffer with 2 mM β-mercapto-ethanol (βME) 
SEC buffer 150 mM NaCl, 20 mM Tris/HCl pH 8 
SDS-PAGE 
4x stacking gel buffer  0.5 M Tris/HCl, 0.4% SDS, pH 6.8  
Stacking gel (5%)  5.8 mL ddH2O, 2.5 ml 4x stacking gel buffer, 1.7 mL 30% 
(w/v) acrylamide (37.5:1), 100 μL 10% (w/v) APS, 10 μL 
TEMED  
4x resolving gel buffer  1.5 M Tris/HCl pH 8.8, 0.4% (w/v) SDS  
Resolving gel (16%)  3.9 mL H2O, 4.5 mL 4x resolving gel buffer, 9.6 mL 30% 
(w/v) acrylamide (37.5:1), 200 μL 10% APS, 20 μL TEMED  
Resolving gel (18%)  2.6 mL H2O, 4.5 mL 4x separating gel buffer, 10.8 mL 30% 
(w/v) acrylamide (37.5:1), 200 μL 10% (w/v) APS, 20 μL 
TEMED 
5x SDS-PAGE sample buffer 50 mM Tris/HCl pH 6.8, 500 mM βME, 50% (v/v) glycerol, 
10% (w/v) SDS, 0.05% (w/v) bromophenol blue 
Running buffer  25 mM Tris/HCl, 200 mM glycine, 0.1 % (w/v) SDS  
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Staining solution  0.2% (w/v) Coomassie Brilliant Blue, 30% (v/v) methanol, 
10% (w/v) acetic acid 
Destaining solution  20% (v/v) methanol, 10% (v/v) glacial acetic acid 
Protein Standard Protein Marker I, 14.4-116 kDa, Peqlab 
Unstained Protein Molecular Weight Marker, Fermentas 
 
5.1.3 Oligonucleotides 
Oligonucleotides used in this study (Table 1) were designed using OligoCalc (Kibbe, 2007) 
and ordered from MWG Eurofins (Munich, Germany). Melting temperatures were calcu-
lated using the nearest neighbor method. The ORFs of the proteins were amplified using 
these oligonucleotides either on P. aeruginosa genomic DNA or on plasmid DNA con-
taining the ORF. Sequences of the ORFs were taken from the Pseudomonas Genome 
Database (Winsor et al., 2011). 
 
Table 1: Oligonucleotides used for cloning and sequencing. Endonuclease restriction sites are listed in 
bold, stop codons are underlined.  
Oligonucleotide Sequence 5’→ 3’ Target vector 
PA0803_NcoI_s AAA TTC CCA TGG ACA CGC CCG CCA GCA ACA pHERD30T 
PA0803_HindIII_as ACG GTC AAG CTT TCA TGC CCA GGG ATC ATA G pHERD30T 
PA0880_NdeI_s ATA GCT CAT ATG CAG ATC GAC CGT CTC GAC pET19m 
PA0880_BamHI_as ATT AAA GGA TCC TTA CAG CGG GTT GCT CAG TTC pET19m 
PA1353_NdeI_s ACC GTC CAT ATG CAA ATC GTC CCC TAC CTG ATC TT pET19m 
PA1353_XhoI_as ATT TTA CTC GAG CTA CCG GTC CTG CTC CTC GCA pET19m 
PA1353_NcoI_s ACC GTC CCA TGG AAA TCG TCC CCT ACC TGA TCT T pHERD30T 
PA1353_HindIII_as ATT CTA AAG CTT CTA CCG GTC CTG CTC GCA  pHERD30T 
PA1354_NdeI_s ATC CCA CAT ATG AGA TTC ATG GTG ATC GTC AAG GC pET19m 
PA1354_XhoI_as TCT CTT CTC GAG TCA GTT GCG TTT TTC CAG CTC pET19m 
PA3127_NcoI_s AAT ATC CCA TGG TGG AAC GCG CAA TCC CGA pHERD30T 
PA3127_HindIII_as AA GTC AAG CTT TCA GTA GCG AGT GAA GGT CA pHERD30T 
PA3128_XhoI_as TAT AAT CTC GAG CTA TCG TCC TCC GCT GAC ATC pET19m 
PA4183opt_NdeI_16s AGC TGT CAT ATG TCC CAA CCG TTT CTG TGG CGT pET19m 
PA4183opt_NdeI_32s CCT ATC CAT ATG GCC GAA CCG CGT GTG TTC ATT C pET19m 
PA4183opt_XhoI_as TGG CAA CTC GAG TTA TGC TTC GCC CGG TTG C pET19m 
PA4518opt_NdeI_s AAT GTC CAT ATG ACC GGT AAT GGT GTT AGC CTG GT pET19m 
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Oligonucleotide Sequence 5’→ 3’ Target vector 
PA4518opt_XhoI_as AAT GTC CTC GAG ATT CGG CAG CAC CAG ATT pET19m 
PA4518opt_QC_s AAT CTG GTG CTG CCG TAA CTC GAG GGA TCC GGC pET19m_PA4518 
PA4518opt_QC_as GCC GGA TCC CTC GAG TTA CGG CAG CAC CAG ATT pET19m_PA4518 
PA4641_NdeI_s ATA GCT CAT ATG TAC GTC CAG CCC TAC GTC TGC pET19m 
PA4641_XhoI_as AAT TTT CTC GAG TCA TGC TCC TGC CTC GCA pET19m 
PA4641_PciI_s ATA GCA ACA TGT ACG TCC AGC CCT ACG TCT G pHERD30T 
PA4641_HindIII_as AAT GTT AAG CTT TCA TGC TCC TGC CTC GCA  pHERD30T 
T7_s TTAATACGACTCACTATAGGGGAA pET19m 
T7_as CTAGTTATTGCTCAGCGGTGG pET19m 
pHERD_SF ATC GCA ACT CTC TAC TGT TTC T pHERD30T 
pHERD_SR TGC AAG GCG ATT AAG TTG GGT pHERD30T 
 
5.1.4 Plasmids and Constructs 
All plasmids used and constructs used in this study are listed in Table 2. Constructs 
cloned into pET19m or pOPINF are produced with an N-terminal His6-tag and a tobacco 
etch virus (TEV) protease cleavage site if not indicated differently. 
 
Table 2: Vectors constructed and used in this study. The vector pET19m_PA3127_PA3128 contains the 
dicystronic operon, amplified from P. aeruginosa PAO1 genomic DNA. DPF = Dortmund Protein Facility, 
MPI = Max Planck Institute. 
Plasmid  Purpose Host Source 
pET19m Cloning E. coli MPI Dortmund 
pET19m_PA0803 Cloning, Protein Production,  
Spot Plates 
E. coli Yu, 2009 
pET19m_PA0880 Protein Production E. coli this study 
pET19m_PA1353 Protein Production, Spot Plates E. coli this study 
pET19m_PA1354 Protein Production E. coli this study 
pET19m_PA1672 Protein Production E. coli Weber, 2011 
pET19m_PA3127 Protein Production, Spot Plates E. coli Bittner, 2012 
pET19m_PA3127_1-114 Protein Production, Spot Plates E. coli Popp, 2013 
pET19m_PA3127_123-267 Protein Production, Spot Plates E. coli Popp, 2013 
pET19m_PA3127_PA3128 Spot Plates E. coli this study 
pET19m_PA4183opt Protein Production E. coli this study 
pET19m_PA4183opt_16-155 Protein Production E. coli this study 
pET19m_PA4183opt_32-155 Protein Production E. coli this study 
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Plasmid  Purpose Host Source 
pET19m_PA4518 Protein Production E. coli this study 
pET19m_PA4641 Protein Production, Spot Plates E. coli this study 
pHERD30T Cloning, Spot Plates P. aeruginosa Qui et al., 2008 
pHERD30T_PA0803 Spot Plates P. aeruginosa this study 
pHERD30T_PA1353 Spot Plates P. aeruginosa this study 
pHERD30T_PA3127 Spot Plates P. aeruginosa this study 
pHERD30T_PA4641 Spot Plates P. aeruginosa this study 
pOPINF_PA1353 Cloning E. coli DPF, MPI Dortmund 
pOPINF_PA4641 Cloning E. coli DPF, MPI Dortmund 
pMA-T_PA4518opt Cloning E. coli GeneArt, Regensburg 
pUC57_PA4183opt Cloning E. coli GeneScript, Piscataway, 
NJ, U.S.A. 
 
Further plasmids constructed in this study can be found in Table 45 in the appendix.  
 
5.1.5 Microorganisms 
All microorganisms and generated strains used for the experiments conducted in this 
study are listed in Table 3.  
 
Table 3: Microorganisms used in this study. P. aeruginosa mutants are transposon insertion mutants 
available from a PAO1 or a PA14 transposon library (Liberati et al., 2006; Held et al., 2012). 
Bacterial Strain Antibiotic Resistance Purpose Source 
E. coli DH5α - Cloning Invitrogen 
E.coli TOP10 Streptomycin Cloning Invitrogen 
E.coli XL1-Blue Tetracycline Cloning Stratagene 
E. coli BL21(DE3) - Protein Production Novagen 
E. coli BL21 (DE3) Codon+ Chloramphenicol Protein Production Novagen 
E. coli BL21 (DE3) pLysS  Chloramphenicol Protein Production Novagen 
E. coli Rosetta 2 Chloramphenicol Protein Production Novagen 
P. aeruginosa PAO1 wild type - Spot Plate Assay Collaborator 
P. aeruginosa PAO1 pHERD30T Gentamicin Spot Plate Assay this study 
P. aeruginosa PAO1 pHERD30T_PA0803 Gentamicin Spot Plate Assay this study 
P. aeruginosa PAO1 pHERD30T_PA1353 Gentamicin Spot Plate Assay this study 
P. aeruginosa PAO1 pHERD30T_PA3127 Gentamicin Spot Plate Assay this study 
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Bacterial Strain Antibiotic Resistance Purpose      Source 
P. aeruginosa PAO1 pHERD30T_PA4641 Gentamicin Spot Plate Assay this study 
P. aeruginosa PAO1 Δ1353 ID 13110 Tetracycline Spot Plate Assay Held et al., 2012 
P. aeruginosa PAO1 Δ1353 ID 48549 Tetracycline Spot Plate Assay Held et al., 2012 
P. aeruginosa PAO1 Δ4641 ID 11551 Tetracycline Spot Plate Assay Held et al., 2012 
P. aeruginosa PAO1 Δ4641 ID 48777 Tetracycline Spot Plate Assay Held et al., 2012 
P. aeruginosa PA14 wild type - Spot Plate Assay Collaborator 
P. aeruginosa PA14 Δ0803 ID 46327 Gentamicin Spot Plate Assay Liberati et al., 2006 
P. aeruginosa PA14 Δ3127 ID 05812 Gentamicin Spot Plate Assay Liberati et al., 2006 
P. aeruginosa PA14 Δ3127 ID 25570 Gentamicin Spot Plate Assay Liberati et al., 2006 
P. aeruginosa PA14 Δ3127 ID 37013 Gentamicin Spot Plate Assay Liberati et al., 2006 
 
5.1.6 Enzymes 
All restriction endonucleases (BamHI, HindIII, NcoI, NdeI, PciI, XhoI), Phusion DNA Poly-
merase, Taq Polymerase, Antarctic Phosphatase as well as T4 DNA Ligase were ordered 
from New England Biolabs (Ipswich, MA, U.S.A.). KAPAHiFi Polymerase was purchased 
from Peqlab (Erlangen, Germany). TEV protease was produced in the laboratory from 
plasmid pHR-MBP_TEV (DPF, MPI Dortmund) as His6-MBP-TEV and purified via Ni(II)-
immobilized metal ion affinity chromatography (Ni(II)-IMAC).  
 
5.1.7 Columns  
HisTrap™ HP 5 mL column    GE Healthcare, Munich, Germany  
HiLoad™75 16/60 Superdex™75 prepgrade   GE Healthcare, Munich, Germany  
HiLoad™75 26/60 Superdex™75 prepgrade   GE Healthcare, Munich, Germany  
Superdex™ 75 10/300 GL      GE Healthcare, Munich, Germany  
Superdex™ 200 10/300 GL      GE Healthcare, Munich, Germany  
 
5.1.8 Kits  
Molecular Biology Kits 
E.Z.N.A.® Gel Extraction Kit Omega bio-tek, Norcross, GA, U.S.A.  
E.Z.N.A.® Cycle Pure Kit Omega bio-tek, Norcross, GA, U.S.A.   
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E.Z.N.A.® Plasmid Mini Kit I Omega bio-tek, Norcross, GA, U.S.A. 
FavorPrep™ Gel/PCR Purification Kit Favorgen, Vienna, Austria 
FavorPrep™ Plasmid DNA Extraction Mini Kit Favorgen, Vienna, Austria 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany 
Crystallographic Kits 
JCSG+, JCSG Core I, II, III and IV Qiagen, Hilden, Germany 
MIDAS™ Molecular Dimensions, Suffolk, U.K. 
 
5.2 Cloning and Plasmid Construction 
5.2.1 Preparation of P. aeruginosa PAO1 genomic DNA 
P. aeruginosa PAO1 were grown in 5 mL LB medium overnight at 37 °C. 1.5 mL of this 
culture was pelleted at 15700×g for 1 min, the supernatant was discarded and the cells 
were resuspended in Genomic DNA buffer (Section 5.1.1). The cell suspension was incu-
bated at 37 °C for 1.5 hours. After addition of 250 µL chloroform and 250 µL phenol, the 
suspension was vortexed for 30 sec and pelleted at 15700×g for 1 min. The aqueous 
phase was then removed to another tube. These four steps were repeated four times. In 
the next step, 500 µL of chloroform were added. The suspension was vortexed and spun 
down at 15700×g for 1 min. The aqueous phase was removed to another tube. An appro-
priate volume of sodium acetate solution was added to a concentration of 0.3 M, as well 
as 1 mL of ethanol. The genomic DNA was then precipitated at -20 °C overnight. On the 
next day, the DNA was pelleted at 15700×g and 4 °C for 5 min. The DNA was washed 
with 70% (v/v) ethanol and resuspended in 100 µL of sterile, PCR grade ddH2O.  
 
5.2.2 Polymerase Chain Reaction  
Polymerase chain reaction (PCR) is used to amplify target DNA. The ORFs encoding the 
proteins used in this study were amplified in PCR reactions from plasmid DNA or P. 
aeruginosa PAO1 genomic DNA. Phusion DNA Polymerase and KAPAHiFi Polymerase 
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(Peqlab) were used for amplification of DNA fragments for cloning, while Taq DNA 
Polymerase was used for colonyPCR (cPCR) reactions (Table 4). 
 
Table 4: Pipetting scheme for PCR reactions. If using genomic DNA, more template DNA is required. 
DMSO is required because of the high GC content of P. aeruginosa genomic DNA. 
 Phusion Polymerase KAPAHiFi Polymerase Taq Polymerase final conc. 
Template DNA X µL  X µL 1 µL* <200 ng/25 µL 
Primer s 0.5 µL 0.75 0.5 µL 2-3 µM 
Primer as 0.5 µL 0.75 0.5 µL 2-3 µM 
dNTPs 0.5 µL 0.75 0.5 µL 200-300 µM 
Buffer 5 µL GC Buffer 5 µL GC Buffer 2.5 µL Thermo Pol 1x 
ddH2O to 25 µL to 25 µL 17.25 µL  
DMSO 1.5 µL 0.5-1.5 µL - ≤ 6% 
Polymerase 0.125 µL 0.5 µL 0.25 µL    
*1 µl of a suspension of a single bacterial colony in 5 µL of ddH2O. 
 
The DNA polymerase was added last to the reaction mixture. Subsequently, the PCR 
programs (Table 5) were started. Denaturation, annealing and elongation were perfor-
med as cycles of 25 to 35 repetitions.  
 
Table 5: Program scheme for PCR reactions. 25-35 cycles of denaturation, annealing and elon-
gation were performed during PCR. Tm= melting temperature of the oligonucleotides; kbp = 
kilo base pairs. 
 Phusion Polymerase KAPAHiFi Polymerase Taq Polymerase 
 T / °C t / s T / °C t / s T / °C t / s 
Initial Denaturation 98 180 95 180 95 180 
Denaturation 98 15 98 20 95 20 
Annealing Tm- 5 20 Tm- 5 15 Tm- 5 20 
Elongation 72 30 / kbp 72 30 /kbp 68 60 /kbp 
Final Elongation 72 300 72 300 68 300 
Storage 8 ∞ 8 ∞ 8 ∞ 
 
After PCR, the samples were mixed with DNA loading buffer and analyzed using agarose 
gel electrophoresis according to 5.2.4.  
 
 25 
- 
35 
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5.2.3 Gradient Polymerase Chain Reaction (Gradient PCR) 
If standard PCR reaction was not successful in amplifying an ORF from P. aeruginosa ge-
nomic DNA, gradient PCR was used to amplify the target ORF. Phusion DNA Polymerase 
(NEB) and KAPAHiFi Polymerase (Peqlab) were used for amplification of these ORFs. 
Pipetting schemes are described in Table 6. 
 
Table 6: Pipetting scheme for PCR reactions. If using genomic DNA, more template 
DNA is required. DMSO is required because of the high GC content of P. aeruginosa 
genomic DNA. 
 Phusion Polymerase KAPAHiFi Polymerase final conc. 
Template DNA X µL  X µL <200 ng/25 µL 
Primer s 0.5 µL 0.75 2-3 µM 
Primer as 0.5 µL 0.75 2-3 µM 
dNTPs 0.5 µL 0.75 200-300 µM 
GC Buffer 5 µL  5 µL  1x 
ddH2O to 25 µL to 25 µL  
DMSO 1.5 µL 0.5-1.5 µL ≤ 6% 
Polymerase 0.125 µL 0.5 µL  
 
The PCR programs (Table 7) were started immediately after addition of the polymerase 
into the reaction mixture. Denaturation, annealing and elongation were performed as 
cycles of 10 (gradient step) and 20 (standard PCR step) repetitions.  
 
Table 7: Program scheme for gradient PCR reactions. 10 cycles of gradient steps and 20 
cycles of standard PCR steps were performed.  
 Phusion Polymerase KAPAHiFi Polymerase 
 T / °C t / s T / °C t / s 
Initial Denaturation 98 180 95 180 
Denaturation 98 15 98 20 
Annealing Tm-5 to Tm+5 20 Tm-5 to Tm+5 15 
Elongation 72 30 / kbp 72 30 /kbp 
Denaturation 98 15 98 20 
Annealing Tm- 5 20 Tm- 5 15 
Elongation 72 30 / kbp 72 30 /kbp 
Final Elongation 72 300 72 300 
Storage 8 ∞ 8 ∞ 
 
 
10 
20 
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After PCR, the samples were mixed with DNA loading buffer and analyzed using agarose 
gel electrophoresis according to 5.2.4.  
 
5.2.4 Agarose Gel Electrophoresis  
Nucleic acids samples from PCR were analyzed using agarose gel electrophoresis. In this 
analysis, 1% agarose gels (1 g of agarose per 100 mL 1x TAE buffer) were supplemented 
with 2 µL of ethidium bromide solution. Samples were mixed with 6x DNA loading buffer 
and loaded on the gel. Voltage of 35 V or 70 V, depending on the size of the agarose gel, 
was applied. The DNA fragments migrate in the agarose gel and are separated according 
to their size. After electrophoresis, gels were inspected under UV light. DNA fragments 
were compared to a molecular weight standard, cut out with a scalpel and purified using 
a DNA purification kit (see Section 5.1.8) according to the manual of the manufacturer. 
  
5.2.5 DNA Restriction 
PCR products and plasmids were treated with endonuclease restriction enzymes (New 
England Biolabs) to generate 3’-overhangs for ligation reactions. Plasmids were additio-
nally treated with Antarctic Phosphatase (New England Biolabs) to dephosphorylate the 
5’-ends of the DNA and decrease the probability for religation. Table 8 depicts the pipet-
ting schemes for digestion reactions of PCR products and plasmid DNA. Buffers were 
chosen according to the manual of the manufacturer.  
 
Table 8: Pipetting schemes for endonuclease restriction digest 
of linear and circular dsDNA. 
 PCR products Plasmid DNA 
Template DNA X µL (700 ng) X µL (1-2 µg) 
10x BSA 5 µL 5 µL 
10x NEB Buffer 5 µL 5 µL 
Restriction Enzyme I 1 µL 1 µL 
Enzyme II 1 µL 1 µL 
Antarctic Phosphatase (AP) - 1 µL 
10x AP Buffer - 5 µL 
ddH2O to 50 µL to 50 µL 
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The DNA was digested for 30 min (PCR products) or 1 hour (plasmid DNA) at 37 °C. Final-
ly, the enzymes were denatured at 65°C for 20 min (80 °C for NcoI) and purified accord-
ing to 5.2.6. 
 
5.2.6 Purification of Linear DNA 
Purification of linear DNA, e. g. from enzymatic digest, was performed using a PCR Puri-
fication Kit (see Section 5.1.8) according to the protocols supplied. DNA was either 
eluted with ddH2O or the supplied elution buffer. 
 
5.2.7 Quantification of Nucleic Acids 
Nucleic acid concentrations were determined using a NanoDrop 1000 or NanoDrop 2000 
(Thermo Scientific). Solutions were measured directly at a UV absorption wavelength of 
λ = 260 nm. A UV absorption of 1 was assumed to be equal to 50 ng/µL of double stran-
ded DNA. Concentrations were calculated accordingly. 
 
5.2.8 Ligation 
After restriction of PCR products and vectors by endonucleases, PCR products (inserts) 
and plasmids were ligated using T4 DNA Ligase in order to generate the desired ex-
pression vectors. The reactions (Table 9) were setup using an insert:plasmid ratio be-
tween 3:1 and 5:1.  
 
Table 9: Pipetting scheme for ligation reactions. 
 Ligase Reaction I Ligase Reaction II 
Insert 6 µL x µL (3-5 equivalents) 
Plasmid 2 µL x µL (1 equivalent) 
Ligase Buffer (NEB) 1 µL 1 µL 
T4 DNA Ligase 1 µL 1 µL 
ddH2O to 10 µL to 10 µL 
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Ligase reaction proceeded at 16 °C for either for one, two, four or 16 hours. After liga-
tion, T4 DNA Ligase was inactivated at 65 °C for 20 min. The reaction mixture was used 
for transformation into E. coli cells without further purification (Section 5.2.13). 
 
5.2.9 Preparation of Circular DNA 
Plasmid DNA was purified from E.coli strains XL1-Blue, TOP10 or DH5α using a Plasmid 
Purification Kit (see Section 5.1.8). Purification was performed according to the protocols 
supplied. DNA was eluted with ddH2O or the supplied elution buffer. 
 
5.2.10 DNA Sequencing 
In order to verify the correct sequence of the constructed plasmids, DNA sequencing 
analysis was performed at MWG Biotech/Eurofins Genomics (Ebersberg, Germany) or by 
the Genome Analytics Facility (GMAK) of the Helmholtz Centre of Infection Research 
(Braunschweig, Germany) according to the respective protocols. Sequencing results 
were analyzed in pairwise alignments using ClustalW2 (European Molecular Biology 
Laboratory, EMBL) (Larkin et al., 2007). 
 
5.2.11 Preparation of E.coli Chemically Competent Cells 
Chemically competent E. coli strains were produced for molecular biology and protein 
production techniques. Magnesium competent and rubidium competent cells were pre-
pared by Norbert Grillenbeck at the University of Bayreuth and Claudia Hanko at the 
Helmholtz Centre for Infection Research, respectively. E. coli cells were prepared accor-
ding to standard protocols, using antibiotics only if the cells were carrying an additional 
plasmid (e.g. chloramphenicol with E. coli BL21(DE3)Codon+ cells). Cells were flash fro-
zen in liquid nitrogen as 100 µL aliquots and stored at -80 °C until further usage. 
 
5.2.12 Preparation of P. aeruginosa Magnesium-Competent Cells 
Magnesium-competent P. aeruginosa PAO1 were prepared for protein production in 
spot plate assays. P. aeruginosa PAO1 were cultivated on LB agar at 37 °C overnight. A 
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20 mL LB culture was inoculated with a single colony and cultivated at 37 °C under vigo-
rous shaking to late stationary phase. Cells were pelleted at 15700×g and LB medium 
was removed. The cells were then suspended in 5 mL of ice cold 0.1 M MgCl2 for 30 min 
at 4 °C. After centrifugation and removal of MgCl2, cells were suspended in 2.5 mL of 
0.15 M MgCl2 and 15% (v/v) glycerol. Aliquots of 100 µL were flash frozen in liquid 
nitrogen and stored at -80 °C.   
 
5.2.13 Heat Shock Transformation of E. coli and P. aeruginosa PAO1 
For plasmid amplification or protein production, 50 µL of E. coli chemically competent 
cell suspension were mixed with 50 ng of plasmid DNA and incubated on ice for 30 min. 
A 90 s heat shock was performed at 42 °C and 1 mL of LB medium was added to the cells. 
After shaking for 10 min (if resistant to ampicillin) or 30 min (if resistant to chloramphe-
nicol), cells were pelleted at 15700×g for 1 min and plated on LB agar containing appro-
priate antibiotics.  
P. aeruginosa PAO1 chemically competent cells were treated in the same manner as E. 
coli. They were shaken for 30 min (gentamicin) in LB medium at 37 °C before they were 
plated on LB agar containing appropriate antibiotics.  
 
5.2.14 Protein Production  
All proteins used in this study were produced in E. coli. An overnight culture of LB medi-
um supplemented with antibiotics was inoculated with a single colony from an agar 
plate with freshly transformed cells. Cells were cultivated at 37 °C and under vigorous 
shaking to an optical density at 600 nm (OD600) of 0.6. The temperature was then set to 
20 °C and cells were cultivated to an OD600 of 0.8, at which gene expression was induced 
with 0.5 mM isopropyl-thio-β-D-galactopyranosid (IPTG). Cells were cultivated at 20 °C 
overnight under vigorous shaking (120 rpm) and harvested by centrifugation at 5000×g 
for 10 min at 4 °C. If not used immediately, the cells were flash frozen in liquid nitrogen 
and stored at -80 °C. Variances in the protein production protocol are listed in the table 
below. All proteins produced during this study and are listed in Table 10. PA3127_1-114 
and PA3127_123-267 were produced by Monika Popp (Popp, 2013). 
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Table 10: Proteins produced in this study. PA3127_1-114 and PA3127_123-267 were produced by M. Popp 
(Popp, 2013). The E. coli strain and plasmid used for production are indicated. 
Protein E. coli strain Plasmid Citation 
His6-PA0803 Rosetta 2 pLysS pET19m_PA0803 Yu, 2009, 16h at 20 °C ON 
His6-PA0880 BL21 (DE3) pET19m_PA0880 this study 
His6-PA1353 BL21 (DE3) Codon+ pET19m_PA1353 Kalawy-Fansa, 2010 
His6-PA1354 BL21 (DE3) pET19m_PA1354 this study 
His6-PA1672 BL21 (DE3) pLysS pET19m_PA1672 this study, Weber, 2011 
His6-PA3127  Rosetta 2 pLysS pET19m_PA3127 this study, Bittner, 2012 
His6-PA3127_1-114 BL21 (DE3) Codon+ pET19m_PA3127_1-114 Popp, 2013 
His6-PA3127_123-267 BL21 (DE3) Codon+ pET19m_PA3127_123-267 Popp, 2013 
His6-PA4183  BL21 (DE3) pLysS pET19m_PA4183opt this study 
His6-PA4183_16-155 BL21 (DE3) Codon+ pET19m_PA4183opt_16-155 this study 
His6-PA4183_32-155 BL21 (DE3) pET19m_PA4183opt_32-155 this study 
His6-PA4518 Rosetta 2 pLysS pET19m_PA4518 this study 
His6-PA4641 BL21 (DE3) Codon+ pET19m_PA4641 Kalawy-Fansa, 2010 
 
5.3 Protein Purification and Characterization 
5.3.1 Protein Purification  
Cell Disruption 
Cells were thawed if previously frozen and then resuspended in an appropriate volume 
of buffer A. If necessary, the suspension was supplied with DNAse K and magnesium 
chloride. The suspension was homogenized by stirring and filtrated. Cells were lysed by 
sonication or in a microfluidizer according to the instructions of the manufacturer. To se-
parate the soluble proteins from the insoluble fraction and cell debris, a centrifugation 
step was performed at 20000×g and 4 °C for 60 min. The supernatant of the centrifuga-
tion containing the soluble target protein was pooled for further purification. Samples 
for sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) were taken 
from the cell lysate and supernatant. 
 
Ni(II) Immobilized Metal Ion Affinity Chromatography (Ni(II)-IMAC) 
A HisTrap™ HP column loaded with Ni(II) and primed with buffer A was connected to an 
ÄKTAprime FPLC system which previously had been flushed with buffers A and B. The 
                                            5   Materials and Methods – βαβββ-Module Resistance Proteins 
 
56 
whole system was primed with buffer A until a stable baseline at an absorption wave-
length of λ = 280 nm (A280) was reached. The supernatant from the previous centrifuga-
tion step was applied to the HisTrap™ HP column at a flow rate of 1-3 mL/min and a ma-
ximum pressure of 0.3 MPa. The column was washed with 2% of buffer B to elute unspe-
cifically bound proteins. After that, a 120 mL gradient of 2-50% buffer B (10-250 mM 
imidazole) was applied to the column in order to elute the pure target protein. The elu-
tion was collected in 2 mL fractions and samples were analyzed by SDS-PAGE. 
 
Dialysis and TEV Cleavage 
The fractions pooled from Ni(II)-IMAC purification containing the soluble target protein 
were filled into a 10 kDa molecular weight cut-off (MWCO) dialysis bag. One equivalent 
of TEV protease was added to 20 equivalents of target protein (calculated as molar ra-
tio). The dialysis bag was sealed and was transferred into 4.5 L of SEC buffer supplemen-
ted with 1 mM βME. Dialysis was performed under continuous stirring at 4 °C overnight. 
 
Reverse Ni(II) Immobilized Metal Ion Affinity Chromatography (revNi(II)-IMAC) 
The protein solution from dialysis and TEV cleavage was used in a revNi(II)-IMAC which 
was performed similarly to Ni(II)-IMAC. However, SEC buffer (instead of buffer A) was 
used to prime the HisTrap™ HP column and the ÄKTAprime FPLC system. Since the His6-
tag of the target protein had been cleaved during dialysis, the target protein was present 
in the flow-through of the HisTrap™ HP column. Fractions of 2 mL of the flow-through 
were collected and analyzed by SDS-PAGE. His6-tagged TEV protease as well as other im-
purities such as non-cleaved target protein bound to the HisTrap™ HP column and were 
therefore eluted in a 100 mL gradient of 0-50% buffer B (0-250 mM imidazole). The elu-
tion fractions were collected and analyzed by SDS-PAGE. This step is very important due 
to the three species of βαβββ-module proteins present in solution: completely cleaved 
dimer, dimer consisting of one cleaved and one uncleaved protein and completely un-
cleaved dimer.  
 
Preparative Size Exclusion Chromatography 
A homogenous protein solution of high purity is crucial for protein crystallization. For 
this purpose, size exclusion chromatography (SEC) was always performed as the last pro-
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tein purification step. Proteins were loaded onto a HiLoad™75 16/60 Superdex™75 prep-
grade or HiLoad™75 26/60 Superdex™75 prepgrade column equilibrated in SEC buffer 
and connected to an ÄKTAprime+ or ÄKTApurifier High-Performance Liquid Chromato-
graphy (HPLC) system (GE Healthcare). Size exclusion chromatography was performed at 
a maximum column pressure of 0.3 MPa or the maximum flow rate possible according to 
the manufacturer’s manual. Proteins were eluted isocratically in SEC buffer and collected 
in 2 mL fractions. Samples were analyzed by SDS-PAGE. Fractions containing pure homo-
genous protein were pooled and concentrated by ultrafiltration. All size exclusion chro-
matography experiments were performed at 4-10 °C. The molecular weight of the target 
protein was calculated from a standard calibration curve obtained from the retention 
times of standard proteins with known molecular weight (Bio-Rad). 
 
Variances in the Purification Protocol 
All proteins used in this study (Table 11) were purified with an N-terminal His6-tag that 
was not cleaved in every case.  
 
Table 11: Proteins purified and/or used in this study. PA3127_1-114 (NTD) and PA3127_123-
267 (CTD) were received from M. Popp (Popp, 2013). 
Protein His6-tag cleaved? Crystallization Citation 
His6-PA0803 no yes Yu, 2009 
PA0880 yes yes this study 
His6-PA1353 no - Kalawy-Fansa, 2010 
His6-PA1354 no yes this study 
PA1672 yes yes this study, Weber, 2011 
PA3127  yes yes this study, Bittner, 2012 
PA3127_1-114 yes - Popp, 2013 
His6-PA3127_123-267 no yes Popp, 2013 
PA4183 insoluble - this study 
PA4183_16-155 yes yes this study 
PA4183_32-155 yes yes this study 
PA4518 yes yes this study 
His6-PA4641 no - Kalawy-Fansa, 2010 
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If the His6-tag was cleaved, all purification steps described above were performed. In 
cases where His6-tag cleavage was not necessary, neither dialysis nor reverse Ni(II)-IMAC 
were performed. After purification on Ni(II)-IMAC, the protein solutions were concentra-
ted as described in 5.3.3 and applied to a size exclusion chromatography column. All pro-
teins, except PA3127_1-114 and PA3127_123-267, were purified during this study. 
 
5.3.2 SDS-PAGE 
Sodium-Dodecyl-Sulfate Gel Electrophoresis (SDS-PAGE) was used to verify the presence 
and analyze the purity of proteins during purification steps. Discontinuous gels consisting 
of a stacking gel (5% polyacrylamide) and a resolving gel (16% or 18% polyacrylamide) 
were prepared following standard protocols (Laemmli, 1970). Samples were prepared by 
adding 5x SDS-PAGE sample buffer to the protein solution and denaturing the sample at 
95 °C for 5 min. After centrifugation at 15700×g, samples were run on the gel at a vol-
tage of 200 V in running buffer until the dye front had reached the end of the gel. After 
SDS-PAGE, the gel was washed with water, stained in staining solution containing Coo-
massie Brilliant Blue and destained in destaining solution or in H2O.  
 
5.3.3 Ultrafiltration 
During and after purification, proteins were concentrated to a desired volume and con-
centration using ultrafiltration. A Millipore Amicon Ultra MWCO or PALL Macrosep® Ad-
vance Centrifugal Device of 10 kDa MWCO was equilibrated with the appropriate buffer 
by centrifugation at 2900×g for 5 minutes. The buffer was removed and the protein solu-
tion was applied to the membrane. The protein solution was concentrated to a desired 
concentration by centrifugation at 2900×g.  
 
5.3.4 Protein Concentration Determination 
Protein concentrations were determined directly by UV absorption at a wavelength of λ 
= 280 nm using a NanoDrop 1000 or NanoDrop 2000 (Thermo Scientific). The theoretical 
molecular weight and extinction coefficients of the proteins (Table 12) were calculated 
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according to the appropriate protein sequence using EXPASY ProtParam (Gasteiger et al., 
2003). Protein concentrations were then determined using Lambert-Beer’s law 
  𝑨 =  𝒄 ·  𝒅 ·  𝜺𝟐𝟖𝟎       (22) 
when A is the absorption, c is the concentration (in M),  d is the path length (in cm) and 
ε280 is the extinction coefficient at λ = 280 nm (in M
-1cm-1).  
  
Table 12: Molecular weight (in kDa) and extinction coefficients ε280 used for con-
centration determination of the proteins used in this study. 
Protein Molecular weight / kDa Extinction coefficient ε280 
His6-PA0803 17.94 27055 
His6-PA0880 15.75 4470 
PA0880 13.87 2980 
His6-PA1353 15.28 22710 
His6-PA1354 18.03 13980 
His6-PA1672 15.49 5960 
PA1672 13.61 4470 
His6-PA3127  31.47 45045 
PA3127  29.60 43555 
PA3127_1-114 12.74 11585 
His6-PA3127_123-267  18.20 33460 
His6-PA4183_16-155 17.46 11460 
PA4183_16-155 15.58 9970 
His6-PA4183_32-155 15.68 5960 
PA4183_32-155 13.80 4470 
His6-PA4518 17.22 32555 
PA4518 15.35 31065 
His6-PA4641 17.28 24325 
 
5.3.5 Analytical Size Exclusion Chromatography 
To determine the oligomerization state of a target protein, analytical size exclusion chro-
matography was performed. Analytical size exclusion chromatography proceeded simi-
larly to preparative size exclusion chromatography described in section 5.3.1. Instead of 
a preparative column, Superdex™ 75 10/300 GL or Superdex™ 200 10/300 GL columns 
(24 mL column volume) connected to an ÄKTA FPLC system was equilibrated with SEC 
buffer. Furthermore, only 1 mg of protein was loaded onto the column. The elution pro-
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file was compared to the one of a molecular weight standard (Bio-Rad), which was used 
to calculate the molecular weight and oligomeric state of the protein of interest. 
 
5.3.6 Bleomycin N-Acetyltransferase Activity Test using HPLC-MS 
Bleomycin was acquired as Bleomedac® from Medac GmbH (Wedel, Germany) as a mix-
ture of bleomycin A2 and B2. HPLC and Mass spectrometry (MS) analysis were performed 
to analyze the enzymatic reactions catalyzed by PA3127 and PA3128. The assay samples 
were prepared using each 260 µM acetyl-Coenzyme A (AcCoA), 200 µM NADPH, 200 µM 
NADP+, 100 µM bleomycin, 5 µM PA3128 and 5 µM PA3127 in a volume of 500 µL of 50 
mM sodium acetate pH 3.6, 4.6 or 5.6 or in 50 mM BisTris pH 5.8, 6.5 or 7.2. The reac-
tions proceeded at 37 °C for 5 min, 15 min, 30 min, 1 hour or 2 hours and stopped by 
heating the sample to 80 °C. The precipitated proteins were pelleted by centrifugation at 
15700×g. The supernatant was freeze-dried in liquid nitrogen and lyophilized overnight. 
The samples were measured according to protocols developed by Ulrike Beutling in the 
laboratory of Prof. Dr. Mark Brönstrup, Department of Chemical Biology at the Helm-
holtz Centre for Infection Research in Braunschweig, Germany.   
 
5.4 Protein Crystallization and Structure Determination 
5.4.1 Determination of Crystallization Conditions 
In order to identify an initial crystallization hit, the vapor diffusion method was used with 
a sitting drop set up. Crystallization trials were set up manually or using liquid handling 
systems (Phoenix, Art Robbins Instruments; Honeybee 961, Zinsser Analytics; OryxNano, 
Douglas Instruments). When using Honeybee 961 or OryxNano, screens were set up on 
Intelli-Plate™ 96-3 LVR plates, while SWISSCI MRC 2-Well or 3-Well crystallization plates 
were used with the Phoenix. When using OryxNano, drops were composed of 0.3 µL of 
reservoir and 0.3 µL of protein solution, when using Honeybee 961 or Phoenix, 0.2 µL of 
reservoir and 0.2 µL of protein solution were pipetted. When setting up plates manually, 
crystallization trials were prepared as 0.8 µL + 0.8 µL drops on SWISSCI MRC 2-Well or 3-
Well crystallization plates. In all cases, the amount of reservoir solution ranged from 35 
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to 70 µL (Table 13). All proteins were screened using the JCSG Core suites I, II, III and IV 
(Qiagen). PA3127_123-267 was additionally screened with the Midas™ screen (Molecu-
lar Dimensions).  
 
Table 13: Proteins used in crystallization trials. Concentration of the protein, crystallization ro-
bot, as well as the reservoir volume are listed. PYO = pyocyanin, DTT = dithiothreitol, AcCoA = 
acetyl-coenzyme A, CoA = coenzyme A, Bm = bleomycin, I3C = 5-Amino-2,4,6-triiodoisophthalic 
acid. 
Protein Concentrations / mg/mL Robot 
Volume of  
reservoir / µL 
His6-PA0803 20 (± 1 mM PYO) Phoenix 40 
His6-PA0880 20 and 15 (+ 2 mM DTT) Phoenix 40 
PA0880 24, 20 and 15 (+ 2 mM DTT) Phoenix, Honeybee 40, 70 
His6-PA1354 30 and 22.5 Phoenix 40 
PA1672 20 and 15 set up manually 40 
PA3127  
20, 15, 10, 8, 4  
(± 2 mM AcCoA / CoA / Bm /  
CoA + Bm / I3C) 
Phoenix, Honeybee 40, 70 
His6-PA3127_123-267 12.6 (± 2 mM AcCoA) Honeybee 70 
PA4183_16-155 25 and 15 Phoenix 35 
PA4183_32-155 30 and 15 OryxNano (at 4 °C) 70 
PA4518 20 and 15 (+ 2 mM DTT) set up manually 40 
 
All crystallization trials were set up at 20 °C, sealed and stored at 20 °C in an automated 
imaging system (Formulatrix). In this system, crystallization screens were imaged regu-
larly according to predefined schedules. 
 
5.4.2 Crystal Optimization 
Initial crystallization hits were reproduced and optimized in a vapor diffusion hanging 
drop setup using Linbro 24-well plates with 22 mm glass slides or VDXm 24-well plates 
and 18 mm glass slides. In these optimization plates, parameters such as the protein 
concentration, the drop size, the concentration of the precipitant or the pH of the reser-
voir were varied to obtain better diffracting crystals. In some cases, optimization plates 
are also used for soaking experiments with ligands or heavy atom-containing solutions. 
Usually, 500 µL of mother liquor were used to equilibrate the crystallization drops usual-
                                            5   Materials and Methods – βαβββ-Module Resistance Proteins 
 
62 
ly composed of 1 µL of reservoir and 1 µL of protein solution. Plates were stored at 20 °C 
and inspected under a microscope for crystals once per day.  
 
Table 14: Initial hits and final crystallization conditions of the proteins investigated in this study. MPD = 
2-Methyl-2,4-pentanediol, MES = 2-(N-morpholino)ethanesulfonic acid. 
Protein (Best) Initial Hit Final Condition 
 
His6-PA0803 
 
JCSG Core IV H6 
0.8 M sodium dihydrogen phosphate, 1.2 M dipotassium hydro-
gen phosphate, 0.1 M sodium acetate pH 4.5, 2.5 mM PYO, 
2.5% (v/v) DMSO 
PA0880 JCSG Core II F3 
0.1 M sodium acetate pH 4.5, 50% (v/v) ethylene glycol, 5% (w/v) 
PEG 1000  
His6-PA1354 JCSG Core I G2 20% (w/v) MPD, 0.1 M sodium acetate pH 5 
PA1672 JCSG Core I H2 0.1 M sodium acetate pH 4.5, 20% (w/v) PEG 3350 
PA3127 JCSG Core III F9 0.1 M MES pH 5.6, 0.8 M ammonium sulfate 
PA3127_123-267 Midas A1 
0.1 M HEPES/NaOH pH 6, 50% (v/v) polypropylene glycol 400,  
5% (v/v) DMSO 
PA4183_16-155 JCSG Core I B1 
0.1 M HEPES/NaOH pH 7.2, 0.2 M sodium chloride, 18% (w/v) 
PEG 3350  
PA4518 JCSG Core II H11 0.1 M sodium citrate pH 3.6, 10% (v/v) MPD 
 
5.4.3 Cryoprotection 
Crystallographic data usually is collected at cryogenic temperatures to reduce radiation 
damage introduced into the protein crystal by X-rays. In order to avoid the formation of 
amorphous ice at these temperatures (usually 100 K), protein crystals were soaked with 
a cryoprotecting solution composed of the mother liquor and high precipitant concentra-
tions, for instance glycerol, sugars, oil or small molecular weight polyethylene glycols 
(PEGs) (Table 15). 
If ligands were present in the crystallization solution, they were added to the cryoprotec-
ting solution at the same concentration, for instance 2.5 mM pyocyanin was added in 
the case of PA0803. After cryoprotection, crystals were isolated in nylon loops of the ap-
propriate size and flash cooled in liquid nitrogen for diffraction experiments. 
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Table 15: Cryoprotectants used for the diffraction experiments on protein 
crystals. The cryoprotecting solution always consists of the mother li-
quor, a cryoprotecting agent and ligands.  
Protein Cryoprotectant 
His6-PA0803 15% (w/v) glycerol 
PA0880 - 
His6-PA1354 - 
PA1672 5% (w/v) PEG 3350, 15% (v/v) glycerol  
PA3127  25% (v/v) glycerol  
His6-PA3127_123-267 - 
PA4183_16-155 12% (w/v) PEG 3350 
PA4518 15% (v/v) MPD 
 
5.4.4 Diffraction Experiments and Data Collection 
After crystals were obtained, isolated and cryoprotected, they were tested for diffraction 
on X-ray home sources. Test images were collected using monochromatic X-rays at the 
Cu-Kα edge (λ = 1.54 Å) together with either an IµS sealed tube anode (Incoatec) and a 
mar345 (Rayonix) image plate detector, or a rotating anode with an R-AXIS IV++ (Rigaku) 
image plate detector or a Saturn 944+ (Rigaku) CCD detector. Well-diffracting crystals 
were sent to a synchrotron for data collection. All datasets were collected on beamline 
14.1 of the BESSY II Synchrotron (Berlin Electron Storage Ring Society for Synchrotron 
Radiation, Helmholtz Centre Berlin (HZB), Berlin, Germany) at cryogenic temperatures 
and at a wavelength of λ = 0.9184 Å (Table 16). 
 
Table 16: Data collection strategies for the crystals used for data collection in this study. 
Protein Beamline Detector Wavelength λ / Å Images Oscillation / ° 
His6-PA0803 + PYO BESSY II 14.1 MarCCD Chess 0.9184 200 0.5 
PA0880 BESSY II 14.1 MarCCD Chess 0.9184 100 1 
His6-PA1354 BESSY II 14.1 MarCCD Chess 0.9184 105 1 
PA1672 BESSY II 14.1 MarCCD Chess 0.9184 100 1 
PA3127 relaxed cell BESSY II 14.1 MarCCD Chess 0.9184 110 1 
PA3127 dehydrated cell BESSY II 14.1 PILATUS 6M 0.9184 1900 0.1 
His6-PA3127_123-267 BESSY II 14.1 PILATUS 6M 0.9184 3600 0.1 
PA4518 BESSY II 14.1 MarCCD Chess 0.9184 100 1 
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5.4.5 Data Processing  
All data were indexed with XDS (Kabsch, 2010) and integrated and scaled using Aimless 
(Evans, 2006, 2011). For every protein and space group, a reference dataset was created. 
This reference dataset was used to assign the identical free R flags to all datasets of this 
protein and space group. By doing so, the statistical parameters of all structures can be 
compared more easily. The final structure factor file was used for refinement and im-
provement of the corresponding protein model.  
 
5.4.6 Phase Determination and Structure Determination 
The crystal structures of the proteins investigated in this part of the study were deter-
mined via MR. This was possible because structures of similar fold and sequence are 
available from the PDB. Structure solution proceeded either in PHASER (McCoy et al., 
2007) from the CCP4 program suite (Winn et al., 2011), or in PHASER from the Phenix 
program suite (Adams et al., 2011). If these approaches were unsuccessful, MR was tried 
using the MR engine BALBES (Long et al., 2007). An overview on the search models used 
in MR and their sequence identities to the target proteins is given in Table 17.  
 
Table 17: Structures determined in this study. All structures were solved by MR with homologues 
proteins, either using PHASER from CCP4 or Phenix, or using the MR engine BALBES. 
Protein Structure Solution Model  sequence identity / % 
   His6-PA0803 rigid body refinement  PA0803 (Yu, 2009) 100 
   PA0880 PHASER, CCP4 3HNQ, dimer 66 
   PA1672 PHASER, CCP4 2R6U, chains BD, polyALA 28 
   PA3127  PHASER, Phenix 
PA3127_1-114, dimer 
PA3127_123-267, dimer 
43 
54 
   His6-PA3127_123-267 BALBES 3JVN, monomer 11 
   PA4518 PHASER, CCP4 3BQX, dimer 37 
 
5.4.7 Model Building and Refinement 
If a structure solution is obtained by MR or phasing, the structural model has to be re-
built and improved by iterative building and refinement cycles. These include the place-
ment of water molecules and ions as well as ligands into the protein structure. For this 
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purpose, model building was done in COOT (Emsley & Cowtan, 2004; Emsley et al., 2010) 
and refinement was carried out with REFMAC5 (Murshudov et al., 2011) and with 
phenix.refine (Afonine et al., 2012). If ligands were placed in the protein structure, 
coordinate files and chemical restraints files were downloaded from the PDB and then 
prepared for refinement using eLBOW (Moriarty et al., 2009) from the Phenix program 
suite (Adams et al., 2011). In case ligands were not available in the PDB, coordinate files 
and chemical restraints files were prepared with ProDRG (Schüttelkopf & van Aalten, 
2004) and eLBOW (Moriarty et al., 2009).  
 
5.4.8 Structural Analysis and Validation 
All structures were validated using MolProbity (Chen et al., 2009) and the Validation 
Server of the PDB (Berman et al., 2000). Figures were prepared with PyMOL (DeLano, 
2002), Chimera (Pettersen et al., 2004) and ChemBioDraw. 
 
5.5 Small Angle X-ray Scattering  
5.5.1 Principles of Small Angle X-ray Scattering  
Small angle X-ray scattering (SAXS) is a technique that is used to visualize the overall 3-
dimensional structure and structural changes of biological macromolecules. The method 
reveals the size and shape of the electron envelope of proteins and protein complexes 
ranging from 5 kDa to 100 MDa, and complements X-ray crystallography, nuclear magne-
tic resonance (NMR) and electron microscopy (EM) (Putnam et al., 2013).    
In a SAXS experiment, a monodisperse protein solution is probed with an X-ray beam (λ 
around 1.5 Å) and the scattered X-rays are detected at low angle (θ = 0.1 - 10°) to the 
incident beam. The amplitude |s| of scattering vector s is 
|?⃗? | = 𝟒𝝅𝒔𝒊𝒏𝜽/𝝀        (23) 
where 2θ is the scattering angle between incident and scattered beam. At values of s < 
1.3Rg, the scattered intensities Is can also be described by the Guinier approximation 
𝑰?⃗? = 𝑰𝟎𝒆
−?⃗? 𝟐𝑹𝒈
𝟐/𝟑        (24) 
                                            5   Materials and Methods – βαβββ-Module Resistance Proteins 
 
66 
where I0 is the intensities at θ = 0 and Rg is the radius of gyration. The Rg is defined as a 
measure for the overall size of the molecule, meaning the average of square center-of-
mass distances in the molecule. Both the Rg and the molecular weight MMP of the mole-
cule of interest can then be determined using the Guinier plot (ln(Is) plotted against s2) 
by the I0 intercept and the slope of the plot, respectively. The MMP can also be deter-
mined by comparison of the forward scattering intensities I0,st and MMst of a reference 
protein solution, for instance BSA (66.4 kDa), with the foward scattering I0,P of the pro-
tein of interest, using  
𝑴𝑴𝑷 = 𝑰𝟎,𝑷/𝒄𝑷
𝑴𝑴𝒔𝒕
𝑰𝟎,𝒔𝒕/𝒄𝒔𝒕
       (25) 
where c is the concentration. Both the Rg and the molecular weight MMP of the molecule 
are used in data processing, together with the excluded volume V (Porod’s volume) of 
the hydrated particle which is computed using Porod’s equation 
𝑽 = 𝟐𝝅𝑰𝟎 ∫ ?⃗? 
𝟐𝑰𝒆𝒙𝒑, 𝒔⃗⃗ 𝒅?⃗? 
∞
𝟎
       (26) 
In data processing, the scattered intensities Is are first Fourier-transformed into 1-dimen-
sional scattering curves. Then, the curves can be interpreted using the distance distribu-
tion function p(r) of the particle  
𝒑(𝒓) = 𝟏 𝟐𝝅𝟐 ∫ 𝑰𝒔?⃗? ?⃗? 𝐬𝐢𝐧 ?⃗? ?⃗? 
∞
𝟎
⁄ 𝒅?⃗?       (27) 
where r is a distance in the particle. The particle distance distribution function repre-
sents all paired sets of distances between the electrons of the molecule of interest. The 
function p(r) yields an ab initio shape of the molecule of interest. This ab initio shape is 
used together with the scattering curves in order to reconstruct the low resolution 3-di-
mensional shell. This process is usually aided by X-ray crystallography or NMR structures 
of the proteins of interest. For this purpose, the protein is represented as a bead model 
from which a theoretical scattering curve can be calculated. The model is altered until 
the theoretical scattering curve fits to the observed scattering curve. An important quali-
ty indicator for this fitting process is the Χ-value  
𝜲𝟐 =
𝟏
𝑵
∑ (𝑰𝒆𝒙𝒑,?⃗? 𝒊 − 𝜼𝑰𝒄𝒂𝒍𝒄,?⃗? 𝒊 𝝈?⃗? 𝒊⁄ )
𝟐𝑵
𝒋=𝟏       (28) 
where N is the number of experimental points, Iexp,si and Icalc,si are the experimental and 
the theoretical intensities, η is a scaling factor and σsi is the experimental error. A Χ-value 
of between 1 and 5 usually indicates a high quality SAXS model.  
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5.5.2 Small Angle X-ray Scattering – Experiments and Data Evaluation 
SAXS measurements were carried out on beamline BM29 of the European Synchrotron 
Radiation Facility (ESRF, Grenoble, France) using a PILATUS 1M detector. Samples were 
prepared as a 100 µL dilution series of purified PA3127 at concentrations of 15, 5, 2.5, 
1.25, 0.75 and 0.375 mg/mL in SEC buffer, which was used as a blank. Solution scattering 
patterns were collected at a sample – detector distance of 2.867 m and a wavelength of 
λ = 0.9919 Å, covering the range of momentum transfer 0.01 < s < 0.45 nm-1 (equation 
23). In case of PA3127, the best sample quality and monodispersity (91.8%) was achie-
ved at a protein concentration of 1.25 mg/mL. This sample was chosen for further ana-
lysis of the scattering data. First, the crystal structure of PA3127 (determined in this 
study) was submitted to the PISA server (Krissinel & Henrick, 2007) in order to determine 
the correct oligomeric assembly for electron shell calculation. All stable protein assem-
blies predicted by PISA were used for SAXS curve fitting in the program CRYSOL (Svergun 
et al., 1995). The quality of each curve fit is indicated by the Χ-value (equation 27), when 
Χ = 1 indicates the optimum fit of the structure and the electron shell computed from 
the recorded scattering data. Then, the program PRIMUS (Konarev et al., 2003) was used 
to normalize and average the scattering data and subtract the buffer blank. Further-
more, PRIMUS evaluates the integral experiment parameters, for instance the radius of 
gyration Rg, zero intensity I0 and molecular weight MMP of the protein of interest and the 
excluded volume V of the hydrated particle. The same parameters were also computed 
using the program GNOM (Svergun, 1992) from the ATSAS package (Petoukhov et al., 
2012). GNOM also provides the maximum diameter Dmax of the particle and evaluates 
the particle distance distribution function ρ(r). Then, GNOM analyzes the one-dimensio-
nal scattering curves fitted by CRYSOL. These data were used for twenty runs of ab initio 
shape determination of the SAXS envelope by the program DAMMIF (Franke & Svergun, 
2009). For this purpose, the oligomeric assembly is represented as a densely packed 
bead model, and DAMMIF uses simulated annealing to determine twenty ab initio mo-
dels of the PA3127 SAXS envelope. These models were aligned and averaged using 
DAMAVER (Volkov & Svergun, 2003). In DAMAVER, first damsel compared all models 
composed in DAMMIF and identified the most probable one as well as outliers. Second, 
damsup aligned the models with the most probable one. Third, damaver averaged the 
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models and computed a model probability map. In the last step, damfilt filters the ave-
raged model at a certain cut-off volume and yields a final SAXS envelope. The SAXS enve-
lope was superimposed with the correct PA3127 assembly using SUPCOMB20 (Kozin & 
Svergun, 2001). The assembly and the final electron shell were visualized using SITUS 
(Wriggers, 2012) and Chimera (Pettersen et al., 2004).  
 
5.6 Isothermal Titration Calorimetry 
5.6.1 Principles of Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) is a highly sensitive method to measure the interac-
tion between two molecules. These molecules can either be two proteins or proteins 
and their small ligands. The actual signal detected in an ITC experiment is the power 
difference between the sample cell and the reference cell generated by molecules that 
absorb or generate heat upon interaction.  
 
 
Figure 21: Experimental setup of isothermal titration calorimetry (ITC). The reference cell and the 
sample cell are enclosed in an adiabatic jacket and are constantly heated with the cell main heaters. 
The temperature difference ΔT between both cells is very small, but measurable. The protein solu-
tion (M) is loaded into the sample cell, and the ligand solution (L) is filled into the stirring syringe. 
When L is injected into P and the complex MP is formed, heat is produced or absorbed. Thus, the 
sample cell solution heats up or cools down, and ΔT≠0. The power needed to equilibrate the system 
to ΔT≈0 again is the signal detected over time in an ITC experiment. 
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The quantitative thermodynamic characterization of macromolecular interactions ren-
ders ITC a powerful method, especially since it has no molecular weight limitation and 
does not require labeling with fluorophors. 
An ITC machine (Figure 21) consists of a reference and a sample cell with volume V0, 
both enclosed in an adiabatic jacket. The cells are constantly heated, and the tempera-
ture difference between them is very small, but can be measured. The macromolecule 
solution (M) with concentration M0 is filled into the sample cell, while the ligand solution 
(L) with concentration L0 is filled into the stirring syringe. During the measurement, a de-
fined volume Vinj of ligand solution is injected into the sample cell at predefined time 
points. The injection changes the concentrations of protein and ligand to Mtot,i and Li, re-
spectively. Upon interaction of the protein and ligand, the complex formation induces 
heat release or absorbance from the sample cell solution. Thus, the temperature of the 
sample cell is altered. The time-dependent power difference Qi that is needed to keep ΔT 
close to zero is measured in the ITC experiment and defined  
𝑸𝒊 = 〈∆𝑯〉𝒊𝑴𝒕𝒐𝒕,𝒊𝑽𝟎 − 〈∆𝑯〉𝒊−𝟏𝑴𝒕𝒐𝒕,𝒊−𝟏(𝑽𝟎 − 𝑽𝒊𝒏𝒋)   (29) 
where <ΔH>i is the change in enthalpy per mole of protein, Mtot,i is the concentration of 
protein after injection i, V0 is the cell volume, Mtot,i-1 is the concentration of protein 
before injection i and Vinj is the injection volume. In case of a stoichiometry of N = 1,  
〈∆𝑯〉𝒊 = ∆𝑯
𝑴𝑳𝒊
𝑴𝒕𝒐𝒕,𝒊
= ∆𝑯
𝑴𝑳𝒊
𝑴+𝑴𝑳𝒊
= ∆𝑯
𝑲𝒂𝑳𝒊
𝟏+𝑲𝒂𝑳𝒊
    (30) 
where ΔH is the change in enthalpy when one mole of ligand binds to one mole of pro-
tein, Li is the ligand concentration after injection i and Ka is the dissociation constant. 
Equations 30 and 31 can be combined and yield  
𝑸𝒊 =
∆𝑯𝑴𝒕𝒐𝒕,𝒊𝑽𝟎𝑲𝒂𝑳𝒊
𝟏+𝑲𝒂𝑳𝒊
−
∆𝑯𝑴𝒕𝒐𝒕,𝒊−𝟏(𝑽𝟎−𝑽𝒊𝒏𝒋)𝑲𝒂𝑳𝒊−𝟏
𝟏+𝑲𝒂𝑳𝒊−𝟏
    (31) 
The concentrations of protein Mtot,i and ligand Li can always be calculated from the cell 
and injection volumes V0 and Vinj and the initial concentrations M0 and L0, and Qi is the 
parameter measured in the experiment. Hence, fitting of the experimental ITC curve to 
equation 31 results in the thermodynamic parameters of the binding interaction, mean-
ing the binding constant Ka, the stoichiometry N and the enthalpy ΔH. The entropy ΔS 
can then be derived using 
∆𝑮 = −𝑹𝑻 𝐥𝐧𝑲𝒂 = ∆𝑯 − 𝑻∆𝑺      (32) 
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In order to conduct a successful ITC experiment, it is important to choose the protein 
concentration according to an appropriate C-value  
𝑪 = [𝑴𝟎] 𝑲𝑫⁄          (33) 
where [M] is the concentration of protein and KD is the dissociation constant which is 
equal to 1/Ka. The optimum C-value ranges between 10 and 100, for instance if the KD is 
100 nM, a protein solution of 5 µM concentration should be used in the experiment. For 
N = 1, the ligand concentration should be 10-fold the protein concentration (50 µM in 
this case). If the C-value become too low or too high, curve fitting will be more difficult 
or even impossible.  
   
5.6.2 Isothermal Titration Calorimetry – Experiments and Data Evaluation 
ITC experiments were performed using a Nano ITC Low Volume (TA Instruments) or a Mi-
croCal™ VP-ITC System (GE Healthcare). Proteins were prepared in SEC buffer at a con-
centration of 100 µM (Nano ITC Low Volume) or 20 µM (MicroCal™ VP-ITC). Ligands 
were prepared in the same buffer at concentrations of 1 mM (Nano ITC Low Volume) or 
200 µM (MicroCal™ VP-ITC). If concentrations differed from these values, it will be indi-
cated. Titration experiments were performed at 307 rpm stirring speed and 25 °C. The 
ligand solution was injected into the sample cell at 0.5 µL/s and with 200-250 s gap time 
between single injections. Data were visualized using NanoAnalyze (TA Instruments), Ori-
gin7 and Origin9 (OriginLab, Northampton, MA). The programs NITPIC, Sedphat and 
Gussi were utilized for thorough data analysis and figure preparation (Houtman et al., 
2007; Keller et al., 2012). 
 
5.7 Microbiological Methods 
5.7.1 Preparation of M9 Agar for Spot Plate Assays 
M9 glucose minimal agar (M9) plates for spot plate assays were prepared by heating 
63.5 mL of 2x agar (30 g/l) to boiling in a microwave. 25 mL of 5x M9 salts, 34.5 mL of 
ddH2O and 3 mL of glucose-salt stock were added and mixed by shaking. 45 mL of this 
solution were transferred to a sterile falcon tube containing an appropriate amount of li-
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gand stock solution. The agar solution was mixed and 15 mL were poured into a petri 
dish for cooling. Agar plates were freshly prepared on the day of the experiment. Pyo-
cyanin and bleomycin were used in spot plate assays to investigate the physiological 
functions of PA0803, PA1353, PA3127, PA3128 and PA4641. A 50 mM pyocyanin stock 
solution in 100% DMSO was used to add pyocyanin to the M9 agar plates in final concen-
trations 10 µM, 100 µM and 1 mM. An appropriate amount of DMSO was added to keep 
its concentration at the same level (0.02%) in all plates. A stock solution of 1 mM bleo-
mycin in SEC buffer was used to add bleomycin added to the plates in final concentra-
tions of 1 µg/mL, 0.5 µg/mL as well as 0.1 µg/mL. 
 
5.7.2 Spot Plate Assay in E. coli 
Spot plate assays were used to demonstrate the function of βαβββ-module proteins in 
living cells. E. coli BL21(DE3) cells were transformed with the respective plasmids accor-
ding to 5.2.13 and grown on LB agar supplemented with appropriate antibiotics at 37 °C 
overnight. A 4 mL culture supplemented with appropriate antibiotics was inoculated 
with a single colony and grown again at 37 °C overnight. 200 µL of this culture were used 
to inoculate a 50 mL LB culture supplemented with appropriate antibiotics. The 50 mL 
culture was grown to an OD600 of 0.8 and induced with 0.5 mM IPTG. After overnight 
protein production at 20 °C under vigorous shaking, the OD600 of the cells was norma-
lized to 1 and a serial dilution was prepared in fresh LB medium without antibiotics in a 
sterile 96-well plate. Using a multichannel pipette, 5 µL of the appropriate dilutions were 
spotted on agar plates. The spots were allowed to dry under the clean bench. Plates 
were incubated at 37 °C overnight and imaged on the following day. 
 
5.7.3 Spot Plate Assay in P. aeruginosa 
5.7.3.1 Transposon Mutants 
P. aeruginosa PAO1wt and PA14wt, as well as transposon mutants ΔPA0803, ΔPA1353, 
ΔPA3127 and ΔPA4641 (Table 3, Liberati et al., 2006; Held et al., 2012) were cultivated in 
LB medium overnight at 37 °C to regenerate them from glycerol shock. On the following 
day, a fresh culture of LB medium was inoculated with 5 µL from the overnight culture 
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and again grown at 37 °C ON using appropriate antibiotics. On the next day, the OD600 of 
the cells was normalized. Using a multichannel pipette, a serial dilution was prepared in 
fresh LB medium without antibiotics in a sterile 96-well plate. 5 µL of the appropriate di-
lutions were spotted on the freshly prepared agar plates (Section 5.7.1). The spots were 
allowed to dry under the clean bench. Plates were incubated at 37 °C overnight and 
imaged on the following day. 
 
5.7.3.2 Gain-of-Function Strains 
P. aeruginosa PAO1wt and P. aeruginosa gain-of-function strains (Table 3) were prepared 
using P. aeruginosa PAO1 magnesium-competent cells (Section 5.2.12) which were 
transformed (Section 5.2.13) with pHERD30T plasmids (Table 2), each carrying one gene 
encoding a βαβββ-module protein PA0803, PA1353, PA3127 or PA4641. The gain-of-
function strains were cultivated in LB medium overnight at 37 °C to regenerate them 
from glycerol shock. On the following day, a fresh culture of LB medium supplemented 
with 12 µg/mL gentamicin was inoculated with 5 µL from the overnight culture and again 
grown at 37 °C. At an OD600 = 0.8, the cells were induced with 0.1% arabinose and grown 
at 20 °C overnight. On the next day, the OD600 of the cells was normalized and a serial 
dilution was prepared in fresh LB medium without antibiotics in a sterile 96-well plate. 
Using a multichannel pipette, 5 µL of the appropriate dilutions were spotted on the 
freshly prepared agar plates (Section 5.7.1). The spots were allowed to dry under the 
clean bench. Plates were incubated at 37 °C overnight and imaged on the following day. 
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6 Results and Discussion 
This work deals with βαβββ-module containing proteins from P. aeruginosa PAO1. First, 
general results on the identification and classification of proteins of this fold family from 
P. aeruginosa will be discussed. Then, a selection of βαβββ-module containing proteins 
from P. aeruginosa PAO1 which were examined during this study will be discussed. For 
this purpose, the proteins will be split into functional groups and discussed separately.  
 
6.1 General Aspects of the βαβββ-Module Protein in P. aeruginosa PAO1 
6.1.1 Identification of βαβββ-Module Proteins in P. aeruginosa PAO1 
In earlier studies, three EhpR-like βαβββ-module containing proteins from P. aeruginosa 
PAO1 have been identified: PA0803, PA1353 and PA4641. These proteins have been 
characterized biophysically by ITC and structurally by X-ray crystallography. They bind 
the blue phenazine pyocyanin, an important P. aeruginosa virulence factor, with low µM 
KD. In order to identify further βαβββ-module containing proteins from P. aeruginosa 
PAO1, the protein fold recognition server Phyre2 (Protein Homology/analogy Recognition 
Engine V 2.0) was employed in a BackPhyre search (Kelley & Sternberg, 2009). In this 
BackPhyre search, a known protein structure is used to browse the genome of a target 
organism to identify genes that might produce proteins of similar fold. In the BackPhyre 
procedure, the sequence and secondary structure information is extracted from the 3D 
structure provided by the user to build a Hidden Markov model (HMM). This model is 
matched to the HMM database of all proteins encoded in the genome of interest.  
Using the crystal structure of EhpR from P. agglomerans (Yu et al., 2011), the genome of 
P. aeruginosa PAO1 was searched for additional βαβββ-module containing proteins. In 
this BackPhyre search the Phyre2 server returned a list of 21 βαβββ-module containing 
proteins. The BackPhyre search was repeated using the crystal structures of PA0803 (Yu, 
2009), PA1353 and PA4641 (Kalawy-Fansa, 2010). Again, the search algorithm yielded 
the same 21 βαβββ-module proteins found using EhpR as a search model, but in slightly 
different order (Table 18). 
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Table 18: Result of the BackPhyre search with EhpR in the P. aeruginosa PAO1 genome that identified 21 
probable βαβββ-module containing proteins. PA4641 was not identified by BackPhyre because it was 
thought to be a pseudogene. In total, 22 βαβββ-module containing proteins are present in the P. aerugi-
nosa genome. The rank, residues modeled, the confidence of the model and the sequence identity (Id.) 
are indicated for the search with EhpR in BackPhyre. These are then compared to sequence identity (Id.) 
of the results from PA0803, PA1353 and PA4641. The results show the low sequence identity, but high 
structural similarity among the βαβββ-module containing proteins. 
Rank 
EhpR 
Protein 
Total 
No. of 
Residues 
Residues 
modeled 
Conf. 
/ % 
Id. 
/ % 
Id. to PA0803 
/ % 
Id. to PA1353 
/ % 
Id. to PA4641 
/ % 
1 PA3956 144 1-132 99.8 16 20 16 17 
2 PA0817 141 3-133 99.8 17 20 13 11 
3 PA3389 137 1-127 99.7 14 16 17 14 
4 PA4518 141 5-128 99.7 20 24 23 16 
5 PA4183 155 31-148 99.7 11 23 15 17 
6 PA0880 126 2-125 99.7 13 17 9 15 
7 PA1129 135 1-115 99.7 16 19 21 14 
8 PA0803 146 1-143 99.7 16 100 14 9 
9 PA2546 143 1-137 99.7 16 16 16 14 
10 PA1672 126 1-121 99.7 15 23 17 11 
11 PA2024 140 4-126 99.7 11 22 12 11 
12 PA5111 176 15-168 99.7 17 16 15 12 
13 PA3503 211 36-157 99.6 11 17 13 13 
14 PA3524 128 1-126 99.6 14 15 23 15 
15 PA0710 131 1-127 99.6 12 19 13 18 
16 PA3127 267 1-115 99.6 18 28 24 19 
17 PA1353 137 4-133 99.3 12 14 100 44 
18 PA1358 132 1-131 99.1 15 16 25 29 
19 PA0865 357 5-138 98.9 5 13 11 13 
20 PA2721 159 2-121 94.9 13 20 21 20 
21 PA0242 634 287-413 93.4 6 18 8 8 
(22) PA4641 137 - - -   100 
 
In total, the genome of P. aeruginosa PAO1 contains 22 βαβββ-module proteins. The 
secondary structure elements of these 22 proteins were modeled with high confidence 
(> 90%), even if most of them share relatively low sequence identity (< 30%). However, 
22 similar proteins are much more than expected. According to SCOPe Database (Version 
2.04 2014-09-11), there are 1205 different protein folds known (Fox et al., 2014). Since 
P. aeruginosa PAO1 possesses 5570 genes (Stover et al., 2000), statistically every protein 
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fold should occur between four and five times, but since the βαβββ-module fold is pre-
sent in 22 proteins of P. aeruginosa PAO1, this fold seems to be privileged. Possibly, this 
is because the modules can be combined easily by gene duplication and horizontal gene 
transfer. Since the binding or active sites are located at the dimer interfaces, few muta-
tions may be sufficient to generate new functions. The low sequence similarity also indi-
cates that mutations might have been introduced all over the protein, as long as the 3D 
structure and fold were conserved. Therefore, only very few residues are conserved in 
the sequence. Due to the low sequence identity among the βαβββ-module proteins, it is 
impossible to assign functions any of the 22 βαβββ-module proteins in P. aeruginosa 
PAO1 just by bioinformatics approaches. Nevertheless, it may be possible to describe 
some general characteristics of these proteins and then to classify them into subgroups.   
 
6.1.2 Functionally or Structurally Characterized βαβββ-Module Proteins 
Four of the 22 βαβββ-module proteins of P. aeruginosa PAO1 have been functionally 
characterized. The proteins PA0701, PA3524 and PA5111 were found to detoxify methyl-
glyoxal. Thus, PA0701, PA3524 and PA5111 were termed GloA2, GloA1 and GloA3, res-
pectively. GloA enzymes have been described in pro- and eukaryotes (Sukdeo & Honek, 
2007). Interestingly, two biochemically distinct classes of GloA enzymes, a Zn(II)-activa-
ted and a non-Zn(II)-activated class exist (Sukdeo et al., 2004). Surprisingly, P. aeruginosa 
possesses enzymes from both metal activation classes: GloA3 belongs to the Zn(II)-con-
taining holoenzymes, while GloA1 and GloA2 can be activated by either Ni(II) or Co(II). 
Furthermore, P. aeruginosa is the only organism known to date to possess three of these 
enzymes (Sukdeo & Honek, 2007). In contrast, PA1129 (PDB entry 1NNR) was characte-
rized as a fosfomycin resistance protein FosA in vitro and in vivo (Rife et al., 2002; Rigsby 
et al., 2004). This Mn(II)- and K+-dependent enzyme catalyzes the detoxification of fosfo-
mycin under GSH consumption.  
Structural analysis of five of the 22 βαβββ-module proteins of P. aeruginosa PAO1 has 
been performed in the past decades. The crystal structures of PA2721 (PDB entry 1U69, 
(Nocek et al., 2006) and PA1358 (PDB entry 1U7I, Osipiuk et al., to be published) have 
been determined. However, both proteins have not been examined biochemically and 
there is no hint for a function of these proteins. Furthermore, the crystal structures of 
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PA0803, PA1353 and PA4641 have been determined and a preliminary function as pyo-
cyanin resistance proteins has been assigned to them using ITC and soaking techniques 
(Yu, 2009; Kalawy-Fansa, 2010).  
 
6.1.3 Sequence Alignment of P. aeruginosa PAO1 βαβββ-Module Proteins 
In order to classify the βαβββ-module proteins of P. aeruginosa PAO1, the structural 
alignment program PROMALS3D (Pei et al., 2008). The crystal structure of PA0803 was 
utilized together with the protein sequences of all βαβββ-module proteins comprising 
two modules per monomer (Figure 22 and Figure 23).  
 
 
Figure 22: Part I of the structural alignment of βαβββ-module proteins with PROMALS3D (Pei et al., 
2008). Sequences of all proteins containing two modules per monomer were aligned to the three-
dimensional crystal structure of PA0803. Red triangles indicate residues conserved for metal-binding 
(H, H, and E), blue stars indicate residues conserved for aromatic compound binding (two out of F, H, 
W, and Y).  
 
The 22 βαβββ-module proteins are not very homologous regarding their overall se-
quence. Still, some amino acids are abundant in these proteins, for instance alanine, 
aspartate, glycine and leucine. Furthermore, there are several positions in which amino 
acids are structurally conserved. Some proteins possess two conserved histidine residues 
and a glutamate in the active center (red triangle). In others these residues are not con-
served, but instead they include two aromatic residues that could be phenylalanine, his-
tidine, tryptophan or tyrosine (blue star). In all remaining proteins, either not all or none 
of these residues important for metal- or aromatic compound-binding are conserved.  
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Figure 23: Part II of the structural alignment of βαβββ-module proteins with PROMALS3D (Pei et al., 
2008). The sequences of all proteins containing two modules per monomer were aligned to the three-
dimensional structure of PA0803. Red triangles indicate residues conserved for metal-binding (H, H, 
and E), blue stars indicate residues conserved for aromatic compound binding (two out of F, H, W, and 
Y).  
 
Further residues are conserved in few positions in the proteins. The residues probably 
are essential to maintain the βαβββ-module structure or the hydrophobic interface at 
the core of the proteins. An example of conserved residues is given in Figure 24. 
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Figure 24: Structurally conserved residues (colored in red in the alignment, Figures 22 and 23) in 
βαβββ-module resistance proteins from P. aeruginosa, using PA1353 (yellow) and FosA (PA1129, teal) 
as examples. Conserved residues are shown as sticks. They are mainly located at the interface of two 
modules within one monomer. Hence, they stabilize the three-dimensional structure of the βαβββ-
module resistance proteins.  
 
PA1129 (FosA) and PA1353 were chosen as examples to analyze the residues in structu-
rally conserved positions. These residues are preferentially found at the intramolecular 
interface of the of βαβββ-module protein monomers. Most of these residues are hydro-
phobic, for instance leucine, alanine or methionine, but also an aspartate is conserved at 
this interface. These residues are most likely important to stabilize the three-dimensio-
nal structure of the βαβββ-module proteins. In contrast, few conserved residues are 
found in the binding site, as mentioned above.  
 
6.1.4 Classification of βαβββ-Module Proteins from P. aeruginosa PAO1 
On the basis of the structural alignment with PROMALS3D, it is possible to classify the 
βαβββ-module proteins from P. aeruginosa PAO1 into three classes I, II and III based on 
the conserved residues in the active center (Table 19). 
In class I, the metal-binding βαβββ-module proteins can be found. These proteins pos-
sess two conserved histidine residues and a glutamate in the active center. They coordi-
nate a divalent metal cation together with a water molecule. Possible cations are Mn(II), 
Fe(II), Co(II), Ni(II), Zn(II) or Mg2+ (Armstrong, 2000), depending on the reaction catalyzed 
by the proteins. The class I βαβββ-module proteins are subgrouped according to the 
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number of βαβββ-modules per monomer. In subgroup I, all proteins with two modules 
per monomer can be found. In subgroup II, the proteins with 4 modules are located. All 
class I proteins probably catalyze detoxification reactions, such as the degradation of 
methylglyoxal (PA0710, PA3524, PA5111) or fosfomycin (PA1129). 
 
Table 19: Classification of βαβββ-module containing proteins in P. aeruginosa PAO1 ac-
cording to alignment with PROMALS3D (Pei et al., 2008). A 
#
 indicates that the structure is 
already known, a 
+
 indicates an additional domain. Conserved residues are given in the se-
cond line. 
Class I Class II Class III 
Metal-Binding Proteins 
Aromatic Compound 
Binding Proteins 
Proteins of 
Unknown Function 
          H, H, E                            H, H, E Two out of F, H, W or Y ? 
Subgroup I 
(2 modules) 
Subgroup II 
(4 modules) 
  
PA0710 (GloA2)   PA0242
+
 PA0803
#
 PA0880 
PA0817 PA0856 PA1353
#
 PA1672 
PA1129 (FosA)
#
  PA3127
+
   PA2721
#
 
PA2024  PA4641
#
   PA1358
#
 
PA2546   PA4183 
PA3389   PA4518 
 PA3503
+
    
PA3524 (GloA1)    
PA3956    
PA5111 (GloA3)    
 
Class II βαβββ-module proteins are proteins that possess two aromatic residues in their 
binding pocket. These residues could be phenylalanine, histidine, tryptophan or tyrosine. 
The aromatic compound is supposed to be sandwiched between the two aromatic resi-
dues via π-stacking interactions. In contrast to class I proteins, class II βαβββ-module 
proteins do not alter their ligand chemically, but may act as a chaperone for the ligand.  
Class III βαβββ-module proteins do neither contain all three metal-binding residues nor 
both aromatic compound binding residues conserved in their active center. Hence no 
functional prediction on these proteins is possible. The proteins might split up into more 
distinct classes if they are investigated structurally and biochemically.  
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6.1.5 βαβββ-Module Proteins in the Focus of This Study 
In order to shed light on some of these βαβββ-module proteins from P. aeruginosa 
PAO1, this research focuses on the structural and functional characterization of βαβββ-
module proteins from class II (aromatic compound binding proteins) and class III (pro-
teins of unknown function). On the one hand, the potential pyocyanin resistance factors 
PA0803, PA1353 and PA4641 as well as the uncharacterized fourth class II protein 
PA3127 will be examined functionally and structurally. This approach will include investi-
gation of PA1354 which is encoded in an operon together with PA1353 (Figure 25).On 
the other hand, the class III proteins of unknown function PA0880, PA1672, PA4183 and 
PA4518 will be subject to 3D structure determination. 
 
 
Figure 25: βαβββ-module proteins in the focus of the study and their predicted operons from P. aeru-
ginosa PAO1 according to DOOR (Mao et al., 2009). Fold, function or subcellular localization are indi-
cated by the following color code: blue: βαβββ-module proteins; red: cytoplasm; light orange; cyto-
plasmic membrane. 
 
6.2 Purification of Recombinant βαβββ-Module Proteins 
The proteins investigated in this study were purified following a common protocol. 
Hence, only the purification of PA3127 is exemplarily described in detail here. 
 
6.2.1 PA3127 as an Example Purification 
The 267-amino acid protein PA3127 was expressed as an N-terminal His6-tag fusion pro-
tein including a TEV protease cleavage site. The purification of PA3127 was performed 
using Ni(II)-IMAC, TEV protease cleavage during dialysis in SEC buffer and revNi(II)-IMAC. 
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As the final purification step, size exclusion chromatography was used to isolate a single 
oligomerization species of the protein (Figure 26). 
 
 
Figure 26: Purification of PA3127. PA3127 was expressed as a fusion protein with an N-terminal His6-
tag and a TEV protease cleavage site. The protein was purified via Ni(II)-IMAC and size exclusion chro-
matography. M: protein standard; -: before induction; +: after induction with IPTG; Ni: after Ni(II)-
IMAC; ucl: uncleaved protein in dialysis; cl: cleaved protein (+TEV) in dialysis; revNi-cl: cleaved protein 
after revNi(II)-IMAC; Mix: mix of uncleaved and cleaved protein in revNi(II)-IMAC; SEC: PA3127 after 
size exclusion chromatography.  
 
The purification yielded 8 mg of protein/L of culture. The protein was >90% pure as 
estimated from SDS-PAGE. 
 
6.2.2 Final Purity of All βαβββ-Module Proteins 
All proteins used in this study were produced and purified following a common protocol. 
Protein purification proceeded using Ni(II)-IMAC and size exclusion chromatography. If 
the His6-tag was cleaved for crystallization, TEV protease was added to the dialysis and 
an additional Ni(II)-IMAC step was performed, before SEC was performed as the final 
purification step. Purification of His6-PA0803, His6-PA1353 and His6-PA4641 has been de-
scribed in detail before (Yu, 2009; Kalawy-Fansa, 2010). Additionally, purification of 
PA1672 and PA3127 has been described in studies under the supervision of the author 
(Weber, 2011; Popp, 2013). In this study, purification of PA0880, His6-PA1354, 
PA4183_16-155, PA4183_32-155 and PA4518 have been performed for the first time. 
The final purity of each protein purified in this study is shown in Figure 27.  
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Figure 27: Final purity of the proteins after the final SEC purification step. 20 µg of protein were 
loaded and compared to a molecular weight standard. This gel is used to estimate the final purity of 
the protein. Most proteins have the expected molecular weight (Table 20). PA1672 is running at a 
lower molecular weight than expected. Most proteins are highly pure >90% as estimated). 
 
All proteins were isolated in high purity and yield from E. coli. A summary on the protein 
purification of the proteins investigated in this study, including yield and purity estima-
tions, is given in Table 20.  
 
Table 20: Protein purification summary. The type of protein, the molecular weight, the purification stra-
tegy (2 = IMAC, SEC; 4 = IMAC, TEV cleavage, revIMAC, SEC) and the yield are listed in this table. Purities 
are estimated from SDS-PAGE gels. - = not subjected to crystallization. 
Protein 
MW / 
kDa 
Purification  
Steps 
Oligomer  
in SEC 
Yield 
/ mg/L of culture 
Final Purity 
/ %  
Crystals 
His6-PA0803 17.94 2 dimer 50 >95 yes 
PA0880 13.87 4 dimer 22 >85 yes 
His6-PA1353 15.28 2 dimer 50 >95 - 
His6-PA1354 18.03 2 dimer 31 >90 yes 
PA1672 13.61 4 dimer 5 >90 yes 
PA3127  29.60 4 dimer 8 >90 yes 
PA4183_16-155 15.58 4 dimer 35 >90 yes 
PA4183_32-155 13.80 4 dimer 32 >80 no 
PA4518 15.35 4 dimer 20 >95 yes 
His6-PA4641 17.28 2 dimer 68 >95 - 
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6.3 Proteins of Unknown Function – PA1354, PA4183, PA1672 and PA4518 
6.3.1 PA1354  
6.3.1.1 Bioinformatic Analysis of PA1354  
The cytoplasmic protein PA1354 is predicted to be encoded in an operon together with 
PA1353, a probable pyocyanin resistance factor. In this study, PA1354 was produced as 
His6-PA1354 fusion protein. This construct yields a 158-amino acid protein with a calcula-
ted molecular weight of 18.03 kDa and a theoretical pI of 5.12 (Gasteiger et al., 2003). 
The amino acid sequence of PA1354 was submitted the PDB, which returned only one 
protein structure, the hypothetical protein PA1349 from P. aeruginosa, with a sequence 
identity of 26%. Additionally, the sequence of PA1354 was submitted to the structure 
prediction server Phyre2 (Table 21), in order to identify structurally related proteins and 
a possible function. The model confidence for PA1354 significantly dropped after the 
first three hits.  
 
Table 21: Models used for Phyre
2
 predictions of PA1354. PF03795 = YCII related domain, PF02426 = mu-
conolactone δ-isomerase. 
PDB ID Functional Annotation 
Sequence 
Identity / % 
Model 
Confidence / % 
PFAM 
family 
1S7I PA1349 from P. aeruginosa; ferredoxin-like, 
YCII-related domain 
29 100 PF03795 
4LBH 5-chloro-2-hydroxyhydroquinone 
dehydrochlorinase from Burkholderia 
phenoliruptrix 
24 98.2 PF03795 
1MWQ hypothetical protein from Haemophilus 
influenzae with a putative active-site 
phosphohistidine 
13 98.1 PF03795 
3ZNU chloromuconolactone dehalogenase ClcF from  
Rhodococcus opacus 
20 89.8 PF02426 
1MLI muconolactone isomerase from Pseudomonas 
putida 
19 79.7 PF02426 
 
On the one hand, Phyre2 relates PA1354 to muconolactone δ-isomerases (PF02426) that 
catalyze the third step in the conversion of catechol to succinate and AcCoA. On the 
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other hand, Phyre2 predicts PA1354 to be a ferredoxin-like, YCII-related domain protein 
(PF03795). According to the Protein Families Database PFAM (Finn et al., 2014), this do-
main might have an enzymatic function catalyzed by a conserved histidine and an aspar-
tate residue. Caulobacter crescentus possesses a protein (UniProt entry Q9A8M4) where 
a YCII domain is fused to a σ70 factor, suggesting that it might play a role in transcription 
initiation. Thus, PA1354 possibly interacts with a σ-factor to initiate the expression of 
distinct genes in P. aeruginosa. 
 
6.3.1.2 Crystallization of His6-PA1354 
Three initial crystallization hits were identified for His6-PA1354 (JCSG Core I G2, H1 and 
JCSG Core II F7). All of them yielded plate-shaped crystals. After optimization, well-dif-
fracting crystals were obtained from 0.1 M sodium acetate pH 5, 20% (w/v) MPD (JCSG 
Core I G2) (Figure 28). In diffraction experiments, they diffracted to 2.5 Å. 
 
 
Figure 28: Crystals of His6-PA1354 are fragile plates, but diffracted to 2.5 Å. Scale bar is 200 µm. 
 
6.3.1.3 Data Collection and Structure Solution Attempts of His6-PA1354 Crystals 
Optimized crystals of His6-PA1354 were flash cooled in liquid nitrogen without additional 
cryoprotectants and subjected to data collection on beamline 14.1 at BESSY II Synchro-
tron of the HZB, Berlin, Germany. 105 images of 1° were collected on a MarCCD Chess 
detector using a wavelength of λ = 0.9184 Å. Data were integrated with XDS (Kabsch, 
2010) and scaled with Aimless from the CCP4 program suite (Evans, 2006, 2011; Winn et 
al., 2011). The space group of His6-PA1354 crystals could not be determined unambigu-
ously, but is most probably P21212 as analyzed by POINTLESS from the CCP4 suite (Winn 
et al., 2011). Data collection and processing statistics are given in Table 22. 
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Table 22: Data collection statistics of a P. aeruginosa PAO1 His6-PA1354 crys-
tal. Values in parentheses are for the highest resolution shell. 
Dataset  His6-PA1354 
Wavelength (Å) / beamline
≠
 0.9184 / BESSY II, 14.1 
Resolution range (Å) 52.04-2.5 (2.6-2.5) 
Space group P21212 
Unit cell parameters    (Å) 
                                         (°) 
52.04   61.46   50.36 
90   90   90 
Mosaicity (°)
†
 0.192 
Total No. of measured reflections 24521 (2749) 
Unique reflections 5927 (647) 
Multiplicity 4.1 (4.2) 
Mean I/σ(I) 14.4 (2.0) 
Completeness (%) 99.7 (99.8) 
Rmeas (%) 6.8 (53.5) 
Rp.i.m. (%) 3.3 (39.1) 
†
Mosaicity values reported by XDS (Kabsch, 2010)  
 
Various MR attempts to determine the structure of His6-PA1354 failed. There are only 
few models available in the PDB, as predicted and seen in the previous BLAST and Phyre2 
searches (Table 22). All of them were used for MR attempts, as well as the MR engine 
BALBES. Thus, phasing strategies such as selenomethionine labeling or heavy atom deri-
vatization will have to be applied in the future in order to phase the structure of PA1354. 
 
6.3.2 Class III βαβββ-Module Protein PA4183 
6.3.2.1 Bioinformatic Analysis of PA4183 
The sequence of the cytoplasmic protein PA4183 was available from the Pseudomonas 
Genome Database (Winsor et al., 2011) and it was identified as a class III βαβββ-module 
protein in P. aeruginosa PAO1 genome by the BackPhyre search using EhpR. According to 
the alignment using PROMALS3D (Figure 22, Figure 23), PA4183 belongs to the class III 
βαβββ-module proteins. As contradictory information was available on which was the 
starting methionine of the open reading frame of PA4183, three constructs His6-PA4183, 
His6-PA4183_16-155 and His6-PA4183_32-155 were cloned. A BLAST Search in the PDB 
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using the sequence of PA4183 returned one hit, an uncharacterized protein MM3218 
from Methanosarcina mazei without any functional characterization. Phyre2 analysis of 
PA4183 returned a high confidence model, but no hint to a function for PA4183.  
 
6.3.2.2 Crystallization of PA4183_16-155 
While His6-PA4183_32-155 was insoluble, His6-PA4183 and His6-PA4183_16-155 were 
soluble and could be purified. However, only His6-PA4183_16-155 crystallized in two 
conditions, JCSG Core I B1 and D7, yielding long needles and rods, respectively. However, 
after optimization no diffracting crystals of PA4183_16-155 were obtained (Figure 29). 
 
 
Figure 29: Rod shaped crystals of PA4183_16-155 showed no diffraction in X-ray test experiments. 
Scale bar is 200 µm. 
 
6.3.3 Class III βαβββ-Module Protein PA1672 
6.3.3.1  Bioinformatic Analysis of PA1672 
PA1672 was produced as a His6 fusion protein in E. coli and purified via Ni
2+-IMAC and 
TEV cleavage of the His6 tag during dialysis overnight. Size exclusion chromatography 
was performed as the last purification step, yielding PA1672 with a calculated molecular 
weight of 13.61 kDa, respectively (Gasteiger et al., 2003). PA1672 is a class III βαβββ-mo-
dule resistance protein of unknown function, lacking two of the three metal-binding re-
sidues as well as both aromatic compound binding residues. The gene encoding PA1672 
is predicted not to be included in operons (Mao et al., 2009). Hence, the genetic context 
is probably not helpful to understand the function of PA1672.  
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A BLAST search in the PDB (E-value cut off 1.0) using the sequence of PA1672 only identi-
fied three hits with sequence similarity over the whole protein, namely RHA04853 from 
Rhodococcus sp. RHA1 (PDB entry 2RU6, 26% sequence identity), a glyoxalase I from Lis-
teria monocytogenes (PDB entry 3E5D, 26% sequence identity) and a glyoxalase/bleo-
mycin resistance protein from Albidiferax ferrireducens (PDB entry 4QB5, 25% sequence 
identity). However, these three proteins lack functional characterization and do not pro-
vide a starting point for functional characterization of PA1672. Phyre2 structure predic-
tions for PA1672 are accurate and predict the structure of PA1672 with high model con-
fidence, and identified 120 potential templates for structural modeling. The top five hits 
are given in Table 23.  
The proteins identified in the Phyre2 search are proteins from glyoxalase subfamilies I, II 
and IV, meaning from metal-binding enzymes or from antibiotic resistance proteins such 
as the mitomycin resistance proteins. For this reason, it is not possible to identify the 
function of PA1672 from this search. 
 
Table 23: Models used for Phyre
2
 predictions of PA1672. PF00903 = glyoxalase I, PF12681 = glyoxalase II, 
PF13669 = glyoxalase IV. * = also identified in the BLAST search in the PDB. 
PDB ID Functional Annotation 
Sequence 
Identity / % 
Model 
Confidence / % 
PFAM 
family 
2R6U* RHA04853 from Rhodococcus sp. RHA1 26 99.9 PF00903, 
PF12681 
4G6X glyoxalase/bleomycin resistance protein from 
Catenulispora acidiphila 
23 99.8 PF00903, 
PF12681 
2I7R protein from Streptococcus pneumoniae 16 99.8 PF12681 
1MPY Catechol-2,3-dioxygenase 
(metapyrocatechase) from P. putida  
23 99.8 PF00903 
1QIP Human glyoxalase I complexed with S-P-
nitrobenzyloxycarbonylglutathione 
16 99.8 PF00903, 
PF12681, 
PF13669 
 
Conserved domain analysis of PA1672 with the Conserved Domain Database (CDD) 
(Marchler-Bauer et al., 2015) correctly classifies PA1672 as a member of the glyoxalase 
superfamily, and identifies it as a catechol-dioxygenase, and more specifically as an 
SgaA_N-like protein. SgaA suppresses the growth disturbance caused by high osmolality 
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and a high concentration of A-factor (2-isocapryloyl-3R-hydroxymethyl-γ-butyrolactone), 
during early growth in Streptomyces griseus. A-factor controls morphological differentia-
tion and secondary metabolism in the S. griseus QS system. However, A-factor has not 
been found in Pseudomonads yet. The protein SgaA might also function as a streptomy-
cin resistance protein. This indicates that is does not bind divalent metal cations, as pre-
dicted in the previous sequence alignment. However, the 3D structure of SgaA is not 
available and cannot be compared with PA1672. 
  
6.3.3.2 Crystallization and Data Collection of PA1672  
Two initial hits were identified for PA1672 (JCSG Core I H2 and Core IV D6). Both hits 
were optimized and yielded well diffracting crystals (Figure 30). However, crystals ob-
tained in 4.3 M sodium chloride, 0.1 M HEPES/NaOH pH 7.5 (JCSG Core IV D6) showed 
perfect twinning. Thus, an untwinned crystal obtained in 0.1 M sodium acetate pH 4.5, 
20% (w/v) MPD was used for crystallographic data collection.  
 
 
Figure 30: Crystals of PA1672. A: Perfectly twinned crystals in 4.3 M sodium chloride, 0.1 M 
HEPES/NaOH pH 7.5. B: Untwinned crystals in 0.1 M sodium acetate pH 4.5, 20% (w/v) MPD were 
used for data collection. Scale bar is 200 µm. 
 
Crystals of PA1672 were cryoprotected in mother liquor supplemented with additional 
5% (w/v) PEG 3350 / 15% (v/v) glycerol before flash cooling in liquid nitrogen. Diffraction 
data of PA1672 crystals were collected as 100 1° images on a MarCCD Chess detector at 
a wavelength of λ = 0.9184 Å on beamline 14.1 at BESSY II Synchrotron of the HZB, 
Berlin, Germany. Data collection and processing statistics are given in Table 24. 
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Table 24: Data collection and processing statistics for a P. aeru-
ginosa PAO1 PA1672 crystal. Values in parentheses are for the 
highest resolution shell.  
Dataset  PA1672 
Wavelength (Å) / beamline
≠
 0.9184 / BESSY II, 14.1 
Resolution range (Å) 44.13-1.81 (1.85-1.81) 
Space group P21212 
Unit cell parameters    (Å) 
                                         (°) 
74.12   88.27   35.15 
90   90   90 
Mosaicity (°)
†
 0.292 
Total No. of measured reflections 85590 (4348) 
Unique reflections 21636 (1211) 
Multiplicity 4.0 (3.6) 
Mean I/σ(I) 17.6 (2.3) 
Completeness (%) 99.4 (94.9) 
Rmeas (%) 5.4 (70.4) 
Rp.i.m. (%) 2.7 (36.3) 
†
Mosaicity values reported by XDS (Kabsch, 2010)  
 
The PA1672 crystal diffracted to a resolution of 1.81 Å at the BESSY II Synchrotron and 
was indexed in orthorhombic space group P21212 with cell parameters a = 74.12, b = 
88.27 and c = 35.15. The Matthews coefficient (Matthews, 1968) was calculated as 2.11 
Å3/Da which corresponds to a solvent content of 42% and two PA1672 molecules (one 
dimer) in the asymmetric unit.  
 
6.3.3.3 Structure Solution and Refinement of PA1672  
The structure of PA1672 was determined by MR in PHASER from CCP4 using a dimer of 
RHA04853 from Rhodococcus sp. RHA1 (PDB entry 2R6U, Zhang et al., to be published) in 
BALBES. RHA04853 is an uncharacterized protein and has 28% sequence identity to 
PA1672. The model building and refinement yielded the structure of PA1672 with Rwork = 
19.8% and Rfree = 24.1% and with 97.9% of the residues in Ramachandran-favored 
regions. The MolProbity score of the PA1672 structure is 1.20 (Table 25). 
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Table 25: Refinement statistics for P. aeruginosa PAO1 
PA1672. Values in parentheses are for the highest resolution 
shell.  
Dataset  PA1672 
Resolution range (Å) 44.13-1.81 (1.85-1.81) 
Rwork (%) 19.8 (24.9) 
Rfree (%) 24.1 (29.7) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
1905 
- 
- 
120 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.007 
1.013 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
38 
- 
- 
41 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
97.9 
0 
MolProbity score
#
 1.20 
#
As reported by MolProbity (Chen et al., 2010) 
 
6.3.3.4 Overall Topology of PA1672  
PA1672 belongs to the class III βαβββ-module proteins of P. aeruginosa and to the Pfam 
clan of glyoxalases and shows the typical overall topology of this protein family (Figure 
31). PA1672 folds into two βαβββ-motifs to form the full monomer. Both modules 
display the typical βαβββ structure and are numbered from β1-β8 and α1-α2 (Figure 
31A). The protein forms a dimer in solution and in the crystal’s asymmetric unit (Figure 
31B). Dimer formation occurs by strong hydrophobic and salt-bridge interactions and is 
essential to form the potential ligand or substrate binding pockets at the two dimer in-
terfaces of the PA1672 dimer. The PA1672 dimer is formed by edge-to-edge dimerization 
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interactions, where β-sheets of the two monomers interact with each other, but α-heli-
ces of the same protein interact (Figure 31C).  
 
 
Figure 31: Overall topology of PA1672. A: The PA1672 monomer displays the typical βαβββ-module pro-
tein structure with two modules per chain. B: PA1672 forms a physiological dimer with two binding 
pockets. These are formed by both proteins of the homodimer. The homodimer is also found in the 
asymmetric unit of the PA1672 crystal. C: Topology diagram of PA1672. The PA1672 dimer is formed by 
edge-to-edge contacts. D: Surface representation of the nearly perfectly globular PA1672. The dimer 
shows arm-to-arm exchange that is stabilized by closure of interacting loops. 
 
A surface representation of the PA1672 dimer clearly demonstrates dimerization via 
arm-to-arm exchange, a typical feature of βαβββ-module proteins. The arm-to-arm ex-
change is stabilized by two interacting loops that close over the N-terminus (Figure 31D). 
However, domain swapping is no observed in PA1672. The binding pocket of PA1672 is 
rather open and large (Figure 31B+D) and may possibly harbor larger molecules than 
other βαβββ-module resistance proteins. 
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6.3.3.5 Potential Active Center of PA1672  
In order to identify potential catalytic residues, the probable substrate binding sites of 
PA1672 are examined (Figure 32). In the PA1672 potential catalytic pocket, several 
potential catalytic residues are located. For instance, histidines such as H6 and H42 often 
play a catalytic role or chelate metal cations (Bartlett et al., 2002). Furthermore, several 
polar residues are found in the binding pocket, such as E8, or E107, S38, R115 and Q119. 
These residues might either be involved in hydrogen bonds or in catalytic activity of 
PA1672. Aromatic residues such as Y62, Y72 or F94 may either aid in establishing π-
interactions with aromatic or hydrophobic compounds, or, in case of the tyrosines, may 
be catalytically involved. Also, M40, I70, L99 or I105 are able to engage in hydrophobic 
contacts with potential ligands. However, only from the presence of these amino acids in 
the binding site, no function of the protein can be deduced.  
 
 
Figure 32: Potential active center of PA1672. A: Location of the ligand/substrate binding site in the 
PA1627 dimer. The binding site is formed by residues from both molecules of the dimer. B: Close-up 
of the potential active site with amino acid residues that might be involved in ligand/substrate 
binding or catalysis of the enzymatic reaction. 
 
For this reason, the structure of PA1672 was submitted to the 3D Search for Protein 
SITEs (SPRITE) server (Nadzirin et al., 2012) to analyze 3D motifs in the active site of 
PA1672 and identify a possible function for PA1672. The SPRITE server returned 17 dis-
tinct protein motif hits derived from PDB structures. The only two hits involving residues 
in the probable catalytic pocket of PA1672 are given in Table 26. No protein of the glyo-
xalase superfamily, but only proteins from unrelated fold families were identified by 
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SPRITE. For this reason, it is unlikely that PA1672 carries out the exact reaction that one 
of these proteins is able to catalyze. PA1672 might catalyze either a hydrolase or transfe-
rase reactions. In contrast, many of the already classified βαβββ-module proteins are 
oxidoreductases or lyases. 
 
Table 26: Two hits of the 3D motif search with PA1672 using the SPRITE server (Nadzirin et al., 2012). 
Only these hits involve residues in the potential binding pocket of PA1672.* = residues in the potential 
active center of PA1672. 
PDB Hit Description r.m.s.d. No. of residues 
Matches 
Pattern | PA0880 
1BGL  β-galactosidase 1.15 3 
E537 | E8* 
Y503 | Y62* 
E461 | E107* 
1ULA purine nucleoside phosphorylase 1.29 3 
H86 | H6* 
E89 | E8* 
N243 | N74* 
 
 
6.3.4 Class III βαβββ-Module Protein PA4518 
6.3.4.1 Bioinformatic Analysis of PA4518 
A BLAST search (E-value cut off 0.001) in the PDB using the sequence of PA4518 identi-
fied two homologous proteins, a glyoxalase-related enzyme from Fulvimarina pelagi 
(PDB entry 3BQX, 37% sequence identity) and a glyoxalase/bleomycin resistance pro-
tein/dioxygenase from Conexibacter woesei (PDB entry 4GYM, 32% sequence identity). 
However, the proteins lack functional characterization and do not provide a starting 
point for functional characterization of PA4518.    
In the Phyre2 structure prediction, 120 potential template structures were identified, and 
a high confidence PA4518 structure was modeled. PA4518 was correctly identified as a 
βαβββ-module protein. The top five hits of the Phyre2 modelling (Table 27) include the 
two hits identified by the BLAST search in the PDB, and also identify a mitomycin resis-
tance protein from S. lavendulae, a metallo-protein from Bacillus cereus and the 2,3-di-
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hydroxybiphenyl-1,2-dioxygenase (DHBD). Thus, PA4518 is homologous to metal-binding 
and aromatic compound binding proteins, indicating that no hint to a certain function is 
provided. 
   
 Table 27: Models used for Phyre
2
 predictions of PA4518. PF00903 = glyoxalase I, PF12681 = glyoxalase II. 
* = also identified in the BLAST search in the PDB. 
PDB ID Functional Annotation 
Sequence 
Identity / % 
Model 
Confidence / % 
PFAM 
family 
3BQX* glyoxalase-related enzyme from Fulvimarina 
pelagi 
31 100 PF00903, 
PF12681 
4GYM* glyoxalase/bleomycin resistance protein/dio-
xygenase from Conexibacter woesei 
22 99.9 PF12681 
1KLL Mitomycin resistance protein from S. 
lavendulae 
20 99.9 PF00903, 
PF12681 
1ZSW Bacillus cereus metallo-protein 18 99.9 PF00903 
1LGT 2,3-dihydroxybiphenyl-1,2-dioxygenase 
(DHBD) 
16 99.9 PF00903 
 
Conserved domain analysis with CDD (Marchler-Bauer et al., 2015) correctly identifies 
PA4518 as a member of the glyoxalase superfamily, specifically as a member of glyoxa-
lase I/bleomycin resistance protein family. Furthermore, it predicts the protein to bind a 
divalent metal cation. However, in the sequence alignment with PROMALS3D (Figure 22 
and Figure 23), only one of the three metal-binding residues seems to be conserved in 
PA4518. Similarly, the aromatic amino acid side chains used for π-stacking interactions 
with aromatic moieties are not conserved in PA4518. This indicates that PA4518 might 
have enzymatic function that does not require divalent metal cations, or that it does 
bind compounds that lack aromatic moieties.  
 
6.3.4.2 Crystallization and Data Collection of PA4518 
Nineteen initial hits were identified for PA4518, but most of them were tiny needles of 
30 µm length or less. Three of the initial hits (JCSG Core II C8, Core III F6 and Core IV F9) 
were optimized. Finally, well-diffracting crystals were obtained from 0.1 M sodium ci-
trate pH 3.6, 10% (w/v) MPD (Figure 33).  
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Figure 33: Crystals of PA4518 in 0.1 M sodium citrate pH 3.6, 10% (w/v) MPD. A: Crystals from the 
screen B: Optimized crystals. Scale bar is 200 µm. 
 
Crystals of PA4518 were cryoprotected in mother liquor supplemented with additional 
15% (v/v) MPD before flash cooling them in liquid nitrogen. Diffraction data a PA4518 
crystal was collected as 100 1° images on a MarCCD Chess detector at a wavelength of λ 
= 0.9184 Å on beamline 14.1 at BESSY II Synchrotron of the HZB, Berlin, Germany. Data 
collection and processing statistics are given in Table 28. 
 
Table 28: Data collection and processing statistics for P. aerugi-
nosa PAO1 PA4518. Values in parentheses are for the highest 
resolution shell.  
Dataset  PA4518 
Wavelength (Å) / beamline
≠
 0.9184 / BESSY II, 14.1 
Resolution range (Å) 46.08-1.47 (1.5-1.47) 
Space group P212121 
Unit cell parameters    (Å) 
                                         (°) 
42.0   72.73   92.16 
90   90   90 
Mosaicity (°)
†
 0.143 
Total No. of measured reflections 198136 (9644) 
Unique reflections 48687 (2362) 
Multiplicity 4.1 (4.1) 
Mean I/σ(I) 11.9 (2.0) 
Completeness (%) 99.7 (99.4) 
Rmeas (%) 9.7 (85.8) 
Rp.i.m. (%) 4.7 (41.5) 
†
Mosaicity values reported by XDS (Kabsch, 2010)  
 
The PA4518 crystal diffracted to a resolution of 1.47 Å at the BESSY II Synchrotron and 
was indexed in orthorhombic space group P212121 with cell parameters a = 42.0, b = 
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72.73 and c = 92.16. The Matthews coefficient (Matthews, 1968) was calculated as 2.29 
Å3/Da which corresponds to a solvent content of 46% and two PA4518 molecules (one 
dimer) in the asymmetric unit. 
  
6.3.4.3 Structure Determination and Refinement of PA4518 
The structure of PA4518 was determined by MR in PHASER from CCP4 using a dimer of 
the crystal structure of an uncharacterized glyoxalase-related enzyme from Fulvimarina 
pelagi (PDB entry 3BQX, Rao et al., to be published) with 37% sequence identity.  
 
Table 29: Refinement statistics for PA4518. Values in pa-
rentheses are for the highest resolution shell.  
Dataset  PA4518 
Resolution range (Å) 46.08-1.47 (1.5-1.47) 
Rwork (%) 13.6 (22.5) 
Rfree (%) 15.6 (23.5) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
2630 
- 
32 
411 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.012 
1.453 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
14 
- 
36 
30 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
98 
0 
MolProbity score
#
 1.27 
#
As reported by MolProbity (Chen et al., 2010) 
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The structure of PA4518 was obtained with an Rwork = 13.6% and an Rfree = 15.6% with 
98% of the residues in Ramachandran-favored regions and a MolProbity score of 1.27 
(Table 29). 
 
6.3.4.4 Overall Topologies of PA4518 
PA4518 belongs to the class III βαβββ-module proteins of P. aeruginosa and to the Pfam 
clan of glyoxalases and folds into two typical βαβββ-motifs (Figure 34).   
 
 
Figure 34: Overall topology of PA4518. A: The PA4518 monomer consists of two βαβββ-modules. 
However, β2 and β6 are degenerate and rather unstructured. Interestingly the protein carries a hinge 
loop with an additional α-helical element. B: PA4518 forms a dimer in solution as well as in the asym-
metric unit of the crystal. C: The topology diagram of PA4518 displays the dimerization via edge-to-
edge contacts. D: Surface representation of PA4518 shows tight arm-to-arm exchange between the 
two monomers. The dimerization is further stabilized by interacting loops that close across the N-ter-
minus.  
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However, β2 and β6 seem to be rather unstructured or only partially structured com-
pared to the β-sheets in PA1672. Interestingly, the protein carries a hinge loop with an 
additional α-helix. PA4518 forms a highly stable dimer in solution and in the crystal’s 
asymmetric unit (Figure 34B). The PA4518 dimer is formed by edge-to-edge interactions, 
where β-sheets of the two monomers interact with each other, but α-helices of the 
same monomer interact (Figure 34C). At the dimer interfaces, the potential ligand or 
substrate binding pockets is formed. This pocket is smaller than the pocket of PA1672. A 
surface representation of the PAPA4518 dimer (Figure 34D) clearly demonstrates dimeri-
zation via arm-to-arm exchange, a typical feature of βαβββ-module proteins. The arm-
to-arm exchange is stabilized by two loops from the other protein which interact and 
close over the N-terminus. 
 
6.3.4.5 Potential Active Center of PA4518 
PA4518 displays two different active site conformations, an open form and a closed form 
(Figure 35A). In the open form, the loop Q103 to Y110 sticks out of the protein with 
W107 pointing towards a neighboring molecule in the crystal. This conformation allows 
the binding pocket to harbor two MPD molecules from the mother liquor (Figure 35D). In 
the closed conformation, this loop Q103 to Y110 turns towards the binding pocket of 
PA4518. In this conformation, W107 is turned into the binding pocket, which causes it to 
be smaller and to contain only one MPD molecule (Figure 35C). The conformational dif-
ferences are caused by crystal packing, but might as well be of physiological relevance.  
As predicted by the sequence alignment with PROMALS3D (Figure 22 and Figure 23), no 
metal-binding site is observed in this protein. Also, no evident aromatic compound bind-
ing motif is found in PA4518. Still, a variety of residues potentially involved in ligand 
binding or catalytic activity is located in the PA4518 binding pocket. For instance, aroma-
tic residues such as F40, Y51, Y113, W 107, F129 and W130 may either aid in establishing 
π-interactions with aromatic or hydrophobic compounds, or, in case of the tyrosines, 
may be catalytically involved. Especially W107 might play a role in ligand/substrate bind-
ing, as it is located in the flexible loop of PA4518. Similarly, L8, V38, L56 and V105 are 
able to engage in hydrophobic contacts. Polar residues such as T10, D59, T73, N103, 
S111, E123 and N127 might either establish hydrogen bonds or in catalytic activity of 
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PA4518. However, no cysteine or histidine residues which are often involved in catalytic 
activity (Bartlett et al., 2002) are found in the binding pocket of PA4518.  
 
 
Figure 35: Potential active center of PA4518 with MPD (green) from the precipitant solution. A: Top 
view of PA4518 with an open (left) and closed (right) conformation of the binding pocket. B: Location 
of the ligand/substrate binding site in the PA4518 dimer. C: Detailed view of the binding pocket in its 
closed conformation with amino acid residues that might be involved in ligand/substrate binding or 
catalysis of the enzymatic reaction. D: Detailed view of the binding pocket in its open conformation. 
 
The structure of PA4518 was submitted to the SPRITE server (Nadzirin et al., 2012) to 
analyze 3D motifs in the active site of the protein and identify a possible function for 
PA4518. Analysis with the SPRITE server returned 31 distinct protein motif hits derived 
from PDB structures. However, none of these hits involves side chains in the binding 
pocket of PA4518. Similarly, analysis of PA4518 with PDBeFold (Krissinel & Henrick, 
2004) identified 180 hits, but as the fold of this families is highly conserved, while the 
sequence is not, this analysis did not aid in identifying a possible function for PA4518.  
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6.4 The Probable Itaconate-Metabolic Enzyme PA0880 
6.4.1 Bioinformatic Analysis of PA0880 
In this study, PA0880 was produced as a His6-PA0880 fusion protein with a calculated 
molecular weight of 15.75 kDa (Gasteiger et al., 2003). After TEV cleavage, two residues 
GH are left on the N-Terminus. The resulting protein is a 128-amino acid protein with a 
calculated molecular weight of 13.87 kDa, a low extinction coefficient of 2980 M-1cm-1 
and a theoretical pI of 5.28 (Gasteiger et al., 2003). The amino acid sequence of PA0880 
was submitted the PDB, which returned three similar structures, all of them βαβββ-
module proteins. Additionally, the sequence of PA0880 was sent to the structure predic-
tion server Phyre2. Phyre2 returned a structural model with high confidence, but no hints 
to a certain protein function. The top five hits, including the three structures identified 
by the BLAST search in the PDB are given in Table 30.  
 
Table 30: Models used for Phyre
2
 predictions of PA0880. PF12681 = glyoxalase II family, PF00903 = Glyo-
xalase/Bleomycin resistance protein family.*= also identified in PDB search 
PDB ID Functional Annotation 
Sequence 
Identity / % 
Model 
Confidence / % 
PFAM 
family 
3ZW5* human glyoxalase domain protein 5 57 99.9 PF12681 
3HUH* biphenyl-2,3-diol 1,2-dioxygenase iii-related 
protein2 from S. typhimurium 
65 99.9 PF12681 
3EY7* mobile metagenome of V. cholera integron 
cassette protein vch_cass1 
60 99.9 PF12681 
1ZSW Bacillus cereus metallo protein from glyoxa-
lase II family  
21 99.9 PF00903 
4HC5 glyoxalase/bleomycin resistance protein from 
Sphaerobacter thermophilus  
17 99.9 PF00903, 
PF12681 
 
Homologs of the P. aeruginosa class III βαβββ-module protein PA0880 belong to the gly-
oxalase I/bleomycin resistance protein family (PF00903) and to the glyoxalase II protein 
family (PF12681). However, no hint pointing to a certain function can be derived from 
the structural homolog predictions or the protein families. Also, no publications on these 
five proteins are available to retrieve hints to the protein functions. Furthermore, BLAST 
searches, domain analysis or secondary structure predictions all yield more than 8000 
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hits, making it impossible to identify a protein with the same or very similar function to 
PA0880 just from sequence homology. Interestingly, the cytoplasmic βαβββ-module pro-
tein PA0880 is predicted to be encoded in an operon with PA0878, PA0879, PA0881, 
PA0882 and PA0883 (Mao et al., 2009). This gene cluster has recently been demonstra-
ted to be involved in itaconate metabolism in P. aeruginosa (Sasikaran et al., 2014).  
 
6.4.2 Background - Itaconate Production and Metabolism 
Itaconate (methylene succinate) is a mammalian metabolite produced in phagocytic cells 
such as macrophages. These cells enclose the invading bacterial cell to form the phago-
some, and later, the phagolysosome, where the bacterium is degraded. Macrophages 
are considered as part of the primary line of defense upon a bacterial infection. Recent-
ly, macrophages were shown to produce and secrete itaconate in response to increased 
interferon γ levels and lipopolysaccharide (Strelko et al., 2011). Itaconate production is 
therefore considered as an antibacterial response of these phagocytic cells (Strelko et 
al., 2011). This is because itaconate is a potent inhibitor of isocitrate lyase (McFadden & 
Purohit, 1977), a key enzyme in the glyoxalate cycle. Many pathogenic bacteria use the 
glyoxalate cycle to assimilate AcCoA produced during fatty acid degradation (Lorenz & 
Fink, 2002) and fatty acids seem to be the main carbon source in macrophages. Additio-
nally, itaconate is secreted and used as a carbon source by extracellular pathogens such 
as P. aeruginosa (Mittal et al., 2009). Thus, the ability of pathogenic bacteria to metabo-
lize itaconate is regarded as an evolutionary advantage that helps the bacteria to survive 
and persist in the host cell.  
The itaconate degradation pathway of P. aeruginosa is slightly different from the one of 
Yersinia pestis. Both pathways have recently been discovered and investigated in the 
same study (Sasikaran et al., 2014). In the first step of itaconate degradation in P. aeru-
ginosa, itaconate is activated to the corresponding CoA ester by succinyl-CoA:itaconate 
CoA transferase (Ict) (Figure 36). Then, itaconyl-CoA is hydrated to (S)-citramalyl-CoA by 
an itaconyl-CoA hydratase (Ich). Finally, (S)-citramalyl-CoA is cleaved to AcCoA and pyru-
vate by an (S)-citramalyl-CoA lyase (Ccl). In P. aeruginosa, the genes encoding the itaco-
nate-degrading enzymes were recently identified via a BLAST search with the Y. pestis 
Ccl (Sasikaran et al., 2014). The P. aeruginosa Ccl (PA0883) is encoded in an operon with 
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Ict (PA0882) and Ich (PA0878). Surprisingly, three additional proteins are encoded in this 
operon: a putative acyl-CoA dehydrogenase (PA0879), an MmgE-PrpD family protein 
(PA0881) and the βαβββ-module protein (PA0880) (Sasikaran et al., 2014). 
 
  
Figure 36: Scheme of the itaconate degradation pathway in P. aeruginosa (Sasikaran et al., 2014). Ita-
conate is activated to itaconyl-CoA by Ict under succinyl-CoA consumption. Ich transforms itaconyl-
CoA into mesaconyl-CoA and hydrates it to form (S)-citramalyl-CoA. Finally, Ccl degrades (S)-citrama-
lyl-CoA into AcCoA and pyruvate. 
 
Since Pseudomonas spp. are also able to metabolize (S)-citramalate, mesaconate and 
methylsuccinate, it is tempting to speculate that the three uncharacterized enzymes 
PA0879, PA0880 and PA0881 might be responsible for channeling these substrates into 
the itaconate degradation pathway (Sasikaran et al., 2014). After potential formation of 
methylsuccinyl-CoA by Ict, PA0879 might catalyze the methylsuccinyl-CoA dehydroge-
nase reaction, while PA0881 might convert mesaconate into (S)-citramalate, because 
mesaconate cannot be activated to the CoA ester by Ict (Sasikaran et al., 2014). How-
ever, a potential function of PA0880 remains elusive. PA0880 might be involved in con-
version of the product of the PA0879 reaction, or conversion of (S)-citramalate to a com-
pound that can be activated by Ict. Assuming that PA0880 might catalyze a standard 
glyoxalase reaction, the protein might act as an isomerase or epoxide-opening enzyme 
(Figure 37,  Armstrong, 2000). Hence, it could catalyze an isomerization reaction on (S)-
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citramalate, or an epimerization reaction on a CoA derivative, such as the methylmalo-
nyl-CoA epimerase. Still, such enzymes require methyl ions.  
 
 
Figure 37: Isomerization and epoxide-opening reactions catalyzed by the metal-depending clade of the 
βαβββ-module proteins. However, PA0880 is predicted not to contain a metal-ion. GS = glutathione 
 
Another possibility could be a nucleophilic attack of a cysteine residue at the carbonyl-
CoA of a CoA derivative. βαβββ-module proteins such as the fosfomycin resistance pro-
teins FosA/B/X (e. g. PA1129)  catalyze such nucleophilic attacks in the opening of the 
epoxide ring of fosfomycin.  
 
6.4.3 Crystallization and Data Collection of PA0880 
PA0880 was screened with the JCSG Core Screens I-IV (Qiagen). Several conditions yiel-
ded needle-shaped crystals. A well-diffracting crystal was obtained directly from the 
screening plate in 0.1 M sodium acetate pH 4.5, 50% (v/v) ethylene glycol and 5% (w/v) 
PEG 1000 (JCSG Core II F3) (Figure 38). However, it was not possible to reproduce and 
optimize crystals of PA0880 in any condition tested on 24-well plates.  
 
 
Figure 38: Crystals of PA0880 from JCSG Core II F3. The crystals could not be reproduced in an opti-
mization plate and therefore not be optimized. Scale bar is 200 µm.  
 
Diffraction data collection of the PA0880 crystal required no further cryoprotection and 
was performed on beamline 14.1 at BESSY II Synchrotron of the HZB, Berlin, Germany, 
where 100 images of 1° oscillation were collected on a MarCCD Chess detector at a 
wavelength of λ = 0.9184 Å. Data collection statistics are given in Table 31. 
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Table 31: Data collection and processing statistics of P. aeruginosa PAO1 
PA0880. Values in parentheses are for the highest resolution shell. 
Dataset  PA0880 
Wavelength (Å) / beamline
≠
 0.9184 / BESSY II, 14.1 
Resolution range (Å) 45.54-1.53 (1.56-1.53) 
Space group P212121 
Unit cell parameters    (Å) 
                                         (°) 
42.86   49.93   111.03 
90   90   90 
Mosaicity (°)
†
 0.091 
Total No. of measured reflections 148584 (7214) 
Unique reflections 36757 (1772) 
Multiplicity 4.0 (4.1) 
Mean I/σ(I) 15.1 (3.0) 
Completeness (%) 99.9 (99.6) 
Rmeas (%) 7.2 (56.2) 
Rp.i.m. (%) 3.6 (27.5) 
†
Mosaicity values reported by XDS (Kabsch, 2010) 
 
The PA0880 crystal diffracted to a resolution of 1.53 Å and was indexed in orthorhombic 
space group P212121 with cell parameters a = 42.86, b = 49.93 and c = 111.03. The 
Matthews coefficient (Matthews, 1968) was calculated as 2.16 Å3/Da which corresponds 
to a solvent content of 43% and two PA880 molecules (one dimer) in the asymmetric 
unit.  
 
6.4.4 Molecular Replacement and Refinement of PA0880  
An appropriate MR model for the structure of PA0880 was identified by a BLAST search 
with the PA0880 sequence in the PDB. The structure of PA0880 was then solved using 
PHASER (McCoy et al., 2007) using a dimer of the virulence protein STM3117 from Sal-
monella typhimurium (PDB entry 3HNQ, Northeast Structural Genomics Consortium, tar-
get ID StR274, Seetharaman et al. to be published). This protein shares 66% sequence 
identity with PA0880, and has also been identified in the previous BLAST and Phyre2 
search in the PDB. It is equivalent to a biphenyl-2,3-diol 1,2-dioxygenase iii-related pro-
tein2 from S. typhimurium (PDB entry 3HUH, Northeast Structural Genomics Consortium, 
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Fedorov et al., to be published). The structure of PA0880 was finally refined to an Rwork = 
15.4% and an Rfree = 17.6% with a MolProbity score of 0.92. In the PA0880 structure, 99.2 
% of the residues are found in Ramachandran-favored regions (Table 32).   
 
Table 32: Refinement statistics for P. aeruginosa PA0880. Values 
in parentheses are for the highest resolution shell.  
Dataset  PA0880 
Resolution range (Å) 45.54-1.53 (1.56-1.53) 
Rwork (%) 15.4 (20.5) 
Rfree (%) 17.6 (20.8) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
2256 
12 
70 
308 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.004 
1.013 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
14 
25 
34 
34 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
99.2 
0 
MolProbity score
#
 0.92 
PDB entry code - 
#
As reported by MolProbity (Chen et al., 2010) 
 
6.4.5 Overall Topology of PA0880 
According to homology predictions, PA0880 belongs to the family of glyoxalase II or 
βαβββ-module resistance proteins (Kanehisa, 2002). In the crystal, the PA0880 mono-
mer folds into two canonical βαβββ-motifs with the first motif reaching from amino acid 
residues 7 to 52 and the second motif from 69 to 125 (Figure 39A). The protein forms a 
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dimer in solution and in the crystal’s asymmetric unit (Figure 39B). The PA0880 dimer is 
formed by edge-to-edge interactions, where β-sheets β1 and β5 of the two monomers 
interact with each other, but α-helices interact intramolecularly (Figure 39C). A surface 
representation of the PA0880 dimer clearly demonstrates dimerization via arm-to-arm 
exchange, a typical feature of βαβββ-module proteins. 
 
 
Figure 39: Overall topology of PA0880. A: PA0880 monomer shows the characteristic architecture with 
two βαβββ-modules. B: Physiological dimer of PA0880 as it is found in the asymmetric unit of the crys-
tal. C: Topology diagram of the PA0880 dimer which is formed by edge-to-edge contacts. D: Surface re-
presentation of the PA0880 dimer shows significant arm-to-arm exchange of the two PA0880 proteins 
forming the homodimer. 
 
The N-terminus of the first protein chain stretches across the whole second protein 
chain (Figure 39D) and vice versa, thereby providing strong dimer interactions. These 
interactions are typically found in proteins of the βαβββ-module protein family.  
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6.4.6 ITC Experiments with PA0880 
As PA0880 was suspected to be involved in conversions of methylsuccinate or (S)-citra-
malate in the itaconate degradation pathway (Sasikaran et al., 2014), twenty potential 
substrates (Figure 40) of PA0880 were selected based on the respective publication and 
examined for binding in ITC experiments.  
  
 
Figure 40: Potential ligands or substrates of PA0880 tested in ITC experiments. The protein showed no 
affinity to any of these potential ligands which were selected on the basis of a publication by Berg and 
coworkers (Sasikaran et al., 2014). Pyocyanin was used as a control. 
 
In the ITC experiments of PA0880, no affinity was detected for the potential twenty 
ligands or substrates. This either demonstrates that none of the substances tested is an 
actual ligand or substrate to PA0880, or that the conditions chosen for the experiment 
were not suitable to test these compounds. As the same conditions were also chosen for 
successful ITC experiments in this study, it is more likely that the tested substances do 
indeed not bind to PA0880. Another reason for the unsuccessful ITC experiments could 
be that PA0880 binds a CoA derivative of one of the ligands. These derivatives have not 
been tested yet in the ITC experiments. For this reason, no protein function can be 
derived from these experiments.  
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6.4.7 Potential Active Center of PA0880 
The potential active center of PA0880 is located at the dimer interface and formed by 
residues from both molecules of the PA0880 dimer (Figure 41). In this binding pocket, 
two histidines H8 and H51 are located, as well as a cysteine C72. These residues are 
often involved in metal-binding or catalysis. However, no metal ion could be found in the 
binding pocket of PA0880. Further residues present are aromatic side chains as F57 or 
Y111, aliphatic amino acids as L119, and polar residues such as K47, N49, D70, R100, 
S109, E121 and S123.  
 
 
Figure 41: Potential active center of PA0880. A: Location of the ligand/substrate binding site in the 
PA0880 dimer. The binding site is formed by residues from both molecules of the dimer. B: Close-up 
of the potential active site with amino acid residues that might be involved in ligand/substrate 
binding or catalysis of the enzymatic reaction. 
 
Histidine and cysteine are the amino acid residues with the highest catalytic propensity 
(Bartlett et al., 2002). This means that they are much more abundant in active centers of 
enzymes than they are over the whole protein. For instance, the motif H8-C72-E121 in 
PA0880 could be a potential Zn(II)-binding motif (Auld, 2001). However, no metal ion is 
coordinated in the structure of PA0880. Cysteine is also often involved in nucleophilic 
attacks, as in hydrolases or proteases. One example for a cysteine protease is papain 
that utilized a histidine-activated cysteine as its catalytic residue.  
The structure of PA0880 was submitted to the SPRITE server (Nadzirin et al., 2012) to 
analyze 3D amino acid motifs in the active site of PA0880 and identify a possible function 
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for PA0880. The SPRITE server returned 26 distinct protein motif hits derived from PDB 
structures. The top five hits are given in Table 33.  
  
Table 33: Top five hits of the 3D motif search with PA0880 using the SPRITE server (Nadzirin et al., 2012). 
Citrate synthase and propionyl-CoA carboxylase bind CoA derivatives.* = residues in the potential active 
center of PA0880. 
PDB Hit Description r.m.s.d. 
No. of 
residues 
Matches 
Pattern | PA0880 
1AJ8  citrate synthase 0.98 3 
H262 | H8*, H223 | H51*, 
D312 | D70* 
1XNY  
propionyl-CoA carboxylase 
complex B 
1.03 5 
H262 | H8*, N465 | N49*, 
H223 | H51*, D312 | D70*, 
C118 | C72* 
1VJV  
ubiquitin carboxyl- 
terminal hydrolase 
1.07 3 
A420 | A45, G182 | G102, 
G183 | G104 
1AL6  citrate synthase 1.07 3 
H447 | H8*, N465 | N49*, 
C118 | C72* 
1CT9 asparagine synthetase B 1.08 10 
H320 | H8*, N175 | N49*, 
H274 | H51*, A420 | A53, 
G419 | G54, G183 | G55,  
G75 | G67, D375 | D70*,  
C25 | C72*, N74 | N118 
 
However, no protein of the glyoxalase superfamily, but only proteins from unrelated fold 
families were identified by SPRITE. Of these top five hits, the ubiquitin carboxyl-terminal 
hydrolase and the asparagine synthetase B do not seem to be similar to PA0880, but 
might catalyze a similar type of reaction. Still, their function may also be completely un-
related to the one of PA0880, as PA0880 is encoded in the itaconate metabolism gene 
cluster of P. aeruginosa. In contrast, citrate synthase catalyzes the condensation of oxa-
loacetate and AcCoA, and propionyl-CoA carboxylase degrades propionyl-CoA to methyl-
malonyl-CoA and then succinyl-CoA. Oxaloacetate, however, has been tested in the ITC 
experiments, but was found to not bind to PA0880. Hence, CoA derivatives should be in 
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the focus of future binding experiments. These experiments can be accelerated by tes-
ting metabolite mixtures of five compounds. Another possibility to probe the active site 
of PA0880 would be by docking of metabolite libraries. 
 
6.5 Pyocyanin Resistance in P. aeruginosa PAO1 
In previous studies, the crystal structures of the PA0803, PA1353 and PA46141 were de-
termined using X-ray crystallography (Yu, 2009; Kalawy-Fansa, 2010). All three proteins 
were shown to bind pyocyanin in ITC experiments and were therefore assigned to be po-
tential pyocyanin resistance factors. Crystals of PA0803, PA1353 and PA4641 were soa-
ked with pyocyanin, and ligand complexes of PA1353 and PA4641 with pyocyanin were 
obtained (Yu, 2009; Kalawy-Fansa, 2010). However, pyocanin was only found in one of 
the four binding sites in the asymmetric unit of PA0803 crystals and the quality of the 
electron density indicated that the ligand was only loosely bound. For this reason, co-
crystallization of PA0803 with pyocyanin was pursued during this study in order to 
obtain a crystal structure of PA0803 with 100% pyocyanin occupancy.  
 
6.5.1 Cocrystallization and Data Collection of PA0803 with Pyocyanin  
PA0803 was preincubated with 1 mM pyocyanin and then screened with PA0803 alone 
as a control. Crystals appeared in 14 different conditions. However, twelve of them con-
tained high concentrations of small PEGs (PEG 200, PEG 300, PEG 400, PEG 600) as the 
apo condition which has been used for the soaking approach (Yu, 2009). For this reason, 
these conditions were discarded, as a PEG 200 molecule occupies the probable pyocya-
nin binding site in the apo structure (Yu, 2009). Only two conditions did not contain 
small PEGs, however, only one of them yielded crystals only in the presence of pyocya-
nin, but no crystals in the absence of pyocyanin (Core IV H6). These crystals were opti-
mized in a 24-well setup. Finally, rod-shaped crystals were obtained from 0.8 M sodium 
dihydrogen phosphate, 1.2 M dipotassium hydrogen phosphate, 0.1 M sodium acetate 
pH 4.5, 2.5 mM pyocyanin and 2.5 mM DMSO (Figure 42). Crystals were cryoprotected in 
mother liquor supplemented with 15% (w/v) glycerol and flash cooled in liquid nitrogen. 
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Figure 42: Rod-shaped green crystal of PA0803 cocrystallized with pyocyanin. 
 
Well-diffracting PA0803 crystals with pyocyanin were sent to the BESSY II Synchrotron of 
the HZB, Berlin. Diffraction data of a PA0803 crystal was collected as 200 images of 0.5° 
rotation at a wavelength of λ = 0.9184 Å (Table 34).  
 
Table 34: Data collection and processing statistics for P. aerugino-
sa PA0803 in complex with pyocyanin. Values in parentheses are 
for the highest resolution shell.  
Dataset  PA0803 + PYO 
Wavelength (Å) / beamline 0.9184 / BESSY, BL14.1 
Resolution range (Å) 46.39-1.71 (1.74-1.71) 
Space group P21212 
Unit cell parameters    (Å) 
                                         (°) 
84.26  101.8  92.77 
90  90  90 
Mosaicity (°)
†
 0.109  
Total No. of measured reflections 357368 (19052) 
Unique reflections 86649 (4588) 
Multiplicity 4.1 (4.2) 
Mean I/σ(I) 11.6 (2.1) 
Completeness (%) 99.9 (99.9) 
Rmeas (%) 9.1 (81.2) 
Rp.i.m. (%) 4.5 (39.3) 
†
Mosaicity values reported by XDS (Kabsch, 2010) 
 
The PA0803-pyocyanin crystal diffracted to 1.71 Å and was indexed in orthorhombic 
space group P21212 with cell parameters a = 84.26, b = 101.8 and c = 92.77. Subse-
quently, these data were used to determine the PA0803 pyocyanin complex. 
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6.5.2 Structure Determination and Refinement of the PA0803-Pyocyanin 
Complex 
As the cell parameters of the PA0803-pyocyanin complex crystal are very similar to the 
ones of the apo crystal (Yu, 2009), this structure could be used in rigid body refinement 
to determine the structure of the PA0803 pyocyanin complex.  
 
Table 35: Refinement statistics for P. aeruginosa PA0803 in com-
plex with pyocyanin (PYO). Values in parentheses are for the 
highest resolution shell.  
Dataset  PA0803 + PYO 
Resolution range (Å) 46.55-1.62 (1.65-1.62) 
Rwork (%) 17.6 (35.5) 
Rfree (%) 20.2 (38.5) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
4430 
- 
52 
705 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.005 
0.999 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
27 
- 
53 
40 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
98.1 
0 
MolProbity score
#
 1.19 
PDB entry code - 
#
As reported by MolProbity (Chen et al., 2010) 
 
After the initial rigid body refinement cycle in REFMAC5, the structural model of PA0803 
was correctly placed in the electron density, confirming the presence of four PA0803 
molecules in the asymmetric unit. Additional positive m|Fobs|-D|Fcalc| electron density 
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clearly demonstrated the presence of pyocyanin in all four binding sites present in the 
asymmetric unit. The model was improved manually and refined using phenix.refine 
(Table 35). The structure of the PA0803 pyocyanin complex was finally refined to an Rwork 
= 17.6% and an Rfree = 20.2% with a MolProbity score of 1.19. In the PA0880 structure, 
98.1% of the residues are in Ramachandran-favored regions. 
Additionally, the diffraction data obtained from PA0803, PA1353 and PA4641 crystals in 
previous studies (Yu, 2009; Kalawy-Fansa, 2010) were reprocessed with XDS and Aimless 
(Evans, 2006, 2011; Kabsch, 2010) and the structures were refined to lower R-factors 
using phenix.refine (Afonine et al., 2012). The statistics can be found in the appendix. 
 
6.5.3 Crystal Structure of PA0803 in Complex with Pyocyanin 
The crystal structure of PA0803 in its apo form as well as in complex with pyocyanin at 
25% occupancy have been extensively discussed in a previous work (Yu, 2009). For this 
reason, only a short overview about the binding mode of pyocyanin to PA0803 in the 
newly determined structure with 100% pyocyanin occupancy will be given here.  
In the crystal structure of PA0803 in complex with pyocyanin (Figure 43), the phenazine 
compound can be observed in all four binding pockets of PA0803 in the asymmetric unit 
by positive m|Fobs|-D|Fcalc| electron density. The main binding interactions are provided 
by H49 and Y122* (* indicating that the residue originates from the other chain of the 
homodimer) which are both 3.5 Å apart from the pyocyanin molecule. Pyocyanin is sand-
wiched between these two side chains by π-stacking interactions. Additionally, Y93* and 
Y142* provide further hydrophobic interactions to position pyocyanin in the binding 
pocket. Two salt bridges between the hydroxyl group of Y142* and the carboxyl group of 
E51 as well as the latter and the imidazole ring of H49 stabilize the binding pocket. The 
orientation of pyocyanin in the PA0803 binding pocket could easily be determined by the 
position of its hydroxyl group, which is clearly visible in the electron density. The hydro-
xyl group is pointing away from the aromatic residues Y93*, Y122* and Y142, towards 
the more open site of the binding pocket. Interestingly, this pyocyanin orientation is dif-
ferent from the one observed in the structure solved in a previous study (Yu, 2009). This 
difference in orientation might be explained by ambiguous electron density caused by 
the reduced occupancy of pyocyanin in that structure. 
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Figure 43: Crystal structure of the PA0803 pyocyanin complex. A: The pyocyanin binding sites of the 
PA0803 homodimer are formed at the dimer interfaces. Pyocyanin is sandwiched between two aro-
matic residues. B: Positive m|Fobs|-D|Fcalc| density (σ-level = 2) confirms the presence of pyocyanin. 
Its orientation is determined by the position of its hydroxyl group. C: Binding interactions of pyocya-
nin and PA0803 are mainly established by π-stacking between H49 and Y122*. Y93* and Y142* pro-
vide further π-interactions. Salt bridges between Y142* and E51 as well as H49 and E51 further stabi-
lize the pyocyanin binding pocket. 
 
The dissociation constant KD of the interaction between pyocyanin and PA0803 has been 
previously determined as 3.92 ± 0.22 µM for PA0803 (Yu, 2009). PA0803, PA1353 and 
PA4641 may act as binding proteins for pyocyanin that should transport the compound 
to efflux pumps. These efflux pumps in turn may secrete pyocyanin into the extracellular 
space. For this reason, the moderate interaction between pyocyanin and its binding pro-
teins might be of physiological importance.  
 
6.5.4 ITC Experiments with PA0803, PA1353 and PA4641 
As previously mentioned, PA0803, PA1353 and PA464 all bind pyocyanin in the low mi-
cromolar range (Yu, 2009; Kalawy-Fansa, 2010). In order to investigate the specificity of 
PA0803, PA1353 and PA4641 towards pyocyanin, phenazines in general and towards 
other compounds containing a number of (aromatic) rings different from three (as the 
phenazines), ITC experiments were conducted with these proteins and a number of sub-
stances (Figure 44).  
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Figure 44: Compounds assayed for binding to PA0803, PA1353 and PA4641 in ITC experiments. Bleo-
mycin, a complex glycopeptide antibiotic was also assayed for binding. FMN = Flavin mononucleotide, 
HHQ = 2-heptyl-4-quinolone, PQS = Pseudomonas Quinolone Signal (2-heptyl-3-hydroxy-4-quinolone). 
 
The ability of PA0803, PA1353 and PA4641 to bind some of these compounds has also 
been investigated previously (Yu, 2009; Kalawy-Fansa, 2010). The compounds tested in 
ITC experiments with PA0803, PA1353 and PA4641 (Table 36) were chosen according to 
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their relevance in P. aeruginosa physiology, or their possible presence in habitats of P. 
aeruginosa. For instance, 2-amino-acetophenone was chosen because it gives the cha-
racteristic smell to P. aeruginosa. Phenazistatin A is a potent inhibitor of phenazine bio-
synthesis and a drug lead that targets PhzB with an affinity of KD = 51 nM (M. Mentel, 
unpublished data). HHQ and PQS were chosen because they are involved in P. aerugi-
nosa QS which controls phenazine biosynthesis. Apart from a variety of phenazine com-
pounds, also three antibiotics, mitomycin C, tetracycline and bleomycin, an anti-cancer 
drug, were chosen for the ITC binding assay. 
 
Table 36: ITC experiments with potential pyocyanin resistance factors PA0803, PA1353 and 
PA4641. 
+
 = tested in a previous study by Yu, 2009. * = tested in a previous study by Kalawy-
Fansa, 2010. - = no binding detected. Comparable KD’s of PA0803 and pyocyanin indicate the 
reproducibility of the results. KD’s obtained from this study are calculated from at least three 
independent measurements. Phz = phenazine.  
ligand PA0803 PA1353 PA4641 
anthranilic acid   -*   -*   -* 
2-amino-acetophenone - - - 
phenazistatin A - - - 
HHQ   -*   -*   -* 
PQS - - - 
1-OH-Phz   75.7 ± 7.2 µM*   4.7 ± 0.68 µM*   0.8 ± 0.18 µM* 
2-OH-Phz - 0.27 ± 0.5 µM 0.14 ± 0.02 µM 
PYO 
  3.92 ± 0.22 µM
+
 
  4.4 ± 0.32 µM* 
2.63 ± 0.15 µM 
  3.4 ± 0.25 µM* 
0.99 ± 0.19 µM 
  0.64 ± 0.35 µM* 
0.40 ± 0.11 µM 
PCA 
  -* 
- 
  24.1 ± 3.1 µM* 
 9.1 ± 3.0 µM 
  8.9 ± 0.7 µM*  
7.7 ± 0.31 µM 
2-OH-PCA - - - 
PDC - - - 
mitomycin C - - - 
FMN   -*   14.1 ± 2.6 μM*   5.9 ± 1.2 μM* 
tetracycline - - - 
bleomycin 4.94 ± 0.59 µM 2.5 ± 0.74 µM 3.27 ± 0.35 µM 
 
In the ITC experiments conducted in this and previous studies (Yu, 2009; Kalawy-Fansa, 
2010), none of the three proteins PA0803, PA1353 or PA4641 shows affinity for anthra-
nilic acid, 2-amino-acetophenone, HHQ or PQS, meaning compounds possessing only 
one or two aromatic rings. Fortunately, no binding affinity is detected for phenazistatin 
A, a promising phenazine biosynthesis inhibitor. This effect is promising for drug deve-
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lopment against phenazine biosynthesis, as the potential resistance proteins do not in-
terfere with this compound. In a previous study, FMN was demonstrated to bind to 
PA1353 and PA4641 with KDs of 14.1 ± 2.6 μM and 5.9 ± 1.2 μM, respectively, but no affi-
nity of FMN to PA0803 was detected (Kalawy-Fansa, 2010). Tetracycline, an antibiotic 
containing four 6-rings, has no affinity to any of the three proteins PA0803, PA1353 and 
PA4641. The scenario is the same for mitomycin C, an antibiotic produced by Streptomy-
ces spp. Interestingly, the complex antibiotic bleomycin was demonstrated to bind to 
PA0803, PA1353 and PA4641 (Figure 45) with affinities of 5.71 ± 0.15 µM, 2.5 ± 0.74 µM 
and 3.27 ± 0.35 µM respectively. However, the proteins slightly precipitate in the ITC ma-
chine upon bleomycin binding, indicating aggregation of the mixture. Still, they could 
have a similar function as another member of the glyoxalase superfamily, BLMT, a bleo-
mycin-binding protein from S. verticillus (PDB entry 1JIF, Sugiyama et al., 2002). 
  
 
Figure 45: Representative ITC experiments. A: Titration of bleomycin into PA4641 is followed by 
binding of bleomycin to PA4641 with a KD = 3.27 ± 0.35 µM. However, the protein seems to 
precipitate in the ITC upon bleomycin binding. B: Titration of 2-OH-Phz into PA1353 yields binding of 
2-OH-Phz to PA1353 with a KD = 0.27 ± 0.05 µM. 
 
The class of compounds that are preferentially bound by PA0803, PA1353 and PA4641 
are the phenazines, as demonstrated also in earlier studies. In this study, binding of pyo-
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cyanin to PA0803, PA1353 and PA4641 and of PCA to PA1353 and PA4641 was con-
firmed (Table 36). Additionally, binding of 2-OH-Phz to PA1353 and PA4641 with affini-
ties of KD = 0.27 ± 0.5 µM and 0.14 ± 0.02 µM was demonstrated, respectively. However, 
no binding of 2-OH-PCA or PDC was observed for any of the three proteins. A reason for 
this might be that the two carboxyl groups of PDC are too bulky for the binding pockets 
of PA0803, PA1353 and PA4641. Taken together, pyocyanin is the best-binding phena-
zine to the proteins PA0803, PA1353 and PA4641, apart from 2-OH-Phz that binds better 
to PA1353 and PA4641. PA4641 has the highest affinity for phenazines in general. All 
three proteins are most likely preferentially binding compounds with three condensed 
aromatic moieties, but compounds other than phenazines may not be generally exclu-
ded as seen for bleomycin.  
 
6.5.5 Spot Plate Assays with PA0803, PA1353 and PA4641 
Spot plate assays using both E. coli and P. aeruginosa were performed in order to investi-
gate the potential role of PA0803, PA1353 and PA464 to mediate pyocyanin resistance in 
vivo. For this purpose, E. coli carrying a pET19m plasmid encoding PA0803 or PA1353 or 
PA3127 or PA4641 were spotted on pyocyanin-doted agar plates (Figure 46). For P. aeru-
ginosa, ΔPA0803 or ΔPA1353 or ΔPA4641 transposon mutants of PAO1 or PA14 strains 
were spotted on pyocyanin-doted agar, or P. aeruginosa PAO1 were transformed with a 
pHERD30T plasmid encoding either PA0803 or PA1353 or PA4641. The latter approach 
resulted in gain-of-function strains which were tested on pyocyanin-agar plates as well.  
Both the spot plate experiments with E. coli or P. aeruginosa were not successful. First, 
E. coli was very sensitive to pyocyanin and grew on remarkably lower pyocyanin concen-
trations (10 µM) compared to P. aeruginosa (> 1 mM). This is in agreement with earlier 
findings (Hassett et al., 1992). E. coli producing no protein or PA4641 still grew when 
spotted at a density of 5x105 cells/mL, although PA4641 shows the highest binding affini-
ty for pyocyanin in vitro. E. coli producing either PA0803 or PA3127 (the protein has no 
affinity for pyocyanin) still grew when spotted at a density of 5x104 cells/mL, while E. coli 
producing PA1353 still grew when spotted at a density of 104 cells/mL. However, these 
differences are not significant, as they usually range between a 103- to 106-fold change in 
growth. 
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Figure 46: Pyocyanin spot plate assays. A: Spot plate assay of E. coli BL21(DE3) transformed with 
pET19m encoding either no protein (-) or PA0803, PA1353, PA3127 or PA4641. No significant evidence 
was found for one of the proteins to mediate pyocyanin resistance, although a slight effect is visible for 
PA1353. B: Spot plate assay of P. aeruginosa PAO1 gain-of-function strains transformed with pHERD30T 
encoding either no protein (-) or PA0803, PA1353, PA3127 or PA4641. Even at the maximum possible 
concentration of pyocyanin in aqueous solutions or media (1 mM), low concentrations of P. aeruginosa 
can still grow on pyocyanin doted agar. Equal results are obtained at even lower bacterial 
concentrations (up to 10
-5
 cells/mL) and with PAO1 and PA14 transposon mutants (data not shown).  
 
As pyocyanin is producing ROS, E. coli are probably under high oxidative stress, which in 
turn inhibits normal growth and kills the bacteria. This effect is possibly stronger than 
the chaperone-like effect of PA0803, PA1353 or PA4641. Another difficulty could be the 
lack of appropriate efflux pumps that may act together with PA0803, PA1353 or PA4641 
to export pyocyanin to the extracellular space. These facts render it more difficult to in-
vestigate the function of PA0803, PA1353 and PA4641. 
For P. aeruginosa spot plates, a maximum concentration of 1 mM pyocyanin was used, 
which is the highest possible concentration of pyocyanin in aqueous solutions or media. 
However, P. aeruginosa cells carrying pHERD30T plasmids, each encoding either no pro-
tein or PA0803, PA1353, PA3127 or PA4641 still grew on spot plates containing 1 mM 
pyocyanin when spotted at a density of 102 cells/mL. The cells were even diluted to 10-5 
cells/mL, but still P. aeruginosa was growing. Exactly the same results were obtained 
with PAO1 and PA14 transposon mutants ΔPA0803, ΔPA1353, ΔPA3127 and ΔPA4641.  
There are several problems encountered when investigating the potential function of 
PA0803, PA1353 and PA4641 in their natural origin organism P. aeruginosa. First, P. ae-
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ruginosa possess several general anti-oxidative defense mechanisms, which are upregu-
lated with increasing pyocyanin concentration (Hassett et al., 1992). These defense me-
chanisms probably interfere with the chaperone-like function of PA0803, PA1353 and 
PA4641. Second, when investigating the effect of the absence of PA0803 in a P. aerugi-
nosa Δ0803 transposon mutant, PA1353 and PA4641 are still present and might comple-
ment the function of PA0803. For this reason, no change in phenotype of P. aeruginosa 
can ultimately be observed. Attempts to generate double and triple deletion mutants of 
PA0803, PA1353 and PA4641 failed during this study due to difficulties in the overlap 
PCR step. Third, pyocyanin is a terminal signaling factor in the P. aeruginosa QS system 
(Dietrich et al., 2006). Pyocyanin regulates its own PYO Stimulon, including 51 genes, 22 
of them upregulated and 29 of them down regulated. Among the upregulated genes, 
eight genes encode putative efflux pumps, which might transport pyocanin to the extra-
cellular space, and two encode transcriptional regulators (Dietrich et al., 2006), for in-
stance the transcriptional regulator SoxR and its regulon. The expression of SoxR and the 
efflux pump MexGHI-OpmD, which is encoded in the phz2 operon of P. aeruginosa, is 
upregulated by 30-fold upon exposure to pyocyanin. This response to pyocyanin is de-
tectable after 10 min of exposure (Dietrich et al., 2006). Taken together, exposure of P. 
aeruginosa to pyocyanin subjects dramatic effects to the gene expression profile of the 
bacterium, activating several hierarchical levels of genes in a very short time frame. Fi-
nally, pyocyanin production itself is regulated by the QS systems of P. aeruginosa, which 
are able to sense the pyocyanin concentration and to dramatically change the expression 
profile of P. aeruginosa, and hence the phenotype and behavior of the bacterium. For 
these reasons, it is very hard to study the potential function of PA0803, PA1353 and 
PA4641 in P. aeruginosa. 
 
6.6 Discovery of Bleomycin Resistance in P. aeruginosa PAO1 
PA3127 is a 29.6 kDa protein with calculated extinction coefficient ε = 43555 M-1 cm-1 
and a theoretical pI of 5.3. Interestingly, the molecular weight of this βαβββ-module 
protein is about double that of usual two-module containing βαβββ-module proteins. 
Phyre2 predictions reveal that PA3127 is indeed a unique βαβββ-module resistance pro-
tein in P. aeruginosa, because it carries an additional N-acetyltransferase domain. The 
6   Results and Discussion – βαβββ-Module Resistance Proteins    
 
121 
presence of this domain indicates that this protein fulfils a particular function, probably 
mediating resistance against a certain antibiotic in the pathogen. This view is encou-
raged by the fact that a similar domain is found in a bleomycin N-acetyltransferase (BAT) 
produced by S. verticillus (Oda et al., 2010). Possibly, PA3127 is the BAT of P. aeruginosa. 
 
6.6.1 Background - Bleomycin and Bleomycin Resistance Proteins 
The natural glycopeptide antibiotic bleomycin is on the World Health Organization’s List 
of essential medicines that are needed for a basic health system. Bleomycin is produced 
by Streptomyces spp. and the term bleomycin therefore includes a number of structural-
ly related compounds. For instance, bleomycin is referred to as a mixture of bleomycin 
A2 and B2 in cancer therapy (Figure 47), where it is to treat Hodgkin’s lymphoma, squa-
mous cell carcinoma and testicular cancer, but also plantal warts or pleurodesis. 
 
 
Figure 47: The complex glycopeptide antibiotic bleomycin. The anti-cancer drug bleomycin (for instan-
ce Bleomedac® used in this study) is a mixture of bleomycin A2 and B2. Bleomycin is biosynthesized by 
non-ribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) in Streptomyces spp.   
 
The metal-bound form of bleomycin causes DNA scission in cells that are not resistant to 
the antibiotic. Two different mechanisms of action of bleomycin are discussed. On the 
one hand, bleomycin might first chelate Fe(II), thereby producing a pseudoenzyme which 
reacts with oxygen. In this manner, superoxide and hydroxide radicals are produced, that 
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in turn cleave the DNA. On the other hand, bleomycin might first bind to the DNA and 
then induce scission by abstracting a hydrogen atom from a base. This hydrogen abstrac-
tion will result in DNA strand cleavage (Hecht, 1999).  
In order to achieve resistance against self-produced bleomycin, S. verticillus produces 
two types of resistance proteins: BLMT, a bleomycin binding protein, and BAT, a bleomy-
cin-N-acetyltransferase (Figure 48).  
 
 
Figure 48: Bleomycin resistance proteins from S. verticillus. BLMT (PDB entry 1JIF, Sugiyama et al., 
2002) is a bleomycin binding protein. BLMT is a βαβββ-module protein and acts as a chaperone to-
wards the metal-bound form of bleomycin. BLMT does not alter bleomycin chemically. BAT (PDB entry 
2ZW7, (Oda et al., 2010) is a bleomycin N-acetyltransferase that catalyzes the acetylation of the 
primary amine of metal-free bleomycin under AcCoA consumption.   
 
BLMT is a homodimer and acts like a chaperone towards the metal-bound form of bleo-
mycin, and does not alter the compound chemically. The protein belongs to the βαβββ-
module proteins and the family of glyoxalase II proteins (PF12681). BLMT possesses two 
bleomycin binding sites at its dimer interfaces. In contrast, BAT is an enzyme that uses 
AcCoA to acetylate the primary amine of metal-free bleomycin, thereby rendering it 
inactive. BAT of S. verticillus forms a homodimers via dimerization of the C-terminal 
βαβββ-module domain. The N-terminal N-acetyltransferase domain is monomeric and 
binds a CoA molecule (the product of the acetylation reaction). Bleomycin is bound in 
both domains and stretches across the whole protein. The bis-thiazole moiety of bleo-
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mycin is bound in the βαβββ-module domain while the primary amine of bleomycin is in 
proximity of the potential acetyl group. 
Interestingly, the domain architecture of the S. verticillus BAT differs from the architec-
ture of the potential BAT PA3127 from P. aeruginosa (Figure 49). The difference in do-
main arrangement indicates that BAT and PA3127 probably do not have a common an-
cestor, but are derived from different gene editing events.  
 
 
Figure 49: Differences in domain arrangement of P. aeruginosa PA3127 and S. verticillus BAT. 
 
The difference in domain arrangement will not allow MR of PA3127 crystals with full 
length BAT from S. verticillus, but rather require MR using separate domains of the 
protein or other βαβββ-module domain or N-acetyltransferase domains as MR models.  
 
6.6.2 Evidence for PA3127 Bleomycin and AcCoA Binding and Catalytic Acetyl-
transferase Activity 
In order to test the hypothesis that PA3127 is a bleomycin N-acetyltransferase, the pro-
tein was subjected to ITC experiments and an HPLC-MS activity tests. In the ITC experi-
ments, PA3127 was tested for binding towards AcCoA, CoA and bleomycin as well as 
some of the substances that were tested in the experiments with the pyocyanin binding 
proteins PA0803, PA1353 and PA4641, namely pyocyanin, PCA, 2-amino-acetophenone 
and phenazistatin A (Figure 44). However, pyocyanin, PCA, 2-amino-acetophenone and 
phenazistatin A had no affinity towards PA3127 or the N-terminal βαβββ-module do-
main of PA3127 alone. In contrast, AcCoA, CoA and bleomycin demonstrate to have high 
affinity to PA3127 (Figure 50). PA3127 bind its product CoA with an affinity of KD=2.7 ± 
0.32 µM (data not shown), while it binds its cosubstrate AcCoA with a 10-fold higher 
affinity of KD = 529 ± 33 nM (Figure 50A). The affinity of PA3127 towards bleomycin is in 
the high nanomolar range with KD = 413 ± 4 nM (Figure 50B).  
The data indicate that PA3127 might indeed be a bleomycin N-acetyltransferase. The 
high affinities of PA3127 for these compounds are probably needed for the physiological 
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function of PA3127, as the enzyme has to detect, bind and detoxify already very small 
amounts of bleomycin, thereby preventing the cell from DNA damage. In order to ensure 
supply with AcCoA, the affinity for the cosubstrate is probably high, so that immediate 
acetylation of bleomycin can occur upon uptake of this toxic compound. 
 
 
Figure 50: ITC experiments with PA3127. Both binding events are exothermic and occur in 1:1 
stoichiometry. The ITC experiments were performed in two different ITC machines, which causes dif-
ferences in the plots. A: Binding of the cosubstrate AcCoA to PA3127 occurs with a KD of 529 ± 33 nM. 
B: Binding of the antibiotic substrate bleomycin to PA3127 occurs with a KD of 413 ± 4 nM.  
 
In the activity test, PA3127 was assayed together with AcCoA, NADPH, NADP+, bleomycin 
and PA3128, the protein encoded in an operon together with PA3127, in 50 mM BisTris 
pH 5.8, 6.5 or 7.2. However, it was not possible to detect AcCoA/CoA and bleomy-
cin/acetyl-bleomycin simultaneously under the conditions tested in HPLC elution. In 
these elution profiles, two reaction times (5 min and 1 or 2 h) are compared for each 
buffer condition (Figure 51). In each sample, a clear AcCoA peak was detectable. In 
contrast, a significant CoA peak is only detectable at a physiological pH of 7.2. In the 
control experiment (no enzymes) no CoA peak was detected. 
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Figure 51: HPLC elution profiles of the reaction mixtures from the PA3127 bleomycin N-acetyltransfe-
rase-assay. The shortest and longest incubation time of each buffer condition are given. A clear AcCoA 
peak can be detected in all samples, however, CoA only seems to appear in significant amount at a 
physiological pH of 7.2. At pH 6.5, only little amounts of CoA are produced, while no CoA is produced 
at pH 5.8. This indicates that PA3127 utilizes AcCoA and produces CoA, and is indeed an acetyltrans-
ferase. However, the substrate bleomycin or the reaction product acetyl-bleomycin could not be de-
tected in this experimental setup.  
 
No differences in the AcCoA/CoA peaks in the samples with different incubation time 
from one buffer condition are observed, meaning that the reaction had taken place after 
5 min. Possibly, no further conversion of AcCoA is observed because bleomycin is com-
pletely consumed. These experiments indicate that PA3127 is able to use AcCoA in an 
acetyltransferase reaction to form CoA.  
 
6.6.3 Crystallization and Data Collection of PA3127 
PA3127 was screened at various concentrations without or with bleomycin, AcCoA or 
CoA and combinations of those, using various crystallization screens. Only one condition 
yielded rod-shaped crystals (JCSG Core III F9) (Bittner, 2012), which were optimized. The 
crystals were rather solid, but difficult to reproduce. A first well-diffracting crystal was 
obtained from 0.1 M MES pH 5.6, 0.8 M ammonium sulfate (Figure 52). Surprisingly, a 
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better-diffracting crystal could be obtained after letting it dehydrate in a 24-well plate 
for 377 days.   
 
 
Figure 52: Crystals of P. aeruginosa PA3127. Initial hit in JCSG Core III F (left) and 
optimized crystals from a 24-well plate (middle/right).  
 
The PA3127 crystal was cryoprotected with 25% (v/v) glycerol before diffraction data 
collection on beamline 14.1 at BESSY II Synchrotron of the HZB, Berlin, Germany (Table 
37). A dataset of the standard cell protein crystal was collected in the course of a bache-
lor thesis under supervision of the author (Bittner, 2012) as 100 images of 1° rotation on 
a MarCCD Chess detector at a wavelength of λ = 0.9184 Å. 
 
Table 37: Data collection statistics for P. aeruginosa PA3127 in complex with residual (Ac)CoA. 
Values in parentheses are for the highest resolution shell.  
Dataset  PA3127 – standard cell PA3127 – dehydrated cell 
Wavelength (Å) / beamline
≠
 0.9184 / BESSY II, BL14.1 0.9184 / BESSY II, BL14.1 
Resolution range (Å) 96.58-2.95 (3.04-2.95) 49.03-2.48 (2.64-2.48) 
Space group P21 P21 
Unit cell parameters (Å) 
                                      (°) 
106.9  121.0  116.2 
90.0  115.35  90.0 
97.6   120.2  106.8 
90.0   112.8   90.0 
Mosaicity (°)† 0.102 0.105 
Total No. of measured reflections 121303 (9989) 259220 (17051) 
Unique reflections 55026 (4540) 70799 (4522) 
Multiplicity 2.2 (2.2) 3.7 (3.8) 
Mean I/σ(I) 8.8 (1.5) 15.7 (2.0) 
Completeness (%) 97.7 (98.5) 99.1 (98.8) 
Rmeas (%) 10.6 (69.6) 7.4 (88.1) 
Rp.i.m. (%) 6.8 (44.5) 3.8 (41.3) 
†Mosaicity values reported by XDS (Kabsch, 2010) 
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Diffraction data of the dehydrated PA3127 were collected as 1900 images of 0.1° rota-
tion using a PILATUS 6M pixel detector at a wavelength of λ = 0.9184 Å. The differences 
in cell parameters between the crystal with the standard cell and the dehydrated cell are 
obvious, as the cell axes a, b and c shrink by 9.3 Å, 0.8 Å and 9.4 Å, respectively. How-
ever, no solution of the PA3127 crystal structure could be identified using MR approa-
ches with different models or the MR engine BALBES (Long et al., 2007). Cocrystallization 
of with 5-amino-2,4,6-triiodoisophthalic acid (I3C) failed to produce crystals, while sele-
nomethionine labeling and heavy atom soaking produced crystals of low quality, either 
with weak or anisotropic diffraction properties.  
 
6.6.4 Divide and Conquer Approach 
Finally, the Divide and Conquer approach was applied to the hypothetical bleomycin-N-
acetyltransferase PA3127. For this purpose, separate constructs of the domains were de-
signed according to structure predictions by Phyre2 (Kelley & Sternberg, 2009) in a study 
parallel to this work and under supervision of the author (Popp, 2013). Diffracting crys-
tals of both the βαβββ-domain PA3127_1-114 (PA3127-NTD) and the N-acetyltransfe-
rase domain PA3127_123-267 (PA3127-CTD) were obtained. However, it was not possi-
ble to successfully determine the PA3127-CTD structure using a 2.7 Å dataset (Popp, 
2013). This was probably due to low data quality. In contrast, the PA3127-NTD structure 
was determined to a resolution of 1.55 Å (Figure 53, Popp, 2013, and Table 48 & Table 
49 in the appendix).  
The N-terminal βαβββ-domain of PA3127, PA3127-NTD, folds into two βαβββ modules 
and forms a homodimer. Binding of the bis-thiazole moiety of bleomycin probably in-
volves residues Y31, Y34 and W96, as seen in BLMT from S. verticillus. W96 is located in a 
flexible loop which probably has to undergo a conformational change upon bleomycin 
binding. A partial MR solution for the PA3127 crystal was obtained in phenix.phaser 
using the structure of PA3127-NTD. This solution includes eight PA3127-NTD molecules 
(four PA3127-NTD homodimers) in the asymmetric unit. Crystal packing suggested that 
there is enough space for the missing eight N-acetyltransferase domains. However, no 
full MR solution was obtained by using the partial solution with various N-acetyltransfe-
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rase structures deposited in the PDB. Hence, it was crucial to determine the structure of 
the PA3127 N-acetyltransferase domain PA3127-CTD alone. 
 
 
Figure 53: Results of the Divide and Conquer approach obtained in a study under supervision of the 
author (Popp, 2013). A: Crystal structure of PA3127-NTD. PA3127 is a βαβββ-module protein and 
forms a homodimer in solution. Residues Y31, Y34 and W96 are probably involved in binding the bis-
thiazole moiety of bleomycin. B: Optimized crystal of PA3127-NTD. C: Optimized crystals of PA3127-
CTD. Figure adapted from Popp, 2013.  
 
6.6.5 Crystallization and Diffraction Data Collection of PA3127-CTD 
PA3127-CTD was screened again in the presence as well as in the absence of 2 mM 
AcCoA during this study. The only initial hit was found in condition A1 of the MIDAS 
screen (0.1 M HEPES/NaOH pH 6, 50% (v/v) polypropylene glycol 400, 5% (v/v) DMSO). 
However, these crystals (Figure 54) could not be reproduced in a 24-well format. For this 
reason, PA3127-CTD crystals were isolated directly from this crystallization experiment 
and were tested for diffraction without further cryoprotection.  
 
 
Figure 54: Crystals of PA3127-CTD in condition A1 of the MIDAS screen. 
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A PA3127-CTD crystal was sent to the BESSY II Synchrotron for data collection on beam-
line 14.1. 3600 images of 0.1° rotation were collected on a PILATUS 6M detector at a 
wavelength of λ = 0.9184 Å (Table 38). 
 
Table 38: Data collection statistics for P. aeruginosa PA3127-CTD. 
Values in parentheses are for the highest resolution shell. AcCoA 
= Acetyl-Coenzyme A. 
Dataset  PA3127-CTD + AcCoA 
Wavelength (Å) / beamline 0.9184 / BESSY, BL14.1 
Resolution range (Å) 39.53-1.70 (1.73-1.7) 
Space group P31 
Unit cell parameters (Å) 
                                      (°) 
78.1   78.1   48.7 
90   90   120 
Mosaicity (°)† 0.134 
Total No. of measured reflections 376739 (20945) 
Unique reflections 36549 (1994) 
Multiplicity 10.3 (10.5) 
Mean I/σ(I) 17.4 (2.1) 
Completeness (%) 100 (100) 
Rmeas (%) 9.1 (128.7) 
Rp.i.m. (%) 2.8 (39.6) 
†
Mosaicity values reported by XDS (Kabsch, 2010) 
 
The PA3127-CTD crystal was indexed in space group P31 with cell parameters a = 78.1, b 
= 78.1, c = 48.7 and γ = 120. Hence, a new cystal form with better diffraction quality has 
been identified compared to the first crystal form (Popp, 2013). 
 
6.6.6 Structure Determination and Refinement of PA3127-CTD 
The structure of PA3127-CTD was successfully determined using BALBES (Long et al., 
2007) using the structure of the aminoglycoside N-acetyltransferase AAC(6')-Iy in com-
plex with CoA and ribostamycin (PDB entry 1S3Z, Vetting et al., 2004) as MR model. This 
protein shares 17% sequence identity with PA3127-CTD. After structure determination 
and initial refinement, the presence of one AcCoA molecule per protein molecule was 
obvious by positive m|Fobs|-D|Fcalc| density in the active site of PA3127-CTD. The structure 
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of the PA3127-CTD AcCoA complex was finally refined to an Rwork = 16% and an Rfree = 
19.1% with a MolProbity score of 1.15. In the PA3127-CTD structure, 99.3% of the resi-
dues are in Ramachandran-favored regions (Table 39).   
 
Table 39: Refinement statistics for P. aeruginosa PA3127-CTD in 
complex with AcCoA. Values in parentheses are for the highest 
resolution shell.  
Dataset  PA3127-CTD + AcCoA 
Resolution range (Å) 39.53-1.70 (1.73-1.7) 
Rwork (%) 16.0 (23.8) 
Rfree (%) 19.1 (28.5) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
2197 
- 
102 
216 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.019 
2.031 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
29 
- 
44 
26 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
99.3 
0.0 
MolProbity score
#
 1.15 
PDB entry code - 
#
As reported by MolProbity (Chen et al., 2010) 
 
6.6.7 Overall Topology of PA3127-CTD 
PA3127-CTD shares about 17-20% sequence identity with aminoglycoside N-acetyltrans-
ferases and diamine N-acetyltransferases and folds into a typical N-acetyltransferase 
(Figure 55A). The protein forms an α-β-α sandwich with the central β-sheet consisting of 
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strands β1 to β5. This sheet is flanked by two helices α1 and α2 as well as α3 and α4 on 
each site.  
 
 
Figure 55: Overall topology of PA3127-CTD in complex with AcCoA. A: The PA3127-CTD monomer folds 
into a typical N-acetyltransferase domain with four α-helices and six β-strands. B: Superposition of ace-
tyltransferases PA3127-CTD and BAT-NTD. Differences in the three-dimensional structure can be ob-
served in the region of α2 (box 2) and the β5/β6 region (box 1). C: The homodimer of PA3127-CTD is 
formed by domain swapping between β5 and β6 which provide key interactions in dimer formation. 
 
Interestingly, the three-dimensional structure of PA3127-CTD partially differs from the 
structure of the N-acetyltransferase domain of BAT from S. verticillus (Figure 55B). The 
arrangement of the C-terminal β5 and β6 strands is different in the proteins (Figure 55B, 
box 1). Similarly, the arrangement of α1 and α2 is different in the Streptomyces protein 
(Figure 55B, box 2). 
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The differences in arrangement of the C-terminal β5 and β6 strands of BAT and PA3127 
are caused by the domain swapping interactions between β5 and β6 strands from two 
PA3127-CTD molecules. These interactions lead to dimerization of two PA3127-CTD mo-
lecules (Figure 55C). The β-strands tightly interact by hydrogen bonds, mainly between 
backbone amides and backbone carbonyl groups.  
  
 
Figure 56: Tight domain swapping interactions by hydrogen bonding between the β5 and β6 strands of 
two PA3127-CTD molecules. These interacions cause stable dimerization of PA3127-CTD.  
 
6.6.8 AcCoA Binding to PA3127-CTD 
PA3127-CTD was cocrystallized with AcCoA which is present in the crystal structure as 
indicated by positive m|Fobs|-D|Fcalc| electron density (Figure 57A). The cosubstrate is 
mainly bound by hydrophobic interactions, for instance with L250 or F251, but also sta-
bilized by hydrogen bonds with PA3127-CTD and water molecules. A CDD search 
(Marchler-Bauer et al., 2015) predicts the AcCoA binding site of PA3127-CTD to include 
residues L206, Y207 and V208 as well as A218, R219 and E220. In fact, AcCoA establishes 
hydrogen bonds to the backbone carbonyl of L206 and the backbone amides of V208, 
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A218 and R219 as well as to the side chain of R214 (Figure 57B). A full plot of the AcCoA 
binding interactions is given in Figure 57C. 
 
 
Figure 57: Interactions of PA3127-CTD with AcCoA. A: Positive m|Fobs|-D|Fcalc|density (σ-level = 2) 
confirms the presence of AcCoA in the PA3127-CTD structure. B: Hydrogen bonding network of AcCoA 
and PA3127-CTD. Main interactions with the protein are established via the backbone carbonyl of 
L206, the backbone amide of V208 and the R214 main and side chain amines. C: Plot of the inter-
actions between PA3127-CTD and AcCoA generated using LigPlot+. AcCoA is stabilized by hydrogen 
bonds and hydrophobic interactions. 
 
6.6.9 Comparison of AcCoA Binding to PA3127 and BAT 
The three-dimensional structures of the N-acetyltransferase domains of PA3127 and BAT 
were submitted to the PROMALS3D alignment server (Pei et al., 2008) to identify con-
served residues. However, very few and only structurally important residues, are con-
served in these domains (Figure 58).  
In the AcCoA binding sites, the spatial positions of AcCoA binding site and residues are 
conserved, however, the residues themselves are not (Figure 58). While AcCoA is mainly 
stabilized by tryptophans in BAT, PA3127 employes hydrophobic amino acids like valine 
and leucine as well as polar arginines as AcCoA binding residues. Also, the AcCoA binding 
mode is different regarding the position of the adenosine moiety of AcCoA (Figure 59A).   
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Figure 58: Structural alignment of the N-acetyltransferase domains of PA3127 (residues 123-267) and 
of BAT (residues 9-176). AcCoA binding residues of BAT are marked with a blue triangle, AcCoA 
binding residues of PA3127 are marked with a green triangle. Structurally conserved residues are 
marked with a 9. 
 
Few amino acids are conserved in BAT and PA3127 (Figure 58, 9, Figure 59B). These 
residues are located far away from the AcCoA binding site and propably structurally sta-
bilize the protein. These conserved residues point to a common ancestor of BAT and 
PA3127, even if the types of residues in their active sites are distinct from each other.   
 
 
Figure 59: Comparison the N-acetyltransferase domains of BAT (cyan) and PA3127 (yellow). A: AcCoA 
binding residues. B: Structurally conserved residues in PA3127 and BAT identified by PROMALS3D (Pei 
et al., 2008). 
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6.6.10 Structure Determination and Refinement of PA3127 Using Both PA3127-
NTD and PA3127-CTD as MR Models 
The crystal structure of PA3127 could finally be determined by using both the PA3127-
NTD and PA3127CTD as MR models. The partial solution obtained using PA3127-NTD be-
fore was fixed in phenix.phaser and eight copies of a truncated structure of PA3127-CTD 
(PA3127-CTD lacking strand β6 for the standard cell and PA3127-CTD lacking helix α2 
and strand β6 for the dehydrated cell) were searched in the remaining asymmetric unit, 
which could finally be located by phenix.phaser.  
 
Table 40: Refinement statistics for P. aeruginosa PA3127 in complex with residual 
AcCoA/CoA. Values in parentheses are for the highest resolution shell.  
Dataset  PA3127 – standard cell PA3127 – dehydrated cell 
Resolution range (Å) 96.58-2.95 (3.04-2.95) 49.03-2.48 (2.64-2.48) 
Rwork (%) 23.7 (32.9) 30.2 (36.4) 
Rfree (%) 29.1 (37.8) 35.3 (44.0) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
15471 
10 
312 
100 
 
15245 
- 
- 
58 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.003 
0.867 
 
0.006 
1.149 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
77 
44 
73 
36 
 
83 
- 
- 
72 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
93.1 
1.1 
 
85.7 
5.2 
MolProbity score
#
 2.05 2.9 
PDB entry code - - 
#
As reported by MolProbity (Chen et al., 2010) 
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Interestingly, AcCoA/CoA was found in the standard cell crystal structure of PA3127. As 
neither the cosubstrate nor the product was added to the crystallization experiment, it 
must originate from the protein production organism E. coli and must have been bound 
to the protein during the whole purification process.  
The structures of PA3127 were finally refined to an Rwork = 23.7% and an Rfree = 29.1% 
with a MolProbity score of 2.05 for the standard cell, and an Rwork = 30.2% and an Rfree = 
35.3% with a MolProbity score of 2.9 for the dehydrated cell (Table 40). In the crystals of 
PA3127 with the standard and the dehydrated cell, 93.1% and 85.7% of the residues are 
found in Ramachandran-favored regions, respectively. Possibly, crystal dehydration and 
shrinking of the unit cell favor unusual rotamers and Ramachandran outliers.  
 
6.6.11 Overall Topology of PA3127  
Crystal packing of the PA3127 crystals with eight molecules in the asymmetric unit is 
given in Figure 60. 
 
 
Figure 60: Crystal packing of the PA3127 crystals with one asymmetric unit containing eight PA3127 mol-
ecules as colored cartoon representation, and other three asymmetric units in grey. The unit cell with 
parameters a = 106.9 Å, b = 121 Å, c = 116.2 Å and α = 90°, β = 115.35° and γ = 90° is shown in green. 
 
In the crystals, the PA3127 molecules are arranged with the βαβββ-module domains 
PA3127-NTD pointing towards the core of the asymmetric unit, and the eight N-acetyl-
transferase domains PA3127-CTD pointing towards the outer boundaries (Figure 61). As 
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discussed previously, the N-terminal domain of PA3127 folds into the typical two-βαβββ-
module architecture and dimerizes via edge-to-edge contacts between the β1 and β5 
strands of two domains to most probably form the binding site for the bis-thiazole moie-
ty of bleomycin. The βαβββ-module domain dimers are found within one asymmetric 
unit (Figure 61, e. g. cyan/violet). Similarly, the C-terminal N-acetyltransferase domain of 
PA3127 folds into a typical structure of the N-acetyltransferase superfamily. This domain 
dimerizes via domain swapping interactions between the β5 and β6 strands of two N-
acetyltransferase domains of PA3127. The N-acetyltransferase domain dimers are 
formed by two domains for different asymmetric units (Figure 61, e. g. blue/green). 
 
 
Figure 61: Two asymmetric units of the PA3127 crystals, each containing eight molecules (colored 
differently), demonstrate that important contacts between single PA3127 molecules are established 
by dimerization interactions between the βαβββ-module domains within one asymmetric unit, and by 
the N-acetyltransferase domains, between molecules from two distinct asymmetric units. AcCoA 
bound to the N-acetyltransferase domain is shown as stick representation. 
 
If PA3127 is assumed to be a homodimer as all typical βαβββ-module proteins with two 
modules per molecule and also BAT from S. verticillus, the latter can be compared to 
                                              6   Results and Discussion – βαβββ-Module Resistance Proteins 
 
138
PA3127 and similarities as well as differences between these bleomycin-N-acetyltransfe-
rases can be pointed out (Figure 62). In BAT from S. verticillus, the two protein molecules 
of the dimer are symmetrically arranged and can be mapped to each other by superposi-
tion of the molecules.  
 
  
Figure 62: Comparison between a PA3127 dimer from P. aeruginosa and a BAT dimer from S. verti-
cillus (PDB entry 2ZW7, Oda et al., 2010). While the BAT dimer is symmetrical and the domains are 
arranged identically in the monomers, the PA3127 dimer is not symmetrical. One N-acetyltransferase 
domain is located in line with its βαβββ-module domain (red). The second N-acetyltransferase is 
kinked in respect to its βαβββ-module domain (grey).  
 
In contrast, the two molecules of the PA3127 dimer are not symmetrical and cannot be 
superimposed to each other. One βαβββ-module domain is in line with its corresponding 
N-acetyltransferase domain (Figure 62, red), while the second N-acetyltransferase do-
main is kinked in respect to its corresponding βαβββ-module domain (Figure 62, grey). 
This asymmetric arrangement is repeated in the additional three dimers of the asymme-
tric unit, which means that every dimer consists of a stretched and a kinked PA3127 mo-
lecule, thereby causing in total four PA3127 molecules to be stretched and the other 
four PA3127 molecules to be kinked. This observation explains why the number of mole-
cules in the PA3127 asymmetric unit could not be determined by calculating a self-rota-
tion function (Winn et al., 2011). Additionally, it explains why the PA3127 structure 
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could not be phased by applying the NCS operators of the βαβββ-module domains to the 
whole protein, thereby improving the electron densities and facilitating structure deter-
mination and refinement.  
However, the orientations of the PA3127 domains relative to each other might be an 
artefact of crystal packing. In order to investigate potential overall conformation and the 
oligomeric state of PA3127 in solution, the protein was subjected to SAXS experiments. 
 
6.6.12 SAXS Reveals PA3127 to be a Tetramer in Solution 
Dimerization of PA3127 can occur via the βαβββ-module domain PA3127-NTD as well as 
the N-acetyltransferase domain PA33127-CTD. In agreement with these observations, 
previous analysis of PA3127 indicated a higher oligomerization state in size exclusion 
chromatography and in blue native PAGE (Bittner, 2012). For these reasons, PA3127 was 
subjected to SAXS experiments on BM29 at the ESRF (Grenoble, France). Solution scat-
tering patterns of a PA3127 dilution series (15, 5, 2.5, 1.25, 0.75 and 0.375 mg/mL in SEC 
buffer) were collected at a wavelength of λ = 0.9919 Å. In case of PA3127, the best 
sample quality and monodispersity (91.8%) was achieved at a protein concentration of 
1.25 mg/mL.  
In order to define the oligomeric state of PA3127, its crystal structure was submitted to 
the PISA server (Krissinel & Henrick, 2007) to determine all possible stable oligomeric 
assemblies. Theoretical scattering curves of these assemblies (dimer, tetramer and octa-
mer) were calculated and compared to the experimentally determined scattering curve 
of PA3127 (Figure 63). The comparison of the calculated and the experimentally deter-
mined SAXS curves yielded curve fits with different fitting values of Χ = 16.215, Χ = 
21.971, Χ = 5.273 and Χ = 5.509 for the octamer, dimer and both tetramers (which are 
structurally identical), respectively. Hence, PA3127 is very likely to be a tetramer in solu-
tion. The calculated tetramer possesses an overall surface area of 47120 Å2 with a buried 
surface of 1790 Å2 according to PISA (Krissinel & Henrick, 2007).  
The experimentally determined SAXS curve and the tetramer of PA3127 were then used 
to calculate the SAXS envelope of the protein which is given in Figure 64. 
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Figure 63: SAXS analysis of the oligomerization state of PA3127. Theoretical scattering curves of the 
PA3127 octamer (A), dimer (B) and tetramer (C: chains BCEF; D: chains ADGH, structurally identical) 
were compared to the experimentally determined SAXS curve. The best fit is achieved using a PA3127 
tetramer, resulting in a Χ-value of 5.273 (C). 
 
The PA3127 tetramer is formed by a dimer of dimers. One dimerization occurs via two 
βαβββ-module domains (Figure 64, blue and orange). The N-acetyltransferase belonging 
to these two βαβββ-module domains then each dimerize with one N-acetyltransferase 
domain from a second PA3127 dimer (Figure 64, yellow and green) to form the full tetra-
mer.  
The PA3127 tetramer fits the computed rhombic-shaped SAXS envelope. However, the 
βαβββ-module domains slightly stick out of this envelope, causing a fitting value of Χ = 
5.273. Probably, the conformation of the tetramer is flat in solution, like the SAXS 
envelope, but bent in the crystal structure. The βαβββ-module domains probably rotate 
into the SAXS envelope. This rotation is possible because of the ten amino acid long lin-
kers between the βαβββ-module and the N-acetyltransferase domains. 
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Figure 64: SAXS envelope of the PA3127 tetramer (in complex with AcCoA) which is a dimer of dimers. 
Its formation occurs by dimerization of two βαβββ-module domain, whose N-acetyltransferase do-
mains dimerize with two N-acetyltransferase domains from another PA3127 dimer. The βαβββ-mo-
dule domains of the tetramer are slightly bent out of the SAXS envelope, which is probably caused by 
crystal packing. In solution, the tetramer might relax and form a plane quaternary assembly. 
 
It is not clear if the tetramer is essential for the physiological function of PA3127.  Possi-
bly it is not essential for the catalytic activity, which might take place within a dimer (for 
instance Figure 64, blue and orange). A similar arrangement was observed in the 
tryptophanase from E. coli (Kogan et al., 2009). Hence, the tetramer most probably 
represents the true PA3127 oligomer in solution, even if it is not catalytically essential.  
 
6.6.13 Spot Plate Assay with PA3127 and Its Operon 
Spot plate assays using both E. coli and P. aeruginosa were performed in order to investi-
gate the potential role of PA3127, PA3128 and both PA3127 and PA3128 (as whole 
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operon) to mediate bleomycin resistance in vivo. For this purpose, P. aeruginosa PA14 
wild type and three ΔPA3127 transposon mutants were spotted on bleomycin-doted 
agar plates. Similarly, P. aeruginosa PAO1 were transformed with pHERD30T plasmids 
encoding either no protein (as a control) or PA3127, and spotted on bleomycin-agar to-
gether with P. aeruginosa PAO1 wild type. However, no differences in growth could be 
observed in the experiments with P. aeruginosa PAO1 and PA14. This might be due to 
unknown factors such as efflux pumps that might act in concert with PA3127.  
For this reason, E. coli was used for the bleomycin spot plate experiments, as this orga-
nism does not possess a bleomycin resistance protein. E. coli carrying pET19m plasmids 
encoding either no protein (as a control), PA3127, PA3128 or both PA3127-PA3128 (en-
coded as the P. aeruginosa operon) were spotted on bleomycin-doted M9 agar plates 
(Figure 65).  
 
 
Figure 65: Spot plate assays with bleomycin using E. coli (indicated as number of spotted cells/mL cul-
ture). Three different concentrations of bleomycin (0.1 µg/mL, 0.5 µg/mL and 1 µg/mL) were used to 
test the ability of PA3127 to render E. coli resistant against bleomycin. The most significant effect is visi-
ble at a concentration of 1 µg/mL bleomycin. PA3127 alone makes E.coli resistant against bleomycin re-
sistance, while the entire operon PA3127-PA3128 makes E.coli even more resistant against this anti-
biotic.  
 
Three different concentrations of bleomycin (0.1 µg/mL, 0.5 µg/mL and 1 µg/mL) were 
used to test the ability of PA3127 to render E. coli resistant against bleomycin. The most 
significant effect is visible at the highest concentration of bleomycin (1 µg/mL, Figure 
65). E. coli carrying an empty pET19m vector only grows to a dilution of 104 cells/mL, 
while E. coli carrying a vector pET19m_PA3127 or pET19m_PA3128 grow to a dilution of 
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102 cells/mL. However, more colonies of E.coli producing PA3127, the proposed bleomy-
cin N-acetyltransferase, grow on bleomycin-doted agar than of E. coli producing PA3128, 
a proposed oxidoreductase encoded in an operon with PA3127. The best growth was 
achieved with E. coli carrying a plasmid pET19m_PA3127-PA3128, producing both pro-
teins of the operon. These data demonstrate that PA3127 is a bleomycin resistance pro-
tein that is able to render E. coli resistant against this antibiotic. Furthermore, the P. ae-
ruginosa operon PA3127-PA3128 is a bleomycin resistance determinant. Together with 
the biophysical and structural data obtained in this study, PA3127 is assigned as a bleo-
mycin-N-acetyltransferase. The function of PA3128 has to be identified in future studies. 
 
6.6.14  Bleomycin Binding  
As no crystal structure of PA3127 with bleomycin could be obtained, the binding mode 
of bleomycin to PA3127 remains elusive. As the mode of bleomycin binding is known in 
BAT from S. verticillus, it may be used to derive possible bleomycin binding modes for 
PA3127. In BAT, bleomycin spans a distance of 32 Å in its bound conformation (Oda et 
al., 2010), while an elongated bleomycin may be able to span a distance of even 40 Å.  
 
 
Figure 66: Evaluation of potential bleomycin binding to the PA3127 tetramer. Direct distances be-
tween acetyl groups and Y31 and Y34 of different dimers of the PA3127 tetramer were measured in 
PyMOL (DeLano, 2002). These distances are too long to be bridged by bleomycin. Also, the real 
distances would be even longer, as the direct distances cross through the protein.  
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In order to determine the possible binding conformations of bleomycin in PA3127, the 
distances between its βαβββ-module domains and the acetyl groups of bound AcCoA 
were measured in PyMOL (DeLano, 2002). However, distances between acetyl groups of 
AcCoA molecules bound to one dimer of the tetramer and Y31 or Y34 belonging to the 
other dimer of the tetramer are too long (40 and 60 Å) to be bridged by bleomycin 
(Figure 66). Four different distances can be measured within a PA3127 tetramer (Figure 
67).   
  
 
Figure 67: Evaluation of potential bleomycin binding to PA3127 dimer. Direct distances between 
acetyl groups and Y31 and Y34 of different dimers of the PA3127 tetramer were measured in PyMOL. 
Two of these distances are too long to be bridged by bleomycin, while two are short enough. How-
ever, steric hindrance does not allow the bleomycin molecule to bind to Y31, Y34 and the acetyl group 
of AcCoA within the same monomer (red arrows).       
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However, the asymmetry in the crystallographic PA3127 tetramer is probably absent in 
solution, as indicated by SAXS analysis. In solution, the βαβββ-module domains probably 
undergo a rotation, leading to a plane and rhombic-shaped tetramer. Still, a potential 
bleomycin binding groove is visible in the PA3127 tetramer (Figure 68). This groove could 
be shortened by the rotation of the βαβββ-module domains, thereby allowing bleomycin 
binding in a stretched conformation as observed in BAT from S. verticillus (Oda et al., 
2010). In this conformation, the primary amine of bleomycin would be able to position 
itself in the vicinity of the AcCoA acetyl group. 
 
 
Figure 68: Potential movement of the βαβββ-domains of PA3127 and potential bleomycin binding 
mode. The βαβββ-domains probably have to turn around to shorten the distance between the bis-
thiazole moiety and primary amine binding sites of bleomycin. Then, bleomycin would be able to bind 
in its stretched conformation.  
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Interestingly, two distinct, stretched bleomycin binding conformations have been obser-
ved in BAT from S. verticillus (Figure 62, Oda et al., 2010). The stretched conformations 
tear the metal ligands of bleomycin, including the primary amine, apart from each other. 
Hence, BAT only binds the metal-free from of bleomycin (Oda et al., 2010). This scenario 
is most likely present in PA3127. In contrast, BLMT and BLMA, two other bleomycin-
binding proteins, both bind the metal-bound form of bleomycin (Maruyama et al., 2001; 
Sugiyama et al., 2002). 
 
6.6.15  Mechanism of Acetyl Transfer from AcCoA to Bleomycin 
Using the structural data obtained in this study and the BAT structure from S. verticillus, 
it is still difficult to propose a molecular model of the active PA3127-AcCoA-bleomycin 
complex and a mechanism of acetyl transfer from AcCoA to bleomycin.  
The acetylation of bleomycin by PA3127 most probably occurs in an ordered sequential 
mechanism: first, AcCoA is bound to the protein, then bleomycin is bound, the acetyl 
transfer occurs, acetyl-bleomycin is released and finally CoA is released. One observation 
supporting this theory is the presence of AcCoA in the PA3127 crystal structure, although 
AcCoA was not added to the crystallization experiment. The same ordered mechanism 
was also proposed for BAT (Oda et al., 2010), but could not be confirmed by kinetic 
analysis. Possibly, the protein is permanently loaded with AcCoA in order to immediately 
catalyze acetyl transfer upon bleomycin binding, as the AcCoA concentration is about 
170 mM in exponential phase and between 40-80 mM in stationary phase in E. coli (Park 
et al., 2011). These amounts are more than 10-fold higher than the KD = 529 ± 33 nM of 
AcCoA and PA3127. Furthermore, the 10-fold higher affinity of AcCoA compared to CoA 
ensures correct loading of the protein with the substrate. If bleomycin is present, its 
large binding surface on PA3127 probably ensures immediate binding to the PA3127-
AcCoA complex. 
As in BAT from S. verticillus, the primary amine of bleomycin is probably positioned in 
close proximity of the acetyl group of AcCoA. This proximity ensures the efficient trans-
fer of the acetyl group to bleomycin (Oda et al., 2010), which occurs by nucleophilic 
attack. This nucleophilic attack is probably a direct attack of the primary amine of bleo-
mycin to AcCoA, as suggested for other members of the N-acetyltransferase superfamily 
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proteins (De Angelis et al., 1998; Tanner et al., 2000a; b). In order to attack as a nucleo-
phile, the primary amine of bleomycin has to be deprotonated (Oda et al., 2010). Proton 
abstraction can either occur by an aspartate or glutamate residue in the vicinity of the 
amine (Trievel et al., 1999; He et al., 2003), or by water molecules that act as a proton 
wire (Hickman et al., 1999).  
 
 
Figure 69: Two AcCoA conformations observed in PA3127. The carbonyl oxygen of AcCoA might be 
stabilized by the backbone amide or carbonyl of Q240, although the latter is unlikely, and the indole 
nitrogen of W252. However, the orientation of the acetyl group cannot be determined without 
uncertainty. The only amino acid that may potentially abstract a proton from the primary amine of 
bleomycin is E205. However, as the binding mode of bleomycin is elusive, no data to corroborate this 
hypothesis are available.   
 
In PA3127, however, the only residue that is potentially able to abstract a proton from 
the primary amine of bleomycin and that is in the vicinity of the acetyl group is E205 
(Figure 69). As the binding mode of bleomycin remains elusive, this hypothesis might 
only be proven by an E205A mutant that might not be possible to abstract the proton 
anymore and therefore might be inactive. Similarly, in the PA3127 structure, the orienta-
tion of the acetyl group of AcCoA cannot be determined with certainty. Possibly, the car-
bonyl oxygen is stabilized by hydrogen bonds to the indole nitrogen of W252 or the 
backbone amine or carbonyl of Q40, although the latter is unlikely. In contrast, the ace-
tyl group of AcCoA does not seem to establish any hydrogen bonds in the PA3127-CTD 
structure.   
Taken together, a cocrystal structure of PA3127 and bleomycin would support a detailed 
analysis of the mechanism of PA3127. Still, PA3127 is definitely a bleomycin-N-acetyl 
transferase, as demonstrated by the spot plate assays in E. coli. In this study, ITC experi-
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ments, X-ray crystallography, SAXS and in vivo microbiological assays were successfully 
combined to corroborate this initial hypothesis.  
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7 Conclusions and Outlook 
In this study, 22 βαβββ-module resistance proteins were identified in P. aeruginosa 
PAO1 using a bioinformatic approach, namely a BackPhyre search with the crystals struc-
ture of EhpR (Yu et al., 2011) in the P. aeruginosa genome. The 22 identified βαβββ-mo-
dule resistance proteins were sorted into three distinct classes using a sequence and 
structural alignment in PROMALS3D (Pei et al., 2008). Class I is constituted by twelve 
metal-binding βαβββ-module resistance proteins with two conserved histidines and a 
glutamate residue as the binding motif for divalent metal cations. Class II is formed by 
four aromatic compound binding proteins, PA0803, PA1353, PA4641 and PA3127. The 
latter is distinct from the other three because it possesses an additional N-acetyltransfe-
rase domain. The aromatic compound binding proteins possess two conserved aromatic 
residues between which aromatic compounds are able to bind via π-stacking interac-
tions. Class III is constituted by six proteins of unknown function which do neither pos-
sess the metal-binding nor the aromatic compound-binding residues.  
 
7.1 βαβββ-Module Resistance Proteins of Unknown Function - PA4183, 
PA1672, PA4518 and PA0880 
The class III βαβββ-module resistance proteins PA0880, PA1672, PA4183 and PA4518 
have been cloned and purified with high yield and purity. The proteins were subjected to 
crystallization, and crystals were indeed obtained of the full proteins PA0880, PA1672 
and PA4518 as well as of a truncated version of PA418. However, the latter crystals did 
not show any diffraction. In contrast, the crystals of PA0880, PA1672 and PA4518 diffrac-
ted to better than 2 Å resolution, allowing data collection and structure determination 
(Figure 70). The proteins are typical βαβββ-module resistance proteins and form homo-
dimers with a binding or active site at each dimer interface.  
Functional characterization of these proteins will be a main task in the future. Several 
bioinformatic approaches using their sequence and structure failed, as they share low 
sequence homology and very few residues seem to determine their catalytic activity and 
function.  
                                          7   Conclusions and Outlook – βαβββ-Module Resistance Proteins 
 
150
 
Figure 70: Crystal structures of the homodimers of the class III βαβββ-module resistance proteins of 
unknown function PA0880, PA1672 and PA4518. 
 
PA0880 is a good starting point for functional studies, as it is most probably involved in 
the itaconate degradation pathway (Sasikaran et al., 2014). For PA0880, further poten-
tial substrates to be tested in future binding experiments are acrylate, cis-aconitate, me-
thylsuccinate, (R)-citramalate as well as (R)-3-, (S)-3- and 4-hydroxybutyrate. Additional-
ly, CoA derivatives of the substances tested in this study as well as additional CoA deriva-
tives, for instance acetyl-, succinyl-, (3S)-malyl-, (3S)-citryl-, β-methyl-malyl-, methylcro-
tonyl-, mesaconyl-, (S)-citramalyl- or (R,S)-3-hydroxy-3-methylglutaryl-CoA could be as-
sayed for affinity to PA0880. However, ITC might not be the optimal method to screen 
for potential ligands and substrates, as it is time-consuming and requires high amounts 
of sample, in contrast to a thermal shift assay or microscale thermophoresis (MST) which 
are probably more suitable for fast screening as they are faster and require less amounts 
of material.  
 
7.2 Future Studies on Proteins of Unknown Function 
In order to functionally characterize the βαβββ-module resistance proteins of unknown 
function, first, bioinformatic approaches have to be explored, for instance the genomic 
context of the proteins has to be examined. Furthermore, the function of the proteins 
may be studied by transcriptomic approaches, which may be able to identify genes that 
are transcribed together with the gene of interest under certain environmental condi-
tions. Additionally, proteomics may be able to identify protein interaction partners of 
PA0880, PA1672 and PA4518. Metabolomic approaches will also play an important role 
in identifying the function of the proteins. This functional identification may either be ac-
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complished by using P. aeruginosa transposon or deletion mutants of the gene of inte-
rest, and preparing cell-free metabolite extracts that can be analyzed via HPLC-MS. 
Another method that can be applied to identify small metabolites interfering with pro-
teins of unknown functions is the BiOLOG System (BiOLOG, Hayward, CA, U.S.A.). In this 
system, bacterial phenotypes are screened in a 96-well plate format against different 
media and nutrients. By doing so, the genotype of a cell can be correlated with a pheno-
type under certain environmental conditions and the cell’s metabolic and chemical sen-
sitivity properties can be characterized. 
 
7.3 Pyocyanin Resistance in P. aeruginosa 
The class II βαβββ-module resistance proteins PA0803, PA1353 and PA4641 have been 
structurally and biophysically characterized in studies prior to this work (Yu, 2009; Kala-
wy-Fansa, 2010). They have been identified as potential pyocyanin resistance determi-
nants in P. aeruginosa, and ITC data as well as cocrystal structures of PA1353 and 
PA4641 with pyocyanin were available (Kalawy-Fansa, 2010). In this study, the cocrystal 
structure of PA0803 with pyocyanin was determined (Figure 71).  
 
 
Figure 71: Crystal structures of the PA0803 homodimer with pyocyanin. A: Overall structure of the 
PA0803 homodimer with two pyocyanin binding sites. B: Positive m|Fobs|-D|Fcalc| electron density (σ-
level = 2) of pyocyanin sandwiched between H49 and Y122* by π-stacking interactions. C: PA0803 
cocrystallized with pyocyanin. 
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Additional ITC experiments revealed that PA0803, PA1353 and PA4641 preferentially 
bind phenazines, and do not bind compound with one, two or four (aromatic) ring moie-
ties. One exception to this rule is the complex antibiotic bleomycin, which possesses four 
aromatic moieties (though distributed over the whole molecule). Bleomycin is bound by 
PA0803, PA1353 and PA4641 with low micromolar affinities. However, the four rings of 
bleomycin are possibly not all bound simultaneously.  
Functional characterization of PA0803, PA1353 and PA4641 in E. coli or P. aeruginosa 
using spot plate assays indicates that additional factors might play a role in pyocyanin re-
sistance, as no differences in growth between wild type bacteria and transposon or gain-
of-function mutants were observed. Hence, PA0803, PA1353 and PA4641 alone are not 
able to render E. coli or P. aeruginosa resistant against pyocyanin. One reason for the 
unsuccessful test may be that E. coli is most probably too sensitive to oxidative stress 
caused by pyocyanin (Hassett et al., 1992). Another reason may be the absence of a 
membrane transporter in E. coli to act in concert with PA0803, PA1353 and PA4641. For 
this reason, E.coli is only able to survive in the presence of low pyocyanin concentrations 
(<10 µM). In contrast, P. aeruginosa wild type and mutants survive in the presence of 
more than 1 mM pyocyanin. Since pyocyanin is a signaling factor in QS of P. aeruginosa, 
the compound interferes with the transcription profile of the bacterium. For instance, 
the MexGHI-OpmD efflux pump, possibly a pyocyanin transporter, is upregulated by 10-
fold upon pyocyanin exposure. Additionally, only single-gene transposon or gain-of-func-
tion mutants were tested in the spot plate assay, meaning that the other two genes are 
not knocked down and the resulting βαβββ-module resistance proteins could compen-
sate for the loss of one βαβββ-module resistance protein.  
 
7.4 Future Studies on PA0803, PA1353 and PA4641 
In order to study the function of the potential pyocyanin resistance proteins PA0803, 
PA1353 and PA4641, clean deletion mutants of P. aeruginosa PAO1 have to be gene-
rated, namely ΔPA0803, ΔPA1353 and ΔPA4641, double-mutants ΔPA0803-ΔPA1353, 
ΔPA0803-ΔPA4641 and ΔPA1353-ΔPA4641 as well as a triple mutant ΔPA0803-ΔPA1353- 
ΔPA4641. These mutants should be tested in the spot plate assay with pyocyanin, be-
cause they might be more sensitive to pyocyanin than the wild type strain. Spot plates 
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assays using bleomycin should also be conducted in order to test the hypothesis that 
these proteins might act as bleomycin resistance proteins, such as BLMT from S. verti-
cillus (PDB entry 1NIQ, to be published). Their potential function as bleomycin resistance 
proteins was indicated by ITC measurements, in which the proteins bound bleomycin 
with low micromolar affinity. 
Other methods should also be applied to test whether PA0803, PA1353 and PA4641 ren-
der P. aeruginosa resistant against pyocyanin. One approach is pyocyanin quantification 
from wild type and deletion mutant cultures under different environmental conditions, 
for instance in King B media which is used to enhance phenazine production. Similarly, 
the amount of transcribed PA0803, PA1353 and PA4641 can be tested under pyocyanin 
producing conditions, for instance by RNA isolation and quantification using real-time 
quantitative PCR. Also, transcriptome data of the deletion mutants can be recorded, or 
vice versa, the transcriptome of P. aeruginosa mutants that either do not produce pyo-
cyanin or produce pyocyanin in large amounts. Then, the transcriptome data have to be 
checked for elevated or decreased levels of PA0803, PA1353 and PA4641.  
Another possibility to generally identify proteins that interact with pyocyanin, protein-
containing P. aeruginosa cell lysates can be prepared and loaded onto a column on 
which pyocyanin is immobilized. This column could be prepared by using biotinylated 
pyocyanin as a probe. Similar approaches have already been used in previous studies 
(Baker et al., 2013). Taken together, functional characterization of the potential pyocya-
nin resistance proteins PA0803, PA1353 and PA4641 in vivo is of great importance to 
finally confirm their function. 
 
7.5 Bleomycin Resistance in P. aeruginosa 
The class II βαβββ-module resistance protein PA3127 from P. aeruginosa carries an addi-
tional N-acetyltransferase domain. A protein with the same domain combination is the 
bleomycin N-acetyltransferase BAT from S. verticillus. Hence, the hypothesis that 
PA3127 is also a bleomycin N-acetyltransferase was tested in this study. ITC experiments 
revealed high AcCoA and bleomycin affinities to PA3127 with KDs of 529 ± 33 nM and 
413 ± 4 nM respectively. In an HPLC-MS based assay the conversion of AcCoA to CoA was 
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successfully observed, however, bleomycin and acetyl-bleomycin were not detectable in 
this setup.  
The crystal structure of PA3127 in complex with AcCoA, probably originating from E. coli, 
was determined using the Divide & Conquer approach. In this approach, both the βαβββ-
module domain and the N-acetyltransferase domain were cloned, expressed, purified 
and crystallized separately in a study parallel to this work and under supervision of the 
author (Popp, 2013). The crystal structure of the βαβββ-module domain was successfully 
determined (Popp, 2013), while the N-acetyltransferase domain had to be rescreened 
for new crystallization conditions in this study. Finally, its structure was determined in 
complex with AcCoA. Then, both domains were used to determine the structure of full 
length PA3127 in two different crystal forms. In contrast to BAT, PA3127 is a tetramer in 
solution, as revealed by SAXS analysis of the protein.  
 
 
Figure 72: SAXS envelope of the PA3127 tetramer (in complex with AcCoA) which is a dimer of dimers. 
Tetramer formation is accomplished by dimerization of two βαβββ-module domain, whose N-acetyl-
transferase domains dimerize with two N-acetyltransferase domains from another PA3127 dimer. The 
βαβββ-module domains of the PA3127 tetramer are slightly bent out of the SAXS envelope. This 
conformation is caused by crystal packing. In solution, the tetramer probably relaxes an forms a plane 
quaternary assembly. 
 
The SAXS envelope is of plane, rhombic shape, while the tetramer of PA3127 is slightly 
bent in the crystal. Thus, it is rather difficult to speculate about the bleomycin binding 
mode to PA3127. Most probably, the metal-free bleomycin stretches along both do-
mains, with its bis-thiazole moiety bound between Y31, Y34 and W96 of the βαβββ-mo-
dule domain, and the primary amine bound in the proximity of the acetyl group of Ac-
CoA. Efficient transfer of the acetyl group of AcCoA to bleomycin probably occurs by 
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direct nucleophilic attack of the primary amine of bleomycin to AcCoA, as suggested for 
other members of the N-acetyltransferase superfamily. The only candidate residue to 
abstract a proton from the primary amine of bleomycin in order to turn it into an effi-
cient nucleophile is E205. However, this hypothesis can probably only be proven by a 
crystal structure of a PA3127-bleomycin-AcCoA complex, or possibly by an inactive mu-
tant of PA3127 that could either be tested in an activity or a spot plate assay. A potential 
mutation candidate is residue E205 which might be able to abstact a proton from the pri-
mary amino group of bleomycin, thereby rendering it an active nucleophile.  
 
7.6 Future Studies on PA3127 and Its Operon 
Future studies on PA3127 should include the cocrystallization of the protein with bleo-
mycin or AcCoA and bleomycin to determine the bleomycin binding mode and the orien-
tation of the substrates towards each other. Furthermore, kinetic assays should be per-
formed to characterize the protein’s catalytic activity. For this purpose, either the HPLC-
MS assay setup has to be optimized, or the assay used for BAT from S. verticillus has to 
be adapted to PA3127. Still, the initial hypothesis of PA3127 being a bleomycin N-acetyl-
transferase could be confirmed by combining ITC, X-ray crystallography, SAXS and in vivo 
microbiological assays.  
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8 Summary 
Ergothioneine is a sulfur derivative of histidine betaine mainly produced by Actinobacte-
ria and Basidiomycota. It has versatile functions as an antioxidant, metal chelator and it 
is involved in the biosynthetic reaction of lincomycin A. Humans are not able to biosyn-
thesize ergothioneine, but resorb it from their diet and store it using a specific ergothio-
neine transporter ETT. Ergothioneine and its transporter are important players in human 
physiology. Disorders in ergothioneine homeostasis are for instance involved in Crohn’s 
disease and induce oxidative stress.  
In order to investigate mycobacterial ergothioneine biosynthesis, the SAM-dependent 
methyltransferase EgtD, the sulfoxide synthase EgtB and the Ntn hydrolase EgtC were 
examined using X-ray crystallography, biophysical and biochemical approaches in colla-
boration with Prof. Dr. Florian P. Seebeck from the University of Basel, Switzerland. The 
apo structures of EgtC and EgtD have been determined in a study prior to this work. 
In this study, substrate complexes of EgtD with Nα,Nα-dimethyl-histidine and SAH were 
obtained by X-ray crystallography, and kinetic data of EgtD were recorded. Using these 
data, an EgtD variant specific for tryptophan was engineered, assayed and crystallized 
with tryptophan and SAH. The data do not only characterize the first and rate-deter-
mining step in ergothioneine biosynthesis, but for the first time they describe aromatic 
amino acid betaine biosynthesis and identify other aromatic amino acid betaine-produ-
cing enzymes. Furthermore, the Ntn hydrolase EgtC was cocrystallized with glutamine 
and its substrate γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide, resolving 
the stereochemistry at the sulfoxide position of the substrate. On the basis of these 
structures, a potential model of the active conformation and binding mode of enzyme 
and substrate was proposed. Additionally, the crystal structure of the sulfoxide synthase 
EgtB was determined via sulfur SAD. The enzyme represents a novel class of sulfoxide 
synthases. A quaternary complex of EgtB with Nα,Nα-dimethyl-histidine and γ-glutamyl-
cysteine reveals the substrates as direct ligands to the iron metal center and allows 
deriving a mechanism that is in agreement with the sulfoxide stereochemistry deter-
mined in the EgtC substrate structure. Finally, inhibitor design for EgtD identified α-
chloro-histidine as the most potent inhibitor with a KI of 2.5 µM in a coupled EgtD assay, 
and lays the basis for further inhibitor design. 
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9 Introduction 
Bacteria, archaea and fungi produce and metabolize a huge variety of substances, 
reaching from chemically rather simple compounds such as fumarate to complex antibio-
tics such as bleomycin. Even if some of these compounds have been known for more 
than hundred years, their biosynthesis and molecular mode of action may not have been 
elucidated yet. This might be due to the fact that their biosynthetic proteins and the res-
pective genes have not been identified. In recent years, the availability and speed of ge-
nome sequencing have increased and bioinformatic tools can easily be applied to se-
quenced genomes. Using this approach, initial information on bacterial and archaeal ge-
nomes can be gained and the functional prediction of the respective genes can be ac-
complished. Additionally, X-ray crystallography is a powerful tool for the identification a 
molecular in-depth characterization of the enzymes catalyzing the biosynthetic reac-
tions. On the one hand, this is important to understand pathogens and their action. On 
the other hand, these metabolites may be potential therapeutics, or their biosynthesis 
may be potential drug targets.  
One example for such a compound is the small metabolite Nα,Nα,Nα-trimethyl-2-thio-his-
tidine (Figure 73) which was isolated from ergot fungus Claviceps purpurea in 1909 and 
therefore named ergothioneine (Tanret, 1909). Ergothioneine is a betaine derivative of 
2-thio-histidine. In principal, ergothioneine exists in two tautomeric forms, a thiol and a 
thione/thioketone form. Under physiological conditions, the thione form is preferred 
over the thiol form (Akanmu et al., 1991), which is a characteristic property of ergothio-
neine.  
 
 
Figure 73: Tautomeric thiol- (left), thione/thioketone (middle) and the mesomeric thioenol forms of 
ergothioneine. The thioketone form (middle) is preferred under physiological conditions.  
 
Additionally, the pKa of the thioimidazole group of ergothioneine is unusually high (>10) 
compared to most alkylthiols (Hartman, 1990).  
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9.1 Properties and Functions of Ergothioneine in Health and Disease 
After being discovered in fungi, ergothioneine was detected in microorganisms, plants 
and mammals (Salt, 1931; Genghof et al., 1956; Melville & Eich, 1956). However, humans 
are not able to biosynthesize ergothioneine, but absorb it with their diet. Although the 
precise function of ergothioneine has to be confirmed in vivo and no proof has been 
found yet that ergothioneine is an essential metabolite in humans, humans possess an 
ergothioneine-specific transporter ETT (Gründemann et al., 2005). The ETT inhomoge-
nously distributes ergothioneine to accumulate it in concentrations of 100 µM to 2 mM 
in tissues that are exposed to oxidative stress. In fact, ergothioneine is mainly found in 
erythrocytes, eye lense, kidney, liver and seminal fluid (Hunter, 1928; Salt, 1931; Leone 
& Mann, 1951; Melville et al., 1954). Silencing of the ETT-encoding gene inhibits ergo-
thioneine uptake, indicating that there is no alternative way of transport (Paul & Snyder, 
2010). Further observations in bacterial, fungal and animal cells indicate that ergothione-
ine is an important player in oxidative stress response and physiology.  
In contrast to glutathione, which is readily oxidized by Cu(II) and Fe(II), ergothioneine is 
stable against oxidation by divalent transition metal cations. Two ergothioneine molecu-
les usually act as chelators of one Cu(II), Fe(II), Ni(II), Cd(II), Zn(II), Hg(II) or Co(II) ion 
(Hanlon, 1971; Motohashi et al., 1974, 1976). More generally, ergothioneine is neither 
prone to oxidation nor to disulfide bond formation. Thus, it is rather present in its redu-
ced form. This finding clearly delimits it from GSH or mycothiol (MSH). The formation of 
oxidized ergothioneine only occurs under strong acidic conditions (Hand & Honek, 2005). 
A reason for ergothioneine preferring the reduced state is the unique redox potential of 
its thiol–disulfide couple (−0.06 V) in contrast to the ones of other naturally occurring 
thiols such as glutathione (−0.2 and −0.32 V) (Jocelyn, 1958). 
Furthermore, mitochondrial DNA damage was found to increase in response to ETT silen-
cing when cells where exposed to H2O2 (Paul & Snyder, 2010). Hence, ergothioneine 
might be able to protect mitochondrial DNA from damage induced by reactive oxygen 
species (ROS) generated by the electron transport chain. In vitro experiments indeed de-
monstrate that ergothioneine is able to scavenge ROS such as peroxonitrite (ONOO-), hy-
pochlorous acid (HOCl) or hydroxyl radicals (•OH) in vitro and to protect cells from UV- 
and γ-radiation damage (Motohashi & Mori, 1986; Akanmu et al., 1991; Franzoni et al., 
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2006). Since ergothioneine is able to absorb light in the UV range, it was suggested to 
block UV-induced ROS generation and damage. The cell viability of keratinocytes signifi-
cantly decreased upon exposure to UV light, but was increased upon addition of ergo-
thioneine (Botta et al., 2008; Markova et al., 2009). However, this hypothesis is contro-
versially discussed in the field of ergothioneine research, since recent findings indicate 
that ergothioneine is required for the production of spores in N. crassa, but does not 
protect against 254 nm UV-induced mutagenesis or kill (Bello et al., 2014). An overview 
on the proposed functions of ergothioneine and ETT is given in Figure 74. 
 
 
Figure 74: Proposed functions of Ergothioneine (EGT). Ergothioneine and its transporter protein ETT 
might be involved in several cellular processes in health and disease in ergothioneine producers as 
well as in non-producers, for instance humans. Figure adapted from Cheah & Halliwell, 2012. 
 
The roles of ergothioneine and its transporter in inflammation are not fully understood 
yet. Mutations of the ETT gene are involved in chronic inflammatory diseases including 
rheumatoid arthritis (Taubert et al., 2009) and Crohn's disease (Peltekova et al., 2004). 
Patients suffering from rheumatoid arthritis and Crohn's disease have elevated ergothio-
neine levels in erythrocytes and monocytes due to gain-of-function mutations in the ETT 
(Peltekova et al., 2004). Silencing of ETT expression in erythrocytes in vitro impairs er-
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gothioneine uptake, induces oxidative stress in HeLa cells and has been shown to be pro-
apoptotic (Nakamura et al., 2007; Paul & Snyder, 2010). Hence, increased ergothioneine 
concentrations under these chronic inflammatory conditions are postulated to promote 
immune cell survival (Taubert et al., 2009; Paul & Snyder, 2010). Additionally, ETT knock-
out mice were shown to be susceptible to intestinal inflammation, suggesting that ergo-
thioneine may counteract intestinal inflammation. In support of this hypothesis, ergo-
thioneine has been shown to inhibit the TNFα-mediated increase of IL-8 in epithelial cell 
cultures (Rahman et al., 2003). Silencing of the ETT in Caenorhabditis elegans decreases 
the life span of this nematode and increases its susceptibility to oxidative stress (Cheah 
et al., 2013). Additionally, ergothioneine protects against palmitic acid-induced apopto-
sis through activation of p38 and JNK kinase signaling pathways and inhibition of IL-6 ex-
pression (Laurenza et al., 2008).  
Taken together, these observations and the presence of a specific transporter for ergo-
thioneine suggest that ergothioneine is a beneficial metabolite. This strongly supports 
the theory that ergothioneine homeostasis is important for human physiology and 
health. Hence, it is important to study its role and its biosynthesis. The latter, however 
cannot be accomplished in humans, but only in organisms that biosynthesize ergothio-
neine, such as the model organism Mycobacterium smegmatis. 
 
9.2 Discovery and in vitro Reconstitution of Ergothioneine Biosynthesis  
Although ergothioneine was discovered more than hundred years ago, its exact biosyn-
thetic pathway and the genes encoding ergothioneine-biosynthetic enzymes remained 
unidentified for decades, because research focused more on the occurrence, isolation 
and on functional characterization of ergothioneine.  
Early studies on mycobacterial isolates confirmed ergothioneine biosynthesis for many 
species belonging to this genus, such as Mycobacterium tuberculosis or M. smegmatis 
(Genghof & Van Damme, 1964, 1968). Today, ergothioneine biosynthesis is known to 
occur in Actinobacteria, Cyanobacteria, Pezizomycotina and Basidiomycota and in nume-
rous α-,β-,γ- and δ-Proteobacteria and Bacteroidetes (Genghof, 1970; Seebeck, 2010; 
Pfeiffer et al., 2011). Historically, first attempts to identify the precursor of ergothio-
neine biosynthesis were made in 1950. Feeding experiments in Neurospora crassa and 
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Claviceps purpurea demonstrated that radioactively labeled histidine was fully and intac-
tly incorporated into ergothioneine (Melville et al., 1957; Heath & Wildy, 1958). Hence, 
histidine was proven to be the precursor amino acid of ergothioneine and in the same 
study, cysteine was concluded to provide the sulfur atom for ergothioneine (Melville et 
al., 1957). On the basis of these results, either 2-thiol-histidine or Nα,Nα,Nα-trimethyl-his-
tidine was proposed to be intermediates of ergothioneine biosynthesis. The latter was 
detected in N. crassa mycelium and postulated to be the first intermediate in ergothio-
neine biosynthesis (Askari & Melville, 1962). At the same time, evidence for a single en-
zyme catalyzing all three methylation reactions of histidine to Nα,Nα,Nα-trimethyl-histidi-
ne was found (Ishikawa & Melville, 1970), and S-adenosyl-methionine (SAM) was identi-
fied as the methyl group donor (McManus, 1962; Ishikawa & Melville, 1970). Later, 
another intermediate of ergothioneine biosynthesis, Nα,Nα,Nα-trimethyl-histidinyl-cys-
teine sulfoxide, was isolated from cell-free N. crassa extracts (Ishikawa et al., 1974). 
 
 
Figure 75: Ergothioneine biosynthesis pathway as proposed by Seebeck, 2010. The ergothioneine-bio-
synthetic gene cluster from M. smegmatis contains five genes egtABCDE. Ergothioneine is produced 
from histidine via a trimethylation reaction catalyzed by the SAM-dependent methyltransferase EgtD. 
The non-heme Fe(II) enzyme EgtB catalyzes the formation of an isopeptide intermediate which is 
hydrolyzed by the Ntn hydrolase EgtC and converted to ergothioneine by the pyridoxal 5-phosphate 
(PLP)-dependent lyase EgtE. γ-glutamyl-cysteine is provided by EgtA. A previously suggested pathway 
in N. crassa (teal) (Ishikawa & Melville, 1970; Ishikawa et al., 1974) turned out to be correct (Hu et al., 
2014). Figure adapted from Seebeck, 2010. 
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The production of this intermediate occurs only in the presence of Fe(II), probably as a 
metal cofactor of an enzyme, and O2 (Ishikawa et al., 1974). On the basis of these results, 
a more detailed path of ergothioneine biosynthesis was proposed (Ishikawa et al., 1974).  
However, it took more than 35 years until ergothioneine biosynthesis was reconstituted 
in vitro and all reaction steps were identified in mycobacterial ergothioneine biosynthe-
sis (Seebeck, 2010). Since it was known that a SAM-dependent methyltransferase, an 
Fe(II)-dependent oxidase and a pyridoxal 5-phosphate (PLP)-dependent lyase are proba-
bly involved in ergothioneine biosynthesis (Ishikawa & Melville, 1970; Ishikawa et al., 
1974), the mycobacterial ergothioneine biosynthesis genes could be identified by a bio-
informatic approach. For this purpose, the genomes of ergothioneine producers N. cras-
sa and Mycobacterium avium were searched for methyltransferases encoded in both ge-
nomes, but not encoded in the genomes of Bacillus subtilis and E. coli, which do not pro-
duce ergothioneine. This approach identified ten methyltransferase in the genome of M. 
avium, but only one of them encoded in an operon with a PLP-dependent lyase. Enzymes 
from this operon were cloned and the intermediates and final product of ergothioneine 
biosynthesis were analyzed via HPLC and Electrospray Ionization Mass Spectrometry 
(ESI-MS) (Seebeck, 2010). As depicted in Figure 75, mycobacterial ergothioneine (5) bio-
synthesis starts from histidine (1) which is Nα-trimethylated by the SAM-dependent me-
thyltransferase EgtD. The reaction product Nα,Nα,Nα-trimethyl-histidine (2), is passed on 
to the non-heme Fe(II) enzyme EgtB. This enzyme catalyzes the O2-dependent carbon-
sulfur bond formation and oxidation of Nα,Nα,Nα-trimethyl-histidine and γ-glutamyl-cys-
teine (produced by EgtA). The product of the EgtB-catalyzed reaction, γ-glutamyl-
Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide (QHC, 3) is then hydrolyzed to glutamate 
and Nα,Nα,Nα-trimethyl-histidinyl-cysteine sulfoxide (4) by the Ntn amidohydrolase EgtC. 
In the final step, the PLP-dependent lyase EgtE catalyzes the formation of ergothioneine. 
  
9.3 Characteristic Features of Ergothioneine Biosynthesis 
9.3.1 Genetics of Ergothioneine Biosynthesis 
In Mycobacteria, the enzymes EgtABCDE catalyze the biosynthesis of ergothioneine. 
These enzymes are encoded in the mycobacterial ergothioneine biosynthesis gene clus-
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ter egtABCDE (Seebeck, 2010). The analysis of more than 2500 ergothioneine-biosynthe-
tic gene clusters revealed that the five-gene ergothioneine cluster is a specific trait of Ac-
tinobacteria (Jones et al., 2014). Actinobacteria might have passed on their ergothione-
ine biosynthesis genes to δ-Proteobacteria (e. g. Myxococcus xanthus). However, some 
ergothioneine producers lack EgtA, EgtC and/or EgtE, the latter being exclusively present 
in Actinobacteria. For instance Cyanobacteria lack EgtACE,  but still produce high levels 
of ergothioneine (Pfeiffer et al., 2011). Possibly, EgtA, EgtC and EgtE can be complemen-
ted by enzymes encoded elsewhere in the genome (Jones et al., 2014).  
Recently, also the first fungal ergothioneine biosynthesis gene Ncegt-1 from N. crassa 
(Bello et al., 2012) has been identified. The resulting protein, NcEgt-1 is probably the 
result of a gene fusion event between ancestral egtB and egtD (Bello et al., 2012). Fungi 
do not produce EgtA, EgtC and EgtE, either. This finding indicates that EgtB and EgtD are 
the key enzymes of ergothioneine biosynthesis (as predicted earlier by (Seebeck, 2010). 
Taken together these findings strongly support that the (myco)bacterial ergothioneine 
biosynthesis route is probably distinct from the fungal pathway (Figure 75, Figure 77A).  
 
9.3.2 Glycine Betaine and Aromatic Amino Acid Betaine Biosynthesis 
Inside the cell, amino acids can be modified to fulfill other functions than being the buil-
ding blocks of proteins. As seen in ergothioneine biosynthesis, they can be modified to 
be amino acid betaines, in this case Nα,Nα,Nα-trimethyl-histidine (Figure 76A). So far, the 
most studied amino acid betaine is glycine betaine. Glycine betaine is biosynthesized 
from its precursors choline or even phosphoethanolamine in a multi-enzyme pathway 
(Figure 76B). In its primary role, it is thought to act as a potent osmoprotectant (Wargo, 
2013). However, the biosynthesis pathway of glycine betaine is hardly adaptable to aro-
matic amino acid betaines, because they are directly synthesized from the corresponding 
amino acid, and not from choline (Figure 76). These betaines constitute a ubiquitous 
class of natural compounds. Aromatic amino acids betaines and their derivatives of all 
four aromatic amino acids phenylalanine, histidine, tryptophan and tyrosine have been 
discovered. They are present in plants and fungi, for instance as phenylalanine betaine 
(Nα,Nα,Nα-trimethyl-phenylalanine), sticticine (dihydroxy-Nα,Nα,Nα-trimethyl-tyrosine) or 
hypaphorine (Nα,Nα,Nα-trimethyl-tryptophan) (Carollo et al., 2010; Mollica et al., 2012). 
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Hence, aromatic amino acid betaines play an important role in life and are part of our 
daily nutrition.  
 
 
Figure 76: Comparison of glycine and histidine betaine biosynthesis. A: In ergothioneine biosynthesis, 
only EgtD is sufficient to produce N
α
,N
α
,N
α
-trimethyl-histidine from histidine. Then, EgtB, EgtC and 
EgtE catalyze all further steps of ergothioneine biosynthesis. B: Glycine betaine is produced from 
phosphoethanolamine in P. falciparum (Lee et al., 2012), but at least from choline, not from its 
corresponding amino acid glycine, in a multi-enzyme pathway. Hence, aromatic amino acid betaine 
biosynthesis is distinct from glycine betaine biosynthesis. 
 
Nα,Nα,Nα-trimethyl-histidine is the aromatic amino acid betaine derivatives which is pro-
duced by EgtD in the first step of ergothioneine biosynthesis. Only this one enzyme is 
sufficient to produce Nα,Nα,Nα-trimethyl-histidine from histidine, while several biosyn-
thetic steps are necessary for the production of glycine betaine. Hence, EgtD structure 
elucidation promotes the understanding of the first step of ergothioneine biosynthesis, 
as well as the structural basis of aromatic amino acid betaine biosynthesis. The structure 
of EgtD will help to identify related enzymes that are able to produce other aromatic 
amino acid betaines. 
 
9.3.3 Sulfur Donors and Sulfoxide Stereochemistry 
As mentioned earlier, mycobacterial ergothioneine biosynthesis is catalyzed by five pro-
teins EgtABCDE (Seebeck, 2010), while fungi probably use NcEgt1 homologs to produce 
ergothioneine (Bello et al., 2012; Hu et al., 2014). The corresponding gene Ncegt-1 is 
most likely the result of a gene fusion event between ancestral egtB and egtD (Bello et 
al., 2012). Hence, Nc-Egt-1 catalyzes the first two steps in N. crassa ergothioneine bio-
synthesis and therefore converts histidine (1) to Nα,Nα,Nα-trimethyl-histidinyl-cysteine 
sulfoxide (4, Figure 77B, Bello et al., 2012). Both NcEgt-1 and EgtB need sulfur donor mo-
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lecules to catalyze their reactions. NcEgt-1 has a 62-fold higher specificity for cysteine as 
a sulfur donor relative to γ-glutamyl-cysteine (Hu et al., 2014), while mycobacterial EgtB 
use γ-glutamyl-cysteine (Ishikawa et al., 1974; Seebeck, 2010; Bello et al., 2012). Since 
Ncegt-1 homologs are distributed across all fungal genomes except for Saccharomycoti-
na species (Jones et al., 2014), this might indicate that all fungi rather use cysteine than 
γ-glutamyl-cysteine as a sulfur donor (Bello et al., 2012). This switch in substrate specifi-
city eliminates the competition between glutathione (needs γ-glutamyl-cysteine as a 
precursor) and ergothioneine biosynthesis in fungal species (needs cysteine as a precur-
sor) (Hu et al., 2014). In N. crassa, the last step of ergothioneine biosynthesis is catalyzed 
by the C-S lyase NCU11365 recently identified by genome mining; subsequently N. crassa 
ergothioneine biosynthesis was also characterized in vitro (Hu et al., 2014). The two 
routes of biosynthesis in Mycobacteria and in fungi are depicted in Figure 77. 
 
 
Figure 77: Comparison of mycobacterial and fungal ergothioneine biosynthesis. A: Mycobacterial er-
gothioneine biosynthesis 5-step pathway as proposed by Seebeck, 2010. Mycobacteria use γ-gluta-
myl-cysteine produced by EgtA as a sulfur donor molecule. B: Ergothioneine biosynthesis in N. crassa 
(Bello et al., 2012; Hu et al., 2014). The first two steps are catalyzed by NcEgt-1, a fusion protein of 
EgtB and EgtC. The C-S lyase NCU11365 from N. crassa then catalyzes the final formation of ergothio-
neine (Hu et al., 2014). 
 
Although fungi and Mycobacteria use different sulfur donor molecules, cysteine and γ-
glutamyl-cysteine, respectively, they both employ EgtB (or the EgtB domain of NcEgt-1 
homologs) to catalyze the central carbon-sulfur bond formation and oxidation step in er-
gothioneine biosynthesis. Interestingly, this step involves the selective formation of one 
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stereoisomer of QHC (3) or Nα,Nα,Nα-trimethyl-histidinyl-cysteine sulfoxide (4) at the re-
spective sulfur atom. However, it is not yet clear how the correct stereoisomers of QHC 
or Nα,Nα,Nα-trimethyl-histidinyl-cysteine sulfoxide are formed, and which of the possible 
stereoisomers is formed in the reaction. Characterization of the product stereochemistry 
is especially difficult because EgtB represents a novel type of C-S bond-forming enzymes 
and no structure of an enzyme from this class is available (Seebeck, 2010; Hu et al., 
2014). The protein is composed of an N-terminal α-helical DinB domain and a C-Lectin 
(CLec)-like domain that is characterized by a very low amount of secondary structure 
elements. Hence, the exact three-dimensional structure as well as the domain arrange-
ment and the atomic detail of the active center remain unknown. Thus, the binding me-
chanism and positioning of the substrates in the active center are unpredictable and 
have to be elucidated. In order to draw conclusions on the enzymatic mechanism em-
ployed by EgtB and on the product stereochemistry, it is essential to obtain structural in-
formation of mycobacterial EgtB and EgtB complexes with its substrates Nα,Nα,Nα-trime-
thyl-histidine and γ-glutamyl-cysteine. Additionally, the structure of this enzyme would 
provide detailed insight into a new type of reaction mechanism, as the structure of EgtB 
would be the first structure of a DinB-CLec protein and the catalytic residues are un-
known. 
The product of the EgtB-catalyzed reaction, QHC (3), is the substrate for the hydrolysis 
catalyzed by the Ntn amidohydrolase EgtC. The apo structure of EgtC has been deter-
mined earlier via Se SAD (Vit, 2010), but no substrate complexes have yet been obtained. 
In order to prove the stereochemistry of QHC, the co-crystallization of an inactive EgtC 
variant in complex with QHC is crucial, since previous attempts to crystallize QHC alone 
failed. Furthermore, there are no EgtC homologs and very few Ntn hydrolase structures 
deposited in the PDB. The structural characterization of EgtC will generate a deeper un-
derstanding of the class of Ntn amidohydrolases. 
 
9.4 Ergothioneine Biosynthesis and EgtD as Therapeutic Targets? 
Ergothioneine is biosynthesized by Actinobacteria, which includes pathogens such as M. 
tuberculosis. This fact classifies ergothioneine biosynthesis as a therapeutic target, for 
instance in tuberculosis treatments. One reason is that the compound seems to fulfill 
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distinct functions in Mycobacteria, different from the functions of other antioxidant such 
as mycothiol. This antioxidant consists of an Nα-acetylated cysteine, a glucosamine moie-
ty and an inositol group. In contrast to ergothioneine, mycothiol is not secreted by M. 
smegmatis (Sao Emani et al., 2013). This explains why mycothiol cannot fully compen-
sate for loss of ergothioneine in Mycobacteria (Ta et al., 2011). Interestingly, ergothione-
ine was recently reported to act as a template molecule in the biosynthesis of lincomycin 
A (Zhao et al., 2015), a sulfur-containing lincosamide antibiotic that has been widely 
used in veterinary medicine. Thus, ergothioneine is involved in an enzymatic reaction 
and biosynthesis pathway itself, indicating that more of these reactions might be disco-
vered in the future. For these reason, it might be additionally beneficial to inhibit ergo-
thioneine biosynthesis. However, the genes that encode the ergothioneine biosynthesis 
proteins were predicted not to be essential for growth of the M. tuberculosis H37Rv la-
boratory strain (Griffin et al., 2011). 
Generally speaking, the first step in a pathway is often a suitable target for drug develop-
ment. In ergothioneine biosynthesis, this first step - the conversion of histidine to 
Nα,Nα,Nα-trimethyl-histidine by EgtD - is essential to initiate further ergothioneine bio-
synthesis steps, as the following enzymes EgtBCE only used trimethylated substrates. 
EgtD has no homologs in humans and was demonstrated to be an essential enzyme in er-
gothioneine biosynthesis, as it is conserved in all ergothioneine producers (Jones et al., 
2014). Elimination of EgtD from M. smegmatis abolishes ergothioneine biosynthesis (Sao 
Emani et al., 2013). These facts further confirm its essential role in ergothioneine biosyn-
thesis. Furthermore, the purification protocol and the crystal structure of EgtD are alrea-
dy available (Vit, 2010; Vit et al., 2014, 2015). Hence, the active center of EgtD can easily 
be assessed to design potent EgtD inhibitors which can then be tested in a biochemical 
assay and eventually be cocrystallized or soaked into EgtD.  
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10 Research Objectives 
The biosynthesis operon of mycobacterial ergothioneine, a betaine derivative of 2-thio-
histidine, has only been reconstituted in vitro in 2010 (Seebeck, 2010). In a study prior to 
this work, the apo structures of the SAM-dependent Nα,Nα,Nα-trimethyltransferase EgtD 
and the Ntn hydrolase EgtC were determined using selenium SAD in X-ray crystallo-
graphy (Vit, 2010). Additionally, substrate binding to EgtD was characterized by isother-
mal titration calorimetry (ITC).  
First, this study aims at structure determination of substrate complexes of EgtD from M. 
smegmatis. These complexes deepen the understanding of the first and rate-determi-
ning step in ergothioneine biosynthesis catalyzed by EgtD. Additionally, they lay the 
structural basis of aromatic amino acid betaine biosynthesis, since EgtD is the first en-
zyme from this family that is structurally characterized. Additionally, EgtD is an interes-
ting therapeutic target, since removal of egtD from M. smegmatis abolishes ergothione-
ine biosynthesis. Crystal structures of EgtD inhibitor complexes were therefore deter-
mined. The Ntn hydrolase EgtC catalyzes the third step in ergothioneine biosynthesis. An 
inactive variant of EgtC was cocrystallized with the isopeptide substrate γ-glutamyl-
Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide (QHC) to unveil the stereochemistry at 
the sulfoxide position.  
Furthermore, the structure of the non-heme Fe(II) enzyme EgtB from M. thermoresisti-
bile was determined. This enzyme catalyzes the oxidative coupling of Nα,Nα,Nα-trimethyl-
histidine and γ-glutamyl-cysteine to Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide. 
Since there is no structure of a two-domain CLec-like protein available in the PDB, EgtB 
would be the first enzyme of this kind. In addition to that, structural and kinetic charac-
terization of EgtB and substrate complexes will answer the question which residues form 
the Fe(II) complex or where and how the substrates bind to the enzyme. The mode of 
substrate binding is crucial for the biosynthesis of the correct stereoisomer of Nα,Nα,Nα-
trimethyl-histidinyl cysteine sulfoxide.  
These structures elucidate the path of ergothioneine biosynthesis, give insights into 
novel protein families, and they will pave the way to novel therapeutics and enzyme en-
gineering approaches. 
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11 List of Publications 
In this section, my own publications associated with mycobacterial ergothioneine biosyn-
thesis are listed. In order to understand the molecular basis of ergothioneine biosynthe-
sis, the ergothioneine biosynthesis proteins EgtB, EgtC and EgtD were investigated in col-
laboration with Prof. Dr. Florian P. Seebeck at the University of Basel in Switzerland. The 
apo structures of the N-terminal nucleophilce (Ntn) amidohydrolase EgtC and the me-
thyltransferase EgtD were determined earlier (Vit, 2010) and parts of the results have 
been published (Vit et al., 2014). The ITC data on EgtD as well as the apo structures of 
EgtD and EgtC were obtained during my master thesis (Vit, 2010). These results form the 
basis for the experiments performed during my PhD studies. In this study, structure elu-
cidation of enzyme substrate complexes of EgtC and EgtD was pursued. As insights into 
the novel sulfoxide synthase reaction of EgtB are of high impact to the field, this novel 
enzyme was investigated exclusively in this study. Additionally, inhibitor complexes of 
EgtD were obtained. 
 
Publication A 
Allegra Vit*, Laëtitia Misson*, Wulf Blankenfeldt and Florian P. Seebeck§. Ergothioneine 
Biosynthetic Methyltransferase EgtD Reveals the Structural Basis of Aromatic Amino 
Acid Betaine Biosynthesis. ChemBioChem. 2015 Jan 2; 16(1): 119-125. 
 
Publication B 
Kristina V. Goncharenko*, Allegra Vit*, Wulf Blankenfeldt§ and Florian P. Seebeck§. 
Structure of the Sulfoxide Synthase EgtB from the Ergothioneine Biosynthetic Pathway. 
Angew. Chem. Int. Ed. Engl. 2015 Feb 23; 54(9): 2821-2824. 
 
Manuscripts in Preparation 
Allegra Vit, Gabriel T. Mashabela, Wulf Blankenfeldt and Florian P. Seebeck§. Structure of 
the Ergothioneine Biosynthetic Amidohydrolase EgtC.  
 
Laëtitia Misson, Allegra Vit, Reto Brun, Sanja Kostic, Wulf Blankenfeldt, Florian P. See-
beck§. Inhibiton of the Ergothioneine Biosynthetic Methyltransferase EgtD. 
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12 Results  
12.1 Ergothioneine Biosynthetic Methyltransferase EgtD Reveals the 
Structural Basis of Aromatic Amino Acid Betaine Biosynthesis  
 
Publication A 
Allegra Vit*, Laëtitia Misson*, Wulf Blankenfeldt and Florian P. Seebeck§. Ergothioneine 
Biosynthetic Methyltransferase EgtD Reveals the Structural Basis of Aromatic Amino Acid 
Betaine Biosynthesis. ChemBioChem. 2015 Jan 2; 16(1): 119-25. 
 
*Both authors contributed equally to this work.  
§Corresponding author. 
 
Author Contribution 
I cloned, produced and purified EgtDwt and produced and purified HyoA for crystalliza-
tion and ITC experiments. Laëtitia Misson cloned all other constructs, purified all pro-
teins for kinetic studies and performed enzyme kinetics and HPLC analysis. I designed 
and performed all protein crystallography experiments, performed data processing, 
structure solution, refinement, model building and analysis of the structures. I also per-
formed the ITC measurements (during my master thesis). Florian P. Seebeck performed 
structural analysis and wrote the manuscript with the help of L. Misson and me. Wulf 
Blankenfeldt assisted in experiment design, structure solution of EgtDwt apo and in wri-
ting the manuscript. F. P. Seebeck designed and managed the project. 
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12.2 Structure of the Sulfoxide Synthase EgtB from the Ergothioneine Bio-
synthetic Pathway 
 
Publication B 
Kristina V. Goncharenko*, Allegra Vit*, Wulf Blankenfeldt§ and Florian P. Seebeck§. 
Structure of the Sulfoxide Synthase EgtB from the Ergothioneine Biosynthetic Pathway. 
Angew. Chem. Int. Ed. Engl. 2015 Feb 23; 54(9): 2821-4. 
 
*Both authors contributed equally to this work.  
§Corresponding authors. 
 
Author Contribution 
Kristina V. Goncharenko performed molecular cloning, protein purification and enzyme 
kinetics of all proteins in this study. I designed and performed protein crystallographic 
experiments as well as structure solution, refinement and analysis. The manuscript was 
written by Florian P. Seebeck who was assisted by K. V. Goncharenko and me. Wulf Blan-
kenfeldt helped in crystallographic analysis and manuscript writing. F. P. Seebeck de-
signed and managed the project. 
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12.3 Structure of the Ergothioneine Biosynthetic Amidohydrolase EgtC 
A five-gene cluster egtABCDE-encoded EgtC is specific for Actinobacteria, and for few 
cyanobacterial and proteobacterial species (Jones et al., 2014). Most other species, es-
pecially fungi, lack an egtA, egtC and/or egtE. The function of these genes might be com-
plemented by other genes located elsewhere in the genome. Hence, the EgtC-catalyzed 
reaction can mainly be considered as an actinobacterial trait. 
EgtC from M. smegmatis is a 25 kDa enzyme that catalyzes the hydrolysis of γ-glutamyl-
Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide (QHC) to glutamate and Nα,Nα,Nα-trime-
thyl-histidinyl cysteine sulfoxide. For this purpose, EgtC utilizes its N-terminal cysteine 
residue C2 as a nucleophile and is therefore classified as an Ntn amidohydrolase (Pfam 
CL0052) (Brannigan et al., 1995). Despite the similarities in reactivity and a common fold, 
members of the Ntn hydrolase superfamily do not necessarily share recognizable se-
quence homology (Oinonen & Rouvinen, 2000). However, for most members of this 
family, a conformational change upon substrate binding to the enzyme is suggested 
(Isupov et al., 1996). After having determined the crystal structure of apo EgtC from M. 
smegmatis via selenium SAD (Vit, 2010), cocrystallization of EgtC with glutamine was 
persued. Additionally, cocrystallization of an inactive EgtC variant EgtCC2A with γ-gluta-
myl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide, the product of the EgtB-catalyzed 
reaction and substrate to EgtC, was attempted. Such a complex would shed light on sub-
strate binding, the reaction mechanism and the stereochemistry of the sulfoxide moiety 
of γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide. For this purpose, the iso-
peptide substrate had to be isolated from an in vitro reaction mixture of recombinant 
enzymes and their substrate via HPLC (performed by G. T. Mashabela). Subsequently, co-
crystallization of EgtC with glutamine and EgtCC2A with γ-glutamyl-N
α,Nα,Nα-trimethyl-his-
tidinyl cysteine sulfoxide yielded a high resolution crystal structure which has been de-
termined by MR using the apo structure of EgtC (1.75 Å). Data collection and refinement 
statistic of the EgtC structures are given in Table 41 and Table 42. These EgtC structures 
reveal the overall topology of this Ntn hydrolase, as well as the key interactions between 
the isopeptide substrate QHC and the enzyme. Most importantly, the stereochemistry at 
the sulfoxide position of γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide can 
be determined using the high resolution complex of EgtCC2A and QHC. 
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Table 41: Data collection statistics for M. smegmatis EgtC apo structure and complexes. Values in parentheses are for the highest resolution shell. Gln = glutamine. QHC 
= γ-glutamyl-N
α
,N
α
,N
α
-trimethyl-histidinyl cysteine sulfoxide. EgtCC2A = inactive variant. 
Dataset  Se SAD
+
 EgtC_apo EgtCwt_apo EgtCwt_Gln EgtCC2A_QHC 
Wavelength (Å) / beamline
≠
 0.9786 / SLS, PXII 0.9792 / SLS, PXII 0.9184 / BESSY II, 14.1 1.000 / PETRA III, P11 
Resolution range (Å) 47.83-1.85 (1.88-1.85) 47.64-1.75 (1.78-1.75) 46.44-1.82 (1.85-1.82) 49.31-1.7 (1.73-1.70) 
Space group P21 P21 P212121 P21 
Unit cell parameters (Å) 
                                      (°) 
129   69.4   160.4 
90   94.73   90 
129   69.5   160.4 
90   94.84   90 
61.8  110  139.3 
90  90  90 
128.5   69.4   159.4 
90   94.67   90 
Mosaicity (°)
†
 0.150 0.170 0.105 0.181 
Total No. of measured 
reflections 
3248829 (162534) 958644 (47488) 355388 (18637) 2062156 (99295) 
Unique reflections 236707 (11572) 283662 (14038) 85790 (4472) 299928 (14544) 
Multiplicity 6.9 (7.0) 3.4 (3.4) 4.1 (4.2) 6.9 (6.8) 
Mean I/σ(I) 15.9 (3.1)
§
 10.3 (1.9) 11.5 (2.0) 16.9 (2.1) 
Completeness (%) 98.3 (97.2) 99.6 (99.8) 99.9 (99.9) 97.8 (96.2) 
Rmeas (%)
‡
 14.2 (112.4) 8.8 (77.7) 14.1 (91.4) 7.7 (104.6) 
Rp.i.m. (%)
$
 5.3 (41.8) 4.7 (41.5) 6.9 (44.5) 2.9 (39.7) 
+
Data collection statistics for unmerged Friedel pairs.                                       
†
Mosaicity values reported by XDS (Kabsch, 2010). 
§
 The anomalous signal is signiﬁcant to 4.6 Å resolution according to Xtriage from PHENIX (Zwart et al., 2005; Evans, 2011). As the resolution was significantly higher, the 
data was cut at mean I/σ(I) = 3.1 in the highest resolution shell. 
≠
 SLS: Swiss Light Source (Paul Scherrer Institute, Villigen, CH), BESSY: Berlin Electron Storage Ring Society for Synchrotron Radiation (Helmholtz Zentrum Berlin, Berlin, D), 
PETRAIII: Positron-Elektron-Tandem-Ring-Anlage III at DESY (Deutsche Elektronen-Synchrotron, Hamburg, D). 
‡
Rmeas = Σhkl (N/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl), where N is the number of observations of the reflection with index hkl and Ii is the intensity of its i
th
 
observation. 
$
Rp.i.m. = Σhkl (1/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl) (Weiss, 2001). 
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Table 42: Refinement statistics for M. smegmatis EgtC apo structure and complexes. Values in parenthe-
ses are for the highest resolution shell. Gln = glutamine. QHC = γ-glutamyl-N
α
,N
α
,N
α
-trimethyl-histidinyl 
cysteine sulfoxide. EgtCC2A = inactive variant. 
Dataset EgtCwt_apo EgtCwt_Gln EgtCC2A_QHC 
Resolution range (Å) 47.64-1.75 (1.78-1.75) 35.46-1.82 (1.84-1.82) 49.31-1.7 (1.73-1.70) 
Rwork (%) 14.9 (22.9) 14.7 (24.4) 14.4 (24.2) 
Rfree (%) 18.0 (25.8) 17.8 (28.2) 17.1 (27.5) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
20469 
- 
419 
2481 
 
6810 
- 
40 
1224 
 
20579 
- 
396 
3083 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.006 
1.176 
 
0.006 
1.037 
 
0.009 
1.246 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
24 
- 
48 
34 
 
15 
- 
10 
32 
 
24 
- 
38 
34 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
96.9 
0.2 
 
97.7 
0.1 
 
97.2 
0 
MolProbity score
#
 1.45 0.97 1.26 
PDB entry code - - - 
#
As reported by MolProbity (Chen et al., 2010). 
 
EgtC forms tetramers in the asymmetric units of the crystals (Figure 78A). The tetramer 
probably resembles the physiological quarternary structure of EgtC according to the bur-
ied surface area and oligomer predictions by the PISA server (Krissinel & Henrick, 2007). 
Similarly, EgtC elutes as a tetramer from analytical size exclusion chromatography. The 
substrate of EgtC coelutes with the protein, demonstrating that it specifically binds to 
EgtC (Figure 78B). Interestingly, at least dimerization of EgtC appears obligatory for 
activity because the substrate binding site is formed by residues from both molecules of 
the dimer (Figure 78A).  
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Figure 78: The crystal structure of EgtCC2A in complex with γ-glutamyl-N
α
,N
α
,N
α
-trimethyl-histidinyl 
cysteine sulfoxide (QHC). A: EgtC is at least an obligate dimer (yellow/teal), because QHC (salmon) 
binding involves two residues from the second EgtC molecule. However, a tetramer is more likely be-
cause of the amount of buried surface. B: QHC coeluates with EgtCC2A from an S200 10/300 GL size ex-
clusion chromatography column. C: The presence of QHC in the EgtCC2A active site is clearly indicated 
by positive m|Fobs|-D|Fcalc| electron density (σ-level = 2). This density could be used to determine the 
stereochemistry of the sulfoxide moiety of QHC. C2
m
 is modeled from the wild type protein. D: QHC is 
recognized by a dense array of hydrogen bonds.   
 
The tertiary structure of EgtC is formed by a four layer α/β assembly with two central 
antiparallel 5- and 6-stranded β-sheets. The characteristic nucleophilic residue of the Ntn 
hydrolase EgtC is provided by the 1,2-aminothiol function of the N-terminal C2. Removal 
of the preceeding residue M1 is probably a result of bacterial methionine aminopepti-
dase activity (Lowther & Matthews, 2000). In the 1.7 Å resolution structure of EgtCC2A 
with γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide, positive m|Fobs|-D|Fcalc| 
electron density clearly confirms the presence of the substrate in the binding pocket 
(Figure 78C). This electron density can be used to elucidate the stereochemical center of 
the sulfoxide moiety of γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide. This 
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sulfoxide stereochemistry in turn sheds light on the catalytic mechanism of the sulfoxide 
synthase EgtB, also investigated in this study. In the complex of EgtB with γ-glutamy-
cysteine and Nα,Nα,Nα-trimethyl-histidine, the predicted O2 binding site makes a clear 
prediction as to which sulfoxide stereoisomer should be generated if suloxidation occurs 
according to this mechanism (Goncharenko et al., 2015). The observed stereochemistry 
of the substrate in the EgtCC2A complex does indeed show this predicted stereochemistry 
and demonstrates that the sulfoxide center is in S configuration (Figure 78C). γ-glutamyl-
Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide is bound by a dense array of hydrogen 
bond interactions in the active center of EgtC (Figure 78D). The amino acid moiety of the 
glutamyl part of γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide is stabilized 
by R88 (carboxyl group), D133 and S134 (amino group) and the backbone of G115. The 
carboxyl group of the cysteine moiety is stabilized by R164, and the sulfoxide moiety 
establishes a hydrogen bond to the N-terminal amino group of EgtC. The trimethylated 
amino group of γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide is recognized 
by Y30* and W66* of the other EgtC molecule of the obligate EgtC homodimer.  
In all crystal structures, EgtC and EgtCC2A adopt very similar conformations and overall 
structures. The only flexible segment is a loop from A90 to P95 above the active site. This 
loop can adopt an open ore a closed conformation and generates a more open or closed 
active site. In the crystal structure of EgtC with glutamine, the flexible loop adopts a 
closed conformation, while the crystal structure of EgtCC2A and γ-glutamyl-N
α,Nα,Nα-tri-
methyl-histidinyl cysteine sulfoxide displays an open loop conformation (Figure 79A). 
The latter conformation and mode of substrate binding seem to be unproductive, be-
cause the cysteine nucleophile is too far away from the carbonyl carbon at which the nu-
cleophile should attack (Figure 79A). However, if both structures of EgtC with glutamine 
and EgtCC2A with γ-glutamyl-N
α,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide are super-
posed, an active conformation of the protein can be derived and modeled, in which the 
cysteine nucleophile is in close proximity of the carbonyl carbon (Figure 79B). 
The proposed active conformation of EgtC indicates that the flexible A90 to P95 loop is 
probably able to push γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide into the 
active site of EgtC, mainly by T91, thereby allowing cytalysis of the hydrolysis reaction. 
This binding mode and loop conformation would be productive, and fit to the hypothesis 
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that enzymes of this family undergo a conformational change upon substrate binding 
(Isupov et al., 1996). 
 
 
Figure 79: Substrate binding to EgtC. A: Superposition of the EgtC glutamine complex (grey) with the 
EgtCC2A γ-glutamyl-N
α
,N
α
,N
α
-trimethyl-histidinyl cysteine sulfoxide (QHC) complex. The flexible A90-P95 
loop is located on top of the active site and adopts an open (teal) and a closed (grey) conformation. In 
this QHC complex, the nucleophilic C2 would be too far away from the carbonyl carbon of QHC to 
hydrolyse the substrate. B: Model of a productive binding mode of QHC to EgtC (purple). The glutamyl 
moiety of QHC adopts the conformation of glutamine form the EgtC glutamine complex, leading to a 
more productiove binding mode. 
 
EgtC and EgtA, the enzyme producing γ-glutamyl-cysteine, have probably been recruited 
into actinobacterial ergothioneine biosynthesis is that these enzymes allow the bacteria 
to use γ-glutamyl-cysteine rather than cysteine for ergothioneine production. The use of  
γ-glutamyl-cysteine is advantageous because it avoides high intracellular cysteine con-
centrations, which might cause production of oxygen radicals catalyzed by cysteine-
chelated transition metals (Fahey, 2013). Hence, γ-glutamyl-cysteine is a safer substrate 
in ergothioneine biosynthesis 
Taken together, EgtC is the first enzyme of the ubiquitous GATase_6 protein family 
(PF13522) with a defined catalytic activity and physiological function described. The ste-
reochemistry of the sulfoxide moiety of γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine 
sulfoxide is in agreement with data on EgtB previously published (Goncharenko et al., 
2015). 
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12.4 Inhibiton of Ergothioneine Biosynthetic Methyltransferase EgtD Using 
Histidine Derivatives 
Since ergothioneine biosynthesis might be a drug target for fighting M. tuberculosis and 
the respective disease, potential inhibitors for EgtD were synthesized (S. Kostic and R. 
Burns). These compounds (Figure 80) were analyzed in a coupled enzymatic EgtD assay 
(Dorgan et al., 2006; Vit et al., 2015) and the inhibition constant KI was determined for 
every compound.  
 
 
Figure 80: Histidine and potential histidine-derived ergothioneine biosynthesis inhibitors. The poten-
tial inhibitors were synthesized (by S. Kostic and R. Burns) and tested in a coupled assay (by L. 
Misson). The KI of N
α
,N
α
,N
α
-trimethyl-histidine, the product of the EgtD-catalyzed reaction, was deter-
mined as 16.1 µM. Hence, the final product N
α
,N
α
,N
α
-trimethyl-histidine affects EgtD by product 
inhibition. N
α
-pyrrolidino-histidine and N
α
-morpholino-histidine are less effective with KIs of 22 µM 
and 27.2 µM, respectively. The most potent EgtD inhibitor is α-chloro-histidine with a KI of 2.5 µM. 
 
In order to investigate the exact positions of the amino group substituents when bound 
to EgtD, apo crystals of EgtD were produced (Vit et al., 2014) and soaked with 20 mM of 
inhibitor in reservoir solution for 30 min. Then, diffraction data were collected on beam-
line 14.1 at the BESSY II synchrotron (HZB, Berlin, Germany). The inhibitor complexes 
were determined via rigid body refinement with the EgtD apo structure. The data collec-
tion and refinement statistics are depicted in Table 43 and Table 44.   
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Table 43: Data collection statistics for M. smegmatis EgtD inhibitor complexes. Values in parentheses are for the highest resolution shell. AVJ = N
α
,N
α
,N
α
-trimethyl-
histidine, AVK = α-chloro-histidine, AVM = N
α
-morpholino-histidine, AVO = N
α
-pyrrolidino-histidine. 
Dataset  EgtD_AVJ EgtD_AVK EgtD_AVM EgtD_AVO 
Wavelength (Å) / beamline
≠
 0.9184/ BESSY II, 14.1 0.9184 / BESSY II, 14.1 0.9184 / BESSY II, 14.1 0.9184 / BESSY II, 14.1 
Resolution range (Å) 49.33-1.75 (1.78-1.75) 49.34-1.83 (1.87-1.83) 48.85-1.85 (1.89-1.85) 49.25-1.9 (1.94-1.9) 
Space group P212121 P212121 P212121 P212121 
Unit cell parameters (Å) 
                                      (°) 
71.0, 79.4, 136.0 
90, 90, 90 
71.2, 79.2, 136.3 
90, 90, 90 
71.7, 76.2, 138.7 
90, 90, 90 
71.8, 79.5, 139.0 
90, 90, 90 
Mosaicity (°)
†
 0.071 0.107 0.131 0.089 
Total No. of measured reflections 1046638 (58915) 897454 (43155) 862107 (46234) 822801 (54415) 
Unique reflections 78334 (4258) 68689 (4158) 65608 (4003) 61947 (3955) 
Multiplicity 13.4 (13.8) 13.1 (10.4) 13.1 (11.5) 13.3 (13.8) 
Mean I/σ(I) 15.3 (1.9) 17.3 (2.1) 18.0 (1.9) 19.7 (2.3) 
Completeness (%) 100.0 (100.0) 99.9 (99.1) 100.0 (100.0) 100.0 (100.0) 
Rmeas (%)
‡
 14.5 (168.5) 11.4 (114.5) 11.7 (146.9) 8.9 (143.4) 
Rp.i.m. (%)
$
 3.9 (44.8) 3.1 (34.8) 3.2 (42.7) 2.4 (38.2) 
†
Mosaicity values reported by XDS (Kabsch, 2010).  
≠
 BESSY: Berlin Electron Storage Ring Society for Synchrotron Radiation (Helmholtz Zentrum Berlin, Berlin, D). 
‡
Rmeas = Σhkl (N/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl), where N is the number of observations of the reflection with index hkl and Ii is the intensity of its i
th
 
observation. 
$
Rp.i.m. = Σhkl (1/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl) (Weiss, 2001).
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Table 44: Refinement statistics for M. smegmatis EgtD inhibitor complexes. Values in parentheses are 
for the highest resolution shell. AVJ = N
α
,N
α
,N
α
-trimethyl-histidine, AVK = α-chloro-histidine, AVM = N
α
-
morpholino-histidine, AVO = N
α
-pyrrolidino-histidine. 
Dataset  EgtD_AVJ EgtD_AVK EgtD_AVM EgtD_AVO 
Resolution range (Å) 49.33-1.75 
(1.78-1.75) 
49.34-1.83 
(1.87-1.83) 
48.85-1.85 
(1.89-1.85) 
49.25-1.9 
(1.94-1.9) 
Rwork (%) 15.1 (23.1) 15.7 (25.9) 16.3 (25.3) 17.0 (28.9) 
Rfree (%) 17.8 (27.2) 18.3 (29.9) 18.4 (25.4) 20.7 (37) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
5046 
1 
70 
732 
 
4955 
1 
48 
525 
 
4929 
- 
44 
479 
 
4940 
- 
30 
309 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.013 
1.6 
 
0.006 
1.01 
 
0.004 
0.93 
 
0.004 
0.876 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
22 
17 
30 
37 
 
28 
20 
34 
36 
 
28 
- 
34 
37 
 
41 
- 
35 
45 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
98.6 
0 
 
98.5 
0.2 
 
98.3 
0 
 
98.3 
0 
MolProbity score
#
 1.07 0.87 0.75 0.78 
PDB entry code - - - - 
#
As reported by MolProbity (Chen et al., 2010) 
 
The crystal structures of EgtD inhibitor complexes were obtained by soaking of the com-
pounds into native apo crystals obtained in the original apo condition reported (Vit et al., 
2014). All complexes were determined at high resolution (1.75-1.9 Å) and refined to rea-
sonable R-factors (Table 44). The m|Fobs|-D|Fcalc| electron densities for α-chloro-histidine 
and Nα,Nα,Nα-trimethyl-histidine were well-defined and interpretable after initial rigid 
body refinement. However, m|Fobs|-D|Fcalc| densities for the N
α-pyrrolidino and Nα mor-
pholino derivatives were not clearly visible initially. This was caused by a slightly more 
open conformation of EgtD induced by the Nα-pyrrolidino and Nα morpholino-moieties 
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of the histidine derivatives. The conformational change is also seen in the r.m.s.d values 
of 0.369 and 0.401 of the Nα-pyrrolidino-histidine and Nα-morpholino-histidine comple-
xes, respectively. These r.m.s.d. values are higher than the r.m.s.d. of the α-chloro-histi-
dine and the Nα,Nα,Nα-trimethylhistidine complex (0.136). For this reason, the residues 
in the Nα-pyrrolidino-histidine and Nα-morpholino-histidine complexes had to be slightly 
rearranged into the density. Only then, the m|Fobs|-D|Fcalc| density for N
α-pyrrolidino- and 
Nα-morpholino-histidine was clearly visible and well defined. All inhibitors were refined 
to reasonable average B-factors of 30 Å2 to 35 Å2, and detailed views, including m|Fobs|-
D|Fcalc| electron densities, are shown in Figure 81.  
 
 
Figure 81: Crystal structures of EgtD with potential inhibitors. Unbiased m|Fobs|-D|Fcalc| electron den-
sities (σ-level = 2) of the compounds confirm their presence in the crystal structures. Typical interac-
tions of the imidazole moiety of the histidine derivatives with M252 and E282 of EgtD are present in 
all four structures. A: EgtD with α-chloro-histidine. B: EgtD with N
α
,N
α
,N
α
-trimethyl-histidine. C: EgtD 
with N
α
-pyrrolidino-histidine. The pyrrolidino group is in boat conformation. D: EgtD with N
α
-morpho-
lino-histidine. The morpholino group is in boat conformation.   
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The crystal structures of EgtD in complex with four different inhibitors demonstrate an 
identical binding mode for the imidazole moiety of histidine as the original EgtD struc-
ture. This binding mode, involving a water molecule, M252 and E282, is not surprising 
because no changes were made to this imidazole moiety, and EgtD is optimized to bind 
this moiety with high affinity. The same is true for the carboxyl group which is establi-
shes hydrogen bonds to the hydroxyl groups of Y56 and Y206, as well as to the amide 
side chain of N166. However, modification of histidine at its α-amino group is very flexi-
ble, and the enzyme is also able to harbor bulky modifications such as the Nα-pyrrolidino 
or Nα-morpholino moieties, which are both present in boat conformation in EgtD. Inte-
restingly, these modifications point into the SAM binding site of EgtD. Hence, EgtD, not 
binding SAM or SAH, could harbor even larger α-amino group modifications than the Nα-
morpholino moiety. However, the Nα-morpholino- and Nα-pyrrolidino-histidine deriva-
tives display less inhibitory potential in the EgtD assay than the derivatives with smaller 
α-amino group substituents. The KI’s of N
α-morpholino-histidine and Nα-pyrrolidino-histi-
dine were determined as 22.0 µM and 27.2 µM, respectively, while the KI’s of α-chloro-L-
histidine and the product of EgtD, Nα,Nα,Nα-trimethyl-histidine, were determined as 2.5 
µM and 16.1 µM, respectively (L. Misson, unpublished data). For this reason, α-chloro-
histidine is the most potent EgtD inhibitor tested in the assay, and it is more effective 
than Nα,Nα,Nα-trimethyl-histidine. This is surprising, because it means that the positive 
charge of the α-amino group of histidine is not crucial for substrate recognition by EgtD. 
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13 Synopsis and Outlook 
Ergothioneine is a sulfur derivative of histidine betaine and plays important physiological 
roles in its producing organisms, for instance Mycobacteria, but also in humans who are 
not able to produce ergothioneine. In order to investigate the mycobacterial biosynthe-
sis of ergothioneine, the SAM-dependent methyltransferase EgtD, the sulfoxide synthase 
EgtB and the Ntn amidohydrolase EgtC were examined using X-ray crystallography and 
biophysical as well as biochemical methods in collaboration with the group of Prof. Dr. 
Florian P. Seebeck from the University of Basel in Switzerland. Taken together, these 
three ergothioneine biosynthesis enzymes were successfully characterized by structural 
biology and biophysical as well as biochemical approaches.  
 
13.1 Methyltransferase EgtD 
In the first step of ergothioneine biosynthesis, the SAM-dependent methyltransferase 
EgtD catalyzes the three consecutive methyl transfers from SAM to L-histidine to pro-
duce Nα,Nα,Nα-trimethyl-histidine. In order to understand the catalytic activity and sub-
strate specificity of EgtD, its apo structure was determined earlier via selenium SAD (Vit, 
2010; Vit et al., 2014). In this study, complexes of EgtD with Nα,Nα-dimethyl-histidine and 
EgtD with Nα,Nα-dimethyl-histidine and SAH have been determined.  
The structure of EgtD revealed a conserved Rossman-fold domain including a seven-
stranded β-sheet (Figure 82A) and a second domain formed by an N-terminal extension 
and an insertion after the fifth β-strand of the central β-sheet. This domain is unrelated 
to any other known methyltransferase domain and is important for substrate specificity. 
The cleft between the two domains harbors the catalytic center in which histidine and 
SAM/SAH are bound (Vit et al., 2015). Upon SAM binding, a slight conformational change 
closes the active site of EgtD. The same conformational change was observed in other 
crystal structures of EgtD which were published recently (Jeong et al., 2014). 
EgtD catalyzes the trimethylation of histidine with remarkable apparent processivity 
(Seebeck, 2010). This processivity is a result of increased affinity towards methylated 
substrates as found in ITC experiments and this increased affinity explains the processivi-
ty of the EgtD-catalyzed reaction (Vit, 2010; Vit et al., 2015). The processivity of the 
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EgtD-catalyzed reaction is important to channel a distinct fraction of the cellular histidine 
pool into ergothioneine biosynthesis without interfering with protein biosynthesis (Vit et 
al., 2015). 
 
 
Figure 82: A: 1.51 Å crystal structure of EgtD with N
α
,N
α
-dimethyl-histidine (DMH) and S-adenosyl-ho-
mocysteine (SAH). B: Active site of EgtD. Residues M252 and E282 form the binding pocket for the 
imidazole moiety together with a water molecule coordinated by T213. N166 stabilizes the amino acid 
function of DMH. One methyl group is in contact with the sulfur atom of SAH. C: m|Fobs|-D|Fcalc| 
electron densities (σ-level = 2.5) of SAH (left) and DMH (right). 
 
The structural basis for substrate specificity and processivity of the EgtD-catalyzed reac-
tion is a result of the dense network of interactions between the dimethylated α-amino 
group of histidine and EgtD (Y39, F47 and N166, Figure 82B) (Vit et al., 2015). Additio-
nally, one Nα-methyl group is in van-der-Waals contact with the sulfur atom of SAH, and 
Nα,Nα-dimethyl-histidine establishes a hydrogen bond between Nτ of the imidazole 
moiety and E282 of EgtD.  
A bioinformatic analysis of mycobacterial and fungal genomes revealed that fungi, in 
contrast to Mycobacteria, often possess an additional EgtD homolog. This additional 
fungal homolog shows large variability in binding site positions 213, 252 and 282 (EgtD 
numbering) (Vit et al., 2015). On the basis of this result, a tyrosine betaine synthase (Ybs) 
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methyltransferase was identified in Aspergillus nidulans. Additionally, a tryptophan be-
taine synthase (HyoA) was identified in the wood-rotting fungus Dichomitus squalens. 
Since purification of HyoA was unsuccessful, a tryptophan-specific variant EgtDM252V,E282A 
was successfully engineered and yielded an enzyme with an active site configuration si-
milar to that in the fungal protein.  
The structure of EgtDM252,E282 with tryptophan and SAH displays the aromatic amino acid 
in the enlarged binding site (Figure 83B). The mode of binding is very similar to the one 
of Nα,Nα-dimethyl-histidine and EgtD, but distinct mutations allow the enzymes to be 
highly specific for one type of aromatic amino acid. In contrast to EgtD (T213, M252, 
E282), tryptophan betaine synthases possess residues T213, V252 and A282 and thus 
they own a larger binding pocket to harbor the indole side chain of tryptophan. Tyrosine 
betaine synthases such as Ybs from A. nidulans probably utilize N213, Q252 and V282 for 
tyrosine binding (Figure 83C).  
 
 
Figure 83: Active centers of aromatic amino acid betaine synthases (residue numbering is based on 
the EgtD sequence). A: EgtD coordinates the imidazole moiety of the histidine substrates by hydrogen 
bond interactions between Nτ and E282 and a water mediated bridge between Nπ and T213. B: 
EgtDM252V,E282A possesses a larger binding pocket that is able to harbor the indole side chain of trypto-
phan via hydrophobic interactions and a water mediated hydrogen bond between the nitrogen atom 
of tryptophan and T213. C: Proposed binding interactions for tyrosine-specific betaine synthases, for 
instance Ybs from A. nidulans. The hydroxyl group of the tyrosine side chain probably establishes by 
two hydrogen bonds to N213 and Q252.  
 
Taken together, the data obtained in this study do not only characterize the first step of 
ergothioneine biosynthesis, but also reveal the structural basis of aromatic amino acid 
betaine biosynthesis, which is distinct from glycine betaine biosynthesis. Additionally, 
aromatic amino acid betaines seem to be common metabolites also in fungi.  
                                 13   Synopsis and Outlook – Mycobacterial Ergothioneine Biosynthesis 
 
198
13.2 Sulfoxide Synthase EgtB 
The second step in ergothioneine biosynthesis is the O2-dependent carbon-sulfur bond 
formation and oxidation between the imidazole ring of Nα,Nα,Nα-trimethyl-L-histidine 
and the thiol side chain of γ-glutamyl-cysteine as well as the sulfoxidation of the sulfur 
atom. These reactions are catalyzed by the sulfoxide synthase EgtB.  
The apo structure of EgtB was phased using the anomalous signal of its intrinsic sulfur 
atoms (11 sulfurs from methionines and cysteines) in a recently developed data collec-
tion approach (Weinert et al., 2015). EgtB consists of an N-terminal DinB domain (resi-
dues 7-150), formed by a four α-helical bundle containing the three Fe(II)-chelating resi-
dues H51, H134 and H138, and a C-terminal C-type lectin fold (CLec) domain, the latter 
poor of secondary structure elements. The two domains are connected by an extended 
two-stranded -sheet linker formed by residues 151-210. 
 
 
Figure 84: Active site of EgtB. Left: EgtB in complex with N
α
,N
α
,N
α
-trimethyl-histidine (salmon). Un-
biased m|Fobs|-D|Fcalc| density for TMH is shown in green. The Nπ of the imidazole moiety of TMH 
coordinates the Fe(II) ion together with H51, H134 and H138. Right: EgtB in complex with N
α
,N
α
-dime-
thyl-histidine (yellow) and γ-glutamyl-cysteine (cyan). Unbiased m|Fobs|-D|Fcalc| density (σ-level = 2.5) 
for DMH and 3GC is shown in green. A dense array of hydrogen bonds positions the substrates in the 
active site of EgtB. 3GC is establishes hydrogen bonds to R87, R90 and R420, as well as D416 and the 
carboxyl group of DMH. The sulfur atom coordinated at the metal center. The orientation of the two 
substrates relative to each other gives hints for the stereochemical center of the reaction product.  
 
The catalytic site of EgtB is located in a 15 Å deep and 10 Å wide pocket formed by re-
sidues 375-420 of the hypervariable region (Figure 84, orange) of the CLec domain and 
residues of helices α2 and α4 of the DinB domain of EgtB. In this study, it was possible to 
identify H51, H134 and H138 as the Fe(II)-complexing residues and direct ligands to the 
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metal center, correcting prior bioinformatic analysis given in the literature. The fourth 
metal ligand is the Nπ of the imidazole moiety of Nα,Nα,Nα-trimethyl-histidine or Nα,Nα-
dimethyl-histidine (Figure 84A+B), the latter serving as a substrate analogue in the qua-
ternary complex. The substrate is bound to EgtB by hydrogen bond interaction of the 
carboxyl groups with R87, R90 and R420. The sulfur atom of γ-glutamyl-cysteine is the 
fifth ligand coordinated at the metal center. The Nα amino function of γ-glutamyl-cys-
teine establishes a hydrogen bond to D416. Interestingly, γ-glutamyl-cysteine forms hy-
drogen bonds to the carboxyl group of Nα,Nα-dimethyl-histidine. In turn, Nα,Nα-dimethyl-
histidine interacts with Q137 and the carbonyl group of Y380 via hydrogen bonds. The 
indole side chain of W415 is in hydrophobic contact with the methylated α-amino group 
of Nα,Nα-dimethyl-histidine. Additionally, a tunnel leading from the surface of EgtB to the 
catalytic Fe(II) center was identified as the probable path taken by an oxygen molecule 
involved in the reaction (Goncharenko et al., 2015). 
On the basis of the structural and kinetic data, a catalytic mechanism for this novel class 
of sulfoxide synthases was proposed. This mechanism allowed the prediction of the sulf-
oxide stereochemistry of the product of the EgtB-catalyzed reaction to be in S configura-
tion. The structure of EgtB and its mechanism are distinct from any known sulfoxide 
synthase.  
 
13.3 Ntn Amidohydrolase EgtC 
The Ntn hydrolase EgtC catalyzes the hydrolysis of γ-glutamyl-Nα,Nα,Nα-trimethyl-histidi-
nyl cysteine sulfoxide to glutamate and Nα,Nα,Nα-trimethyl-histidinyl cysteine sulfoxide. 
Its characteristic Ntn hydrolase (Pfam CL0052) (Brannigan et al., 1995) nucleophile is 
provided by N-terminal cysteine residue C2. The apo of EgtC has been determined pre-
viously (Vit, 2010), while structures of EgtC with glutamine as well as of an inactive EgtC 
variant EgtCC2A with its substrate γ-glutamyl-N
α,Nα,Nα-trimethyl-histidinyl cysteine sulf-
oxide were determined in this study.  
EgtC forms tetramers in size exclusion chromatography and in the crystals (Figure 85A). 
Interestingly, dimerization of EgtC appears obligatory for activity because the substrate 
binding site is formed by residues from both molecules of the dimer (Figure 85A).  
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Figure 85: The crystal structure of EgtCC2A in complex with γ-glutamyl-N
α
,N
α
,N
α
-trimethyl-histidinyl 
cysteine sulfoxide (QHC). A: EgtC is at least an obligate dimer (yellow/teal), because QHC (salmon) 
binding involves two residues from the second EgtC molecule. However, a tetramer is more likely be-
cause of the amount of buried surface. B: QHC coelutes with EgtCC2A from an S200 10/300 GL size ex-
clusion chromatography column. C: The presence of QHC in the EgtCC2A active site is clearly indicated 
by positive m|Fobs|-D|Fcalc| electron density (σ-level = 2). This density could be used to determine the 
stereochemistry of the sulfoxide moiety of QHC. C2
m
 is modeled from the wild type protein. D: QHC is 
recognized by a dense array of hydrogen bonds.   
 
Positive m|Fobs|-D|Fcalc| electron density clearly confirms the presence of the substrate in 
the EgtC binding pocket (Figure 85C), with the substrate stabilized by a dense network of 
hydrogen bonds (Figure 85D). The electron density was used to elucidate the stereoche-
mistry of the sulfoxide moiety of γ-glutamyl-Nα,Nα,Nα-trimethyl-histidinyl cysteine sulf-
oxide. The sulfoxide moiety of the substrate does indeed show the previously predicted 
S configuration (Figure 85C, Goncharenko et al., 2015). However, the mode of substrate 
binding to EgtC seems to be unproductive, because the C2 nucleophile is too far away 
from the carbonyl carbon at which the nucleophile should attack. Interestingly, a flexible 
loop A90-P95 is located above the active site, either adopting an open (EgtC with gluta-
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mine) or a closed (EgtCC2A with its substrate) conformation, thereby generation a more 
open or closed active site. This loop is probably able to push γ-glutamyl-Nα,Nα,Nα-trime-
thyl-histidinyl cysteine sulfoxide into the active site of EgtC, leading to a more productive 
substrate binding mode in which the hydrolysis reaction can take place. This model is in 
agreement with the hypothesis that enzymes of this family undergo a conformational 
change upon substrate binding (Isupov et al., 1996).  
 
13.4 Inhibition of EgtD by Histidine Derivatives 
Interestingly, EgtD is essential for ergothioneine biosynthesis in Mycobacteria (Cheah et 
al., 2013). Inhibition of this pathway might present a target for novel therapeutics, for 
instance against M. tuberculosis. Thus, the structure of EgtD provides the basis for ratio-
nal design of ergothioneine biosynthesis inhibitors (Vit et al., 2015).  
 
 
Figure 86: Future design of EgtD inhibitors. A: Overall structure of EgtD with N
α
-morpholino-histidine. B: 
Close-up of the N
α
-morpholino-histidine binding site. The N
α
-morpholino moiety, in boat conformation, 
points into the large cleft in EgtD, where SAM/SAH is normally bound. Possibly, EgtD is able to harbor in-
hibitors with more bulky α-amino group modifications. 
 
Potential histidine derivative inhibitors with modification on the α-amino group of the 
compounds were designed by Florian Seebeck and coworkers. The compounds α-chloro-
histidine, Nα,Nα,Nα-trimethyl-histidine, Nα-pyrrolidino-histidine and Nα-morpholino-histi-
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dine were successfully assayed regarding their inhibitory potential towards EgtD, and 
their KI’s were determined as 2.5 µM, 16.1 µM, 27.2 µM and 22.0 µM, respectively (L. 
Misson, unpublished data). Hence, α-chloro-histidine is the most potent EgtD inhibitor. 
This is surprising, because it means that a positive charge on the α-amino group is not 
required for substrate recognition by EgtD. Crystal structures of EgtD with each of the 
four EgtD inhibitors were obtained by soaking approaches. The inhibitors are well-
defined in the active site. Possibly, EgtD is even able to harbor inhibitors with more bulky 
α-amino group modifications (Figure 86) that reach into the SAM/SAH binding site. 
 
13.5 Outlook – Future Studies on Ergothioneine-Biosynthetic Proteins 
Further investigations on ergothioneine biosynthesis may include detailed mechanistic 
studies on EgtB, using enzyme engineering approaches to prove the proposed reaction 
mechanism, or to shift the substrate specificity of EgtB to other cysteine derivatives by 
generating tailor-made sulfoxide synthases.  
EgtC been characterized structurally, but not in a kinetic assay, which would be a future 
task. In this assay, the activity of EgtC towards other compounds, for instance glutamine, 
should also be examined. Furthermore, EgtC was demonstrated to be an obligate dimer, 
because the substrate binding pocket is formed by residues from two distinct EgtC mole-
cules. However, oligomer assembly predictions by the PISA server indicate that EgtC is a 
homotetramer (Krissinel & Henrick, 2007). In order gain additional and unambiguous in-
formation on the oligomeric state of EgtC, dynamic light scattering (DLS) or SAXS mea-
surements of EgtC could be conducted in the future.  
Inhibitor design for EgtD has been started, but requires a larger variety of compounds to 
improve the affinity of the inhibitors towards the enzyme. The inhibitors can be easily 
tested in the EgtD coupled assay established by L. Misson, and their KI’s can be deter-
mined. Crystal structures of the inhibitors in the active site of EgtD facilitate further im-
provement of the initial inhibitors. 
Three of the five mycobacterial ergothioneine biosynthesis enzymes have successfully 
been characterized using structural biology and biophysical as well as biochemical ap-
proaches. In order to characterize the whole mycobacterial ergothioneine biosynthetic 
pathway, the two remaining enzymes, the glutamate-cysteine ligase EgtA and the PLP-
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dependent lyase EgtE should be subjected to structure determination. For EgtA, struc-
ture determination and kinetic data would complement already existing biochemical 
characterization of a similar enzyme from Haloferax volcanii (Malki et al., 2009). Myco-
bacterial EgtE and its fungal variant Nc-Egt1 from N. crassa have not been structurally 
characterized at all. Hence, structure determination of EgtE would elucidate the last step 
in ergothioneine biosynthesis and complete the picture of the ergothioneine biosynthe-
sis pathway. 
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14 Supporting Information 
This section contains the supporting information for the publications presented in this 
study. The supporting information includes additional details experimental methods as 
well as further results and figures. Crystallographic data collection, processing and 
refinement statistics are also found in this section.  
 
14.1 Supporting Information for Publication A 
Full supporting information is available online:  
http://onlinelibrary.wiley.com/store/10.1002/cbic.201402522/asset/supinfo/cbic_201402522_s
m_ miscellaneous_information.pdf?v=1&s=fee4509a74cd3ce5fe81f309f30ba42b6f86947a 
 
 
Figure S1: m|Fobs|-D|Fcalc| densities. Left: Density for N
α
,N
α
-dimethyl-histidine (2σ) from EgtD in 
complex with N
α
,N
α
-dimethyl-histidine. Middle: Density for S-adenosyl-homocysteine (SAH) and N
α
,N
α
-
dimethyl-histidine (2σ) from EgtD in complex with SAH and N
α
,N
α
-dimethyl-histidine. Right: Density for 
S-adenosyl-homocysteine and tryptophan (1.5σ) from EgtDM252,E282 in complex with SAH and tryptophan. 
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Table S1: Data collection statistics for M. smegmatis EgtD apo structure and complexes. Values in parentheses are for the highest resolution shell. AVI=N
α
,N
α
-dimethyl-
L-histidine, SAH=S- adenosyl-L-homocysteine, TRP=L-tryptophan, HyoA = tryptophan-specific EgtD variant (EgtDM252V,E282A). 
Dataset  Se SAD
+
 EgtD_apo EgtD_Se_apo EgtD_AVI EgtD_AVI_SAH HyoA_TRP_SAH 
Wavelength (Å) / beamline
≠
 0.9786 / SLS, PXII 0.9786 / SLS, PXII 0.9184 / BESSY II, 14.1 0.9184 / BESSY II, 14.1 0.9184 / BESSY II, 14.1 
Resolution range (Å) 48.72–2.77 (2.92 – 2.77) 48.72 –1.75 (1.78-1.75) 50-1.9 (2.0 – 1.9) 50-1.51 (1.59-1.51) 41.86-1.8 (1.9-1.8) 
Space group P212121 P212121 P212121 P21 P21 
Unit cell parameters    (Å) 
                                         (°) 
71.8   75.5   138.7 
90   90   90 
71.8   75.5   138.7 
90   90   90 
72.0   74.8   137.8 
90   90   90 
56.7   67.5   79.7 
90   110.98   90 
79.04   67.63   112.13 
90   109.24   90 
Mosaicity (°)
†
 0.115 0.115 0.313 0.148 0.22 
Total No. of measured reflections 250555 (39024) 1013484 (57635) 294015 (42418) 275925 (38056) 391092 (56192) 
Unique reflections 19504 (2761) 74528 (3977) 59396 (8575) 87536 (12354) 103604 (15045) 
Multiplicity 6.9 (7.4) 13.6 (14.5) 5 (4.9) 3.2 (3.1) 3.8 (3.7) 
Mean I/σ(I) 43.6 (28.1)
§
 18.8 (2.5) 10.9 (2.3) 8.9 (2.0) 7.4 (2.1) 
Completeness (%) 99.1 (98.6)
+
 97.4 (95.8) 100 (100) 98.8 (95.9) 100 (99.9) 
Rmeas (%)
‡
 5.0 (8.9) 11.0 (132.2) 10.5 (75.4) 10.6 (66.5) 12.8 (68.6) 
Rp.i.m. (%)
$
 1.9 (3.3) 3.0 (34.5) 4.7 (33.5) 5.9 (36.9) 6.5 (35.1) 
+
Data collection statistics for unmerged Friedel pairs .                               
≠
 SLS: Swiss Light Source (Paul Scherrer Institute, Villigen, CH), BESSY: Berlin Electron Storage Ring Society for Synchrotron Radiation (Helmholtz Zentrum Berlin, Berlin, D). 
†
Mosaicity values reported by XDS.
[1]
  
§
 The anomalous signal is signiﬁcant to 2.77 Å resolution according to Xtriage from Phenix.
[2]
 Hence, the data were cut at mean I/σ(I) = 28.1 in the highest resolution shell. 
‡
Rmeas = Σhkl (N/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl), where N is the number of observations of the reflection with index hkl and Ii is the intensity of its i
th
 
observation. 
$
Rp.i.m. = Σhkl (1/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl).
[3]
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Table S2: Refinement statistics for M. smegmatis EgtD apo structure and complexes. Values in parenthe-
ses are for the highest resolution shell. AVI=N
α
,N
α
-dimethyl-L-histidine, SAH=S-adenosyl-L-homocyste-
ine, TRP=L-tryptophan, HyoA = tryptophan-specific EgtD variant (EgtDM252V,E282A). 
Dataset  EgtD_Se_apo EgtD_AVI EgtD_AVI_SAH HyoA_TRP_SAH 
Resolution range (Å) 48.72 –1.75 
(1.82-1.75) 
50-1.9 
(2.0 – 1.9) 
50-1.51 
(1.59-1.51) 
41.86-1.8 
(1.9-1.8) 
Rwork (%) 15.64 (22.9) 19.8 (41.6) 14.8 (24.1) 19.4 (27.8) 
Rfree (%) 18.66 (26.5) 24.1 (44.9) 18.0 (27.4) 23.9 (36.4) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
4999 
8 
- 
834 
 
4933 
25 
26 
680 
 
4987 
7 
78 
985 
 
9679 
3 
164 
1371 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.009 
1.116 
 
0.003 
0.790 
 
0.008 
1.278 
 
0.007 
1.104 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
25 
34 
- 
39 
 
29 
33 
21 
35 
 
13 
30 
8 
27 
 
22 
23 
17 
30 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
98.2 
0.2 
 
98.4 
0 
 
98.6 
0 
 
97.9 
0.1 
MolProbity score
#
 0.95 0.88 0.94 1.15 
PDB entry code 4PIM 4PIN 4PIO 4PIP 
#
As reported by MolProbity.
[4]
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14.2 Supporting Information for Publication B 
Full supporting information is available online: 
http://onlinelibrary.wiley.com/store/10.1002/anie.201410045/asset/supinfo/anie_201410045_s
m_miscellaneous_information.pdf?v=1&s=2883ace3ed2b1a75519a3845f7420232a2636e2b  
 
Materials. All standard reagents were purchased from Aldrich/Sigma if not otherwise 
stated. Synthetic oligonucleotides were purchased from Microsynth, Switzerland. N-glu-
taryl-cysteine was synthesized from glutaric anhydride and cysteine and characterized by 
ESI-MS (m/z calc. 236.059; meas.: 236.1) and 1H NMR (400 MHz, DMSO--‐d6) δ ppm 7.43 
(d, J = 6.9 Hz, 1H), 4.01 (dt, J = 6.8, 5.1 Hz, 1H), 2.82 (dd, J = 13.0, 4.7 Hz, 1H), 2.73 (dd, J = 
13.0, 5.6 Hz, 1H), 2.13 (t, J = 7.4 Hz, 2H), 2.04 (t, J = 7.4 Hz, 2H), 1.67 (p, J = 7.4 Hz, 2H).  
 
Recombinant EgtB constructs. Cloning and production of EgtBsmegmatis was described pre-
viously.[1] The gene for EgtB from Mycobacterium thermoresistibile (EgtBthermo, 
WP_003925249) was codon-optimized for protein production in E. coli and purchased 
from GenScript. The gene was ligated as NdeI-XhoI fragment into a pET28b cloning vec-
tor. The corresponding construct induced E. coli cells to produce the following proteins:  
 
EgtBsmegmatis:  
GSSHHHHHHSSGLVPRGSHMIARETLADELARARERTLRLVEFDDAELHRQYNPLMSPLVWDLAHIGQQ 
EELWLLRDGNPDRPGMLAPEVDRLYDAFEHSRASRVNLPLLPPSDARAYCATVRAKALDTLDTLPEDDP 
GFRFALVISHENQHDETMLQALNLREGPPLLDTGTPLPTGRPGVAGTSVLVPGGPFVLGVDALTEPHSL 
DNERPAHVVDIPSFRIGRVPVTNAEWREFIDDGGYDEPRWWSPRGWAHRQEAGLVAPQFWNPDGTRTRF 
GHIEEIPGDEPVQHVTFFEAEAYAAWAGARLPTEIEWEKACAWDPVAGARRRFPWGSAQPSAALANLGG 
DARRPAPVGAYPAGASAYGAEQMLGDVWEWTSSPLRPWPGFTPMIYERYSTPFFEGTTSGDYRVLRGGS 
WAVAPGILRPSFRNWDHPIRRQIFSGVRLAWDV 
 
m/z(EgtBsmegmatis): calc.: 49859.76 Da, meas.: 49998.4 Da 
ε280(EgtBsmegmatis): 108400 M-1 cm-1 
 
EgtBthermo: 
GSSHHHHHHSSGLVPRGSHMGVAVPHRAELARQLIDARNRTLRLVDFDDAELRRQYDPLMSPLVWDLAH 
IGQQEELWLLRGGDPRRPGLLEPAVEQLYDAFVHPRASRVHLPLLSPAQARRFCATVRSAVLDALDRLP 
EDADTFAFGMVVSHEHQHDETMLQALNLRSGEPLLGSGTALPPGRPGVAGTSVLVPGGPFVLGVDLADE 
PYALDNERPAHVVDVPAFRIGRVPVTNAEWRAFIDDGGYRQRRWWSDAGWAYRCEAGLTAPQFWNPDGT 
RTRFGHVEDIPPDEPVQHVTYFEAEAYAAWAGARLPTEIEWEKACAWDPATGRRRRYPWGDAAPTAALA 
NLGGDALRPAPVGAYPAGASACGAEQMLGDVWEWTSSPLRPWPGFTPMIYQRYSQPFFEGAGSGDYRVL 
RGGSWAVAADILRPSFRNWDHPIRRQIFAGVRLAWDVDRQTARPGPVGGC 
 
 
                               14  Supporting Information – Mycobacterial Ergothioneine Biosynthesis 
 
208
m/z(EgtBthermo): calc.: 51342.67 Da, meas. 51373.70 Da; Delta: 31 Da*  
ε280(EgtBthermo): 111380 M
-1 cm-1  
 
* The calculated mass is 31 Da smaller that the measured mass. This may be due to two 
oxidation events, for example on methionine and cysteine residues. The exposed C-ter-
minal Cys residue (Cys446) is a possible recipient of this oxidation. However, but this re-
sidue is invisible in the X-ray structures. 
 
EgtB variants. EgtBsmegmatis,C100S, EgtBD194N and EgtBD416N were constructed by primer exten-
sion using the following primers. The resulting fragments were cloned into pET28b vec-
tors. For protein crystallization we cloned the EgtBthermo gene into a modified vector 
pET19m to encode an EgtB fusion construct with an N-terminal His6-tag followed by a 
TEV (tobacco etch virus) protease cleavage site. 
 
D416Ns:   5‘-TAT ATC GCA ATT GGA ACC ACC CGA TTC -3‘ 
D416Na:   5’-TAT AGA ATC GGG TGG TTC CAA TTG CGA -3’ 
EgtBthermos:   5’-TAT ACA TAT GGG TGT CGC CGT GC -3’ 
EgtDthermoa:   5’-ATA TCT CCG AGC TAA CAA CCA CCC ACC GG -3’ 
C100Ss:   5‘-ATG CGC GCG CCT ACT CTG CGA CGG TGC GGG CCA A-3‘ 
C100Sa:   5’-CCG CAC CGT CGC AGA GTA GGC GCG CGC ATC CGA A-3’ 
EgtBsmegmatiss:   5’-ATA TCA TAT GAT CGC ACG CGA GAC ACT-3’ 
EgtDsmegmatisa:  5’-ATA TCT CGA GTT AGA CGT CCC AGG CCA G-3’ 
 
m/z(EgtBD416N): calc.: 51341.68 Da, meas.: 51373 Da 
ε280(EgtBD416N): 111380 M
-1 cm-1  
 
m/z(EgtBsmegmatis,C100S): calc.: 49843.7 Da, meas.: 49843 Da;  
ε280(EgtBsmegmatis,C100S): 108400 M
-1 cm-1 
 
m/z(EgtBthermo without His6-tag): calc.: 49504.73 Da, meas.: 49536 Da; Delta: 31 Da 
 
 
Recombinant protein production. E. coli BL21(DE3) transformed with the EgtB expres-
sion vectors were cultured in LB medium supplemented with 50 μg/mL kanamycin 
(pET28b) or 100 μg/mL ampicillin (pET19m) and 30 μg/mL chloramphenicol. At an optical 
density of OD600 of 0.8, protein production was induced with 0.5 mM IPTG for 16 hours 
at 19 °C. Cells were harvested by centrifugation, resuspended in buffer A (300 mM NaCl, 
50 mM Na2HPO4 pH 8.0) and lysed by sonication. After centrifugation for 1 h at 48000 
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rpm, the protein was purified using Ni2+ NTA Agarose beads (Qiagen) by washing the 
beads with buffer A containing 10 mM imidazole and then by elution in buffer A 
supplemented with 250 mM imidazole. The proteins were dialyzed into 50 mM Tris/HCl, 
50 mM NaCl buffer, pH 8.0 and stored at -80°C. Protein homogeneity was assessed by 
SDS PAGE, protein concentration was determined by UV using calculated extinction coef-
ficients.[2] Removal of the N-terminal histidine-tag from EgtBthermo with recombinant TEV 
protease proceeded after Ni2+ NTA Agarose purification during dialysis against 50 mM 
Tris/HCl, 50 mM NaCl pH 7.5 overnight at 277 K. Unprocessed EgtB and TEV were separa-
ted by filtration through Ni2+ NTA Agarose. The protein was further purified by size exclu-
sion chromatography (S300) and concentrated to 15 mg ml-1 and stored at ‐80°C. 
 
   
 
 
Figure S1: Quaternary structure of EgtBs. Left: Cartoon diagram of the asymmetric unit of EgtBthermo 
indicating Cys105 and the crystallographic interface. The interface in EgtBthermo does not form a 
disulfide bond because the equivalent Cys residues (Cys105) are not in close distance and point to 
the inside of the protein. Hence, EgtBthermo is monomeric. In EgtBsmegmatis, the orthologous residue is 
Cys100, suggesting that this protein adopts a different dimer structure in solution. Right: Analytical 
size-exclusion chromatography of EgtBsmegmatis, EgtBsmegmatis,C100S and EgtBthermo (Superdex200 size 
exclusion chromatography, at room temperature using 50 mM Tris-HCl pH 7.4, 200 mM NaCl, as 
running buffer, flow rate: 0.2 mL/min). Purified EgtBsmegmatis elutes as a monomer-dimer mixture. 
Treatment with TCEP turns the protein into a homogeneous monomer, suggesting that the dimer-
interaction is mediated by an intramolecular disulfide bond. Consistently, the EgtBsmegmatis,C100S 
variant does not  dimerize during protein purification. The crystallographic dimer interface in 
EgtBthermo does not form a disulfide bond and the equivalent Cys residues (Cys105) are not in close 
distance suggesting that the protein adopts a different dimer structure in solution. In the crystal 
structure of EgtBthermo we also detected an intermolecular disulfide bond between two Cys243 
residues. 
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Figure S2: EgtB activity depends on the presence of 1 equivalent iron. EDTA dialyzed EgtBsmegmatis 
showed no measurable activity when assayed in a reaction containing 100 mM HEPES, pH 8.0, 100 
mM NaCl, 2 mM TCEP, 2 mM ascorbate, 0.4 μM TMH, 1.2 mM γGC and 1.6 µM EgtBsmegmatis but no 
FeSO4. Titration of this reaction with FeSO4 induced 80% activity in the presence of 1 equivalent of 
iron (II) and full activity (Vmax) in presence of > 2 equivalents of iron (II). Consequently all EgtB 
activities were determined in presence of 4 equivalents of FeSO4. Comparison of EgtB activities in 
absence or presence of exogenous FeSO4 suggest that the recombinant proteins purify to a 
significant extent as holoenzymes (Table S1). Iron content of purified EgtB proteins was also 
determined by a ferrozine-based colorimetric assay. The data displayed in Table S1 are averages 
from three independent measurements. 
 
 
Table S1: Iron content in recombinant EgtB enzymes. 
Protein Ferrozine Assay 
(equivalent x 100) 
Activity assay 
(% residual activity) 
EgtBthermo 98 ± 2 95 ± 2 
EgtBthermos,D416N 55 ± 6 61 ± 3 
EgtBsmegmatis 61 ± 6 54 ± 4 
 
 
 
Figure S3 (below). Michaelis‐Menten plots/Enzyme assay. All enzymes were analyzed under the 
following standard conditions. Reactions contained 100 mM HEPES, 100 mM NaCl, 2 mM TCEP, 2 mM 
ascorbate, sulfur acceptor TMH (or alternative sulfur acceptors) and EgtB. Reactions were started by 
addition of γGC and incubated at 26 °C. Aliquots of the reactions were quenched by addition of 20 µl 1 
M phosphoric acid and analyzed by cation exchange HPLC using 20 mM phosphoric acid at pH 2 as a 
mobile phase.
[3]
 Compounds were eluted in a NaCl gradient. All HPLC chromatograms were recorded 
at 265 nm. The data were fitted to the function v = Vmax[s]/(KM + [s]). All reported data represent 
averages of at least two independent measurements. Michaelis-Menten plots are shown below. Kcat 
and kcat/KM were determined in the presence of co‐substrate at a concentration at least 3-fold higher 
than the corresponding  KM, cosubstrate and in air saturated buffers. 
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Figure S4. Left: γGC-dependent inactivation is reversible by addition of ascorbate. Product formation 
by EgtBthermo in a HEPES buffered solution (100 mM, pH 8.0), containing 100 mM NaCl, 0.8 mM TMH, 
1.2 mM γGC and 0.9 µM EgtBthermo at 26 °C, was monitored by HPLC. On reaction contained 2 mM 
ascorbate (red line). In absence of ascorbate EgtBthermo activity ceased after 30 turnovers (black line). 
The enzyme reaction resumed after addition of 2 mM ascorbate. Middle: EgtBthermo is inactivated by 
preincubation with γGC.  EgtBthermo  was incubated at 4 °C for 1 h with either 0.5 mM γGC or 0.5 mM 
TMH or buffer as a control. The remaining activities of these proteins (1.4 µM) were assayed in 
reactions containing 100 mM HEPES buffer, pH 8.0, 100 mM NaCl, 2 mM TCEP, 0.8 mM TMH and 1.2 
mM γGC. Product formation was monitored by HPLC. The initial rates of the three reactions indicate 
that incubation with γGC reduces EgtBthermo activity by at least 80-fold. Incubation with TMH leaves 
EgtBthermo activity unchanged. Right: Number of catalyzed turnovers by EgtBthermo in absence of 
ascorbate: Reaction mixtures containing HEPES buffer pH 8.0, 100 mM NaCl, 2 mM ascorbate, 0.4 mM 
TMH, 1.2 mM γGC, 2 mM TCEP were initiated by addition of 0.2, 0.5 or 1 µM EgtBthemo. Product 
formation was monitored by HPLC. Product formation ceases after 120 ± 20 turnovers.  
 
 
 
 
Figure S5. Absorption spectra of a) 100 μM EgtBthermo in 50 mM Tris (pH 8.0), 50 mM NaCl (black); b) 
sample a plus 500 µM γGC (red); c) sample b plus 1 mM ascorbate (blue). In the presence of γGC 
EgtBthermo is characterized by a strong absorbance band at 565 nm consistent with a charge transfer 
from γGC to the iron (III) center (LMCT – band).
[4]
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Figure S6. Superposition of EgtBthermo (grey/red/orange) and FGEhuman (2AIJ, violet).
[5]
 The segments 227-
269 (red) and 370-392 (orange) (EgtBthermo numbering) diverge significantly from the same segments in 
FGEhuman (violet). This unusual loop-rich structure is remarkably conserved in at least two proteins with 
entirely different functions and less than 30% sequence homology.
[5-6]
 The backbones of EgtBthermo 
(residues 155-434) and FGE superimpose with an r.m.s.d. of 0.741 when two peripheral loops are 
excluded (residues 227-269 and 370 - 392). FGE uses a concave patch formed by a C-terminal segment of 
30 residues (327-369, FGEhuman) to harbor an active site. The same surface in EgtBthermo combines with 
the N-terminal DinB domain for form the sulfoxide synthase active site. 
 
 
 
 
Figure S7: m|Fobs|-D|Fcalc| electron densities (σ-level = 2.5) of bound ligands are shown. Left: 
Difference electron density for TMH bound to EgtBthermo. Right: Difference electron density for DMH 
and γGC bound to EgtBthermo. 
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Figure S8: The view down the broad active site tunnel (15 Å deep and 10 Å wide) of the ternary 
complex reveals the iron binding site (active site residues in green) with ligated TMH (yellow). A water 
molecule (orange) ligates to iron and also hydrogen bonds with Tyr377. This ligand sits at the mouth 
of a narrow tunnel (arrow) which leads out to the protein exterior.  It seems possible that this tunnel 
allows O2 to reach the iron center to initiate the oxidation reaction. 
 
 
Crystallization. Initial crystallization conditions of EgtBthermo were determined with the 
vapor diffusion method in a sitting drop 96-well format. Drops were set up using a 
dispensing robot (Honeybee, Zinsser Analytic) mixing 0.2 µL of EgtB solution (23 mg mL-1) 
with 0.2 µL of reservoir solution equilibrated against 70 µL reservoir solution. The 
screens were stored at 20 °C in an automated imaging system (Formulatrix). Several ini-
tial hits were identified and optimized in 24-well plates using a hanging drop setup. 1 µL 
of protein solution (20 mg mL-1) was mixed with 1 µL mother liquor and equilibrated 
against 500 µL of reservoir at 20 °C. The final condition of EgtB crystals contained 0.2 M 
MgCl2, 0.1 M Tris/HCl pH 7 – 8, 6 - 10% (w/v) PEG 6000. Apo crystals of EgtB were 
cryoprotected in reservoir solution supplemented with 20% (v/v) glycerol, flash cooled in 
liquid nitrogen and tested on an X-ray home source including a Saturn 944+ CCD detec-
tor (Rigaku). Crystals of EgtB in complex with DMH or TMH were obtained by overnight 
soaking in reservoir solution supplemented with 15 % (v/v) glycerol and 10 mM ligand. 
EgtB crystals in complex with DMH and γQC were obtained by iterative addition of com-
pounds to the reservoir solution (i) 80 mM manganese chloride, 100 mM glutamate and 
overnight soaking (ii) 10 mM DMH and three hours soaking and (iii) 10 mM γQC and 15 
% (w/v) glycerol and soaking for two hours. Well-diffracting crystals of EgtB were sent to 
a synchrotron for data collection.  
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Data collection, data processing, structure solution and refinement. Single anomalous 
diffraction (SAD) data of an EgtB apo crystal were collected at a wavelength of 2.06642 Å 
on beamline X06DA at the Swiss Light Source (SLS, Paul Scherrer Institute, Villigen, Swit-
zerland) using a Pilatus 2M detector (Dectris). A native dataset was collected from a 
different EgtB apo crystal at a wavelength of 1.0 Å. All data were indexed and integrated 
with XDS[7] and scaled with AIMLESS[8] from the CCP4 program suite.[9] For the SAD data, 
hkl2map[10] was used to employ SHELXC[11] in extraction of the anomalous signal and 
SHELXD[12] in locating the anomalous scatterers, before SHELXE was used for density mo-
dification and automated model building. Since native data extended to a resolution of 
1.7 Å, SAD data and native data were combined. An initial model was generated using 
arp/Warp 7.0.[13] Diffraction data of EgtB ligand complexes were collected at the SLS 
(Villigen, Switzerland) or at the BESSY II Synchrotron (HZB, Berlin, Germany) at cryogenic 
temperatures. Data were processed with XDS and AIMLESS. In order to solve the EgtB li-
gand complexes, the apo structure of EgtBthermo was used for rigid body refinement in 
REFMAC5.[14] Manual adjustment of all models was done in COOT[15] which included the 
placement of ions and ligands. Ligands were prepared using PRODRG[16] and eLBOW[17] 
for refinement with phenix.refine.[18] The structures were validated with MolProbity.[19] 
Figures were prepared with PyMOL.[20] Data collection and refinement statistics are 
presented in Tables S2 and S3. 
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Table S2: Data collection statistics for M. thermoresistibile EgtB apo structure and complexes. Values in parentheses are for the highest resolution shell. AVI = N
α
,N
α
-
dimethyl-histidine, AVJ = N
α
,N
α
,N
α
-trimethyl-histidine, 3GC = γ-glutamyl-cysteine. 
Dataset  S SAD
+
 EgtB_apo EgtB_apo EgtB_AVI EgtB_AVJ EgtB_AVI_3GC 
Wavelength (Å) / beamline
≠
 2.06642 / SLS, PXIII 1.0 / SLS, PXIII 1.0 / SLS, PXIII 1.0 / SLS, PXIII 0.9184 / BESSY II, BL14.1 
Resolution range (Å) 48.83-2.27 (2.33-2.27) 48.75-1.7 (1.73-1.7) 48.7 -1.85 (1.88-1.85) 48.97-1.6 (1.63-1.6) 47.83-1.98 (2.01-1.98) 
Space group P43212 (96) P43212 (96) P43212 (96) P43212 (96) P43212 (96) 
Unit cell parameters (Å) 
                                      (°) 
135   135   141.5 
90   90   90 
134.8   134.8   141.2 
90   90   90 
134.3   134.3   141.4 
90   90   90 
135.2   135.2   142 
90   90   90 
135.3   135.3   141.3 
90   90   90 
Mosaicity (°)
†
 0.078 0.113 0.157 0.094 0.072 
Total No. of measured 
reflections 
2559724 (68788) 3781286 (191591) 2904833 (147156) 4581822 (223195) 1216498 (56796) 
Unique reflections 58661 (3294) 142371 (6966) 110295 (5375) 172557 (8463) 91436 (4456) 
Multiplicity 43.6 (20.9) 26.6 (27.5) 26.3 (27.4) 26.6 (26.4) 13.3 (12.7) 
Mean I/σ(I) 64.2 (10.5) 24.6 (2.7) 20.9 (1.9) 32 (2.3) 13.4 (2.1) 
Completeness (%) 96.4 (71) 100 (100) 100 (100) 100 (100) 100 (100) 
Rmeas (%)
‡
 5.8 (30.2) 12.0 (160.8) 13.6 (240.2) 8.1 (187.1) 15.5 (132) 
Rp.i.m. (%)
$
 1.2 (8.8) 2.3 (30.6) 2.6 (45.7) 1.6 (36.3) 4.2 (36.8) 
+
Data collection statistics for unmerged Friedel pairs .                               
≠
SLS: Swiss Light Source (Paul Scherrer Institute, Villigen, CH), BESSY: Berlin Electron Storage Ring Society for Synchrotron Radiation (Helmholtz Zentrum Berlin, D) 
†
Mosaicity values reported by XDS.
[7]
  
§
The recommended resolution cut off for anomalous substructure search is 3.3 Å resolution (mean I/σ(I) =89.3) according to Xtriage from Phenix.
[18]
 The data were cut at 
2.27 Å resolution (mean I/σ(I) =10.5) in the highest resolution shell. 
‡
Rmeas = Σhkl (N/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl), where N is the number of observations of the reflection with index hkl and Ii is the intensity of its i
th
 
observation. 
$
Rp.i.m. = Σhkl (1/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl).
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Table S3: Refinement statistics for M. thermoresistibile EgtB apo structure and complexes. Values in pa-
rentheses are for the highest resolution shell. AVI = N
α
,N
α
-dimethyl-histidine, AVJ = N
α
,N
α
,N
α
-trimethyl-
histidine, 3GC = γ-glutamyl-cysteine 
Dataset EgtB_apo EgtB_AVI EgtB_AVJ EgtB_AVI_3GC 
Resolution range (Å) 48.75-1.7 
(1.73-1.7) 
48.7 -1.85 
(1.88-1.85) 
48.97-1.6 
(1.63-1.6) 
47.83-1.98 
(2.01-1.98) 
Rwork (%) 13.8 (20.1) 15.9 (26.2) 14.5 (23.8) 15.1 (22.8) 
Rfree (%) 15.7 (21.8) 17.9 (27.8) 16.3 (28.5) 17.3 (25.8) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
6782 
8 
60 
1203 
 
6708 
14 
116 
640 
 
6809 
13 
100 
1106 
 
6827 
23 
64 
1015 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.009 
1.214 
 
0.013 
1.360 
 
0.010 
1.307 
 
0.006 
1.045 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
26 
27 
38 
40 
 
37 
49 
51 
44 
 
30 
40 
28 
42 
 
33 
28 
28 
43 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
99.0 
0.2 
 
98.9 
0.2 
 
99.1 
0.2 
 
98.8 
0.2 
MolProbity score
#
 0.95 1.08 1.04 0.83 
PDB entry code 4X8B - 4X8D 4X8E 
#
As reported by MolProbity.
[19]
 
 
 
 
 
 
 
 
 
 
                               14  Supporting Information – Mycobacterial Ergothioneine Biosynthesis 
 
218
References 
 
[1] F. P. Seebeck, J. Am. Chem. Soc. 2010, 132, 6632-6633.  
[2] C. N. Pace, F. Vajdos, L. Fee, G. Grimsley, T. Gray, Prot. Sci. 1995, 4, 2411-2423.  
[3] A. Braunshausen, F. P. Seebeck, J. Am. Chem. Soc. 2011, 133, 1757-1759.  
[4] J. D. Gardner, B. S. Pierce, B. G. Fox, T. C. Brunold, Biochemistry 2010, 49, 6033-6041.  
[5] T. Dierks, A. Dickmanns, A. Preusser-Kunze, B. Schmidt, M. Mariappan, K. von Figura, 
R. Ficner, M. G. Rudolph, Cell 2005, 121, 541-552.  
[6] J. Le Coq, P. Ghosh, Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 14649-14653.  
[7] W. Kabsch, Acta Crystallog. D Biol. Crystallogr. 2010, 66, 125-132.  
[8] P. R. Evans, Acta Crystallog. D Biol. Crystallogr. 2011, 67, 282-292.  
[9] M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, Evans, P. R., R. M. 
Keegan, E. B. Krissinel, A. G. W. Leslie, A. McCoy, et al., Acta Crystallog. D Biol. 
Crystallogr. 2011, 67.  
[10] T. Pape, T. R. Schneider, J. Appl. Cryst., 843-844.  
[11] G. M.  Sheldrick, Acta Crystallog. D Biol. Crystallogr. 2010, 66, 479-485.  
[12] T. R. Schneider, G. M. Sheldrick, Acta Crystallog. D Biol. Crystallogr. 2002, 58, 1772-
1779.  
[13] G. Langer, S. X. Cohen, V. S. Lamzin, A. Perrakis, Nat. Protoc. 2008, 3, 1171-1179.  
[14] G. N. Murshudov, P. Skubak, A. A. Lebedev, N. S. Pannu, R. A. Steiner, R. A. Nicholls, 
M. D. Winn, F. Long, A. A. Vagin, Acta Crystallog. D Biol. Crystallogr. 2011, D67, 355-367.  
[15] P. Emsley, K. D. Cowtan, Acta Crystallog. D Biol. Crystallogr. 2004, 60, 2126-2132.  
[16] A. W. Schuttelkopf, D. M. F. van Aalten, Acta Crystallog. D Biol. Crystallogr. 2004, 60, 
1355-1363. 
[17] N. W. Moriarty, R. W. Grosse‐Kunstleve, P. D. Adams, Acta Crystallog. D Biol. 
Crystallogr. 2009, 65, 1074‐1080.  
[18] P. V. Afonine, R. W. Grosse‐Kunstleve, N. Echols, J. J. Headd, N. W. Moriarty, M. 
Mustyakimov, T. C. Terwilliger, A. Urzhumtsev, P. H. Zwart, P. D. Adams, Acta Crystallog. 
D Biol. Crystallogr. 2012, 68, 352-367.  
[19] V. B. Chen, W. B. Arendall, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. Kapral, L. 
W. Murray, J. S. Richardson, D. C. Richardson, Acta Crystallog. D Biol. Crystallogr. 2009, 
66, 12-21.  
[20] W. L. DeLano, The PyMOL User’s Manual, DeLano Scientific, San Carlos, CA, USA; 
2002.  
15   References   
 
219 
15 References 
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Echols, N., Headd, J. J., Hung, L.-
W., Jain, S., Kapral, G. J., Grosse Kunstleve, R. W., et al. (2011). Methods. 55, 94–106. 
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., 
Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012). 
Acta Crystallogr. D Biol. Crystallogr. 68, 352–367. 
Ahuja, E. G., Janning, P., Mentel, M., Graebsch, A., Breinbauer, R., Hiller, W., Costisella, 
B., Thomashow, L. S., Mavrodi, D. V., & Blankenfeldt, W. (2008). J. Am. Chem. Soc. 130, 
17053–17061. 
Akanmu, D., Cecchini, R., Aruoma, O. I., & Halliwell, B. (1991). Arch. Biochem. Biophys. 
288, 10–16. 
De Angelis, J., Gastel, J., Klein, D. C., & Cole, P. A. (1998). J. Biol. Chem. 273, 3045–3050. 
Armstrong, R. N. (2000). Biochemistry. 39, 13625–13632. 
Askari, A. & Melville, D. B. (1962). J. Biol. Chem. 237, 1615–1618. 
Auld, D. S. (2001). Biometals Int. J. Role Met. Ions Biol. Biochem. Med. 14, 271–313. 
Baker, Y. R., Galloway, W. R. J. D., Hodgkinson, J. T., & Spring, D. R. (2013). Molecules. 18, 
11783–11796. 
Baron, S. S. & Rowe, J. J. (1981). Antimicrob. Agents Chemother. 20, 814–820. 
Bartlett, G. J., Porter, C. T., Borkakoti, N., & Thornton, J. M. (2002). J. Mol. Biol. 324, 105–
121. 
Bello, M. H., Barrera-Perez, V., Morin, D., & Epstein, L. (2012). Fungal Genet. Biol. 49, 
160–172. 
Bello, M. H., Mogannam, J. C., Morin, D., & Epstein, L. (2014). Fungal Genet. Biol. 73, 
120–127. 
Bergdoll, M., Eltis, L. D., Cameron, A. D., Dumas, P., & Bolin, J. T. (1998). Protein Sci. 7, 
1661–1670. 
Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. 
N., & Bourne, P. E. (2000). Nucleic Acids Res. 28, 235–242. 
Bittner, J. (2012). B. Sc. Thesis: Charakterisierung von PA3127 und PA3956 aus Pseudo-
monas aeruginosa. Universität Bayreuth. 
                                                                                                                       15   References 
 
220
Blankenfeldt, W., Kuzin, A. P., Skarina, T., Korniyenko, Y., Tong, L., Bayer, P., Janning, P., 
Thomashow, L. S., & Mavrodi, D. V. (2004). Proc. Natl. Acad. Sci. U. S. A. 101, 16431–
16436. 
Blankenfeldt, W. & Parsons, J. F. (2014). Curr. Opin. Struct. Biol. 29, 26–33. 
Botta, C., Di Giorgio, C., Sabatier, A.-S., & De Méo, M. (2008). J. Photochem. Photobiol. B. 
91, 24–34. 
Brannigan, J. A., Dodson, G., Duggleby, H. J., Moody, P. C. E., Smith, J. L., Tomchick, D. R., 
& Murzin, A. G. (1995). Nature. 378, 416–419. 
Caldwell, C. C., Chen, Y., Goetzmann, H. S., Hao, Y., Borchers, M. T., Hassett, D. J., Young, 
L. R., Mavrodi, D., Thomashow, L., & Lau, G. W. (2009). Am. J. Pathol. 175, 2473–2488. 
Cameron, A. D., Olin, B., Ridderström, M., Mannervik, B., & Jones, T. A. (1997). EMBO J. 
16, 3386–3395. 
Carollo, C. A., Calil, A. L. A., Schiave, L. A., Guaratini, T., Roberts, D. W., Lopes, N. P., & 
Braga, G. U. L. (2010). Fungal Biol. 114, 473–480. 
Cheah, I. K. & Halliwell, B. (2012). Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1822, 784–
793. 
Cheah, I. K., Ong, R. L. S., Gruber, J., Yew, T. S. K., Ng, L. F., Chen, C. B., & Halliwell, B. 
(2013). Free Radic. Res. 47, 1036–1045. 
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., 
Murray, L. W., Richardson, J. S., & Richardson, D. C. (2009). Acta Crystallogr. D Biol. 
Crystallogr. 66, 12–21. 
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., 
Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010). Acta Crystallogr. D Biol. 
Crystallogr. 66, 12–21. 
DeLano, W. L. (2002). DeLano Sci. San Carlos, CA, USA. 
Denning, G. M., Railsback, M. A., Rasmussen, G. T., Cox, C. D., & Britigan, B. E. (1998a). 
Am. J. Physiol. 274, L893–L900. 
Denning, G. M., Wollenweber, L. A., Railsback, M. A., Cox, C. D., Stoll, L. L., & Britigan, B. 
E. (1998b). Infect. Immun. 66, 5777–5784. 
Diederichs, K. & Karplus, P. A. (1997). Nat. Struct. Mol. Biol. 4, 269–275. 
Dietrich, L. E. P., Price-Whelan, A., Petersen, A., Whiteley, M., & Newman, D. K. (2006). 
Mol. Microbiol. 61, 1308–1321. 
Dietrich, L. E. P., Teal, T. K., Price-Whelan, A., & Newman, D. K. (2008). Science. 321, 
1203–1206. 
15   References   
 
221 
Dorgan, K. M., Wooderchak, W. L., Wynn, D. P., Karschner, E. L., Alfaro, J. F., Cui, Y., 
Zhou, Z. S., & Hevel, J. M. (2006). Anal. Biochem. 350, 249–255. 
Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002). Pediatr. 
Pulmonol. 34, 91–100. 
Emsley, P. & Cowtan, K. (2004). Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132. 
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010). Acta Crystallogr. D Biol. 
Crystallogr. 66, 486–501. 
Engebrecht, J., Nealson, K., & Silverman, M. (1983). Cell. 32, 773–781. 
Evans, P. (2006). Acta Crystallogr. D Biol. Crystallogr. 62, 72–82. 
Evans, P. R. (2011). Acta Crystallogr. D Biol. Crystallogr. 67, 282–292. 
Fahey, R. C. (2013). Biochim. Biophys. Acta. 1830, 3182–3198. 
Finn, R. D., Bateman, A., Clements, J., Coggill, P., Eberhardt, R. Y., Eddy, S. R., Heger, A., 
Hetherington, K., Holm, L., Mistry, J., et al. (2014). Nucleic Acids Res. 42, D222–D230. 
Fox, N. K., Brenner, S. E., & Chandonia, J.-M. (2014). Nucleic Acids Res. 42, D304–D309. 
Franke, D. & Svergun, D. I. (2009). J. Appl. Crystallogr. 42, 342–346. 
Franzoni, F., Colognato, R., Galetta, F., Laurenza, I., Barsotti, M., Di Stefano, R., Bocchetti, 
R., Regoli, F., Carpi, A., Balbarini, A., et al. (2006). Biomed. Pharmacother. Bioméd. 
Pharmacothérapie. 60, 453–457. 
Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R. D., & Bairoch, A. (2003). 
Nucleic Acids Res. 31, 3784–3788. 
Genghof, D. S. (1970). J. Bacteriol. 103, 475–478. 
Genghof, D. S. & Van Damme, O. (1964). J. Bacteriol. 87, 852–862. 
Genghof, D. S. & Van Damme, O. (1968). J. Bacteriol. 95, 340–344. 
Genghof, D. S., Inamine, E., Kovalenko, V., & Melville, D. B. (1956). J. Biol. Chem. 223, 9–
17. 
Giddens, S. R., Feng, Y., & Mahanty, H. K. (2002). Mol. Microbiol. 45, 769–783. 
Goncharenko, K. V., Vit, A., Blankenfeldt, W., & Seebeck, F. P. (2015). Angew. Chem. Int. 
Ed. 2821–2824. 
Griffin, J. E., Gawronski, J. D., DeJesus, M. A., Ioerger, T. R., Akerley, B. J., & Sassetti, C. 
M. (2011). PLoS Pathog. 7, e1002251. 
                                                                                                                       15   References 
 
222
Gründemann, D., Harlfinger, S., Golz, S., Geerts, A., Lazar, A., Berkels, R., Jung, N., 
Rubbert, A., & Schomig, E. (2005). Proc. Natl. Acad. Sci. U. S. A. 102, 5256–5261. 
Hand, C. E. & Honek, J. F. (2005). J. Nat. Prod. 68, 293–308. 
Hanlon, D. P. (1971). J. Med. Chem. 14, 1084–1087. 
Han, S., Eltis, L. D., Timmis, K. N., Muchmore, S. W., & Bolin, J. T. (1995). Science. 270, 
976–980. 
Hao, Y., Kuang, Z., Walling, B. E., Bhatia, S., Sivaguru, M., Chen, Y., Gaskins, H. R., & Lau, 
G. W. (2012). Cell. Microbiol. 14, 401–415. 
Hartman, P. E. (1990). Methods in Enzymology, A.N.G. Lester Packer, edited by, pp. 310–
318. Academic Press. 
Hassan, H. M. & Fridovich, I. (1980). J. Bacteriol. 141, 156–163. 
Hassett, D. J., Charniga, L., Bean, K., Ohman, D. E., & Cohen, M. S. (1992). Infect. Immun. 
60, 328–336. 
Hassett, D. J., Ma, J. F., Elkins, J. G., McDermott, T. R., Ochsner, U. A., West, S. E., Huang, 
C. T., Fredericks, J., Burnett, S., Stewart, P. S., et al. (1999). Mol. Microbiol. 34, 1082–
1093. 
Hauser, A. R., Jain, M., Bar-Meir, M., & McColley, S. A. (2011). Clin. Microbiol. Rev. 24, 
29–70. 
Heath, H. & Wildy, J. (1958). Biochem. J. 68, 407–410. 
Hecht, S. M. (1999). J. Nat. Prod. 63, 158–168. 
He, H., Ding, Y., Bartlam, M., Sun, F., Le, Y., Qin, X., Tang, H., Zhang, R., Joachimiak, A., 
Liu, J., et al. (2003). J. Mol. Biol. 325, 1019–1030. 
Held, K., Ramage, E., Jacobs, M., Gallagher, L., & Manoil, C. (2012). J. Bacteriol. 194, 
6387–6389. 
Hendrickson, W. A. (1985). Trans. Am. Cryst. Assoc. 21, 11–21. 
Hickman, A. B., Namboodiri, M. A., Klein, D. C., & Dyda, F. (1999). Cell. 97, 361–369. 
Houtman, J. C. D., Brown, P. H., Bowden, B., Yamaguchi, H., Appella, E., Samelson, L. E., 
& Schuck, P. (2007). Protein Sci. 16, 30–42. 
Hunter, G. (1928). Biochem. J. 22, 4–10. 
Hu, W., Song, H., Sae Her, A., Bak, D. W., Naowarojna, N., Elliott, S. J., Qin, L., Chen, X., & 
Liu, P. (2014). Org. Lett. 
Ishikawa, Y., Israel, S. E., & Melville, D. B. (1974). J. Biol. Chem. 249, 4420–4427. 
15   References   
 
223 
Ishikawa, Y. & Melville, D. B. (1970). J. Biol. Chem. 245, 5967–5973. 
Isupov, M. N., Obmolova, G., Butterworth, S., Badet-Denisot, M.-A., Badet, B., 
Polikarpov, I., Littlechild, J. A., & Teplyakov, A. (1996). Structure. 4, 801–810. 
Jacob, C., Jamier, V., & Ba, L. A. (2011). Curr. Opin. Chem. Biol. 15, 149–155. 
Jeong, J.-H., Cha, H. J., Ha, S.-C., Rojviriya, C., & Kim, Y.-G. (2014). Biochem. Biophys. Res. 
Commun. 452, 1098–1103. 
Jocelyn, P. C. (1958). Biochem. J. 70, 656–660. 
Jones, G. W., Doyle, S., & Fitzpatrick, D. A. (2014). Gene. 549, 161–170. 
Kabsch, W. (2010). Acta Crystallogr. D Biol. Crystallogr. 66, 125–132. 
Kalawy-Fansa, E. (2010). M. Sc. Thesis: Untersuchungen an Glyoxalase I / Bleomycin-
Resistenz-Proteinen aus Pseudomonas aeruginosa PAO1. Master Thesis. MPI Dortmund. 
Kanehisa, M. (2002). Novartis Found. Symp. 247, 91–101; discussion 101–103, 119–128, 
244–252. 
Keegan, R. M. & Winn, M. D. (2008). Acta Crystallogr. D Biol. Crystallogr. 64, 119–124. 
Keller, S., Vargas, C., Zhao, H., Piszczek, G., Brautigam, C. A., & Schuck, P. (2012). Anal. 
Chem. 84, 5066–5073. 
Kelley, L. A. & Sternberg, M. J. E. (2009). Nat. Protoc. 4, 363–371. 
Kendrew, J. C., Bodo, G., Dintzis, H. M., Parrish, R. G., Wyckoff, H., & Phillips, D. C. (1958). 
Nature. 181, 662–666. 
Kibbe, W. A. (2007). Nucleic Acids Res. 35, W43–W46. 
Kogan, A., Gdalevsky, G. Y., Cohen-Luria, R., Goldgur, Y., Phillips, R. S., Parola, A. H., & 
Almog, O. (2009). BMC Struct. Biol. 9, 65. 
Koley, D., Ramsey, M. M., Bard, A. J., & Whiteley, M. (2011). Proc. Natl. Acad. Sci. 108, 
19996–20001. 
Konarev, P. V., Volkov, V. V., Sokolova, A. V., Koch, M. H. J., & Svergun, D. I. (2003). J. 
Appl. Crystallogr. 36, 1277–1282. 
Kozin, M. B. & Svergun, D. I. (2001). J. Appl. Crystallogr. 34, 33–41. 
Krissinel, E. & Henrick, K. (2004). Acta Crystallogr. D Biol. Crystallogr. 60, 2256–2268. 
Krissinel, E. & Henrick, K. (2007). J. Mol. Biol. 372, 774–797. 
Kuspa, A., Kroos, L., & Kaiser, D. (1986). Dev. Biol. 117, 267–276. 
                                                                                                                       15   References 
 
224
Laemmli, U. K. (1970). Nature. 227, 680–685. 
Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., 
Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., et al. (2007). Bioinformatics. 23, 2947–
2948. 
Lau, G. W., Ran, H., Kong, F., Hassett, D. J., & Mavrodi, D. (2004). Infect. Immun. 72, 
4275–4278. 
Laurenza, I., Colognato, R., Migliore, L., Del Prato, S., & Benzi, L. (2008). BioFactors Oxf. 
Engl. 33, 237–247. 
Lee, J., Wu, J., Deng, Y., Wang, J., Wang, C., Wang, J., Chang, C., Dong, Y., Williams, P., & 
Zhang, L.-H. (2013). Nat. Chem. Biol. 9, 339–343. 
Lee, J. & Zhang, L. (2014). Protein Cell. 
Lee, S. G., Kim, Y., Alpert, T. D., Nagata, A., & Jez, J. M. (2012). J. Biol. Chem. 287, 1426–
1434. 
Leone, E. & Mann, T. (1951). Nature. 168, 205–206. 
Levitt, M. & Chothia, C. (1976). Nature. 261, 552–558. 
Liberati, N. T., Urbach, J. M., Miyata, S., Lee, D. G., Drenkard, E., Wu, G., Villanueva, J., 
Wei, T., & Ausubel, F. M. (2006). Proc. Natl. Acad. Sci. U. S. A. 103, 2833–2838. 
Long, F., Vagin, A. A., Young, P., & Murshudov, G. N. (2007). Acta Crystallogr. D Biol. 
Crystallogr. 64, 125–132. 
Look, D. C., Stoll, L. L., Romig, S. A., Humlicek, A., Britigan, B. E., & Denning, G. M. (2005). 
J. Immunol. Baltim. Md 1950. 175, 4017–4023. 
Lorenz, M. C. & Fink, G. R. (2002). Eukaryot. Cell. 1, 657–662. 
Lowther, W. T. & Matthews, B. W. (2000). Biochim. Biophys. Acta. 1477, 157–167. 
Lyczak, J. B., Cannon, C. L., & Pier, G. B. (2002). Clin. Microbiol. Rev. 15, 194–222. 
Malki, L., Yanku, M., Borovok, I., Cohen, G., Mevarech, M., & Aharonowitz, Y. (2009). J. 
Bacteriol. 191, 5196–5204. 
Mao, F., Dam, P., Chou, J., Olman, V., & Xu, Y. (2009). Nucleic Acids Res. 37, D459–D463. 
Marchler-Bauer, A., Derbyshire, M. K., Gonzales, N. R., Lu, S., Chitsaz, F., Geer, L. Y., Geer, 
R. C., He, J., Gwadz, M., Hurwitz, D. I., et al. (2015). Nucleic Acids Res. 43, D222–D226. 
Markova, N. G., Karaman-Jurukovska, N., Dong, K. K., Damaghi, N., Smiles, K. A., & 
Yarosh, D. B. (2009). Free Radic. Biol. Med. 46, 1168–1176. 
15   References   
 
225 
Martin, T. W., Dauter, Z., Devedjiev, Y., Sheffield, P., Jelen, F., He, M., Sherman, D. H., 
Otlewski, J., Derewenda, Z. S., & Derewenda, U. (2002). Structure. 10, 933–942. 
Maruyama, M., Kumagai, T., Matoba, Y., Hayashida, M., Fujii, T., Hata, Y., & Sugiyama, M. 
(2001). J. Biol. Chem. 276, 9992–9999. 
Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. 
Mavrodi, D. V., Blankenfeldt, W., & Thomashow, L. S. (2006). Annu. Rev. Phytopathol. 44, 
417–445. 
Mavrodi, D. V., Peever, T. L., Mavrodi, O. V., Parejko, J. A., Raaijmakers, J. M., 
Lemanceau, P., Mazurier, S., Heide, L., Blankenfeldt, W., Weller, D. M., et al. (2010). 
Appl. Environ. Microbiol. 76, 866–879. 
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, 
R. J. (2007). J. Appl. Crystallogr. 40, 658–674. 
McFadden, B. A. & Purohit, S. (1977). J. Bacteriol. 131, 136–144. 
McManus, I. R. (1962). J. Biol. Chem. 237, 1207–1211. 
Melville, D. B. & Eich, S. (1956). J. Biol. Chem. 218, 647–651. 
Melville, D. B., Eich, S., & Ludwig, M. L. (1957). J. Biol. Chem. 224, 871–877. 
Melville, D. B., Horner, W. H., & Lubschez, R. (1954). J. Biol. Chem. 206, 221–228. 
Mentel, M., Ahuja, E. G., Mavrodi, D. V., Breinbauer, R., Thomashow, L. S., & 
Blankenfeldt, W. (2009). ChemBioChem. 10, 2295–2304. 
Mittal, R., Aggarwal, S., Sharma, S., Chhibber, S., & Harjai, K. (2009). FEMS Immunol. 
Med. Microbiol. 57, 156–164. 
Mollica, A., Locatelli, M., Stefanucci, A., & Pinnen, F. (2012). Molecules. 17, 6083–6099. 
Moriarty, N. W., Grosse-Kunstleve, R. W., & Adams, P. D. (2009). Acta Crystallogr. D Biol. 
Crystallogr. 65, 1074–1080. 
Motohashi, N. & Mori, I. (1986). J. Inorg. Biochem. 26, 205–212. 
Motohashi, N., Mori, I., & Sugiura, Y. (1976). Chem. Pharm. Bull. (Tokyo). 24, 2364–2368. 
Motohashi, N., Mori, I., Sugiura, Y., & Tanaka, H. (1974). Chem. Pharm. Bull. (Tokyo). 22, 
654–657. 
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., 
Winn, M. D., Long, F., & Vagin, A. A. (2011). Acta Crystallogr. D Biol. Crystallogr. 67, 355–
367. 
                                                                                                                       15   References 
 
226
Nadzirin, N., Gardiner, E. J., Willett, P., Artymiuk, P. J., & Firdaus-Raih, M. (2012). Nucleic 
Acids Res. 40, W380–W386. 
Nakamura, T., Sugiura, S., Kobayashi, D., Yoshida, K., Yabuuchi, H., Aizawa, S., Maeda, T., 
& Tamai, I. (2007). Pharm. Res. 24, 1628–1635. 
Nixon, G. M., Armstrong, D. S., Carzino, R., Carlin, J. B., Olinsky, A., Robertson, C. F., & 
Grimwood, K. (2001). J. Pediatr. 138, 699–704. 
Nocek, B., Cuff, M., Evdokimova, E., Edwards, A., Joachimiak, A., & Savchenko, A. (2006). 
Proteins Struct. Funct. Bioinforma. 63, 1102–1105. 
Oda, K., Matoba, Y., Noda, M., Kumagai, T., & Sugiyama, M. (2010). J. Biol. Chem. 285, 
1446–1456. 
Oinonen, C. & Rouvinen, J. (2000). Protein Sci. Publ. Protein Soc. 9, 2329–2337. 
O’Malley, Y. Q., Reszka, K. J., Spitz, D. R., Denning, G. M., & Britigan, B. E. (2004). Am. J. 
Physiol. Lung Cell. Mol. Physiol. 287, L94–L103. 
Papaioannou, E., Utari, P. D., & Quax, W. J. (2013). Int. J. Mol. Sci. 14, 19309–19340. 
Park, C.-H., Park, C.-H., Lee, Y.-J., Lee, S.-Y., Oh, H.-B., & Lee, J.-W. (2011). Bull. Korean 
Chem. Soc. 32, 524–530. 
Parsons, J. F., Calabrese, K., Eisenstein, E., & Ladner, J. E. (2003). Biochemistry. 42, 5684–
5693. 
Parsons, J. F., Calabrese, K., Eisenstein, E., & Ladner, J. E. (2004a). Acta Crystallogr. D 
Biol. Crystallogr. 60, 2110–2113. 
Parsons, J. F., Song, F., Parsons, L., Calabrese, K., Eisenstein, E., & Ladner, J. E. (2004b). 
Biochemistry. 43, 12427–12435. 
Paul, B. & Snyder, S. (2010). Cell Death Differ. 17, 1134–1140. 
Pei, J., Kim, B.-H., & Grishin, N. V. (2008). Nucleic Acids Res. 36, 2295–2300. 
Peltekova, V. D., Wintle, R. F., Rubin, L. A., Amos, C. I., Huang, Q., Gu, X., Newman, B., 
Oene, M. V., Cescon, D., Greenberg, G., et al. (2004). Nat. Genet. 36, 471–475. 
Petoukhov, M. V., Franke, D., Shkumatov, A. V., Tria, G., Kikhney, A. G., Gajda, M., Gorba, 
C., Mertens, H. D. T., Konarev, P. V., & Svergun, D. I. (2012). J. Appl. Crystallogr. 45, 342–
350. 
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., 
& Ferrin, T. E. (2004). J. Comput. Chem. 25, 1605–1612. 
Pfeiffer, C., Bauer, T., Surek, B., Schömig, E., & Gründemann, D. (2011). Food Chem. 129, 
1766–1769. 
15   References   
 
227 
Pierson, L. S., Gaffney, T., Lam, S., & Gong, F. (1995). FEMS Microbiol. Lett. 134, 299–307. 
Pierson, L. S. & Thomashow, L. S. (1992). Mol. Plant-Microbe Interact. MPMI. 5, 330–339. 
Popp, M. (2013). M. Sc. Thesis: Charakterisierung von PA3127 und PA3128 aus 
Pseudomonas aeruginosa PAO1. Universität Bayreuth. 
Putnam, D. K., Lowe, E. W., & Meiler, J. (2013). Comput. Struct. Biotechnol. J. 8,. 
Rada, B. & Leto, T. L. (2013). Trends Microbiol. 21, 73–81. 
Rahman, I., Gilmour, P. S., Jimenez, L. A., Biswas, S. K., Antonicelli, F., & Aruoma, O. I. 
(2003). Biochem. Biophys. Res. Commun. 302, 860–864. 
Recinos, D. A., Sekedat, M. D., Hernandez, A., Cohen, T. S., Sakhtah, H., Prince, A. S., 
Price-Whelan, A., & Dietrich, L. E. P. (2012). Proc. Natl. Acad. Sci. 109, 19420–19425. 
Reszka, K. J., O’Malley, Y., McCormick, M. L., Denning, G. M., & Britigan, B. E. (2004). Free 
Radic. Biol. Med. 36, 1448–1459. 
Rife, C. L., Pharris, R. E., Newcomer, M. E., & Armstrong, R. N. (2002). J. Am. Chem. Soc. 
124, 11001–11003. 
Rigsby, R. E., Rife, C. L., Fillgrove, K. L., Newcomer, M. E., & Armstrong, R. N. (2004). 
Biochemistry. 43, 13666–13673. 
Rupp, B. (2009). Biomolecular Crystallography: Principles, Practice, and Application to 
Structural Biology New York: Garland Science. 
Salt, H. B. (1931). Biochem. J. 25, 1712–1719. 
Sao Emani, C., Williams, M. J., Wiid, I. J., Hiten, N. F., Viljoen, A. J., Pietersen, R.-D. D., van 
Helden, P. D., & Baker, B. (2013). Antimicrob. Agents Chemother. 57, 3202–3207. 
Sasikaran, J., Ziemski, M., Zadora, P. K., Fleig, A., & Berg, I. A. (2014). Nat. Chem. Biol. 10, 
371–377. 
Schüttelkopf, A. W. & van Aalten, D. M. F. (2004). Acta Crystallogr. D Biol. Crystallogr. 60, 
1355–1363. 
Seebeck, F. P. (2010). J. Am. Chem. Soc. 132, 6632–6633. 
Sillitoe, I., Cuff, A. L., Dessailly, B. H., Dawson, N. L., Furnham, N., Lee, D., Lees, J. G., 
Lewis, T. E., Studer, R. A., Rentzsch, R., et al. (2013). Nucleic Acids Res. 41, D490–D498. 
Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey, M. J., 
Brinkman, F. S. L., Hufnagle, W. O., Kowalik, D. J., Lagrou, M., et al. (2000). Nature. 406, 
959–964. 
Strelko, C. L., Lu, W., Dufort, F. J., Seyfried, T. N., Chiles, T. C., Rabinowitz, J. D., & 
Roberts, M. F. (2011). J. Am. Chem. Soc. 133, 16386–16389. 
                                                                                                                       15   References 
 
228
Sugiyama, M., Kumagai, T., Hayashida, M., Maruyama, M., & Matoba, Y. (2002). J. Biol. 
Chem. 277, 2311–2320. 
Sukdeo, N., Clugston, S. L., Daub, E., & Honek, J. F. (2004). Biochem. J. 384, 111. 
Sukdeo, N. & Honek, J. F. (2007). Biochim. Biophys. Acta BBA - Proteins Proteomics. 1774, 
756–763. 
Svergun, D., Barberato, C., & Koch, M. H. J. (1995). J. Appl. Crystallogr. 28, 768–773. 
Svergun, D. I. (1992). J. Appl. Crystallogr. 25, 495–503. 
Tanner, K. G., Langer, M. R., & Denu, J. M. (2000a). Biochemistry. 39, 11961–11969. 
Tanner, K. G., Langer, M. R., Kim, Y., & Denu, J. M. (2000b). J. Biol. Chem. 275, 22048–
22055. 
Tanret, C. (1909). Compt. Rend. Acad. Sci. 49, 222–224. 
Ta, P., Buchmeier, N., Newton, G. L., Rawat, M., & Fahey, R. C. (2011). J. Bacteriol. 193, 
1981–1990. 
Taubert, D., Jung, N., Goeser, T., & Schömig, E. (2009). Gut. 58, 312–314. 
Trievel, R. C., Rojas, J. R., Sterner, D. E., Venkataramani, R. N., Wang, L., Zhou, J., Allis, C. 
D., Berger, S. L., & Marmorstein, R. (1999). Proc. Natl. Acad. Sci. 96, 8931–8936. 
Usher, L. R., Lawson, R. A., Geary, I., Taylor, C. J., Bingle, C. D., Taylor, G. W., & Whyte, M. 
K. B. (2002). J. Immunol. Baltim. Md 1950. 168, 1861–1868. 
Vetting, M. W., Magnet, S., Nieves, E., Roderick, S. L., & Blanchard, J. S. (2004). Chem. 
Biol. 11, 565–573. 
Vit, A. (2010). M. Sc. Thesis: Charakterisierung von Enzymen aus der Ergothioneinbiosyn-
these. TU Dortmund. 
Vit, A., Misson, L., Blankenfeldt, W., & Seebeck, F. P. (2014). Acta Crystallogr. Sect. F 
Struct. Biol. Commun. 70, 676–680. 
Vit, A., Misson, L., Blankenfeldt, W., & Seebeck, F. P. (2015). ChemBioChem. 16, 119–125. 
Volkov, V. V. & Svergun, D. I. (2003). J. Appl. Crystallogr. 36, 860–864. 
Wang, Y., Kern, S. E., & Newman, D. K. (2010). J. Bacteriol. 192, 365–369. 
Wang, Y. & Newman, D. K. (2008). Environ. Sci. Technol. 42, 2380–2386. 
Wargo, M. J. (2013). Appl. Environ. Microbiol. 79, 2112–2120. 
15   References   
 
229 
Weber, I. (2011). B. Sc. Thesis: Biochemische und strukturelle Untersuchungen zu Glyo-
xalase I/Bleomycinresistenzproteinen aus Pseudomonas aeruginosa PAO1. Universität 
Bayreuth. 
Weinert, T., Olieric, V., Waltersperger, S., Panepucci, E., Chen, L., Zhang, H., Zhou, D., 
Rose, J., Ebihara, A., Kuramitsu, S., et al. (2015). Nat. Methods. 12, 131–133. 
Weiss, M. S. (2001). J. Appl. Crystallogr. 34, 130–135. 
Wilson, R., Sykes, D. A., Watson, D., Rutman, A., Taylor, G. W., & Cole, P. J. (1988). Infect. 
Immun. 56, 2515–2517. 
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, 
R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011). Acta Crystallogr. D Biol. 
Crystallogr. 67, 235–242. 
Winson, M. K., Camara, M., Latifi, A., Foglino, M., Chhabra, S. R., Daykin, M., Bally, M., 
Chapon, V., Salmond, G. P., & Bycroft, B. W. (1995). Proc. Natl. Acad. Sci. 92, 9427–9431. 
Winsor, G. L., Lam, D. K. W., Fleming, L., Lo, R., Whiteside, M. D., Yu, N. Y., Hancock, R. E. 
W., & Brinkman, F. S. L. (2011). Nucleic Acids Res. 39, D596–D600. 
Wriggers, W. (2012). Acta Crystallogr. D Biol. Crystallogr. 68, 344–351. 
Yu, S. (2009). PhD Thesis: Assessment of Pseudomonas Quinolone Signal Response 
Protein PqsE and Preliminary Functional Annotation of Hypothetical Protein PA0803 
from Pseudomonas aeruginosa. MPI Dortmund. 
Yu, S., Vit, A., Devenish, S., Mahanty, H. K., Itzen, A., Goody, R. S., & Blankenfeldt, W. 
(2011). BMC Struct. Biol. 11, 33. 
Zhao, Q., Wang, M., Xu, D., Zhang, Q., & Liu, W. (2015). Nature. 518, 115–119. 
Zwart, P. H., Grosse-Kunstleve, R. W., & Adams, P. D. (2005). CCP4 Newsl. Winter, 
Contribution 7. 
 
                            16   Appendices – βαβββ-Module Resistance Proteins from P. aeruginosa 
 
230
16 Appendices 
16.1 Additional Plasmids Generated in This Study 
Additional plasmids generated during this study are listed in Table 45.  
 
Table 45: Additional plasmids generated during this study or related 
studies under the supervision of the author.  
Plasmid  restrictions sites Host Source 
pET19m_PA0817 NdeI / XhoI E. coli Weber, 2011 
pET19m_PA0865 NdeI / BamHI E. coli this study 
pET19m_PA1359 NdeI / XhoI E. coli this study 
pET19m_PA2024 NdeI / XhoI E. coli this study 
pET19m_PA2546 NdeI / BamHI E. coli this study 
pET19m_PA2721 NdeI / XhoI E. coli this study 
pET19m_PA3127_1-257 NdeI / BamHI E. coli this study 
pET19m_PA3128 NdeI / XhoI E. coli this study 
pET19m_PA3389 NdeI / XhoI E. coli this study 
pET19m_PA3505 NdeI / XhoI E. coli this study 
pET19m_PA3956 NdeI / XhoI E. coli this study 
pET19m_PA4184 NdeI / XhoI E. coli this study 
 
16.2 Additional Datasets Processed and Structures Refined in This Study 
The crystal structures of PA0803, PA1353, PA3127-NTD and PA4641 have been deter-
mined in studies by Yu, 2009, Kalawy-Fansa, 2010, and Popp, 2013. The crystallographic 
data obtained at that time was reprocessed with current software versions of XDS and 
Aimless and the crystal structures were rebuild and re-refined in the course of this study. 
This procedure resulted in optimized structural models as well as improved data collec-
tion, processing and refinement statistics and. These statistics are given in Table 46, 
Table 47, Table 48 and Table 49. 
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Table 46: Data collection statistics for P. aeruginosa βαβββ module containing proteins PA0803 and PA1353. Data were collected in studies by Yu, 2009, and Kalawy-
Fansa, 2010. Values in parentheses are for the highest resolution shell. PYO = pyocyanin 
Dataset  PA0803 Se SAD
+
 PA0803 apo PA0803 PYO PA1353 apo 
Wavelength (Å) / beamline
≠
 0.9792 / SLS, X10SA (PXII) 1.5418/ MPI Dortmund 0.9184 / BESSY II, BL14.1 0.9787 / SLS, X10SA (PXII) 
Resolution range (Å) 19.84-1.95 (2.0-1.95) 46.55-1.62 (1.65-1.62) 46.39-1.71 (1.74-1.71) 49.11-1.75 (1.78-1.75) 
Space group P21212 P21212 P21212 P212121 
Unit cell parameters (Å) 
                                      (°) 
85.35  101.6  92.57 
90  90  90 
84.91  102.1  93.11 
90  90  90 
84.26  101.8  92.77 
90  90  90 
64.31  66.54  76.07 
90  90  90 
Mosaicity (°)
†
 0.234 0.211 0.109 0.286 
Total No. of measured 
reflections 
622550 (41972) 1258371 (12836) 357368 (19052) 387835 (20979) 
Unique reflections 58285 (4029) 102661 (4811) 86649 (4588) 33644 (1820) 
Multiplicity 5.6 (5.4) 12.3 (2.7) 4.1 (4.2) 11.5 (11.5) 
Mean I/σ(I) 31.0 (11.8) 14.9 (3.5) 11.6 (2.1) 17.1 (2.1) 
Completeness (%) 98. 3 (98) 99.4 (95.4) 99.9 (99.9) 100 (100) 
Rmeas (%)
‡
 5.2 (17.7) 15.7 (37.6) 9.1 (81.2) 7.9 (122.4) 
Rpim (%)
$
 2.4 (8.4) 3.5 (21.9) 4.5 (39.3) 2.3 (35.8) 
+
Data collection statistics for unmerged Friedel pairs 
≠
 SLS: Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland), BESSY: Berlin Electron Storage Ring Society for Synchrotron Radiation (Helmholtz Zentrum Berlin, 
Berlin, Germany) 
†
Mosaicity values reported by XDS (Kabsch, 2010)  
‡
Rmeas = Σhkl (N/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl), where N is the number of observations of the reflection with index hkl and Ii is the intensity of its i
th
 
observation. 
$
Rpim = Σhkl (1/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl) (Weiss, 2001)
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Table 47: Refinement statistics for P. aeruginosa βαβββ module containing proteins PA0803 and 
PA1353. Data were collected in studies by Yu, 2009, and Kalawy-Fansa, 2010. Values in parentheses are 
for the highest resolution shell. PYO = pyocyanin 
Dataset PA0803 apo PA0803 PYO PA1353 apo 
Resolution range (Å) 46.55-1.62 (1.65-1.62) 46.39-1.71 (1.74-1.71) 49.11-1.75 (1.78-1.75) 
Rwork (%) 17.75 (35.51) 15.37 (26.28) 17.43 (23.84) 
Rfree (%) 20.20 (38.47) 18.45 (31.45) 21.58 (28.48) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
4430 
- 
52 
705 
 
5282 
10 
80 
799 
 
2119 
- 
- 
249 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.005 
0.999 
 
0.008 
1.166 
 
0.020 
1.818 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
27 
- 
53 
40 
 
23 
50 
38 
38 
 
33 
- 
- 
42 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
98.1 
0 
 
97.8 
0.2 
 
98.2 
0.4 
MolProbity score
#
 1.19 1.17 1.09 
PDB entry code - - - 
#
As reported by MolProbity (Chen et al., 2010) 
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Table 48: Data collection statistics for P. aeruginosa βαβββ module containing proteins PA1353, PA3127-NTD and PA4641. Data were collected in studies by Kalawy-
Fansa, 2010 and Popp, 2013. Values in parentheses are for the highest resolution shell. PYO = pyocyanin 
Dataset  PA1353 PYO PA3127-NTD apo PA4641 apo PA4641 PYO 
Wavelength (Å) / beamline
≠
 0.9787 / SLS, PXII 0.9184 / BESSY II, BL14.1 0.9787  / SLS, PXII 0.9787 / SLS, PXII 
Resolution range (Å) 46.57-1.45 (1.47-1.45) 38.12-1.55 (1.58-1.55) 44.79-1.95 (2.0-1.95) 48.90-1.85 (1.89-1.85) 
Space group P212121 P1 P1 P1 
Unit cell parameters (Å) 
                                      (°) 
65.58  66.13  76.05 
90  90  90 
43.38  43.6  66.2 
89.92  78.41  61.6 
30.96  49.32  86.69 
96.39  91.25  91.81 
30.95  49.24  86.97 
96.46  91.28  91.99 
Mosaicity (°)† 0.133 0.142 0.242 0.095 
Total No. of measured 
reflections 
488313 (23926) 215582 (10142) 97274 (6923) 88049 (5619) 
Unique reflections 59343 (2908) 58424 (2829) 35220 (2465) 40844 (2526) 
Multiplicity 8.2 (8.2) 3.7 (3.6) 2.8 (2.8) 2.2 (2.2) 
Mean I/σ(I) 20.6 (2.4) 16.9 (2.2) 6.9 (2.2) 9.6 (2.3) 
Completeness (%) 100 (100) 96.9 (95.3) 94.8 (95.6) 93.9 (94.7) 
Rmeas (%)
‡
 5.8 (102.1) 4.7 (66) 10.4 (49.2) 6.9 (54.1) 
Rpim (%)
$
 2.0 (35.4) 2.4 (34.6) 6.0 (28.0) 4.3 (34.8) 
≠
 SLS: Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland), BESSY: Berlin Electron Storage Ring Society for Synchrotron Radiation (Helmholtz Zentrum Berlin, 
Berlin, Germany) 
†
Mosaicity values reported by XDS (Kabsch, 2010)  
‡
Rmeas = Σhkl (N/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl), where N is the number of observations of the reflection with index hkl and Ii is the intensity of its i
th
 
observation. 
$
Rpim = Σhkl (1/(N – 1))
1/2
 Σi | Ii (hkl) – < I (hkl) > | / Σhkl Σi Ii (hkl) (Weiss, 2001). 
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Table 49: Refinement statistics for P. aeruginosa βαβββ module containing proteins PA1353, PA3127-
NTD and PA4641. Data were collected in studies by Kalawy-Fansa, 2010 and Popp, 2013. Values in pa-
rentheses are for the highest resolution shell. PYO = pyocyanin 
Dataset PA1353 PYO PA3127-NTD apo PA4641 apo PA4641 PYO 
Resolution range (Å) 46.57-1.45 
(1.47-1.45) 
38.12-1.55 
(1.58-1.55) 
44.79-1.95 
(2.0-1.95) 
48.90-1.85 
(1.89-1.85) 
Rwork (%) 16.24 (24.68) 17.05 (24.2) 18.6 (23.38) 16.48 (24.14) 
Rfree (%) 18.93 (23.9) 19.41 (28.9) 22.47 (27.98) 20.28 (32.33) 
No. of non-H atoms 
  Protein 
  Ion 
  Ligand 
  Water 
 
2184 
- 
32 
295 
 
3506 
- 
14 
330 
 
4245 
- 
- 
238 
 
4252 
- 
64 
274 
R.m.s. deviations 
  Bonds (Å) 
  Angles (°) 
 
0.016 
1.534 
 
0.008 
1.248 
 
0.0056 
0.950 
 
0.006 
0.957 
Average B factors (Å
2
) 
  Protein 
  Ion 
  Ligand 
  Water 
 
26 
- 
26 
38 
 
25 
- 
32 
35 
 
33 
- 
- 
42 
 
30 
- 
27 
39 
Ramachandran plot 
  Favored regions (%) 
  Outliers (%) 
 
98.6 
0 
 
97.3 
0 
 
96.5 
0 
 
97.4 
0.2 
MolProbity score
#
 1.14 0.95 1.32 0.93 
PDB entry code - - - - 
#
As reported by MolProbity (Chen et al., 2010) 
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